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Abstract 
 
Five membered nitrogen-containing heterocycles exhibit a wide range of biological activities. In 
this study we set out to demonstrate the utility of isocyanides in the synthesis of these 
heterocycles, and to identify hit scaffolds demonstrating the ability to disrupt important HIV-1-
host protein-protein interactions. In this project study, isocyanide synthons were used to 
generate different libraries of five membered nitrogen-containing heterocycles. In the first part 
of the project (Chapter 2), para-toluenesulfonylmethyl isocyanide (TosMIC) was reacted with N-
(arylidene)alkylamines (generated from aryl aldehydes and primary amines) under basic 
conditions using both a conventional and microwave-assisted van Leusen approach to generate a 
series of novel 5-aryl-1H-imidazole compounds. This family of 25 imidazole-based compounds 
were assessed for biological activity in an HIV-1 IN-LEDGF/p75 AlphaScreen assay and six 
compounds were found to be inhibitors of this interaction. In order to improve the potency of 
the hit fragments, a carboxylic acid functionality was introduced at the imidazole moiety of the 
hit compound to give novel 1,5-diaryl-1H-imidazole-4-carboxylic acid compounds as second 
generation of compounds. Biological evaluation of these carboxylic acid scaffolds in the HIV-1 
IN-LEDGF/p75 AlphaScreen assay identified compounds exhibiting more than 50% inhibition, 
with four inhibitors surpassing the percentage inhibition of the hit scaffold.  
 
In the second part of the thesis (Chapter 3), TosMIC was reacted with various aryl aldehydes 
under basic conditions via a microwave-assisted van Leusen reaction to afford a set of 5-aryl-1,3-
oxazole derivatives. However, attempts to prepare similar scaffolds in acetonitrile afforded the 
oxazoline intermediates instead, which were easily converted into the corresponding 5-aryl-1,3-
oxazoles in one additional step. This family of 12 compounds did not significantly inhibit the 
HIV-1 IN-LEDGF/p75 AlphaScreen assay and the binding of antiVpu to Vpu. To improve the 
percentage inhibition of the original scaffolds, insertion of an N-aryl-carboxamide at the 4-
position of the oxazole moiety was carried out. Initial, attempts via formation of 2-isocyano-N-
aryl-acetamide intermediates and oxidation of N,5-aryl-4,5-dihydrooxazole-4-carboxamide 
intermediates met with failure. However, this second generation of novel N,5-diaryl-4-
carboxamide-1,3-oxazole derivatives were then synthesized successfully using benzoyl chloride 
and ethyl isocyanide as starting reagents. Evaluation of the desired 11 novel N,5-diaryl-4-
carboxamide-1,3-oxazoles in the HIV-1 IN-LEDGF/p75 assay showed that at least two 
compounds with the N-aryl-4-carboxamide moiety showed increased inhibition potency at 100 
μM relative to the first generation of oxazoles. 
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In the third part of the study (Chapter 4), TosMIC was reacted with ethyl 2-
(arylideneamino)acylate intermediates (generated from simple amino acids) under basic 
conditions via a van Leusen reaction to give a family of novel 5-aryl-1H-imidazoyl acylates. 
However, isolation of adducts derived from D-leucine proved to be impossible. A series of 5-
aryl-1H-imidazoyl-acylates derived from glycine were further transformed into two novel sets of 
5-aryl-1H-imidazoyl-acetic acid and 5-aryl-1H-imidazoyl-acetohydrazide compounds. This family 
of 25 novel 5-aryl-1H-imidazo-yl-based compounds was screened for biological activity. In direct 
HIV-1 IN-LEDGF/p75 AlphaScreen assay, one compound was found to be active while seven 
compounds were identified as inhibitors of HIV-1 Vpu- host BST-2 interactions. To improve 
the percentage inhibition of these compounds in the HIV-1 IN-LEDGF/p75 AlphaScreen, N'-
arylidene and carboxamide groups were introduced which resulted in the generation of two sets 
of novel (E)-N'-arylidene-2-(5-aryl-1H-imidazol-1-yl)acetohydrazides and, N,5-diaryl-2-(1H-
imidazol-1-yl)acetamide compounds. From this library, at least three compounds with the 4-tert-
butylphenyl motif were found to be a disruptor of HIV-1 IN and LEDGF/p75 interactions.  
 
In the fourth part of the study (Chapter 5), aryl isocyanide synthons were reacted with 2-halo-
arylethanone oximes to afford a series of 3-aryl-5-amino-isoxazole derivatives in poor yields. The 
poor yields were attributed to the low reactivity of the isocyanide and instability of the 
nitrosoalkene generated in situ from 2-halo-arylethanone oxime intermediates. Better yields of 3-
aryl-5-amino-isoxazoles were obtained when methyl isocyanoacetate was used instead of aryl 
isocyanide. Additionally, treatment of 2-halo-arylethanone oxime intermediates with potassium 
cyanide in MeOH afforded 3-aryl-isoxazol-5-amine derivative in varying yields. From this library, 
10 isoxazole-based compounds were biologically evaluated in an HIV-1 IN – LEDGF/p75 
interaction assay at 100 μM and, with the exception of two compounds, all the compounds 
displayed marginal activities.  
 
All compounds showing significant inhibitory activity in one of the protein-protein interaction 
assays were tested for activity in a cell based anti-HIV-1 assay. Unfortunately, none of the 
compounds was found to be active in this cell based assay.  
 
Lastly in Chapter 6, the synthesized libraries of the five membered nitrogen containing 
heterocyclic compounds were assessed for their antimicrobial activity using MIC methods. At 
least four compounds exhibited moderate antimicrobial activity against gram positive bacterial 
strains and a yeast strain.  
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CHAPTER 1: Literature Review 
 
1. INTRODUCTION 
The drug discovery process has positively produced a great number of treatments that can 
suppress, stop or reverse the effects of viral and bacterial infections, resulting in the 
improvement of the quality and extension of lives.  However, the emergence of new viral strains 
and the high mutation rate in several pathogens has led to multi-drug resistance.  This has 
prompted the search for new effective and innovative therapeutic treatments.  One path that 
holds great potential is to design new small molecular entities, which are selective, safe and can 
battle the new strains. 
For the development of small molecules, identification of and insight into potential targets are of 
paramount importance to act as a guide for researchers. In addition, setting up usable protocols 
for testing activity at the target is important before commencing the actual design of drug 
candidates.  Once the target is established, chemical libraries of compounds obtained from 
commercial vendors or through in-house synthetic efforts are screened using relevant 
approaches. Once the active molecules (hits) are identified, they can further undergo structural 
modifications to afford analogues called leads, with increased affinity and selectivity.  The lead 
compounds additionally undergo structural alteration to optimise their physicochemical 
properties until being developed into potential drug candidates.  These drug candidates are then 
subjected to different phases of pre-clinical trials to determine parameters such as 
pharmacokinetics, pharmacodynamics and bioavailability until they are accepted by relevant 
approval agencies and marketed for a specific disease. 1,2 
 
This chapter provides an overview of the relatively newly exploited binding cavities on the HIV-
1 lifecycle as a potential target for the development of a novel class of antiretroviral inhibitors. 
The second section of this chapter explores the fragment-based screening method as an 
alternative new drug discovery approach towards the identification of hit compounds to turn 
into leads. Heterocyclic compounds often possess interesting biological activities; therefore, the 
review also explores the importance of the para-toluenesulfonylmethyl isocyanide and aryl 
isocyanide synthons in the preparation of five membered nitrogen containing heterocycles.  
 
1.1. The Targets: Human immunodeficiency Virus (HIV-1)  
The infectious disease recognized as Acquired Immunodeficiency Syndrome (AIDS) initiated by 
the Human Immunodeficiency Virus type 1 (HIV-1) remains life-threatening to public health 
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worldwide, especially in low- and middle-income nations.  According to the World Health 
Organization (WHO) in 2015, an estimated 16 million people worldwide were under 
antiretroviral treatment and roughly 36.9 million people globally were living with HIV-1.3  The 
financial toll of HIV/AIDS is tremendous and it is projected that South Africa alone spent 
approximately $1 billion in 2014 on HIV/AIDS treatment and awareness programmes.4  Since 
the identification of HIV as the causative agent of AIDS, research scientists have tried to find an 
effective vaccine for the disease. Although attempts at discovering a cure have thus far been 
unsuccessful, therapeutic treatments that can sufficiently suppress the viral load to below 
detection levels have been developed.5  This has resulted in a significant decrease in the mortality 
rate and extends the lifespan of infected individuals worldwide.  HIV-1 progression is managed 
through the process of using mixtures of more than one drug called highly active antiretroviral 
therapy (HAART).6,7 Although current HIV-1 treatments have much improved the clinical 
outcome, the high mutation rate of the virus has led to the development of drug resistance in 
many viral strains, thereby emphasizing necessity to develop novel anti-HIV-1 drugs that target 
relative newly exploited HIV-1 integrase (IN) - host lens epithelium-derived growth factor 
(LEDGF/p75) and HIV-1 viral protein U (Vpu) - host bone marrow stromal cell antigen 2 
(BST-2) interactions. 
 
The replication cycle of HIV-1 (Figure 1.1) begins with the contact of the viral glycoprotein 120 
(gp120) with the CD4+ receptor and the co-receptor CCR5 or CXCR4 on a susceptible cell, 
which subsequently allows fusion of the viral envelope with the cell membrane.8,9,10,11,12  Upon 
fusion, the viral capsid is released and dissembled to the allow the viral genome into the host 
cell.13,14,15 The viral genome codes for the necessary proteins and enzymes to complete the life 
cycle.  Inside the host cell, the viral reverse transcriptase enzyme transcribes the single-stranded 
RNA genome into a double-stranded DNA, which is then introduced into the host nucleus by 
the viral enzyme integrase (IN). 16,17 
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Figure 1.1:  Schematic representation of the HIV-1 replication cycle (Figure taken from 
Engelman et al.) 18 
 
1.1.1 HIV-1 integrase 
The 32 kDa monomeric form of IN is made up of 288 amino acids and comprises of three 
structural domains, the N-terminal zinc finger domain (NTD), a catalytic core domain (CCD) 
and the C-terminal DNA-binding domain (CTD).19  IN enzyme plays two essential enzymatic 
roles during the HIV-1 replication life cycle, namely: the 3‟-processing and DNA strand transfer. 
During the 3‟-processing, the IN displaces two conserved dinucleotides by attaching itself to the 
ends of long terminal repeat strands (LTR) of proviral complementary DNA.20,21  The resulting 
cleaved DNA is then used as a template for the strand transfer that involves the trans-
esterification of 3′-OH viral ends leading to the proper insertion of viral DNA into the host cell 
chromatin.  This DNA insertion has been presented as one of the targets for antiviral drug 
discovery and development.  The molecules that inhibit insertion of the pre-integration complex 
(PIC) into the DNA of the host cell are known as strand transfer inhibitors (INSTIs). 22,23,24 
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1.1.2. Co-factor LEDGF/p75- HIV-1 IN proteins interaction  
HIV-IN relies on cellular co-factors for the tethering and correct insertion of the viral genome 
into the host cell chromatin (Figure 1.2). 25,26  It is evident that IN efficiently integrates the DNA 
by using its catalytic domain catalytic core (IN-CCD) and N-terminal domains.  This critical step 
is successfully accomplished through interaction with the C-integrase domain of the host lens 
epithelium-derived growth factor, or transcriptional coactivator p75 (LEDGF/p75).25-26  As a 
result the LEDGF/p75 - IN interaction has been recognised as one of the new essential targets 
for development of a novel generation of HIV-1 inhibitors.  In addition,  mutagenesis analysis 
established that the Lys364, Ile365, Asp366, Phe406, Val408 residues of the LEDGF/p75 binds 
to the Ala128, His171, Thr174, Trp131, Trp132, Gln168 residues of an IN dimer.  
 
 
 
Figure 1.2: Interaction between LEDGF/p75-HIV-1 IN. (Figure taken from Harrison, A. T. 
Master‟s thesis) 27 
 
Once the DNA is properly inserted inside the nucleus, it is then converted into messenger RNA 
by the cellular machinery, which is then translated into long polyproteins.  The viral long 
polyproteins are cleaved by viral protease to afford functional proteins and viral components are 
packaged into newly formed virions.  The newly formed virions sustain the downregulation of 
CD4 in the endoplasmic reticulum (ER), enable budding and enhance release of new virions 
from the plasma membrane, thus promoting the spread of infection. 28,29,30,31 
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1.1.3. Viral protein U 
The degradation of CD4 and enhancement of extracellular viral particle release by HIV-1 relies 
on the viral protein U (Vpu), a type I integral protein of 81 amino acids, which is one of four 
accessory genes encoded in HIV-1.32,33,34  Vpu consists of a hydrophobic N-terminal domain in 
the transmembrane region, which has a well-defined α-helix structure, and a hydrophilic C-
terminal domain (Figure 1.3).35,36  The C-terminal domain in the cytoplasmic region consists of 
two α-helix domains, which are linked together by two phosphorylated serine residues.  The 
phosphorylation of the two serine residues in Vpu is mediated by casein kinase II enzyme. 
 
 
 
Figure 1.3: Structural domain of Vpu with two helices of the cytoplasmic domain oriented 
parallel to each other.  (Figure taken from Strebel).35  
 
1.1.4. Bone marrow stromal cell antigen 2 (BST-2) 
BST-2, also known as tetherin, CD317 or HM1.24, is a type II transmembrane protein of 180 
amino acids.  This interferon inducible (α-IFN) host restriction factor bears a short cytoplasmic 
N-terminal tail region (CT) of 21 amino acids, an α-helical transmembrane domain (TM) of 21 
amino acids, a central coil-coiled extracellular domain (EC) of 116 amino acids and a C-terminal 
glycosylphosphatidylinositol (GPI) domain (Figure 1.4).  The TM α-helical structure serves as an 
anchor of the molecule to the plasma membrane while GPI, which forms part of the C-terminal 
domain, acts as a secondary anchor connecting the BST-2 back to the cell membrane.  Both TM 
and GPI anchors of BST-2 are critical for restriction of virus release.  The EC domain provides 
dimer stability through formation of a disulfide bond between cysteine residues, which is 
necessary for retention of antiviral activity. 37, 38,39  
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Figure 1.4: Representation of the structure of the BST-2 domain. (Figure taken from Arias et 
al).37  
 
1.1.5. The interaction between BST-2 and viral Vpu protein 
Evidence suggests that interaction of Vpu with BST-2 is of critical importance in HIV-1 
replication. 40,41,42  Although BST-2 inhibits the release of viral particles from the infected cell, 
Vpu manages to mediate the removal of the BST-2 from the cell membrane through a 
mechanistic pathway which is still under debate.  Several reports suggest that downregulation of 
BST-2 by Vpu occurs as a result of several possible mechanistic actions, which include lysosome-
dependent degradation of BST-2 via recruitment of a cellular co-factor called beta-transducing 
repeat-containing protein (β-TrCP) or proteasomal degradation.36,43  Arias et al. suggested that 
Vpu antagonises BST-2 by interfering with biosynthetic/secretory pathways, which reduces the 
supply of newly formed BST-2 to the cell membrane.44  Regardless of the mechanistic pathway, 
the ability of Vpu to interact with BST-2 is of crucial importance in the downregulation of BST-
2.  Biological assays, computational and NMR spectroscopic studies confirmed that Vpu 
counteracts BST-2 via interaction through their α-helical transmembrane domains (Figure 
1.5).44,45,46,47  Mutation analysis revealed that critical interacting residues on Vpu are Ala10, Ala14, 
Ala18 and Trp22, which are spaced at four residue intervals.  Analysis of mutations on BST-2 
revealed that Val30, Ile33, Ile34, leu37, Leu41 and Thr45 are the residues involved in the 
interaction.  These residues are on the same side of the helix in proteins. 40-48 
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Figure 1.5: Representation of the interaction of HIV-1 Vpu and BST-2 through their 
transmembrane domains (Arias et al.). 44 
 
 
1.1.6. Therapeutic intervention on HIV-1 IN 
Since recognition of HIV-1 IN as a target, the Food and Drug Administration (FDA) has 
approved three clinical HIV-1 integrase strand transfer inhibitors (INSTIs) which are currently 
on the market; namely: elvitegravir,49 dolutegravir,50 and raltegravir 51,52(Figure 1.6). These INSTIs 
selectively target strand transfer through a unique mode of action, which involves the chelating 
of active site divalent metal ions, thereby preventing the insertion of the proviral DNA into the 
host DNA.  Although these inhibitors have managed to suppress HIV-1 as part of highly active 
antiretroviral therapy (HAART), the emergence of new viral strains has resulted in development 
of resistance which has led to cytotoxicity and restricted the long-term prescription of these 
inhibitors. Therefore, the search for novel effective inhibitors to balance existing treatment 
approaches remains one of the key objectives in HIV drug discovery.  
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Figure 1.6: FDA approved IN inhibitors. 
 
During the past decade, a lot of attention has been devoted to the development of inhibitors that 
can disrupt the formation of the HIV-1-IN and cofactor LEDGF/p75 complex, which led to 
the discovery of the small molecules listed in Figure 1.7.53,54,55  These small molecules have been 
identified by various approaches such as in silico virtual screening of compound libraries, 
fragment based drug discovery (FBDD) and structure-based de novo design.54,56,57  Some of these 
compounds contain carboxylic acid functionalities embedded within their chemical structures 
which proved to be significant to their binding properties.  For instance, Du and co-workers55 
have identified a carboxylic acid containing compound, D77 as an inhibitor of IN-LEDGF 
interactions through molecular docking, site-directed mutagenesis analysis and surface plasmon 
resonance (SPR); while De Luca and colleagues57 identified a class of indole molecules (CHIBA 
3053 is one example, Figure 1.7), through AlphaScreen assay and computational studies, which 
has the ability to interrupt the catalytic activity of IN. An AlphaScreen assay, in silico docking and 
cell based assay study of libraries of compounds conducted by Christ and co-workers53-54 resulted 
in the discovery of the class of acetic acid scaffolds such as CX14442, BI-224436 and ALLIN 
(Figure 1.7) that inhibit interaction between the IN binding domain (IBD) of LEDGF/p75 and 
the catalytic core domain (CCD) of the HIV-1 IN proteins. BI-224436 was found to have 
significant antiretroviral activity and was further advanced into Phase I clinical development but 
was later withdrawn from clinicals without any reasons offered. Moreover, a virtual screening, 
docking studies, molecular dynamics and synthetic approach adopted by Ferro and co-workers58 
has led to the development of a rhodamine based family of compounds (Figure 1.7) which 
exhibited inhibitory effects by preventing the HIV-1 IN interaction with its cellular cofactor 
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LEDGF/p75 at micromolar concentration. Recently, a virtual screening of natural compounds 
and synthetic efforts conducted by Agharbaoui et al.59 led to the identification of a set of 
lavendustin B derivatives (Figure 1.7) which exhibited IN-LEDGF/p75 inhibitory activity as well 
as decreased HIV-1 IN activity via an allosteric mechanistic pathway. These types of compounds 
are categorized as allosteric HIV-1 inhibitors and are a promising next generation of 
antiretroviral drugs. 
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Figure 1.7: Examples of reported small molecule inhibitors of LEDGF/p75-IN interaction. 
 
Furthermore, Sharma et al. modified ALLINI and designed a new class of pyridine-based 
compounds, KF115 and KF116 (Figure 1.8). Interestingly, these pyridine based compounds were 
found to promote the HIV-1 IN multimerization in virus particles but did not detectably disrupt 
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IN-LEDGF/p75 binding. Thus these compounds are classified as a new class of novel 
multimerization selective IN inhibitors.60  In addition, a combination of different computational 
techniques and AlphaScreen-based IN dimerization assays conducted by Tintori and co-
workers61 resulted in the discovery of hydrazine based compounds as promising HIV-1 IN 
dimerization inhibitors. 
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Figure 1.8: Novel class of multimerization selective IN inhibitors. 
 
1.1.7. Therapeutic intervention on HIV-1 Vpu BST-2 interaction  
Targeting HIV-1 Vpu and the host protein BST-2 interactions has attracted attention as a 
valuable approach to developing novel anti-HIV-1 inhibitors.  To date, no antiretroviral drugs 
that target the HIV-1 Vpu - BST-2 complex formation have been approved in the market, which 
makes this target really interesting. However, in recent years, literature has reported three small 
molecules that can restrict the role of HIV-1 Vpu protein, therefore permitting the operation of 
the host BST-2 (Figure 1.9).62,63,64  For instance, BIT 225 has been reported as a potential inhibitor 
of Vpu ion channels, thereby preventing the assembly of the newly formed virions within the 
host cells.62 Recently, the use of an ELISA cell-based assay led to the discovery of two small 
molecules, IMB-LA and 2-thio-6-azauridine which were reported to specifically inhibit down-
regulation of BST-2 mediated by HIV-1 Vpu.63-64  These molecules have been found to restrict 
the function of Vpu protein through diminished localization of BST-2 to lysosomes, but do not 
necessarily prevent the binding of BST-2 to Vpu.63-64  Although these compounds do not 
 
11 
 
necessarily disrupt the interaction between BST-2 and Vpu proteins; they offer the proof of 
concept that small molecules could be developed to block the release of new virions.  
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Figure 1.9: Structure of small molecules that inhibit Vpu mediated BST-2 degradation. 
 
 
1.2. The Method: Fragment Based Approach to Drug Discovery 
The fragment based approach to drug discovery has emerged as an interesting starting point for 
identification of high-affinity „hit‟ molecules against targets of interest.65,66,67,68,69,70,71,72,73 This 
protocol involves screening of libraries of very small molecules called fragments with typically 
less than 350 Da mass, to search for affinities to their targets.65-73  The idea of fragment screening 
was first initiated by Verlinde et al. in 199071 and later proposed by Shuker and co-workers72 in 
1996. 74,75,  Since then it has been employed by various research laboratories,  and resulted in 
some of the compounds in clinical trials.76  For example, vemurafenib for the treatment of late-
stage melanoma was designed through fragment screening methodology and approved by the 
FDA in 2011.76  There are several potential benefits of using fragment screening as a starting 
point for identification of „hit‟ molecules as compared to primary strategies such as conventional 
high-throughput screening (HTS),77,78 structure based-drug design79 and analogue-based drug 
design80.  One of the advantages is that the structure activity relationships (SAR) of „hit‟ 
molecules can be established at an early stage because various analogues can be synthesized 
without difficulty or acquired from commercially available sources due to their simplicity and low 
molecular weight.73  Another advantage is that the low molecular weight fragments can optimally 
bind to the target because they are less selective, which allows exploration of the chemical 
space.81,82  Moreover, the fragment screening approach can identify lead compounds for 
previously undruggable proteins due to their relatively small size. .83,84  Furthermore,  screening of 
small libraries of fragments comprising 500-2000 compounds is usually carried out, in 
comparison to HTS where compound libraries consist of  100,000 to 1,000,000 compounds, 
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typically with a molecular mass between 350 -500 Da.85  The scaffolds within a fragment library 
are usually governed by the so-called “rule of three”69 in comparison to Lipinski‟s86 rule of five 
used for classification of drug like compounds.  The rule of three (Ro3) states that fragments 
should ideally have: molecular weight < 300 g/mol, a number of hydrogen bond donors and 
acceptors ≤ 3, XlogP ≤ 3, a number of freely rotatable bonds ≤ 3 and polar surface area ≤ 60 
Å2. 
 
Lower molecular weight fragments have lower affinity for their targeted proteins. Therefore, 
arrays of physical screening protocols that are sensitive and robust have been developed to 
detect low binding affinity between fragments and their target of interest.  These include 
Saturated Transfer Difference Nuclear Magnetic Resonance spectroscopy (STD-NMR), 73,87,88,89  
Isothermal Titration Calorimetry (ITC),90,91 and AlphaScreening Assay,92,93,94,95 to mention a few 
and which will be discussed in more detailed below. 
 
 1.2.1 Saturated Transfer Difference Nuclear Magnetic Resonance (STD NMR) 
Spectroscopy 
STD NMR spectroscopy has emerged as one of the essential approaches to studying the 
interaction between fragments and the protein of interest.73,87  It measures the difference between 
two proton NMR spectra obtained with (on resonance) and without (off resonance) saturated 
receptor protein.  The first step in STD NMR spectroscopy involves the recording of an off-
resonance spectrum of a reference protein after sample irradiation at a frequency region far from 
both receptor and ligand resonances.  In parallel, the on-resonance spectrum is registered by 
irradiation of the protons of the receptor protein (in the presence of ligand) in the selected 
region by a selective radio frequency pulse towards the proton NMR spectrum of the ligand.  
The irradiation causes magnetisation transfer through intra-molecular proton-proton cross-
relaxation pathways from the protein to the small molecule, which results in the saturation of its 
proton NMR spectroscopic signals.  Upon dissociation, the intensity of the NMR spectroscopic 
signals of the saturated molecule are reduced, leaving the signals of non-binding molecules 
unaffected.  The difference between the on- and off-resonance spectra results in the saturation 
difference spectrum, with only the signals from ligands that are bound to the protein being 
present. 
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1.2.2. Isothermal Titration Calorimetry (ITC) 
ITC is a consistent and precise screening tool for understanding not only the binding of protein 
to protein, but also the interactions between small molecules and receptor proteins.90-91  This 
protocol measures the heat evolved or absorbed upon binding of two molecules.  The heat 
exchange is determined through thermodynamic parameters, which are characterised using the 
binding constant, stoichiometry and enthalpy of binding.  During binding evaluation by the ITC 
approach, a ligand is injected into the reaction cell containing the protein, which causes heat 
exchange proportional to the amount of small molecule interacting with the protein.  The heat 
evolved by each injection is calculated based on the area under the peak produced.  
 
1.2.2.3. Amplified Luminescent Proximity Homogeneous assay (AlphaScreen)  
AlphaScreen technology is a biochemical analytical technique which allows the study of the 
interactions between small molecules and receptor proteins, but it‟s also an essential tool when 
looking at protein-protein interactions.92-95  This approach is based on donor and acceptor bead 
chemistry.  The donor bead consists of photosynthesized phthalocyanine, which can be 
illuminated at 680 nm to excite ambient oxygen to the singlet oxygen state.  The acceptor beads 
consist of thioxene, anthracene and rubrene chemical dyes that produce a luminescent response 
at 520-620 nm.  A typical AlphaScreen experiment for determining the prevention of interaction 
between protein-protein by a ligand is carried out by attaching one protein to a donor bead and 
the other protein and a small molecule to the acceptor bead.  During irradiation of the donor 
bead, the singlet oxygen generated reacts with the acceptor bead to emit energy in the form of 
light.  However, if the small molecule prevents binding between two proteins, there will be no 
reaction between the donor bead and acceptor bead resulting in no light emission. If the ligand 
slightly prevents the interaction, the intensity of light produced is then reduced.  The luminescent 
energy produced is then determined in terms of percentage; the higher the percentage the better 
the inhibition.  One of the drawbacks possessed by the AlphaScreen is that compounds such as 
reactive compounds or chelators can still interfere by directly quenching the signal or reacting 
with the singlet oxygen. However, this drawback has been overcome by subjecting positive hits 
through the Truhit AlphaScreen assay. This assay is intended to eliminate false positives 
interfering with the AlphaScreen signal.96 This kit contains streptavidin donor and biotinylated 
acceptor beads, which interact with each other to produce an AlphaScreen signal.  Any 
compounds which are colour quenchers, singlet oxygen quenchers, light scatterers, and biotin 
mimetics interfering with the AlphaScreen signal are thus identified as false positives. 
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1.3. The Chemistry: TosMIC Synthon  
Synthetic building blocks that can be manipulated by varying reaction conditions resulting in 
diverse nitrogen containing molecules are of utmost importance in medicinal organic synthesis 
and para-toluenesulfonylmethyl isocyanide TosMIC 1 has been proven to be such an entity. 
TosMIC 1 (Figure 1.10) has received great interest due to its 1,3-dipolar characteristics under 
basic conditions. 97,98,99,100 It was first described by professor Daan van Leusen and co-workers in 
1977.99 It is stable, non-volatile and unscented at room temperature, and it is also commercially 
available (CAS Number 36635-61-7). 101  
The sulfonyl substituent of TosMIC plays a prominent role as it enriches the acidity of α- 
protons as well as acting as a leaving group, while the isocyano group can undergo α- addition to 
produce α-adducts. 99-100 
 
  
 
Figure 1.10: Structure of TosMIC (1).  
 
1.3.1. Preparation of TosMIC and its analogues 
TosMIC 1 can be easily accessed in two stepwise processes.  The initial stage involves a 
Mannich-type condensation, in which sodium 4-methylbenzenesulfonate 2 reacts with 
formamide 3 and formaldehyde 4 in water (H2O) and formic acid (HCOOH) at 90-95
oC to 
produce N-(p-tolylsulfonylmethyl)formamide 5.  The formamide 5 is then dehydrated with 
phosphoryl chloride (POCl3) in the presence of triethylamine (Et3N) using dimethoxyethane 
(DME) and diethyl ether (Et2O) as solvents to afford TosMIC 1 in reasonable yield (Scheme 
1.1).102, 103,104  
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Scheme 1.1: Synthesis of TosMIC 1. 
 
Analogues of TosMIC 1 have also has been prepared by various groups.105,106,107,108  One of the 
approaches to access such scaffolds was also documented by van Leusen and co-workers.105  In 
their approach, the α-acidic proton on the carbon adjacent to the isocyano group is deprotonated 
under phase transfer catalyst (PTC) conditions, followed by alkylation to afford the desired 
TosMIC derivatives 6 (Scheme 1.2).  Furthermore, monosubstituted-alkenyl and long chain alkyl 
groups have also been introduced at the α-acidic centre of TosMIC 1 under similar PTC 
conditions.106-107 
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Scheme 1.2: Synthesis of derivatised TosMIC via PTC. 
 
In another contribution, Sisko and co-workers108  have described a method which introduces aryl 
groups at the α-methylene proton of TosMIC.  In their protocol, formamide 3 was reacted with 
benzaldehydes 7 and p-toluenesulfinic acid 8 in the presence of chlorotrimethylsilane (TMSCl) 
using a 1:1 mixture of acetonitrile (MeCN) and toluene (PhMe) as solvents at 50oC to generate α-
(p-toluenesulfonyl)-4-benzylformamide derivatives 9 in reasonable yields (Scheme 1.3).  These 
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benzylformamide derivatives 9 were then subjected to a dehydration reaction with POCl3 using 
Et3N as a base in tetrahydrofuran (THF) to afford the aryl-substituted TosMIC analogues 10.  
The derivatised TosMIC 10 has been found to be more reactive than TosMIC 1 itself, which is 
attributed to the further enhancement of the acidity of the α-proton by the substituents at the 
methylene group.   
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Scheme 1.3: Synthesis of derivatised TosMIC 10 as described by Sisko and co-workers. 
 
Furthermore, a variety of synthetic analogues of TosMIC with substitution at the sulfonyl group 
by different aliphatic and aromatic rings have recently been exploited by Lujan-Montelongo and 
co-workers.103  In this method, formamide 3 was treated under Mannich-type condensation with 
formaldehyde 4 and methyl aliphatic-substituted-benzoates/carboxylates 11 in the presence of 
HCOOH using both conventional and microwave heating at 90-110oC to afford the N-
(aryl/aliphatic-sulfonylmethyl)formamide derivatives 12, which further undergo dehydration with 
POCl3 in the presence of isopropylamine (iPrNH2) to furnish the desired aryl/aliphatic methyl 
isocyanide derivatives 13 in good yields (Scheme 1.4).  The presence of the different substituents 
on the aromatic ring had little effect on the product yields.  
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Scheme 1.4: Synthesis of aryl/aliphatic methyl isocyanide derivatives. 
 
TosMIC and its analogues are very reactive synthons and their reputation is credited to their 
ability to act as nucleophile and electrophile as well as radical depending on the reaction 
conditions. 97-100 They have been found to be valuable reagents and their greatest principal 
function has been in the preparation of five-membered nitrogen containing heterocycles such 
imidazoles,109,110,111,112,113  oxazoles 114,115 and pyrroles.116,117,118  However, in recent years TosMIC has 
been used to generate six membered heterocyclic ring systems,119,120,121  and also react with Baylis-
Hillman products to generate ethyl 2-[(tosylmethylcarbamoyl)methyl]-3-phenylacrylate and 3-
phenyl-2-(tosylmethyl)acrylonitrile derivatives,106,122  as well as in multi-component reactions to 
produce diverse mandelamide products. 123 
 
1.3.2. Synthesis of five membered ring systems 
1.3.2.1. Imidazole  
Imidazoles 14 are an important class of aromatic compound.  This planar five membered-ring 
heterocycle contains two nitrogen atoms in its structure (Figure 1.11).  Compounds incorporating 
the imidazole moiety have been shown to exhibit a variety of biological activities such as anti-
fungal,124,125 anti-HIV,126,127 anti-microbial,128, 129 and anti-cancer activity.130,131 
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Figure 1.11: Structure of substituted-1-R”-imidazoles. 
 
Because of their diverse pharmacological activities, the synthesis of compounds containing the 
imidazole core is of great importance in medicinal chemistry.2-9 A number of divergent 
approaches have been applied for imidazole synthesis such as Wallach Synthesis,132, Markwald 
synthesis,133  Debus imidazole synthesis134 and van Leusen imidazole synthesis. 109-113 
In Wallach imidazole synthesis, the N, N-dimethyloxamide 15 is heated in the presence of 
phosphorus pentachloride (PCl5) to give a chlorinated N-methyl-imidazole 16, which then 
undergoes reduction using hydroiodic acid (HI) to afford N-methyl-imidazole 17 (Scheme 1.5). 
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Scheme 1.5:  Wallach imidazole synthesis 
 
In Markwald synthesis,135 an α-amino ketone or aldehyde 18 is treated with potassium 
thiocyanate to give 2-thiol-substituted-imidazoles 19, followed by removal of sulfur under 
oxidative conditions to yield the desired imidazoles 20 as shown in Scheme 1.6. 
 
H2N
O
N
H
H
N
R
SH
N
H
N
18 19 20
R
R
KSCN
R
[O]
R
R
 
 
Scheme 1.6: Markwald imidazole synthesis. 
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In Debus imidazole reaction, 134  formaldehyde 21 is reacted with glyoxal; 1,2-diketones or 
ketoaldehydes 22 in ammonia to afford imidazole derivatives 23 as illustrated in Scheme 1.7.  
Even though this reaction is still employed towards generation of the C-substituted imidazoles, 
the relatively low yield of the products is a major drawback.  
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Scheme 1.7: Debus imidazole synthesis 
 
TosMIC 1 has been used as a synthon to generate mono-di and/or tri-substituted 1H-imidazoles.  
A typical method that employs TosMIC 1 as a starting building block is known as the van Leusen 
imidazole synthesis.110   In this protocol, TosMIC 1 reacts with aldimines or Schiff base 24 using 
catalytic base such as potassium carbonate (K2CO3), potassium tert-butoxide (
tBuOK) or sodium 
hydride (NaH) in the presence of aprotic solvent to furnish 1,5-disubstituted-1H-imidazoles 14 
(Scheme 1.8).  This reaction was later expanded to the 3-component van Leusen reaction 
       (3-CvL), in which an aldimine or Schiff base 24 is generated in situ, followed by addition of 
TosMIC to afford the desired 1,5-disubstituted-1H-imidazole derivatives 14.99  As a result of the 
reagents reacting in a stepwise manner; the 3-CvL reaction is not a true multicomponent 
reaction. 
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Scheme 1.8: van Leusen imidazole synthesis. 
 
A possible mechanistic pathway for the above mentioned reaction is illustrated in Scheme 1.9.  
Initially, a base catalyzed deprotonation of one of the α-acidic protons of TosMIC 1 occurs to 
generate an α-carbanion 25.  The carbanion 25 is then involved in the nucleophilic attack on the 
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polarised carbon-nitrogen double bond (–C=N) of the aldimine or Schiff base moiety 24, 
followed by cyclisation to afford a five membered ring (26 and 27), and protonation to form the 
imidazoline intermediate 28.  Elimination of p-toluenesulfinic acid provides the desired 
disubstituted-1H-imidazole products 14. 
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Scheme 1.9: Mechanism of the van Leusen imidazole synthesis. 
 
In the past decade, aryl-substituted TosMIC analogues 10 have been described to react in a single 
pot with polyfuctional imines 24 (generated in situ from aldehyde and primary amine) in the 
presence of K2CO3 in dimethyl formamide (DMF) or aqueous methanol (MeOH) containing 
sodium hydroxide (NaOH) to furnish 1,4,5-trisubstituted-1H-imidazoles 29 (Scheme 1.10). 111 
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Scheme 1.10: Synthesis of 1,4,5-trisubstituted-1H-imidazoles 29. 
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Moreover, TosMIC 1 has been found to undergo [3+2] cyclo-addition reaction with N-[2-(1-
alkylnyl)phenyl)carbodiimides 30 in the presence of cesium carbonate (CS2CO3) in dimethyl 
sulfoxide (DMSO) to achieve the indolyl imidazole scaffolds 31 in good yields (Scheme 1.11).112  
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Scheme 1.11: Indoyl imidazoles synthesis 22. 
 
Furthermore, TosMIC 1 reacts with substituted-trifluoroacetimidoyl chlorides 32 in the presence 
of sodium hydride in THF at room temperature to access 5-(trifluoromethyl)-1-(substituted-
phenyl)-4-tosyl-1H-imidazole derivatives 33 in good yields.  The advantage of this protocol is the 
ability to accommodate both electron donating and withdrawing groups (Scheme 1.12).113 
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Scheme 1.12: Synthesis of imidazole derivatives. 
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1.3.3.2. Oxazoles 
Oxazole 34 is a five membered heterocycle containing both an oxygen and a nitrogen atom at 
the 1- and 3-positions of the ring (Figure 1.12).  This scaffold has been associated with a variety 
of pharmacological activities such as antifungal,136,137 antimicrobial, 138,139,140  anti-HIV 141, and anti-
inflammatory activity.142  Numerous classic methodologies have been reported towards synthesis 
of oxazole and its derivatives; these include the Robinson-Gabriel synthesis,143,144,145  the Fischer 
oxazole synthesis,146,147 and the Van Leusen oxazole reaction.98,108, 114-115  
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Figure 1.12: Structure of 5-substituted-1,3-oxazole. 
 
In the Robinson-Gabriel synthesis, 2-acylaminoketones 35 undergo an intramolecular reaction 
promoted by cyclodehydration reagents (such as concentrated H2SO4, PCl5, POCl3, SOCl2, and 
anhydrous HF), followed by the removal of water to yield 2,5-di- and 2,4,5-trialkyl, aryl- and 
heteroaryl-oxazoles 36 in various yields (Scheme 1.13). 
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Scheme 1.13: Robinson-Gabriel oxazole synthesis. 
 
In the Fischer oxazole synthesis, an aldehyde 37 reacts with cyanohydrins 38 in the presence of 
dry HCl using anhydrous ether as a solvent to give 2,5-disubstituted-1,3-oxazoles 39 as depicted 
in Scheme 1.14.   The major drawback in this protocol is the formation of 2,5-diaryl-4-
oxazolidones and oxazolid-4-ones as side products especially when an aliphatic aldehyde is used 
as a synthon. This problem may be overcome by using thionyl chloride in the reaction mixture.  
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Scheme 1.14: Fischer oxazole synthesis. 
 
In the so-called van Leusen oxazole reaction, TosMIC 1 undergoes a cyclo-addition reaction to 
an aldehyde 37 under basic conditions to furnish 5-monosubtituted-1,3-oxazoles 34 (Scheme 
1.15).98,108, 114-115  
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Scheme 1.15: Synthesis of 5-monosubstituted-1,3-oxazoles. 
 
TosMIC 1 has been reported to react with aryl/heteroaryl substituted-oxazolone scaffolds 40 
catalyzed by copper (I) iodide in the presence of Cs2CO3 in DMF under inert atmospheric 
conditions to give 2,5,4‟-trisubstituted-4,5-bisoxazoles 41 (Scheme 1.16).114  
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Scheme 1.16: Synthesis of bisoxazoles. 
 
1.3.3.3. Pyrroles  
Pyrrole is a five membered hetero-aromatic compound containing one nitrogen atom.  It is an 
essential moiety in organic chemistry due its wide variety of biological properties. 148,149,150,151,152  
An efficient approach for the construction of substituted pyrroles was developed using TosMIC 
1 as a building block.  In the protocol, TosMIC undergoes a Michael addition reaction under 
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basic conditions to the acceptor substituted alkenes 42, followed by ring closure between the 
isocyano group and enolate carbon and then aromatisation via elimination of the tosyl group to 
afford the pyrroles 43 in reasonable yields (Scheme 1.17).116-118  This transformation is carried 
out in the presence of a base such as DBU, NaOH, NaH or tBuOK using solvents such as 
ethanol (EtOH), THF, isopropyl alcohol (iPrOH) or DMF. 
 
S
O
O
N
C
+
R R'
R''
     NC    =
     Ph 
     2,3-diClPh 
     MeO2C
     4-OMePh
= CO2Et
    NC
 = H
    NO2 
    CO2H
    CO2Et
Base, Solvent
N
H
R
R'
1 42 43
 
 
Scheme 1.17: Reaction of TosMIC with Michael acceptor alkenes. 
 
In addition, TosMIC 1 also has been described to react with Michael acceptor alkynes 44 in the 
presence of base to afford 2-tosylpyrrole derivatives 45 (Scheme 1.18). 153 
 
S
O
O
N
C
1
+ CO2RRO2C
N
N
(cat.)
S
O
O
N
RO2C
CO2R
rt, 2 h
30
31
 
Scheme 1.18: Reaction of TosMIC with Michael acceptor alkynes. 
 
1.3.3. Synthesis of six membered rings 
In recent years, TosMIC 1 has been used in the preparation of six-membered nitrogen-
containing heterocycles.  For instance, Zhou and co-workers119 have described the preparation of 
functionalised quinolinones 46 through tandem cyclo-addition of TosMIC 1 to N-(2-
haloaryl)propionamide 47 under copper (I) iodide catalyzed reaction conditions using Cs2CO3 in 
DMF as illustrated in Scheme 1.19.  
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Scheme 1.19: Synthesis of quinolinone derivatives using TosMIC. 
 
Ni and co-workers120 have illustrated the construction of six membered anti-malarial 
marinoquinolines using TosMIC 1 as the starting synthon.  In their protocol, the α-acidic carbon 
of TosMIC 1 reacts with the α,β-unsaturated ester acrylate derivatives 48 under basic conditions 
to form ethyl 4-(2-acetamidoaryl)-1H-pyrrole-3-carboxylate intermediates 49, which are then 
subsequently cyclized upon treatment with POCl3 in MeCN to afford the desired 
marinoquinoline 50 (Scheme 1.20).  
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Scheme 1.20: Synthesis of marinoquinoline 50 from TosMIC. 
 
Coppola and co-workers have also detailed the involvement of the α-acidity of TosMIC towards 
construction of the anti-proliferative natural alkaloid variolin B.  In their reaction, methyl 4-
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methoxy-2-methyl-1H-pyrrolo[2,3-b]pyridine-1-carboxylate 51 reacts with N-bromosuccinimide 
(NBS) in DCM to give 3-bromo-2-(bromomethyl)-4-methoxypyrrolo[2,3-b]pyridine 52, which 
when treated with TosMIC under basic conditions generated 7-carboxylated-pyrido [2,3, 
4,5]pyrrolo[1,2-c]pyrimidine derivatives 53 (Scheme 1.21).121 
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Scheme 1.21: Involvement of TosMIC towards synthesis of Variolin B. 
 
1.3.4. TosMIC and Baylis-Hillman adducts 
Over the past decade, the reaction of TosMIC with Baylis- Hillman adducts has been explored.  
In 2010, Yadav and co-workers  described the reaction of TosMIC 1 with Morita-Baylis-Hillman 
acetates 55 through Sn2 allylic nucleophilic substitution catalysed by BF3.OEt under mild 
conditions to provide ethyl 2-[(tosylmethylcarbamoyl)methyl]-3-phenylacrylate derivatives 56 in 
high yields (Scheme 1.22). 106  This protocol has been found to furnish the products as a mixture 
of isomers with high E-selectivity. 
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Scheme 1.22: Reaction of TosMIC with Morita-Baylis-Hillman acetates. 
 
Garima et al. in 2011 reported an expansion of the methodology developed by Yadav described 
above.  In their approach, TosMIC directly sulfonylated Baylis-Hillman alcohols 57 using a 
Brønsted acidic ionic liquid, 1-butyl-3-methylimidazolium hydrogen sulfate {[Hmim]HSO4} as a 
promoter of reaction to give the corresponding 3-phenyl-2-(tosylmethyl)acrylonitrile products 58 
in good yields (Scheme 1.23).122 
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Scheme 1.23: Reaction of TosMIC with Baylis-Hillman alcohol. 
 
1.3.5. TosMIC in multicomponent reactions 
TosMIC has also been exploited in multi-component reaction strategies.  For example, Krishna 
and co-workers reported the contribution of TosMIC in 3-component diastereoselective 
Passerini reactions.  In this protocol, TosMIC 1 is reacted with organic acids 59 (such as benzoic 
acid, 1,2,3,4-di-O-isopropylidene-α-D-galacturonic acids) and sugar-derived aldehydes 60 in the 
presence of DCM to afford diverse mandelamide products 61 in moderate to good yields (Scheme 
1.24).123 
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Scheme 1.24: TosMIC in 3-component diastereoselective Passerini reactions. 
 
1.4. The Chemistry: Aryl isocyanides  
Aryl isocyanide is one of the building blocks reported to be valuable in the construction of 
nitrogen-containing compounds in organic chemistry. 154,155 Subsequently, aryl isocyanides have 
also attracted interest in coordination and organometallic chemistry, owing to the probability of 
partial delocalization of electron density into the aromatic rings.156 Unlike TosMIC, aryl 
isocyanides lack the hydrocarbon substituent adjacent to the isocyanide group, which affects 
their stability under ambient conditions. 157,158  
 
1.4.1. Preparation of aryl isocyanides  
There are numerous synthetic methodologies that have been established for the preparation of 
aryl isocyanides. These include protocols such as dehydration of aryl formamide, 159  Hoffmann 
carbylamine reaction160 and deprotonation of aryl imidates,161 just to mention a few.  
 
1.4.1.1. Dehydration of aryl formamide 
Dehydration of aryl formamide is a most useful method for preparing the aryl isocyanide. In this 
approach, aryl formamide 62 reacts with a dehydrating agent in the presence of a base in organic 
solvent to give aryl isocyanides 63 (Scheme 1.25).159 The most commonly employed combination 
of dehydration agent and base for the formation of isocyanide is POCl3 and triethylamine. 
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Another combination such as secondary amine with PCl5, P2O3 or PPh3 and PPh3/CCl4/Et3N 
has also been reported. 162 
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Scheme 1.25: Dehydration of aryl formamide. 
 
1.4.1.2. Hoffmann carbylamine reaction 
In the Hoffmann carbylamine reaction, the primary aryl amine 64 is treated with an aqueous 
solution of potassium hydroxide/chloroform (KOH/CHCl3) to afford the corresponding aryl 
isocyanide 63 in moderate yields (Scheme 1.26).163 
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Scheme 1.26: The Hoffmann carbylamine synthesis of aryl isocyanide. 
 
1.4.1.3. Deprotonation of aryl imidates  
The preparation of aryl isocyanides has also been reported by Pornet and Miginiac.161 In their 
protocol, aryl imidate ethers 65 are treated with magnesium diisopropylamide to give the 
corresponding aryl isocyanides 63 in reasonable yields (Scheme 1.27). In the extension of this 
method, disubstituted aryl imidate ethers are reacted with lithium dialkylamides to furnish the 
corresponding disubstituted aryl isocyanide in excellent yields. 
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Scheme 1.27: The Hoffmann carbylamines synthesis of aryl isocyanide. 
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The aryl isocyanides are very reactive and their utility as valuable reagents has been demonstrated 
in several synthetic transformations such as synthesis of isoxazoles and benzimidazoles. 164 
 
1.4.2. Isoxazoles 
Isoxazole is a five-membered heterocyclic compound containing an oxygen atom adjacent to the 
nitrogen atom. Compounds containing the isoxazole moiety have been found to possess a broad 
range of properties including anti-inflammatory,165,166,167 anticancer168,169 and antibacterial 
activities.170,171,172,173 A few approved drugs (like valdecoxib, dicloxacillin and flucoxacillin) and 
natural drugs (such as ibotenic acid) with the isoxazole motif are given in Figure 1.13.174 
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Figure 1.13: Structure of compounds containing isoxazole. 
 
In view of the emerging importance of the isoxazole ring system, several synthetic protocols 
have been established to access this privileged scaffold.  These methods include cyclo-
isomerization of α,β-acetylenic oximes catalysed by AuCl3,
175 an alkynyliodide cycloaddition 
strategy176 and  reaction of the 2-haloacetophenoneoxime with aryl isocyanide164 to mention a 
few.  
 
Praveen et al. synthesized 3-substituted, 5-substituted or 3,5-disubstituted-isoxazoles 67 in very 
good yields by the cyclo-isomerization of α,β-acetylenic oximes 66 in the presence of AuCl3 
catalyst in DCM under moderate reaction conditions (Scheme 1.28).
175  
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Scheme 1.28: Synthesis of isoxazole using AuCl3 catalyst. 
 
Crossley and Browne176 described a regio-selective synthesis of iodoisoxazoles 70 in excellent 
yields through cycloaddition of alkynyliodide 68 to nitrile oxides 69 in the presence of 0.25 M aq. 
Na2CO3 using DME as solvent under heating for 24 hours as shown in Scheme 1.29.
  
 
N
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Scheme 1.29: Synthesis of iodoisoxazoles using an alkynyliodide cycloaddition strategy. 
 
Buron and co-workers164 reported the synthesis of 5-amino-3-isoxazole derivatives 73 from 
reaction of isocyanide 72 with 2-bromo-ketone oximes 71 in the presence of sodium carbonate 
in DCM under mild conditions (Scheme 1.30). Reasonable yields were obtained when the 
electron deficient ketone oximes such as ethyl bromo-pyruvate oxime and trifluoromethyl-
substituted oxime were used. 
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Scheme 1.30:  Synthesis of 5-amino-3-substituted isoxazole from isocyanides. 
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2. Project strategy and Aims  
The five-membered nitrogen-containing heterocycles have attracted a great deal of interest over 
the years as useful building blocks for drug discovery platforms. Their aromatic character 
contributes to their wide variety of biological properties and as a result they have functioned as a 
privileged core of several compounds inhibiting various stages of the HIV-1 replication cycle 
(Figure 1.14). For example; capravirine177 (Figure 1.14) which contains the imidazole scaffold has 
been described as a non-nucleoside HIV-1 reverse transcriptase inhibitor with a unique 
resistance mode of action, while a series of 2-methyl-5-nitroimidazole-based analogues 
(DAMNI)178,179 with the imidazole motif are known to inhibit the HIV-1 reverse transcriptase 
(RT) enzyme at submicromolar concentrations. 
 Furthermore, another set of imidazole containing compounds known as 5-carbonyl-1H-
imidazole-4-carboxamide derivatives180 were established as a class of potential inhibitors that 
could disrupt the formation of the HIV-1 integrase-LEDGF/p75 interaction complex.  
Ritonavir, 181 which contains a thiazole moiety, is an HIV-1 protease inhibitor that is now used 
clinically as a pharmacokinetic inhibitor to constrain cytochrome P540 metabolism of other 
HIV-1 protease inhibitors. Moreover, a class of isoxazole sulfonamide derivatives182 has been 
found to inhibit HIV-1 infection in human CD4+ lymphocytic T cells. 
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Figure 1.14: Structural formulae of some clinically used compounds containing five-membered 
nitrogen heterocycles. 
 
The fragment screening approach has emerged as an important approach in drug discovery, 
where it is used as a starting point to identify valuable hits against a new target. The screening of 
small fragment collections with low molecular weight presented medicinal chemists with an 
effective starting point for synthetic optimization of hit candidates. Our laboratory has focused 
its research activities on the synthesis and screening of five membered nitrogen-containing 
heterocyclic fragments, in order to identify hits that exhibit the ability to interrupt the HIV-1-
host protein-protein interactions.  Virtual screening is a useful tool to identify promising 
scaffolds as the starting point for designing and synthesizing potentially active compounds for a 
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specific target. The huge number of possible compounds is reduced using a computerized system 
to a more convenient number of compounds for synthesis and screening in a biochemical assay 
against the relevant biological targets, which could lead to possible drug contenders.183,184  Thus, 
we undertook preliminary virtual screening of the pepMMsMIMIC database using a BST-2 
template (PDB code: 2LK9) for querying purposes and identified candidate molecules containing 
heterocyclic systems such as benzimidazole and benzoxazole scaffolds (Figure 1.15, see Appendix 
A).185 This prompted us to commence our research efforts by exploring the synthesis of 5-aryl-
imidazoles and 5-aryl-oxazoles as simplified versions of these benzimidazole and benzoxazole 
scaffolds (Figure 1.15). The introduction of structural diversity at several positions on these 
heterocyclic systems could allow for the possible development of a new series of compound 
displaying interesting biological activity.  
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Figure 1.15: Nitrogen heterocyclic scaffolds of interest. 
 
The established versatility and great potential of isocyanide chemistry led us to consider 
employing in the synthesis of five membered nitrogen-containing heterocyclic fragments. We 
hypothesized that isocyanide synthons such as TosMIC and aryl isocyanides could be used to 
synthesise small libraries of  five membered nitrogen-containing heterocyclic compounds. These 
compounds could then be assessed as possible inhibitors of  HIV-1 protein -protein interactions. 
Biological assays of these libraries could identify templates to design and synthesise the second 
generation of  compounds. The current research project was achieved through the 
accomplishment of the following specific objectives: 
 
1. Application of TosMIC towards the generation of a small library of 1-substituted-5-aryl-
1H-imidazole compounds and biological evaluation as possible HIV-1 inhibitors. 
2. Synthesis of aryl-1,3-oxazole derivatives by means of microwave assisted van Leusen 
reaction and their biological evaluation as possible HIV-1 inhibitors.  
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3. Incorporation of simple amino acids into the imidazole scaffold using the van Leusen 
reaction to generate a library of imidazo-1-yl-based derivatives and their elaboration as 
possible HIV-1 agents. 
4. Synthesis of 3-aryl-N-arylisoxazol-5-amine scaffolds using aryl isocyanides and their 
usefulness as building blocks for possible inhibitors of HIV-1 protein- host protein 
interactions. 
5. Evaluation of the antimicrobial effects of the synthesized five membered nitrogen 
hetereocyle containing libraries of compounds. 
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CHAPTER 2 
Application of TosMIC towards the synthesis of a small library of 
imidazole-based compounds and biological evaluation as possible 
inhibitors of HIV-1 protein-protein interactions 
 
2.1. Introduction  
In line with our project objectives defined in Chapter 1, the synthesis of a small library of 
substituted-imidazoles using isocyanide chemistry was undertaken with the intention of 
producing viable hits that could be used as templates to design drug-like molecules to target 
protein-protein interactions. Thus the current chapter is concerned with the preparation of a 
small library of 1-substituted-5-aryl-1H-imidazole scaffolds using TosMIC, and their assessment 
as potential disruptors of the interactions between the HIV-1 IN and host LEDGF/p75 
proteins. Synthetic hurdles, isolation, characterization, yields and plausible mechanisms are 
described. 
 
2.2. Synthesis of 1-substituted-5-aryl-1H-imidazole derivatives using a van Leusen 
reaction  
The van Leusen imidazole reaction is well-documented.99,186   It involves the cycloaddition of the 
α-acidic centre of TosMIC 1 to the imine double bond motif 24 to afford 1,5-disubstituted-1H-
imidazoles 14, promoted by a catalytic base (see Scheme 1.8, Chapter 1).  In this study, the initial 
challenge was to synthesize imine building blocks as van Leusen intermediates. Imines contain 
the moiety R-C=N-R‟, with the nitrogen atom linked to either an aryl (Schiff bases) or alkyl 
moiety.187  These carbon-nitrogen double bond containing scaffolds are routinely prepared by 
condensation of a primary amine with an aldehyde or ketone in a given solvent and/or with a 
drying agent (to drive the reaction), generating aldimines or ketimines respectively.188,189,190 The 
synthesis began by making use of readily available benzaldehydes 7a-g and primary amines 74a-c 
to produce N-(arylidene)alkylamine building blocks (azomethines) as van Leusen intermediates. 
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2.2.1. Synthesis of the key N-(arylidene)alkylamine intermediates 
 
 
Scheme 2.1: Synthesis of N-(arylidene)alkylamines. 
 
A series of benzaldehydes 7a-g was reacted with primary amines 74a-c (n-butyl-, cyclohexyl- and 
cyclopropyl-amines) in the presence of MgSO4 in dichloromethane at room temperature for 16 
hours affording N-(arylidene)alkylamine products 75-78 as outlined in Scheme 2.1 (Method 
A).190,191  The product yields were obtained in a 72- 96% range (Table 2.1), and were comparable 
to values reported in literature. 192,193,194,195 The products did not require further chromatographic 
purification. The use of microwave irradiation in organic synthesis has proven to significantly 
decrease reaction times and increase yields.196,197,198 Therefore, selected benzaldehydes 7a-i and 
primary amines 74a-b and d were microwave irradiated neat, at a set temperature of 60oC 
(Scheme 2.1, method B).  Remarkably, the desired N-(arylidene)alkylamine products 75a-f, 75h-
i, 76a-f, 76h-i, and 78a-e were obtained in just 4 minutes in yields ranging from 73-100% (Table 
2.1). Therefore, method B constitutes an improvement over published procedures,192,193 the use 
of microwave irradiation not only increases the reaction rate but also improves the already good 
yields obtained (Table 2.1).   
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Table 2.1: Comparative yields of the synthesized N-(arylidene)alkylamines. 
R
N
R'
 
Compound 
Entry 
R R' Conventional 
Yield (%) 
Microwave  
Yield 
75a 4-F n-butyl 87 98 
75b 2-Cl n-butyl 94 99 
75c 3-OMe n-butyl - 97 
75d 2,4-diOMe n-butyl 84 98 
75e 3,4-OCH2O- n-butyl 96 100 
75f 4-tert-butyl n-butyl 84 93 
75g 3,4-OCH2CH2O n-butyl 84 - 
75h 2-NO2 n-butyl - 73 
75i 4-NO2 n-butyl - 91 
76a 4-F cyclohexyl 85 88 
76b 2-Cl cyclohexyl 86 89 
76c 3-OMe cyclohexyl 71 88 
76d 2,4-diOMe cyclohexyl 81 99 
76e 3,4-OCH2O cyclohexyl 90 97 
76f 4-tert-butyl cyclohexyl 93 99 
76h 2-NO2 cyclohexyl - 95 
76i 4-NO2 cyclohexyl - 91 
77a 4-F cyclopropyl 77 - 
77c 3-OMe cyclopropyl 92 - 
77d 2,4-diOMe cyclopropyl 87  
78a 4-F benzyl - 92 
78b 2-Cl benzyl  93 
78c 3-OMe benzyl - 98 
78d 2,4-diOMe benzyl - 90 
78e 3,4-OCH2O benzyl - 95 
- = reaction not performed 
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The identity of N-(arylidene)alkylamine products 75-78 was confirmed by NMR spectroscopic 
analysis and the data was consistent with that of the expected chemical structures as described in 
the literature.195,199,200,201,202,203  The key changes are mainly observed in the chemical shifts of the 
substituents attached to the nitrogen atom and the aryl ring.  A unique feature in the 1H NMR 
spectra of these products 75-78 was the presence of a methine proton double bonded to a 
nitrogen atom which resonates as a singlet in the region of δ 8.0 ppm to 8.9 ppm while their 13C 
NMR spectra showed the methine carbon atom double bonded to a nitrogen atom in the region 
of δ 154-161 ppm.  
The 13C NMR spectra of the fluorinated N-(arylidene)alkylamines 75a, 76a, 77a and 78a show 
the corresponding aryl signal splitting due to fluorine coupling, i.e. for compound 75a, the para-C 
of the phenyl ring resonates at ca. δ 164.1 ppm with a 1JF,C coupling constant of 250 Hz, whilst 
the carbon atom at position-1 on the aryl ring appears at δ 132.6 ppm with a 4J F,C value of 3 Hz. 
The ortho-carbon resonates at δ 129.8 ppm with a 3J F,C of 9 Hz, whereas the meta-carbon atom at 
δ 115.5 ppm splits with a 2J F,C coupling constant of 22 Hz. 
 
2.2.2. The van Leusen approach towards the synthesis of 1-substituted-5-aryl-1H-
imidazoles  
The cycloaddition of TosMIC 1 to synthesized N-(arylidene)alkylamines was then carried out 
using both conventional, stepwise microwave-assisted van Leusen reaction, as well as the so-
called 3-component van Leusen reaction (3-CvL) under microwave irradiation. The reactions 
were monitored by thin layer chromatography (TLC).  
 
2.2.2.1. Stepwise cycloaddition of TosMIC to N-(arylidene)alkylamines 
2.2.2.1.1. Synthesis of 1-substituted-5-aryl-1H-imidazoles using conventional van Leusen 
reaction  
Initially efforts were directed towards the use of the van Leusen imidazole synthesis using 
conventional methods. A series of selected N-(arylidene)alkylamines 75a-g, 76a-f, 77a, 77c-d 
and 78a, 78c-e, with TosMIC 1 in the presence of K2CO3 were refluxed in dry acetonitrile under 
inert conditions for 72 hours as shown in Scheme 2.2 (Route 1, method C).  Work up and 
purification of the crude brown materials by column chromatography afforded the 
corresponding pure 1-substituted-5-aryl-1H-imidazoles 79a-g; 80a-f, 81a; 81c-d; 82a and 82c-e 
in yields ranging from 20-80% (see Table 2.2).  
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75 R'= n-butyl
76 R'= cyclohexyl
77 R'= cyclopropyl
78 R'= CH2Ph
Method C    TosMIC,  K2CO3, MeCN,
                     Reflux, 72 h, inert atm
Method D    TosMIC, K2CO3, MeCN,
                     MW: 120W, 90oC, 7 h, inert atm
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74g R'= 2.4-diFPhenyl
74h R'= 2,4-diBrPhenyl
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Scheme 2.2: Synthesis of 1-substituted-5-aryl-1H-imidazoles by the van Leusen approach. 
 
Although the desired imidazole products were successfully obtained, the major drawbacks for 
the method are the long reaction times and low yields obtained for some of the imidazole 
derivatives. 
 
2.2.2.1.2. Microwave-assisted synthesis of 1-substituted-5-aryl-1H-imidazoles using van 
Leusen reaction 
Aiming to improve the reaction times for their synthesis, the synthesis of these scaffolds under 
microwave irradiation was investigated. TosMIC 1, N-(arylidene)alkylamines (75a-f, 76a-f, 77a, 
c-d and 78a, c-e) and K2CO3 in dry acetonitrile under inert conditions were microwave 
irradiated at 90oC and 120 Watts for 7 hours (Scheme 2.2, Route 1, method D). Work up and 
separation by column chromatography successfully afforded the corresponding imidazole 
products 79a-f, 80a-f, 81a, c-d and 82a, c-e in yields ranging from 23% to 87% (see Table 2.2).  
Although yields did not dramatically improve, reaction times were shortened 10-fold.  
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Table 2.2: Isolated yields (%) of the 1-substituted-5-aryl-1H-imidazole derivatives. 
1
N
2
3
N4
5
R'
R  
Substrate R R’ Method C 
yields (%) 
Method D Yields (%) 
79a 4-F n-Butyl 38 55 
79b 2-Cl n-Butyl 20 26 
79c 3-OMe n-Butyl - 60 
79d 2,4-diOMe n-Butyl 80 87 
79e 3,4-OCH2O- n-Butyl 43 48 
79f 4-t-Butyl n-Butyl 44 52 
79g 3,4-OCH2CH2O- n-Butyl 54 - 
80a 4-F Cyclohexyl 46 51 
80b 2-Cl Cyclohexyl 23 29 
80c 3-OMe Cyclohexyl 47 53 
80d 2,4-diOMe Cyclohexyl 64 74 
80e 3,4-OCH2O- Cyclohexyl 35 54 
80f 4-t-Butyl Cyclohexyl 29 50 
81a 4-F Cyclopropyl - 23 
81c 3-OMe Cyclopropyl - 40 
81d 2,4-diOMe Cyclopropyl - 68 
82a 4-F CH2Ph - 26 
82c 3-OMe CH2Ph - 24 
82d 2,4-diOMe CH2Ph - 74 
82e 3,4-OCH2O- CH2Ph - 22 
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2.2.2.2. Synthesis of 1-substituted-5-aryl-1H-imidazoles using three component van 
Leusen approach (3-cvL)  
2.2.2.2.1. 3-CvL Synthesis in MeCN 
The synthesis of 1-substituted-5-aryl-1H-imidazole derivatives was also carried out using the so-
called three component van Leusen approach (3-CvL).  A series of selected benzaldehydes 7d-e 
and aliphatic amines 74a and 74b were reacted neat using microwave irradiation (for 4 minutes at 
60oC), followed by the addition of TosMIC 1, K2CO3 and MeCN to further irradiate at a set 
power of 120 Watts and a temperature of 90oC for 7 hours under inert conditions (Scheme 2.2, 
Route 2, method E).  Work up and chromatographic purification on silica gel gave rise to the 
desired 1-substituted-5-aryl-1H-imidazoles 79d-e, and 80d-e in yields similar to those obtained 
in the stepwise manner, therefore rendering the isolation of N-(arylidene)alkylamine 
intermediates unnecessary (Table 2.3).  
 
Imidazoles derived from aryl amines were also readily prepared in a two-step one pot reaction by 
neat irradiation of substituted benzaldehydes 7a, d-e and 4-bromoaniline 74e, followed by 
addition of TosMIC 1, K2CO3 and acetonitrile (Scheme 2.2, Route 2, method E).  The crude 
reaction mixtures were then subjected to the microwave conditions described above to give the 
corresponding 1H-imidazole derivatives 83a, d-e in yields ranging from 38-68% (see Table 2.3). In 
comparison with the N-aliphatic 4-fluorophenyl derivatives 79a, 80a, 81a and 82a, the N-
aromatic imidazole 83a was obtained in higher yield (68%), whilst the 1-(4-bromophenyl)-5-(2,4-
dimethoxyphenyl)-1H-imidazole 83d gave the lowest yield (38%).  Any attempts to synthesize 
1H-imidazoles derived from anilines with dihalide substituents at the ortho- and para-positions 
(74f, 74g and 74h) of the aryl ring were unsuccessful. Only reaction of the monosubstituted-
aniline 74e proceeded smoothly under the conditions described. This can be attributed to the 
fact that the two electron-withdrawing halides cause a decrease in the nucleophilicity of the 
aniline NH2.  
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Table 2.3: Isolated yields (%) of the 1-substituted-5-aryl-1H-imidazole products obtained from 
3-CvL in MeCN. 
1
N
2
3
N4
5
R'
R  
Substrate R R’ 
Method E 
Yields (%) 
79d 2,4-diOMe n-Butyl 81 
79e 3,4-OCH2O- n-Butyl 55 
80d 2,4-diOMe Cyclohexyl 73 
80e 3,4-OCH2O- Cyclohexyl 50 
83a 4-F 4-BrPhenyl 68 
83d 2,4-diOMe 4-BrPhenyl 38 
83e 3,4-OCH2O- 4-BrPhenyl 62 
 
 
2.2.2.2.2. 3-CvL Synthesis in MeOH 
Most of the conventional van Leusen imidazole reactions are reported to employ a protic solvent 
such as methanol.99 We conducted the one pot 3-CvL reaction in methanol under microwave 
irradiation in order to assess the effect of solvent on the reaction yields, as per the conditions 
illustrated in Scheme 2.3.  
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7d R= 2,4-dioMe
Method F i. MW:60oC
                ii.  TosMIC, K2CO3, MeOH
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                      inert atm
H2N
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N OMe
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Scheme 2.3: The 3-cvL imidazole synthesis in MeOH under MW irradiation. 
 
According to NMR spectroscopic analysis, two additional unknown compounds were observed 
in the reactions giving 1-substituted-5-aryl-1H-imidazoles 80a, 80d and 80e. These compounds 
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were UV inactive (at 254 nm) but co-eluted with the products during purification. The 1H NMR 
spectrum in Figure 2.1 of the mixture of compound 80d with the unknown compounds revealed 
the presence of two singlets at 3.30 and 3.34 ppm which could be later assigned to two methoxy 
groups, while two doublets at 4.58 ppm (with J = 6.8 Hz) and 4.70 ppm (with 7.2 Hz) were 
assigned to methylene protons, and signals {a doublet ( J = 11.6 Hz) and a singlet} at 8.17 and 
8.30 ppm were assigned to N=CH groups, suggesting the presence of possible geometric 
isomers (E- and Z-) of OH-CH2-N=CH(OMe) 84.  The isomer ratio obtained varies with the 
substitution on the reacting aldehyde aryl group. For example for 1H-imidazoles 80a, 80c and 
80d 1H  NMR spectra show ratios of isomers to imidazole (isomer 1: isomer 2: product) of 1: 
1.7:1; 1:1.7:1.6 and 1:1.5:11 respectively.  Further attempts to separate the mixture by 
chromatographic elution with different solvents in different ratios, aided by visualization of TLC 
plates under different revealing reagents was unsuccessful.  
 
 
 
Figure 2.1: 1H NMR spectrum with trace of 80d and suspected (E- and Z-) 
HOCH2N=CH(OMe) in CDCl3. 
 
 
The unexpected isomeric compounds 84 obtained when the reaction is conducted in MeOH may 
be attributed to the partial decomposition of TosMIC 1 in the presence of the solvent and the 
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base. van Leusen et al..99 isolated three products, one of them MeOCH2N=CH(OMe), from the 
reaction between TosMIC 1 and MeOH only in the presence of K2CO3 as catalyst (at room 
temperature for 20 hours).  
A probable mechanism shown in Scheme 2.4, which is similar to the one proposed by van 
Leusen and co-workers,99 could be offered as an explanation for the formation of compounds 
84.  The initial step is believed to involve the nucleophilic attack by MeO- on the isocyano 
carbon of TosMIC 1 to afford 85, followed by protonation to provide 86.  The water generated 
as a by-product of the van Leusen reaction then displaces the tosyl group through an addition-
elimination reaction to give 84. These results discourage the use of MeOH as solvent in the van 
Leusen synthesis of imidazoles under microwave irradiation, in favour of the use of MeCN as 
the solvent of choice.   
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Scheme 2.4: Suggested mechanism of the decomposition of TosMIC in MeOH.99  
 
Sisko and co-workers111 described the preparation of imidazoles via 3-CvL reaction using 
derivatised TosMIC reagents and surprisingly reported that neither TosMIC nor its alkyl 
derivatives were reactive under the mild conditions in protic solvents using t-BuNH2 or K2CO3 
as a base. In our hands TosMIC has proved to be equally effective under microwave irradiation 
in acetonitrile, in both stepwise and in one pot procedures. A plausible mechanistic pathway of 
the formation of the 1-subtituted-5-aryl-1H-imidazole products has been discussed in Chapter 1 
(Scheme 1.9). 
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2.2.2.3. Effect of the aryl ring substituents on the reaction yield 
The 1-substituted-5-aryl-1H-imidazole fragments were isolated in different yields according to 
the nature of the functional groups present on the aryl aldehyde. The highest yields of the series 
(independent of the energy source applied), were obtained when both the ortho- and para-
positions of the aryl ring were occupied by the electron donating methoxy groups (79d, 80d and 
81d), while on the other hand, the presence of an electron withdrawing bulky chlorine atom in 
the ortho-position gave the lowest yields in the series (79b and 80b).  To determine the influence 
of the substituents on the yield obtained, N-(arylidene)alkylamine intermediates 75h-i and 76h-i 
bearing an electron-withdrawing NO2 group were subjected to the conditions described in 
Scheme 2.2 (Route 1, method D) and afforded 1-substituted-nitrophenyl-1H-imidazoles 79h-i 
and 80h-i in even lower yields than their chlorine counterparts 79b and 80b (10-15%). The poor 
overall yields for the imidazoles could then be attributed to the electron-withdrawing effect of 
the nitro and chlorine substituents, confirming that the van Leusen reaction does not perform 
well in the presence of these groups on the benzaldehyde ring. 
 
2.2.2.4. Structure elucidation of the van Leusen products 79-83 by FTIR, NMR and 
HRMS techniques 
Examination of FTIR, 1-D and 2-D NMR spectra of the pure products was used to characterize 
and confirm the structures of obtained compounds 79-83. The FTIR spectra of these products 
showed the C-H adsorption bands in the 2860 cm-1 to 3130 cm-1 regions, whilst the C=C 
stretching band appears at a range of 1614 cm-1 to 1675 cm-1. The absorption bands in the 1434 -
1489 cm-1 region were assigned to C-N stretching modes of the imidazole motif.  The 1H NMR 
spectra of compounds 79-83 exhibited two singlet signals in the region of δ 7.4-7.7 ppm and δ 
6.8-7.2 ppm corresponding to the two methine protons of the imidazole moiety. In the 13C NMR 
spectra, the methine carbon atoms of the imidazole motif displayed two characteristics signals at 
δ 134-138 ppm and δ 127-128 ppm. 
Electrospray-ionisation Liquid Chromatography Mass Spectrometry (ESI-LCMS) was used to 
confirm preparation of the scaffolds 79-83. Chromatograms exhibited a single peak 
corresponding to their protonated parent molecular ion [M+1]+ (a UV-vis detector was used in 
parallel with the mass detection). By way of example, compounds 79d, 80b, 80d, 81d with 
molecular formulae C15H21N2O2, C15H18ClN2, C17H23N2O2 and C14H17N2O2, respectively, showed 
parent molecular ion peaks [M+1]+ at m/z 261.1587, 261.1155, 287.1770 and 245.1290, which 
correspond well with the theoretical calculated values for their formulae(Table 2.4). More 
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importantly, these compounds showed an acceptable tolerance of isotopic pattern fit factor 
(mSigma) lower than 20 (the lower the mSigma value the better the match) as shown in Table 2.4. 
 
Table 2.4: HRMS results of the 1-substituted-5-aryl-1H-imidazoles compounds and their 
mSigma values. 
Compds 
Measured 
(m/z) 
Formula 
[M+1]+ 
Theoretical 
(m/z) 
Err 
[mDa] 
Err 
[ppm] 
mSigma 
79a 219.1294 C13H16FN2 219.1292 -0.2 -0.9 0.8 
79b 235.1002 C13H16ClN2 235.0995 -0.7 -2.5 19.4 
79c 231.1498 C14H19N2O 231.1492 -0.6 -2.4 3.3 
79d 261.1587 C15H21N2O2 261.1598 1.1 3.9 1.4 
79e 245.1276 C14H17N2O2 235.1285 0.9 3.5 5.3 
79f 257.2008 C17H25N2 257.2012 0.4 1.6 5.2 
79g 259.1434 C15H19N2O2 259.1441 0.7 2.7 4.7 
79h 246.1240 C13H16N3O3 246.1237 -0.3 -0.2 7.5 
78i 246.1238 C13H16N3O3 246.1237 -0.1 -3.0 7.2 
80a 245.1475 C15H18FN2 245.1449 -2.7 -10.8 19.3 
80b 261.1155 C15H18ClN2 261.1153 -0.8 -0.2 3.1 
80c 257.1668 C16H21N2O 257.1648 -1.9 -7.4 10.4 
80d 287.1770 C17H23N2O2 287.1754 -1.6 -5.4 2.1 
80e 271.1464 C16H19N2O2 271.1481 1.8 6.5 6.5 
80f 283.2190 C19H27N2 283.2162 -2.1 -7.5 17.2 
80h 272.1393 C15H18N3O2 272.1394 1.1 4.2 13.8 
80i 272.1382 C15H18N3O2 272.1394 1.2 0.2 13.8 
81a 203.0974 C12H12FN2 203.0979 0.5 2.4 2.8 
81c 215.1188 C13H15N2O 215.1179 -0.9 -4.3 7.5 
81d 245.1290 C14H17N2O2 245.1285 -0.5 -2.3 3.3 
82a 253.1138 C16H14FN2 253.1136 -0.3 -1.1 17.2 
82c 265.1329 C17H17N2O 265.1335 0.6 2.3 8.6 
82d 295.1408 C18H19N2O2 295.1441 3.3 11.1 3.9 
82e 279.1143 C17H15N2O2 279.1128 -1.5 -5.4 13.2 
83a 317.0115 C15H1179BrFN2 317.0090 -2.5 -7.9 4.9 
83d 359.0394 C17H1679BrN2O2 359.0395 0.1 0.2 4.8 
83e 343.0099 C16H1279BrN2O2 343.0082 -1.7 -5.2 10.5 
 
Overall, a total of twenty seven 1-substituted-5-aryl-1H-imidazole compounds were synthesized 
from the van Leusen imidazole reaction described above and 26 compounds are, to the best of 
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our knowledge, novel (only 82e was previously reported but it was prepared using sodium 
cyanide in aprotic solvent under heating at 137°C for 16 h).204  The synthesized imidazole based 
compounds 79-83 were submitted for biological evaluation. 
 
2.2.3. Biological evaluation of library of 1-substituted-5-aryl-1H-imidazole derivatives 
The compounds 79-83 were assessed for their biological activity using two HIV-1 protein 
inhibition assays; namely HIV-1 IN - LEDGF/p75 inhibition, and the HIV-1 Vpu binding 
assays, in the hope of identifying viable hits which could be further developed. The compounds 
were also intended for targeting the interaction between HIV-1 Viral protein U (Vpu) and the 
host Bone Marrow Stroma-antigen-2 (BST-2) protein; however, tests capable of biologically 
evaluating the compounds as HIV-1 Vpu/ BST-2 inhibitors were unavailable at the time of the 
completion of the synthetic work. As a result, this imidazole based family of compounds were 
only assessed using the two HIV-1 inhibition assays mentioned above. The screening of 
compounds was conducted by the Centre of Metal Drug Discovery group (CMDD), Advanced 
Material Division, Mintek (Randburg, South Africa).  Only compounds which exceeded the 50% 
inhibition benchmark were considered for further determination in a dose-response assay for 
determining their half maximum inhibitory concentration (IC50), cellular cytotoxicity (CC50) and 
antiviral activities.  
 
2.2.3.1. Direct HIV- 1 integrase (IN)-LEDGF AlphaScreen assay  
Initially, a set of twenty seven fragments belonging to a family of 1-substituted-5-aryl-1H-
imidazoles were tested using the AlphaScreen ® assay 205 to determine the percentage inhibition 
of the interactions between the HIV integrase (IN)-LEDGF/p75 proteins at a concentration of 
10 µM.  The experiments were carried out in triplicate and average results are presented in Table 
2.5. 
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Table 2.5: The HIV-1 IN-LEDGF/p75 inhibition activities of the 1-substituted-5-aryl-1H-
imidazole compounds 79-83. 
1
N
2
3
N4
5
R
1
N
2
3
N4
5
R
1
N
2
3
N4
5
R
1
N
2
3
N4
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R
1
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3
N4
5
R
Br79 80 81 82 83  
C
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s 
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Biochemical target assays 
 
Cell-based assays (MT-4 cells) 
HIV-1 IN – LEDGF (%) 
inhibition @ 10 µM 
(AlphaScreen)  
HIV-1 IN – 
LEDGF 
inhibition IC50 
(AlphaScreen) 
(µM) 
 
CC50 (µM) 
79a 29.89 ± 2.96   
79b 36.62 ± 1.87   
79c 51.10 ± 0.98 30.35 ± 4.92 29.59 ± 10.94 
79d 25.88 ± 2.73   
79e 34.72 ± 2.73   
79f 55.68 ± 0.85 22.40 ± 1.46 23.93 ± 2.36 
79g 20.72 ± 2.44   
79h 29.72 ± 2.39   
79i 26.59 ± 1.67   
80a 44.65 ± 1.84   
80b 31.33± 1.46   
80c 55.01 ± 2.43 21.94 ± 0.489 27.72 ± 5.44 
80d 39.68 ± 2.14   
80e 37.79 ± 7.70   
80f 61.79 ± 0.53 14.58 ± 0.24 21.77 ± 2.84 
81a 30.86 ± 2.18   
81b 34.82 ± 3.35   
81c 40.22 ± 0.36   
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HIV-1 IN – LEDGF (%) 
inhibition @ 10 µM 
(AlphaScreen)  
HIV-1 IN – 
LEDGF 
inhibition IC50 
(AlphaScreen) 
(µM) 
 
CC50 (µM) 
    
81d 27.66 ± 2.78   
82a 24.68 ± 2.43   
82c 20.82 ± 2.06   
82d 17.03 ± 3.99   
82e 43.20 ± 1.91   
83a 52.41 ± 1.67 25.07 ± 2.47 48.00 ± 12.58 
83c 47.94 ± 4.04   
83d 52.08 ± 0.99 6.99 ± 1.49 55.47 ± 16.25 
CX05168 91.37+-0.85 1.38+-0.29  
HIV-1 IN 
and 
LEDGF/p75  
0   
* IC50 - concentration of compound required to inhibit 50% of the specific biological process 
*CC50 – concentration of compounds that causes 50% reduction of cell growth 
 
Of the twenty six imidazole-based compounds screened, six compounds showed more than 50% 
inhibition at a dose concentration of 10 µM (Figure 2.2). The best inhibitor in the series with 62% 
inhibition and an IC50 value of 15 µM was compound 80f, which contained a cyclohexyl moiety 
at the 1-position of the imidazole core.  The replacement of the cyclohexyl group by an n-butyl 
moiety, (compound 79f) gave rise to a compound with lower inhibitory activity of 56% and an 
IC50 value of 22 µM.  Both 79f and 80f contained a tert-butyl substituent at the para-position of 
the benzene ring attached at the 5-position of the imidazole moiety. The tert-butyl group is likely 
to occupy the hydrophobic pocket of the target protein. Compound 80c, an analogue of 80f, 
containing a methoxy substituent at the meta-position inhibited the protein-protein-interaction by 
55% with an IC50 value of 22 µM, whilst two compounds, 83a and 83d, both with a 4-
bromophenyl group at the 1-postion of the imidazole moiety prevented IN-LEDGF/p75 
interaction by 52% inhibition each.  In dose response assays, 83d with the methoxy substituents 
at the ortho- and para-positions on the 5-aryl ring displayed the best IC50 value (7 µM) in the series, 
while its counterpart with a fluorine atom at the para-position 83a produced an IC50 value of 25 
µM. The lower IC50 value of compound 83d could be attributed to the methoxy group which can 
provide the possibility of hydrogen-bonding interactions with some of the amino acid residues 
 
51 
 
within the binding site, leading to higher binding affinity. Amongst the best six compounds with 
51% inhibitory activity is an analogue of 79f, compound 79c, containing a meta-methoxy 
substituent and with an IC50 value of 30 µM in a dose response assay. Interestingly, another 
analogue of 83a and 83d, compound 83c displayed 48% inhibition.  The data suggest that the 
presence of the 4-bromophenyl at the 1-position of the imidazole motif might be of significance 
for the binding ability of these scaffolds. Attempts to synthesise imidazole derivatives from 
analogue 74f-h were unsuccessful. Other compounds in this family of imidazole-based 
derivatives exhibited only marginal inhibitory activities towards IN - LEDGF/p75 interaction, 
ranging from 17% to 44%.  
To eliminate the possibility of false positive results arising from the compound signal interfering 
with the AlphaScreen assay, the best six compounds, 79c, 79f, 80c, 80f, 83a and 83d (Figure 2.2) 
were subjected to the Truhit counter assay with all six showing true inhibition ability of the 
interaction between the HIV-1 integrase and LEDGF/P75 proteins. 
 
N
N
N
N
           80f
%inhibition = 61.79 ± 0.53%
                 IC50 = 14.58 ± 0.24µM
                CC50 = 21.77 ± 2.84µM
N
N
O
O
N
N
F
Br Br
N
N
O
N
N
O
80c
%inhibition = 55.01 ± 2.43%
                 IC50 = 21.94 ± 0.489µM
                CC50 = 27.72 ± 5.44µM
79f
%inhibition = 55.68 ± 0.85%
                 IC50 = 22.40 ± 1.46µM
                CC50 = 23.93 ± 2.36µM
          83a
%inhibition = 52.41 ± 1.67%
                 IC50 = 25.07 ± 2.47µM
                CC50 = 48.00 ± 12.584µM
79c
%inhibition = 51.10 ± 0.98%
                 IC50 = 30.35 ± 4.92µM
                CC50 = 29.59 ± 10.94µM
83d
%inhibition = 52.08 ± 0.99%
                 IC50 = 6.99 ± 1.49µM
                CC50 = 55.47 ± 16.25µM
 
Figure 2.2: Six fragments exceeding 50% inhibition for the HIV-1 IN - LEDGF/p75 assays 
ranked according to their percentage inhibition with the cell based MT-4 assay data 
included. 
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The best six imidazole-based compounds (79c, 79f, 80c, 80f, 83a and 83d) were further assessed 
for their cytotoxicity and antiviral activity in the metallothionein type 4 cell line (MT4). In a dose 
range cytotoxicity assay these scaffolds produced CC50 values ranging from 55.47 to 21.77 µM.  
Unfortunately, none of the best six compounds displayed any viral inhibition at 10 µM within the 
MT-4 cell line. The lack of antiviral activity suggests either an inability of these compounds to 
reach the target or possibly point to poor compound solubility.  Another crucial fact is that they 
lack the functionality that could make crucial hydrogen bonds with important residues at the 
binding sites.  It is apparent that the best six fragments may be considered as templates for 
further development as inhibitors of IN-LEDGF/p75 interactions. Based on this, one of the 
best six fragments, 83a, was chosen for further development in order to understand the SAR 
involved, as well as add extra functionalities which could lead to improved inhibitory 
performance against the target interaction.   
 
2.2.3.2. Direct Viral protein u (Vpu) binding ELISA assay 
To further test the biological activity of the synthesized compounds, twenty six imidazole-based 
compounds 79-83 were also submitted for screening in a second biochemical assay for their 
ability to inhibit the binding of the antibody (anti-Vpu) to Vpu at 10 µM concentration using an 
ELISA assay. The binding site is the same region where Vpu binds to CD74 and to CD4.  The 
biological data of the assessed compounds is recorded in Table 2.6.  
 
Table 2.6: HIV-1 Vpu inhibition activities of 1-substituted-5-aryl-1H-imidazoles. 
1
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R
Br79 80 81 82 83  
Compounds Entry 
HIV-1 Vpu – binding (% inhibition) @ 10 µM 
using ELISA 
79a 0 
79b 0 
79c 35.25 
79d 8.51 
79e 8.42 
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Compounds Entry 
HIV-1 Vpu – binding (% inhibition) @ 10 µM 
using ELISA 
  
79f 0 
79g 7.93 
79h 0 
79i 9.21 
80a 0 
80b 0 
80c 0 
80d 0 
80e 2.17 
80f 0 
81a 0 
81b 0 
81c 23.41 
81d 37.06 
82a 6.76 
82c 17.86 
82d 0 
82e 0 
83a 4.04 
83d 6.79 
 
 
These scaffolds 79-83 were found to be well below the 50% benchmark to be considered further 
as promising candidate inhibitors of Vpu.  It is likely; however, that these fragments cannot 
sufficiently block any interaction, as the protein binding site is rather large. Compound 81d 
showed the highest inhibition (37%) of binding of the anti-Vpu to Vpu protein. These 
compounds were not deemed suitable to be pursued further for development as Vpu inhibitors. 
 
2.3. Synthesis of 1,5-diaryl-1H-imidazole-4-carboxylic acid analogues as second 
generation compounds 
Encouraged by the interesting biological data, the modification of one of the best six fragments 
was pursued as an ideal starting point for fragment growth into possibly more potent inhibitors 
of the LEDGF/p75-IN interaction.  Examination of the best six compounds shows the absence 
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of key structural features that have been shown to enhance the disruption of the LEDGF/p75-
IN interaction. A review of molecules reported as inhibitors of the LEDGF/p75-IN interaction 
indicate that some of them contain a carboxylic acid functionality which could be significant to 
their binding properties.53,206,207,208,209 Based on these observations, the introduction of a carboxylic 
acid functionality might improve the potency of the active fragments. Of the best six 
compounds, 1-(4-bromophenyl)-5-(4-fluorophenyl)-1H-imidazole 83a was chosen as a suitable 
template (hit) for further modification because of the simplicity of its chemical structure and in 
vitro potency (IC50 =25.07 ± 2.47 µM). Therefore, a series of analogues of 83a, namely 1-(4-
bromophenyl)-5-(4-fluorophenyl)-1H-imidazole-4-carboxylic acid were envisaged (Scheme 2.5).  
 
1N
2
3
N4
5
F
Br
N
N
F
Br
O
HO
Target molecule
87
83a
-COOH
 
 
Scheme 2.5: Integration of -COOH group on the 1-(4-bromophenyl)-5-(4-fluorophenyl)-1H-
imidazole fragment 83a. 
 
2.3.1. Retrosynthesis of target compounds  
The first step was to design a plausible synthetic route towards the desired 1-(4-bromophenyl)-5-
(4-fluorophenyl)-1H-imidazole-4-carboxylic acid 87. The retrosynthesis idea was primarily initiated 
by 1990 Nobel Prize winner in chemistry, Prof E. J. Corey.210 Since then it has been frequently 
exercised by organic chemists to map and develop synthetic pathways. By definition, 
retrosynthesis is the breaking down of a target molecule into simple and easily accessible 
commercially available synthons as starting points for a synthesis.210  
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Scheme 2.6: Retrosynthesis of target compound 87. 
 
As depicted in Scheme 2.6, the retrosynthesis of target compound 87 can be attained in four 
stepwise reactions. Compound 87 can be obtained by hydrolysis of the ester group of 
carboxylate scaffold 88. Further disconnection of bonds on the chemical structure 88 as shown 
in Scheme 2.6 can lead to a commercially available ethyl isocyanoacetate 89 and intermediate 90 
(where X is a leaving group). The presence of the leaving group could facilitate the C=C double 
bond formation at the 4- and 5-positions of the imidazole ring. Intermediate 90 can be obtained 
from the N-aryl benzamide 91, which in turn can be easily produced from two commercially 
available synthons, aniline 74 and benzoyl chloride derivatives 92. 
 
2.3.2. Synthesis of the ethyl 1,5-diaryl-1H-imidazole-4-carboxylic acid derivatives  
With the planned synthetic pathway in hand, the synthesis of the family of ethyl 1,5-diaryl-1H-
imidazole-4-carboxylic acid derivatives was pursued, starting with the synthesis of the 
iminochlorides 90 through their diarylamide intermediates 91. 
 
2.3.2.1. Synthesis of N-aryl-benzamide chlorides 
To better understand the SAR between the compounds and the targets under investigation, 
various readily available benzoyl chlorides and aniline derivatives were employed.  Initially, the 
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essential intermediates, N-aryl benzimidoyl chlorides 90 were prepared in two steps in 
accordance with reported methods as illustrated in Scheme 2.7. 211,212  Thus benzoic chlorides 
92a-d were reacted with aniline scaffolds 74e-f and 74i-j in the presence of triethylamine and 
using ethyl acetate as solvent at room temperature for 16 hours.211  Work-up afforded N-aryl-
benzamide products 91a-j in yields ranging from 83-93% as recorded in Table 2.7.   
 
NH
ONH2O
Cl
91
+
R
R'
R'
R
    
92a R= 4-F
92b R= 3-F
92c R= 3-OMe
92d R=  H
74e R'= 4-Br
74f R'=2,4-diCl
74i R'= 2,4-diOMe
74j R'=  2,4-diMe
Et3N, AcOEt
0oC-rt, 16h
N
Cl
90
R'
R
83-93%
SOCl2
reflux, 8h
88-91%
 
Scheme 2.7: Synthesis of N-aryl-benzimidoyl chloride intermediates 90. 
 
Table 2.7: Isolated yields (%) of the N-aryl-benzamide products 91a-j. 
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1
NH2
O
R'
R
 
R R’ Yields (%) 
91a 4-F 4-Br 91 
91b 3-F 4-Br 91 
91c 3-OMe 4-Br 90 
91d 3-Me 4-Br 89 
91e H 4-Br 86 
91f 4-F 2,4-diOMe 83 
91g 4-F 2,4-diMe 88 
91h 3-OMe 2,4-diMe 90 
91i 4-F 2,4-diCl 93 
91j 3-F 2,4-diCl 90 
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NMR spectroscopic analysis confirmed the structures and correlated with previously reported 
data in the literature.213,214,215,216 These scaffolds were therefore used in the next step without 
further purification. The products 91a-j were all characterised by the clear presence of an N-H 
signal in the region of δ 7.8-10.6 ppm in the 1H NMR spectra and a carbonyl carbon atom in the 
region of δ 163-170 ppm in their 13C NMR spectra. The presence of an N-H group was also 
evident in their FTIR spectra, where this band appears between 3226 and 3369 cm-1 whilst a 
strong absorption band around 1642-1783 cm-1 corresponds to the carbonyl group of the amide, 
as shown in Table 2.8. 
 
Table 2.8: FTIR spectroscopic data of N-aryl-benzamide products 91a-j showing N-H and 
C=O absorption bands.  
Compds 91a 91b 91c 91d 91e 91f 91g 91h 91i 91j 
υNH (cm-1) 3345 3315 3329 3329 3332 3286 3286 3226 3386 3369 
υC=O(cm-1) 1642 1656 1658 1658 1656 1650 1652 1648 1783 1660 
 
 
A series of N-aryl-benzamide scaffolds 91a-j were then heated neat with thionyl chloride (SOCl2) 
for 16 hours as shown in Scheme 2.7.212  Upon completion, the excess thionyl chloride was 
removed by co-evaporation with toluene, affording most of the N-arylbenzimidoyl chloride 
products 90a-h in excellent yields (see Table 2.9).  However, when the aniline ring was occupied 
by chlorine substituents at the para- and ortho-positions (91i-j) only trace amounts of products 
were observed (NMR spectroscopy). This may be due to the electron-withdrawing effects of the 
two chlorine atoms which may influence the stability of these products 90 at room temperature.  
The obtained products 90a-h were immediately subjected to the next reaction step. 
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Table 2.9: Isolated yields (%) of the N-aryl-benzimidoyl chloride products 90a-h. 
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1
N2
Cl
R'
R
 
R R’ Yields (%) 
90a 4-F 4-Br 96 
90b 3-F 4-Br 95 
90c 3-OMe 4-Br 98 
90d 3-Me 4-Br 98 
90e H 4-Br 96 
90f 4-F 2,4-diOMe 95 
90g 4-F 2,4-diMe 98 
90h 3-OMe 2,4-diMe 96 
 
 
In spite of the instability of compounds 90a-h, 1D and 2D NMR spectra were used to confirm 
their structures. In solution, the 1H NMR spectra in each case revealed that these compounds are 
isolated as a single geometrical isomer (likely E-isomer), which agrees with the reported 
literature.217,218  The 1H NMR spectra of 90a-h showed the disappearance of the secondary imide 
proton, while their 13C NMR spectra showed the disappearance of the carbonyl signal and the 
appearance of a new signal at δ 143 ppm, assigned to the carbon atom directly attached to the 
chlorine atom. 
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2.3.2.2. Synthesis of ethyl 1,5-diaryl-1H-imidazole-4-carboxylates  
 
 
 
Scheme 2.8: Synthesis of ethyl 1,5-diaryl-1H-imidazole-4-carboxylate derivatives 88. 
 
Ethyl isocyanoacetate 89 was then subjected to a cycloaddition reaction with N-aryl-benzimidoyl 
chloride derivatives 90a-h as depicted in Scheme 2.8 (Route 1).  N-aryl-benzimidoyl chloride 
90a-h was added to a mixture of ethyl isocyanoacetate 89 and DBU in dry THF under argon at 
  -78oC.  The resulting reaction mixtures were then allowed to warm to room temperature and 
were stirred for 48 hours (monitored by TLC). Work up and column chromatography afforded 
novel ethyl 1,5-diaryl-1H-imidazole-4-carboxylate derivatives 88a-e bearing a 4-bromophenyl 
substituent at the 1- position of the imidazole moiety. These products 88a-e were isolated in 
yields ranging from 18% to 64% (Table 2.10).  The highest yields were obtained when the aryl 
ring attached at the 5-position of the imidazole core contained fluorine atoms (88a-b).  On the 
other hand, compounds 90f-h failed to convert to the desired products; this may be attributable 
to the electron donating effects of the methoxy and methyl groups, which tend to disfavour 
cycloaddition.  
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With low yields of some of the products and failed conversions of some of the N-aryl-
benzimidoyl chlorides 90f-h, an attempt was made to directly synthesise the desired heterocyclic 
products 88 from N-aryl-benzamides 91 using a previously reported procedure219,220 as illustrated 
in Scheme 2.8 (Route 2). Therefore, N-aryl-benzamides 91a-h were treated with diethyl 
chlorophosphate in the presence of catalytic base, tBuOK in anhydrous THF under argon at       
 -10oC, with the intention of generating unstable iminophosphates in situ, followed by subsequent 
addition of ethyl isocyanoacetate 89 and tBuOK with further stirring for 4 hours.  Unfortunately, 
none of the desired products 88 could be detected (TLC); even extending the reaction time to 48 
hours didn‟t have any effect on the formation of the products. The challenging nature of the 
reaction may be attributed to the instability of the iminophosphates which were generated in situ.   
  
Table 2.10: Isolated yield (%) of compounds 88a-e. 
5
N1
2
N
34
O
O
R
Br  
Compound Entry R Yields (%) 
88a 4-F 64 
88b 3-F 58 
88c 3-OMe 18 
88d 3-Me 30 
88e H 22 
 
 
2.3.2.2.1 Mechanism for the formation of ethyl 1,5-diaryl-1H-imidazole-4-carboxylates 88 
A plausible mechanistic pathway for the formation of ethyl 1-(4-bromophenyl)-5-aryl-1H-
imidazole-4-carboxylates 88a-e is illustrated in Scheme 2.9.  The initial step is thought to 
involve an activation of ethyl isocyanoacetate 89 by DBU to generate anion 93. This intermediate 
93 is then involved in a nucleophilic attack on the C=N double bond of N-phenyl-benzimidoyl 
chloride 90 to afford intermediate 94, with elimination of a Cl atom as the DBU hydrochloride 
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salt. Intermediate 94 tautomerises to give 95, which then undergoes in situ cyclisation and proton 
transfer to give the desired products 88.  
 
 
 
Scheme 2.9: Plausible mechanism for the formation of ethyl 1-(4-bromophenyl)-5-aryl-1H-
imidazole-4-carboxylates 88. 
 
The newly synthesized compounds 88a-e were characterised by FTIR as well as NMR 
spectroscopy, with the data obtained being in agreement with the expected structures. The FTIR 
spectra showed a strong absorption band assigned to the C=O stretching of the ester 
functionality at 1708-1716 cm-1, whilst the bands between 1562-1587 cm-1 were assigned to C=N 
of the imidazole moiety. Other frequencies between 1449 and 1497 cm-1 were attributed to C-N 
stretching of the imidazole motif (see Table 2.11). 
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Table 2.11: FTIR spectroscopic data for ethyl 1-(4-bromophenyl)-5-aryl-1H-imidazole-4-
carboxylates 88 showing the C=O, C=N, and C-N stretch signals.  
Compound 88a 88b 88c 88d 88e 
υC=O (cm-1)  1716 1708 1715 1713 1709 
υC=N (cm-1)  1560 1582 1587 1552 1556 
υC-N (cm-1)  1375 1372 1374 1372 1373 
 
 
NMR spectra of compound 88c will be discussed in detail below, being representative of this 
compound class. The 1H NMR spectrum of compound 88c shows the following characteristic 
features: a singlet corresponding to the methine proton of the imidazole ring at δ 7.61 ppm; the 
signals in the region of δ 6.70-7.37 ppm confirming the presence of two aryl rings; a quartet at δ 
4.19 ppm with a coupling constant of 7.2 Hz assigned to the protons of the methylene group 
(ethyl moiety); an upfield triplet at δ 1.18 ppm (J = 7.0 Hz) corresponding to the methyl protons 
of the ethyl group and a singlet at δ 3.63 ppm corresponding to the protons of the ortho-methoxy 
group. The 13C NMR spectrum of compound 88c shows the carbonyl carbon atom resonating at 
162.6 ppm, while the methine carbon atom of the imidazole motif resonates at 137.6 ppm. The 
ortho-methoxy carbon atom resonates at 55.1 ppm while the methylene and methyl carbon atoms 
of the ethyl group are observed at 60.4 and 14.1 ppm, respectively.  
 
2.3.2.3. Hydrolysis of 1-(4-bromophenyl)-5-aryl-1H-imidazole-4-carboxylates  
The ester group of the ethyl 1-(4-bromophenyl)-5-aryl-1H-imidazole-4-carboxylates 88a-e were 
then hydrolysed under reflux in the presence of NaOH in methanol and water for 2 hours, 
followed by acidification (Scheme 2.10).  Work up afforded the novel 1-(4-bromophenyl)-5-aryl-
1H-imidazole-4-carboxylic acid derivatives 87a-e in yields of up to 78% (Table 2.12).  
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N
O
HO
Br
R
N
N
O
O
Br
R
i. NaOH, , MeOH, H2O, reflux, 2 h
ii. 1M HCl, H2O
88a R= 4-F
88b R= 3-F
88c R= 3-OMe
88d R= 3-Me
88e R= H
87a R= 4-F
87b R= 3-F
87c R= 3-OMe
87d R= 3-Me
87e R= H
63-78%
 
 
Scheme 2.10: Hydrolysis of ethyl 1-(4-bromophenyl)-5-aryl-1H-imidazole-4-carboxylates 
 
Table 2.12: Isolated yields (%) of the 1-(4-bromophenyl)-5-aryl-1H-imidazole-4-carboxylic acids 
87a-e. 
5 N 1
2
N
3
4
6
O
HO
7
R
Br  
Compound Entry R Yields (%) 
87a 4-F 68 
87b 3-F 72 
87c 3-OMe 78 
87d 3-Me 75 
87e H 63 
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2.3.2.3.1. Structure elucidation of 1-(4-bromophenyl)-5-aryl-1H-imidazole-4- carboxylic 
acids 87a-e 
The title compound structures were confirmed by NMR spectroscopic analysis, FTIR 
spectroscopy and LCMS. Complete hydrolysis to yield products 87a-e was confirmed by the 
disappearance of signals due to the ethyl group and emergence of the broad downfield signal at 
ca. δ 12 ppm corresponding to the acid proton in their 1H NMR spectra. The disappearance of 
the ethyl group was also evident in their 13C NMR spectra, while the FTIR spectra exhibited a 
decrease in C-H stretch signals due to the loss of the ethyl group and appearance of a slightly 
broad signal in the region of 2470-2565 cm-1 attributed to the OH group of the carboxylic acids.  
ESI-LCMS provided additional proof that the hydrolysis of the ester had occurred as it confirms 
the presence of the required molecular ion in all cases. For example, compounds 87b and 87d, 
with molecular formulae C16H11
79BrFN2O2
+and C17H14
79BrN2O2
+ showed protonated molecular 
ion peaks [M+H+] at 360.9987 and 357.0244, respectively, which differ from the ester derivatives 
with molecular ions of 389.0301 (88b, C18H15
79BrFN2O2
+) and 385.0557 (88d, C19H18
79BrN2O2
+).  
Molecular ion peaks are all within acceptable SigmaFit™ values (below 20) (Table 2.13).  
 
Table 2.13: HRMS results of compounds 87a-e and 88a-e with their mSigma values. 
Compds 
Measured 
(m/z) 
Formula 
[M+1]+ 
Theoretica
l 
(m/z) 
Err 
[mDa] 
Err 
[ppm] 
mSigma 
87a 360.9991 C16H1179BrFN2O2+ 360.9982 -0.8 -2.3 3.2 
87b 360.9987 C16H1179BrFN2O2+ 360.9982 -0.7 -1.9 8.7 
87c 373.0201 C17H1479BrN2O3+ 373.0182 -1.8 -4.9 6.0 
87d 357.0244 C17H1479BrN2O2+ 357.0233 -1.7 -4.9 6.6 
87e 343.0089 C16H1279BrN2O2+ 343.0077 -1.3 -3.7 8.1 
88a 389.0301 C18H1579BrFN2O2+ 389.0295 -0.6 -1.5 10.4 
88b 389.0301 C18H1579BrFN2O2+ 389.0295 -0.5 -1.4 7.6 
88c 401.0487 C19H1879BrN2O3+ 401.0495 0.8 2.0 19.0 
88d 385.0557 C19H1879BrN2O2+ 385.0546 -1.1 -2.8 18.3 
88e 371.0398 C16H1679BrN2O2+ 371.0390 -0.8 -2.2 12.5 
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Overall, the carboxylic acid moiety was incorporated at the 4-position of the imidazole ring using 
isocyanide chemistry. Five new 1-(4-bromophenyl)-5-aryl-1H-imidazole-4-carboxylic acids 87a-e 
were obtained, which together with their ester intermediates 88a-e, were submitted for biological 
evaluation in the IN-LEDGF/p75 binding assay. 
 
2.3.3. Biological evaluation of 1-(4-bromophenyl)-5-(4-fluorophenyl)-1H-imidazole 
analogues 
2.3.3.1. Direct Integrase-LEDGF/p75 AlphaScreen Assay  
Because of weak binding affinity of small molecules for the protein target and the poor 
sensitivity of some biochemical assays, it is recommended to screen small fragments at 
concentrations between 100 and 200 µM. 221,222,223,224,225  Therefore, compounds 87a-e and 88a-e 
were assessed and hit compound 83a was re-assessed at 100 μM for their ability to interrupt 
HIV-1IN-LEDGF/p75 interactions using the AlphaScreen assay.  All biological evaluations 
were carried out in duplicate and the average results are recorded in Table 2.14. 
 
Table 2.14:  The HIV-1 IN-LEDGF/p75 inhibition activities of the compounds 83a, 87a-e and 
88a-e at 100 µM. 
Compounds 
Entry 
Biochemical target assays 
HIV-1 IN – LEDGF 
(%)inhibition @ 100µM  
(AlphaScreen) 
HIV-1 IN – LEDGF inhibition 
IC50 (AlphaScreen)  
µM 
83a 61  ± 3.96  
87a 57 ± 6.24 33.4± 1.34 
87b 79 ± 2.24 37.3 ± 3.24 
87c 100 ± 11.18 38.9 ± 4.54 
87d 100 ± 6.76 302.0 ± 1.34 
87e 75 ± 3.13 50.6 ± 23.90 
88a 13 ± 1.21  
88b 17 ± 1.89  
88c 48 ± 4.98  
88d 13 ± 7.37  
88e 68 ± 5.23  
CX05168 91.37+-0.85 1.38+-0.29 
HIV-1 IN and LEDGF 
with DMSO 
0  
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At a single dose concentration of 100 μM, hit compound 83a exhibited 61% inhibition 
compared to the previously obtained 52% inhibition at 10 μM (see Table 2.14).  Insertion of a 
carboxylate ester group at the 4-position of the imidazole core produced carboxylate derivatives 
88a-d which were found to be 1 to 5 times less potent than 83a. The only ester showing 
significant inhibitory activity was 88e (68%), which may be attributed to the absence of 
substituents on the 5-aryl ring which might allow the compound to adopt a geometry that 
favours the binding interaction.   
However, after hydrolysis all five free acid derivatives 87a-e exhibited more than 50% inhibition, 
with four compounds surpassing the inhibition of hit compound 83a. Compound 87c with a 
methoxy substituent at the meta-position of the 5-aryl ring exhibited 100% inhibition in the 
AlphaScreen assay. Similarly, when a methyl substituent was present at the meta-position (87d) 
there was also comparable inhibition.  Moreover, replacing the electron-donating group at the 
meta-position in 87c by a fluorine atom (87b) showed a decrease to 81% inhibition. In 
compound 87e where there is no substituent on the 5-aryl ring, 75% inhibition was still shown. 
Lastly, the analogue with a 4-fluorine atom (87a) showed inhibition of 57%.  Compounds 87a-e 
were further evaluated via the Truhit kit assay to determine whether there were colour quenchers, 
light scatterers, singlet oxygen quenchers and biotin mimetics meddling with the signal of the 
AlphaScreen test. The compounds, however, were confirmed as true hits (not false positives).  
Although the number of compounds tested was small, the following information can be 
abstracted from their biological data: (i) the presence of meta-substituents on the 5-aryl ring 
seems to have a significant impact in the inhibition ability, and (ii) the presence of the carboxylic 
acid group plays a major role in preventing the interaction between the HIV-1 IN and host 
LEDGF/p75 proteins as previously reported.,226,227 
In a dose range assay, these compounds 87a-e produced IC50 values ranging from 33.4± 1.34 μM 
to 302.0±1.34μM as recorded in Table 2.14. These IC50 values were much higher than the IC50 
value of the hit compound 83a (25.07±2.47 µM). The IC50 values of compounds 87a-e appeared 
to be high, but these values may not be reliable because the compounds were found to have 
poor aqueous solubility. The best five compounds 87a-e were subsequently assessed for their 
preliminary in vitro cytotoxicity and antiviral activity. The cytotoxicity study showed that the best 
five compounds 87a-e did not reduce the viability of the MT-4 cell line. In the antiviral assay, no 
activity was seen for any of the compounds tested, which may be due to poor solubility or an 
inability of the compounds to reach the target due to their poor permeability. This is not of 
instant concern given the fact that most of the compounds described to be inhibitors of 
LEDGFp75 and IN interactions display a deficiency in antiviral activity in the cell based assay. 228 
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2.3.3.2. Assessment through ADME parameters of the synthesized compounds 87a-e 
Since a lack of solubility was suspected to be the possible reason for the higher IC50 values 
obtained, it was of interest to calculate in silico their ADME (Absorption, Distribution, 
Metabolism and Excretion) properties so as to determine the compliance of compounds 87a-e 
using BIOVIA Discovery Studio version 4.0. Applying an ADME descriptors algorithm, distinct 
pharmacokinetic parameters like human intestinal absorption, aqueous solubility, blood brain 
barrier (BBB) penetration and cytochrome P450 (CYP2D6) inhibition can be mathematically 
estimated. Standard values of ADME parameters are listed in Table 2.15.  
 
Table 2.15: Standard level information of ADME descriptors from Discovery Studio version 
4.0. 
Aqueous Solubility  
Blood Brain 
Barrier 
Penetration 
Human Intestinal 
Absorption 
CYP2D6 
level intensity level Intensity level intensity level intensity 
0 Extremely low 0 Very high 0 Good 0 
Non 
inhibitor 
1 slight 1 High 1 Moderate 1 Inhibitor 
2  low 2 Medium 2 Poor   
3  good 3 Low 3 Very poor   
4 optimal 4 Undefined     
5 too soluble       
 
The well-known FDA approved integrase inhibitor, raltegravir, was used as a positive control 
and the results of ADME predictions are recorded in Table 2.16.  Predicted aqueous solubility 
(expressed as logSw as conducted in water at 25°C) for compounds 87a-e indicate they may be 
slightly soluble in water (level 2) whereas for raltegravir the prediction was good (level 3). The 
low solubility predicted for 87a-e could be seen as a possible indication that low solubility may 
have had some effect on their (higher) IC50 values. Furthermore, the predicted ADME AlogP98 
results (associated with lipophilicity) indicate that these compounds could be poorly absorbed by 
the intestine (compared to raltegravir). The ADME BBB (Blood Brain Barrier) predicted levels 
were medium to high (level 2 to 1) suggesting that these scaffolds may pass through the blood 
brain barrier. These compounds were predicted to be non-inhibitors of cytochrome P450 
(CYP2D6), which could indicate that they might well be processed in phase I metabolism. 
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Besides the low aqueous solubility and human intestinal absorption, prediction results are 
encouraging. 
 
Table 2.16: ADME prediction for the synthesized compounds 87a-e obtained from Discovery 
Studio version 4.0. 
Compounds 
 
ADMET 
Solubility 
values 
 
ADMET 
Solubility 
Level 
 
Human 
Intestinal 
Absorption 
(ADMET_ 
AlogP98) 
 
Blood-Brain 
Barrier 
(ADMET_BBB 
level) 
 
CYPD2D6 
inhibition 
87a -4.052 2 2.847 2 No 
87b -4.563 2 2.847 1 No 
87c -4.318 2 2.625 2 No 
87d -4.061 2 3.128 2 No 
87e -4.311 2 2.642 2 No 
Raltegravir -2.198 3 -0.994 4 No 
 
 
2.3.4. Molecular modeling of the synthesized 1-(4-bromophenyl)-5-aryl-1H-imidazole-4-
carboxylic acid derivatives 87a -e 
Molecular modelling has become a critical process in drug design, offering an insight into the 
specific chemical features involved in the possible interactions between the modelled docked 
compounds and the protein of interest.  Five compounds 87a-e (i.e. scaffolds with more than 
50% inhibition in the AlphaScreen assay) were modelled to predict their binding mode by 
docking into the HIV-1 allosteric site at the IN-LEDGF/ p75 interface. The X-ray structure of 
the HIV-1 IN in complex with the LEDGF/p75 (PDB code: 2B4J) was retrieved from the 
protein databank, followed by removal of the LEDGF/p75 from the complex, preparing the 
HIV-1 IN, pinpointing the binding pocket at the IN monomers interface and then defining them 
as spheres (Figure 2.3) using the BIOVIA Discovery StudioTM version 4.0 package.229 Before 
docking, compounds were minimized to their lowest energy and all possible 3D structures of 
molecules were created using the prepare ligand procedure. The scaffolds were then primarily 
positioned in the same site where LEDGF/p75 binds to the HIV-1 IN dimer using the LibDock 
protocol, resulting in the generation of hundreds of poses for each compound. These poses were 
exposed to Jain, PLP2 and LibDock scoring protocols, and then analysed, and further optimised 
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by in-situ-energy-minimisation and flexible docking. The binding energies of the best poses 
generated from flexible docking were then calculated and the results are shown in Table 2.15. 
 
 
 
Figure 2.3: The dimeric structure of HIV-1 IN with monomer A in yellow and monomer B in 
green. 
 
The predicted models of the docked compounds 87a-e were analysed based on the interaction 
of four structural features, namely: carboxylic acid group, imidazole moiety, substituted-aryl ring 
and 4-bromophenyl group.  The docking results predicted that compound 87c was most 
favourable with the lowest calculated binding energy (-102.6620 kcal/mol) followed by other 
scaffolds in binding energy order of 87d < 87b < 87e < 87a (Table 2.17). The lower the binding 
energy the tighter the compound binds to the target. The order predicted by the binding energies 
correlates with the percentage inhibition data obtained from the AlphaScreen assay. Molecular 
docking further suggested that compounds 87a-e were interacting with amino acid residues of 
the HIV-1 IN at the interface in a manner similar to that of the LEDGF/p75 protein. Models 
also suggested that the carboxylic acid group and the various substituents on the 5-aryl group 
have some impact on the binding of these compounds.   
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Table 2.17:  A list of in silico interactions of compounds 87a-e and binding site amino acids 
according to order of -PLP2 scoring function and their binding energy.  
 
Compds. 
Binding 
energy 
Kcal/mol 
Amino acids 
interactions 
(-)PLP2 
scoring 
function 
Jain 
scoring 
function 
LibDocked 
Scoring 
functions 
87c -102.6620 
Gln95, Tyr99, Ala98, Leu102, 
Ala128,Ala129, Ala169, 
Trp131 
72.44 5.09 39.9524 
87d -75.9690 
Gln95, Ala98, Leu102, 
Ala128, Glu170, His171, 
Trp131 
71.29 1.32 52.7142 
87b -75.7536 
Gln95, Ala98, Ala169, 
Glu170, His171, Trp131, 
Trp132 
64.62 1.90 53.0888 
87e -33.6241 
Gln95, Ala98, Glu170, 
His171, Trp131 
62.97 1.92 28.3279 
87a -13.2486 
Gln95, Ala98, Ala169, 
Glu170, His171, Trp131, 
Trp132 
61.74 1.70 49.3002 
 
 
A detailed examination of the predicted model for 87c (Figure 2.4) at the HIV-1 IN interface 
reveals its carboxylic acid group formed two hydrogen bonds with the Gln95 and the Tyr99 
residues whilst its meta-methoxy group was projected to make a hydrogen bond with the Ala169 
residue.  Furthermore, the 5-aryl group and the imidazole moiety exhibited a hydrophobic 
contact with the Gln95, Leu102 and Ala129 residues. Additionally, the 4-bromophenyl group 
and its bromine atom were predicted to occupy the hydrophobic pockets formed by the residues 
Ala128 and Trp131.   
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Figure 2.4: Predicted binding models of 87c in grey, red and blue stick docked onto IN (yellow 
and green on the left and right side indicate the zoomed binding residues) at the LEDGF/p75 
binding interface 
 
For the carboxylic acid group of compound 87d (Figure 2.5) two hydrogen bond interactions 
with backbone His171 of monomer B and one hydrogen bond to the Gln95 of monomer A 
were observed, whilst the imidazole moiety was projected towards the hydrophobic pockets 
formed by the Glu170 residue of monomer B. Additionally, the meta-methyl group was observed 
to be packed into hydrophobic pockets of the Ala98 and the Leu102 residues whereas its aryl 
ring formed hydrophobic interactions with the Ala98 and the Ala128 of monomer A. Finally, the 
bromine atom was projected to interact via a hydrophobic contact with Trp131 of monomer A.  
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Figure 2.5: Predicted binding models of 87d in grey, red and blue stick docked onto IN (yellow 
and green on the left and right side indicate the zoomed binding residues) at the LEDGF/p75 
binding interface. 
 
The binding model of 87b (Figure 2.6) predicted that the carboxylic acid group formed one less 
hydrogen bond to the His171 residue of subunit B and the imidazole moiety made similar 
interactions to those in the model of compound 87d, while a meta-fluorine atom formed an 
interaction with the Ala98 residue and its aryl group was projected to be packed into the 
hydrophobic pockets formed by IN residues Ala98 and Gln95 of monomer A. The bromine 
atom is shown to make hydrophobic interactions with both Tryp131 and Tryp132 of subunit A.  
 
  
Figure 2.6: Predicted binding models of 87b in grey, red and blue stick docked onto IN (yellow 
and green on the left and right side indicate the zoomed binding residues) at the LEDGF/p75 
binding interface 
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Inspection of the binding model of compound 87e (Figure 2.7) revealed that its carboxylic acid 
group and unsubstituted aryl ring formed similar interactions observed in the predicted binding 
model of compound 87b, whilst the imidazole core formed similar hydrophobic interactions to 
those observed in both compounds 87b and 87d. The bromine atom showed a similar binding 
mode to that exhibited by compounds 87b, 87c and 87d.  
 
  
 
Figure 2.7: Predicted binding models of 87e in grey, red and blue stick docked onto IN (yellow 
and green on the left and right side indicate the zoomed binding residues) at the LEDGF/p75 
binding interface. 
 
The model of compound 87a (Figure 2.8) is predicted to have a similar binding mode to 87b and 
87d whilst its para-fluorine atom interacts with the Gln95 residue of monomer A.  However, this 
compound further showed that the aryl ring of the bromophenyl group was involved in 
hydrophobic interactions with the Ala169 amino acid of monomer B, while its bromine atom 
displays similar hydrophobic interactions exhibited by compound 87b. 
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Figure 2.8: Predicted binding models of 87a in grey, red and blue stick docked onto IN (yellow 
and green on the left and right side indicate the zoomed binding residues) at the LEDGF/p75 
binding interface. 
 
In brief, the results suggest that the presence of a meta-substituent on the 5-aryl group could be 
associated with better potency. The methoxy group was most favourable due to the presence of 
an electronegative group which could form a hydrogen bond with Ala169. Possible binding 
modes for compounds 87a-e to HIV-1 IN were predicted using molecular modeling and it was 
found that these scaffolds were making some hydrogen bonds and hydrophobic interactions 
with essential amino acid residues significant for IN-LEDGF/p75 interactions. 
 
2.3.5. Preliminary Isothermal Calorimetry Titration (ITC) Study 
We attempted to determine the thermodynamic parameters of 1,5-diaryl-1H-imidazole-4-
carboxylic acid based HIV-1 IN-LEDGF/p75 inhibitors 87a-e alongside CX05168 as a control 
compound (a compound known to inhibit  HIV-1 IN-LEDGF/p75 interactions)53 using a VP-
ITC MicroCalorimeter TM. The ITC studies were conducted at the University of the 
Witwatersrand, Department of Protein Structure-Function Research Unit in the School of 
Molecular and Cell Biology under guidance of Professor Yasien Sayed.  
The ITC experiments were conducted by titrating the compound into the ITC cell containing 
HIV-1 IN. Initially the intention was to establish the proper protocol which can demonstrate the 
thermodynamic parameters of compound CX05168 binding to the HIV-1 IN protein as a 
control experiment.  The ITC experiment was designed to initially inject 500 µM concentration 
of control compound into an ITC cell containing 25 µM of HIV -1 IN. The first injection 
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produced a small peak, which can be attributed to diffusion of titrant into titrate during 
equilibration. The preliminary ITC data (Figure 2.9 A and B) showed that the titration of control 
compound into HIV-1 IN displayed an exothermic titration reaction. As the titration continues, 
heat released gradually decreases but saturation could not be reached at a compound 
concentration of 500 µM. The integration and normalization of the exothermic peaks produced a 
hyperbolic curve relating to the amount of control compound added. The hyperbolic curve 
obtained was missing a pre-transition state region. However, increasing the concentration of the 
control compound to 1000 µM allowed for saturation to be successfully attained but the pre-
transition was still deficient (Figure 2.10 C and D). The non-existence of the pre-transitions in the 
hyperbolic curve make it difficult to obtain the correct thermodynamic parameters such as 
enthalpy change (ΔH) for the experiment, which means that the free binding energy (ΔG) of the 
experiment could not be properly determined. Hence the binding affinity (KD) of the control 
compound which is directly related to ΔG, could not be properly established.   
The ITC experiment was also conducted using compound 87b which was identified as a 
potential inhibitor of HIV-1 -IN LEDGF/p75 interaction through AlphaScreening. The 
preliminary ITC experiment results showed that titration at 500 µM concentration of the 
compound 87b into an ITC cell containing HIV-1 IN was an exothermic reaction. However, as 
the titration continued, saturation could not be reached. Even further optimization by varying 
the concentration of compound 87b between 1000 µM to 20 mM (Figure 2.11), did not allow 
saturation to be reached. The results suggest that compound 87b could be weakly binding to the 
HIV-1 IN protein.  The inability of this compound 87b to reach saturation could also be 
attributed to the fact that the part of the scaffold also binds to the LEDGF/p75 protein, which 
is not present in the titration. Although the preliminary ITC data of compound 87b thus far 
shows that the scaffold did not reach saturation, the data obtained offers proof that the 
compound is truly binding to HIV-1 IN. Further investigations into proper protocols to 
establish the binding constants (KD) and other thermodynamic parameters of both synthesized 
compounds and the control compound to the HIV-1 IN protein are ongoing, but due to time 
constraints no further results could be included here. 
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A  
B  
 
Figure 2.9: A) Raw titration data of CX05168 compound (500 µM) with HIV-1 IN (25 µM) 
measured in µJ/s. Each peak corresponds to a single injection of compound solution 
into the HIV-1 suspension; B) The fitted titration data to the injection of 500 µM of 
control compound into 20 µM of HIV-1 IN. 
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C  
D   
 
Figure 2.10: C) Raw titration data of CX05168 compound (1000 µM) with HIV-1 IN (25 µM) 
measured in µJ/s. Each peak corresponds to a single injection of compound solution 
into the HIV-1 suspension; D) The fitted titration data to the injection of 500 µM of 
control compound into 20 µM of HIV-1 IN. 
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Figure 2.11: Raw titration data of compound 87b (20 mM) with HIV-1 IN (25 µM) measured in 
µJ/s. Each peak corresponds to a single injection of compound solution into the HIV-1 
suspension. 
 
2.4. Conclusions 
With the aim of producing small heterocyclic fragments from which to identify viable hits to be 
developed into drug like compounds, a small library of imidazole-based fragments was 
successfully synthesized via the van Leusen reaction. Intermediate N-(arylidene)alkylamines were 
obtained in excellent yields by reacting benzaldehydes and primary amine derivatives using both 
conventional and microwave heating, with microwave irradiation resulting in an increase in the 
reaction rates.  Further treatment of N-(arylidene)alkylamines with TosMIC and K2CO3 in dry 
MeCN, by both conventional and microwave assisted methods, gave a series of 1-substituted-5-
aryl-1H-imidazole derivatives in yields ranging from poor (for those with electron-withdrawing 
substituents at the ortho-position of the phenyl ring) to high (for those with electron-donating 
groups in both para and ortho positions).  The 1-substituted-5-aryl-1H-imidazole derivatives were 
also obtained in a one pot synthesis by in situ generation of the N-(arylidene)alkylamines by 
irradiation of a mixture of aryl aldehydes and aliphatic amines; followed by addition of TosMIC 
and K2CO3 in MeCN, with yields similar to those obtained in a stepwise manner. The 
preparation of imidazoles in MeOH proved to be more challenging due to the inherent 
preference of TosMIC to react with MeOH to afford products such as E and Z- 
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HOCH2N=CH(OMe).  Out of the twenty six prepared 1-substituted-5-aryl-1H-imidazole 
derivatives, twenty five are new and only one has been reported previously. Biological screening 
of compounds was performed in an HIV-1 IN-LEDGF/p75 assay and a Vpu binding assay. 
Six fragments exhibited more than 50% inhibition of the HIV-1 IN- LEDGF/p75 interaction. 
These compounds produced IC50 values of 7-30 µM and were not toxic to MT-4 cells, with CC50 
values between 21.77 - 55.47 µM.  None of the compounds showed activity in the Vpu binding 
assay. 
As part of the efforts to improve the potency of the hit compounds in the HIV-1 IN- 
LEDGF/p75 assay, hit analogues were designed and synthesized by introducing a carboxylic 
functionality at the 4-position of the imidazole moiety. This was successfully achieved by first 
react various anilines with benzoic chlorides using Et3N in ethyl acetate at room temperature, 
affording N-aryl-benzamides in good yields. These N-aryl-benzamides were then treated with 
SOCl2 to give N-aryl-benzimidoyl chlorides 90 in excellent yields.
 However, when the aniline ring 
was occupied by chlorine substituents at the para-and ortho-positions only traces of the desired 
chlorides were observed (1H NMR spectroscopy). The N-aryl-benzimidoyl chlorides obtained 
were further reacted with ethyl isocyanide catalyzed by DBU in THF at -78oC to room 
temperature for 48 hours, affording a series of new ethyl 1,5-diaryl-1H-imidazole-4-carboxylates 
bearing 4-bromophenyl substituted at the 1-position of the imidazole moiety in low to moderate 
yields. Attempts to improve the low yields and failed conversion for some of the N-aryl-
benzimidoyl chlorides by direct conversion of benzamides into ethyl 1,5-diaryl-1H-imidazole-4-
carboxylates using diethyl chlorophosphate in the presence of catalytic tBuOK in THF at low 
temperature were unsuccessful. These carboxylate derivatives obtained were then hydrolysed 
into the corresponding 1,5-diaryl-1H-imidazole-4-carboxylic acids in excellent yields. 
 
All newly synthesized compounds including the carboxylate derivatives and chosen hit 
compound 83a were evaluated as potential inhibitors of the HIV-1 IN- LEDGF/p75 interaction 
in an AlphaScreen Assay at 100 µM. The introduction of the ester group in ethyl 1,5-diaryl-1H-
imidazole-4-carboxylate derivatives resulted in 1 to 5 times lower percentage inhibition than the 
original hit. However, after hydrolysis all five 1,5-diaryl-1H-imidazole-4-carboxylic acid 
derivatives exhibited more than 50% inhibition in the AlphaScreen assay, with four compounds 
surpassing that of the hit. These 1,5-diaryl-1H-imidazole-4-carboxylic acids were confirmed as 
true hits (not false positives) via the Truhit kit assay. However, in dose range assays these 
compounds produced higher IC50 values than the original hit compound which could be due to 
their insolubility.  In silico docking studies predicted favourable interaction of 1,5-diaryl-1H-
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imidazole-4-carboxylic acids with critical amino acids in a similar way to how the LEDGF/p75 
protein binds to HIV-1 IN, while their binding energies are in accordance with the % inhibition 
activity emerging from AlphaScreen data.  It was apparent that the introduction of a carboxylic 
acid group and the presence of meta-substituents on the 5-aryl ring have a significant impact on 
the binding capability of the scaffolds.  Although these compounds did not reduce the viability 
of the MT-4 cell line, they also did not display antiviral effects in cell based assays, which may be 
due to poor permeability or even poor compound solubility. 
 
Overall: Novel 1,5-diaryl-1H-imidazole-4-carboxylic acid derivatives were designed and 
synthesized as a second generation of 1,5-diaryl-1H-imidazoles. Four compounds showed better 
inhibition of the HIV-1 IN -LEDGF/p75 interaction in a direct single dose assay at 100 μM 
than their non-carboxylated 1,5-diaryl-1H-imidazole predecessors. The newly synthesized 
compounds described in this chapter have not been used previously reported nor have they used 
been evaluated for targeting the interaction between LEDGF/p75-HIV-1 IN proteins. 
 
2.5. Future work 
The structural modification of substituents at the 1- and 5-positions of the imidazole ring, as well 
as extension of the chain along the carboxylic acid moiety,  will be conducted with the potential 
to improve the direct inhibition values and ADME properties (such as better solubility and 
permeability) towards more effective inhibitors of HIV-1 viral replication (Figure 2.12).  
 
N
NX
O
R3
R1
R2
X= O, NH
R1,R2 , R3 = aryl, alkyl  
 
Figure 2.12: Possible structural modification of  the imidazole motif. 
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CHAPTER 3 
Synthesis of 5-aryl-1,3-oxazole compounds by means of microwave assisted 
van Leusen reaction and their biological evolution as possible HIV-1 
inhibitors 
 
3.1. Introduction  
Synthesis of a library of 5-aryl-1,3-oxazole fragments was undertaken in the hope that the 
screening of these oxazoles might also provide a starting point for synthetic optimization of 
identified hits that could demonstrate the capability to disrupt the interactions between HIV-1 
protein and host protein. In line with our objectives described in Chapter 1, we wished to 
explore the preparation of the 5-aryl-1,3-oxazole scaffolds via the van Leusen approach using 
microwave irradiation (MW) as a source of reaction energy. This chapter addresses the synthesis, 
characterization, mechanistic pathways and biological data of the synthesized oxazole 
compounds. 
 
3.2. Synthesis of 5-aryl-1,3-oxazoles  
The approach that utilizes TosMIC 1 as a synthon, in the preparation of oxazole heterocyclic 
compounds is commonly known as the van Leusen oxazole reaction. 230 In this synthetic 
protocol, TosMIC 1 undergoes cyclo-addition to the carbonyl compounds 37 in the presence of 
catalytic base using aprotic solvents to provide 5-substituted-oxazole derivatives 34 (see Scheme 
1.15, Chapter 1). In many instances, microwave irradiation has been shown to decrease 
significantly reaction time and increase reaction yields.196-199  In chapter 2, application of 
microwave irradiation to the van Leusen imidazole reaction was indeed shown to reduce the 
reaction time.  With this in mind, and considering our interest in finding a more convenient 
preparation to build heterocyclic rings, we then focused our synthetic efforts on exploring the 
use of TosMIC 1 as a starting material under microwave irradiation to produce oxazoles in 
methanol or acetonitrile as solvents. Reaction progress was monitored by Thin Layer 
Chromatography (TLC). 
 
3.2.1. Using MeOH as solvent  
The synthesis of the desired heterocycles was first carried out in methanol as depicted in 
Scheme 3.1 (Route 1). Precisely, a mixture of TosMIC 1, benzaldehyde 7a-h and a catalytic 
amount of K2CO3 in dry MeOH was microwave irradiated in a pressurized vessel, at a set 
temperature of 75oC and 120 Watts under inert conditions. Remarkably, TLC analysis indicated 
 
82 
 
that the reaction reached completion after just 7 minutes of irradiation.  Isolation and 
purification of the crude materials using column chromatography afforded the corresponding 5-
aryl-1,3-oxazoles 96a-h in yields ranging from 43 % to 84 % (see Table 3.1).  
 
O
N
S
O
O
H
O
R
O
N
R
R
TosMIC 
K2CO3, MeOH
MW: 120 Watt
         75 oC, 7 min
TosMIC 
K2CO3, MeCN
7a R= 4-F
7b R= 2-Cl
7c R= 3-OMe
7d R= 2,4-diOMe
7e R=3,4-OCH2O-
7f R= 4-tBu
7h R= 4-NO2 
7i R= 2-NO2
7j R= H
43-84%
97(rac)
Toluene
 reflux.1 
h
96e (69%), 
96h (63%)
96i  (60%)
MW: 120 Watt
        90 oC, 12 min
Route 2 Route 1
96a-h
 
 
Scheme 3.1: Synthesis of 5-aryl-1,3-oxazole 96 and (4R,5R)/(4S,5S)-5-aryl-4-tosyl-4,5-dihydro-
1,3-oxazoles 97 under MW. 
 
Table 3.1:  Isolated yields (%) of the 5-aryl-1,3-oxazoles 96a-h by route 1. 
1
O
2
3
N4
5
R  
Compounds R Yields (%) 
96a 4-F 84 
96b 2-Cl 74 
96c 3-OMe 60 
96d 2,4-diOMe 44 
96e 3,4-OCH2O- 43 
96f 4-tBu 59 
96g 4-NO2 73 
96h 2-NO2 68 
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3.2.2. Using MeCN as solvent  
In order to investigate the effect of other solvents on the reaction, three aldehydes with different 
electron donor substituents on the ring (7e, 7h and 7i) were chosen to react under the above 
described conditions, but using dry acetonitrile as solvent as shown in Scheme 3.1 (Route 2). 
After 12 minutes TLC analysis showed the consumption of the starting materials, however the 
isolation of the products showed that the elimination of the para-toluenesulfonyl group had not 
occurred, affording instead the 5-aryl-4-tosyl-2,4-dihydro-1,3-oxazole intermediates 97e, 97h, 
and 97i each as a racemic mixture in yields ranging from 65-80% (Table 3.2). We assume the 
geometry of these products to be trans, corresponding to the (4R, 5R) / (4S, 5S)-isomers, which 
matches the NMR spectroscopic data, including coupling constants, reported in the literature. 231 
These (4R,5R)/(4S,5S)-5-aryl-4-tosyl-2,4-dihydro-1,3-oxazoles 97e, 97h and 97i were then 
refluxed in toluene for 1 hour in accordance with the reported literature to afford the 
corresponding 5-aryl-1,3-oxazoles 96e, 96h and 96i after column chromatography.232 The overall 
yields of these three compounds via the acetonitrile reaction were higher than their 
corresponding yields in MeOH.  
A possible explanation for non-aromatization of compounds 97 in MeCN could be attributed to 
a decrease in acidity of the proton at the 5-position of the five-membered ring, which allows the 
reaction to stop at the oxazoline intermediate. An alternative explanation could be that the 
nucleophilic protic solvent MeOH may assist in the elimination of the tosyl group.  
 
Table 3.2:  Isolated yields (%) of (4R,5R)/(4S,5S)-5-aryl-4-tosyl-4,5-dihydro-1,3-oxazoles 97. 
1
O
2
3
N
4
5
S
O
O
R rac  
Compounds R Yields (%) 
97e 3,4-OCH2O- 80 
97h 2-NO2 65 
97i H 76 
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Table 3.3 below shows a comparative summary between literatures reported conventional 
methods, and the microwave methods developed here.  
 
Table 3.3: Conventional vs microwave assisted reaction times for the preparation of oxazoles 
96b and 96h and oxazolines 97e and 97i under similar conditions. 
Compound Reference Solvent Base Temp. Time 
Yields 
(%) 
Oxazoles 
 
96b 
Flegeau et 
al.233 
MeOH K2CO3 Reflux 14 h 84 
MW ” ” 75oC 7 min 74 
96h 
Mayuko et 
al.234 
MeOH K2CO3 70oC 7 h 67 
MW ” ” 75oC 7 min 68 
Oxazolines 
97e 
Companyó 
et al.232 
MeOH Et3N r.t 16 h 80 
MW ACN K2CO3 90oC 12 min 68 
97i 
van Leusen 
et al.231 
MeOH ” r.t 2 h 94 
MW ACN ” 90oC 12 min 76 
 
 
3.2.3. Mechanism for the formation of oxazoles 96 and oxazolines 97 
The formation of the products 96 and 97 can be explained by the mechanistic pathway illustrated 
in Scheme 3.2. The first step involves the deprotonation of one of the α-methylene protons of 
the TosMIC by catalytic base to generate anion 16.230 This anion 16 then attacks the aldehyde 7 to 
give an intermediate 98, which then undergoes cyclization through the bond formation between 
the oxygen atom and the isocyano group to give the five membered ring system 99. The 
protonation of 99 affords the oxazoline intermediate 97, followed by aromatization by 
displacement of the tosyl group to afford the desired 5-aryl-1,3-oxazoles 96. 
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Scheme 3.2: Mechanism for the formation of the 5-aryl-1,3-oxazoles 96.  
 
Although further investigation on the effect of reaction conditions under microwave irradiation 
on these oxazole derivatives might be undertaken, the microwave-assisted preparation of 5-aryl-
1,3-oxazoles and (4R,5R)/(4S,5S)-5-aryl-4-tosyl-2,4-dihydrooxazoles, when compared to 
conventional methods, clearly results in a reduction in the reaction times from several hours to a 
few minutes. Furthermore, these 5-aryl-1,3-oxazoles 96a-h and (4R,5R)/(4S,5S)-5-aryl-4-tosyl-
2,4-dihydro-1,3-oxazole intermediates (97e, 97h, and 97i) have previously been reported, but the 
use of microwave irradiation to the best of our knowledge is a new synthetic approach.  In total 
twelve (12) compounds were obtained from the microwave assisted-van Leusen reaction. 
 
3.2.4. NMR Spectra of 5-aryl-1,3-oxazole and (4R,5R)/(4S,5S)-5-aryl-4-tosyl-4,5-dihydro-
1,3-oxazole fragments 
In depth NMR spectroscopic analysis of synthesized oxazole 96d and oxazoline 97e will be 
described below as examples representing these compound classes. Other related 5-aryl-1,3-
oxazoles 96 and (4R,5R)/(4S,5S)-5-aryl-4-tosyl-4,5-dihydro-1,3-oxazole compounds 97 show 
similar spectra (changes are mainly observed in chemical shifts of the substituents of the phenyl 
ring).  
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The unique feature in the 1H NMR spectrum of compound 96d was the presence of two singlets 
at δ 7.85 and 7.42 ppm, corresponding to the two methine protons of the oxazole motif while in 
the 13C NMR spectrum, the two methine carbon atoms of the oxazole ring appear at δ 148.9 
ppm and 123.5 ppm.  
On the other hand, the 1H NMR spectrum for compound 97e was characterized by a doublet at 
δ 7.18 ppm (J = 1.2 Hz) corresponding to the 2-methine proton of the oxazoline motif. This 
splitting pattern observed is due to long range coupling with the 4-methine proton at 4.99 ppm, 
which resonates as a doublet of doublets with coupling constants of 4.4 Hz and 1.6 Hz (due to 
further coupling with the 5-methine proton).  Furthermore, the 5-methine proton resonates at δ 
5.94 ppm as a doublet with a J value of 6.0 Hz. Meanwhile, the 13C NMR spectrum for 
compound 97e showed the 2-methine carbon atom at δ 159.3 ppm, whilst the 4- and 5-methine 
carbon atoms resonated at δ 94.2 ppm and 79.4 ppm. 
 
3.2.5. Mass spectral analysis of 5-aryl-1,3-oxazoles 
The obtained products were further analyzed using electrospray ionization mass spectrometry 
(ESI-MS), providing accurate identification of the compounds.  In order to determine the 
accurate formula of the compounds obtained, the results were analyzed using the Bruker 
SmartFormula3D®, with a mass accuracy of 5 ppm (5 mDa).  All compounds showed an 
acceptable tolerance of isotopic pattern fit factor (mSigma) lower than 20 (the lower the mSigma 
value the better the match) and their mass correlated with expected values (Table 3.4).  
 
Table 3.4: HRMS results of compounds 96 and their mSigma values. 
Compds 
Calculated 
m/z 
Chemical 
formula 
[M+1] 
Measured 
m/z 
Err 
(mDa) 
Err 
(ppm) 
mSigma 
value 
96a 164.0506 C9H7FNO 164.0508 -0.2 -1.2 3.0 
96b 180.0211 C9H7ClNO 180.0245 -0.3 -8.9 12.2 
96c 176.0706 C10H10NO2 176.0736 -3.0 -7.2 2.6 
96d 206.0812 C11H12NO3 206.0839 -2.8 -3.4 6.1 
96e 190.0499 C10H8NO3 190.0528 -2.9 -5.2 5.6 
96f 202.1242 C13H16NO 202.1234 -2.8 -7.6 2.3 
96g 191.0451 C9H7N2O3 191.0458 -0.7 -3.6 2.7 
96h 191.0451 C9H7N2O3 191.0475 1.6 8.6 3.8 
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3.2.6. Biological Evaluation of a series of 5-aryl-1,3-oxazoles and 5-aryl-4-tosyl-4,5-
dihydrooxazoles 
A total of 12 compounds were submitted to be evaluated in two biochemical assays and cell-
based assays. The tests were conducted in triplicate and the findings are summarized in Table 3.5. 
 
Table 3.5:  The biological activities of the 5-aryl-1,3-oxazole 96 and (4R,5R/4S,5S)-5-aryl-4-
tosyl-4,5-dihydro-1,3-oxazole derivatives 97. 
C
o
m
p
o
u
n
d
 
 
Biochemical target assays 
 
Cell-based assays (MT-4 cells) 
HIV-1 IN – 
LEDGF/p
75 (%) 
inhibition 
assay 
@ 10 µM  
(AlphaScre
en) 
HIV-1 Vpu – binding 
assay 
@ 10 µM (% 
inhibition) 
(ELISA) 
Viability @ 10 µM 
(Absorbance value ± STD 
DEV) 
96a 23.37±3.44 3.99 1.26 ±0.18 
96b 33.35± 0.97 0.92 1.32± 0.25 
96c 32.98±0.60 0 1.29±0.187 
96d 41.55±1.59 17.63 1.20±0.12 
96e 34.64±1.56 14.30 1.21±0.22 
96f 35.34±3.76 9.70 1.23±0.26 
96g 29.48±2.03 25.66 1.34±0.11 
96h 32.58±3.96 0 1.20±0.13 
96i 30.57 ± 1.79 15.97 1.26 ± 0.28 
97e 32.90 ± 4.92 15.76 1.43 ± 0.26 
97h 38.00 ± 0.60 10.24 1.34 ± 0.21 
97i 33.85 ± 1.72 11.67        1.33± 0.17 
CX05168 
91.37+-0.85 
at 100 µM 
  
HIV-1 IN and 
LEDGF with 
DMSO 
0   
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3.2.6.1 Biochemical target assays 
The compounds were assessed using two biochemical assays; namely the HIV- 1 IN-
LEDGF/p75 inhibition assay and the HIV-1 Vpu binding assay.  
3.2.6.1.1. HIV-1 IN -LEDGF/p75 assay 
The compounds were initially evaluated at 10 µM to determine percentage disruption of the 
HIV-1 IN-LEDGF/75 interaction using AlphaScreen technology. Unfortunately, the scaffolds 
showed marginal activity on the disruption of IN-LEDGF/p75 interactions. Compound 96d 
exhibited the highest inhibitory activity of 42% at 10 µM for the 5-aryl-1,3-oxazole group of 
compounds while compound 97h was highest for the (4R,5R)/(4S,5S)-5-aryl 4-tosyl-2,4-dihydro-
1,3-oxazole derivatives, with 38% inhibition against LEDGF/p75-IN interaction. This value is, 
however, below our pre-defined cut off value of 50%. 
 
3.2.6.1.2. HIV-1 Vpu binding assay 
In the second biochemical assay, the compounds were tested for their ability to inhibit the 
binding of the antibody (anti-Vpu) to Vpu using an ELISA method.  None of the tested 
compounds showed inhibition of the antigen-antibody interaction. It is likely, however, that 
small molecules cannot sufficiently block this interaction as the binding site is rather large. 
 
3.2.6.2. Cell based assay 
Each compound was evaluated for toxicity in the MT-4 cell line at 10 µM.  At this initial 
concentration, none of the compounds reduced the viability of the cells as determined by MT-2 
lymphocyte cell line; therefore the compounds are regarded as not overly toxic. 
 
3.3. Synthesis of N,5-diaryl-1-3-oxazole-4-carboxamides as second generation 
compounds 
Based on the disappointing biological results obtained from the first fragment library, we wished 
to explore possible second generation compounds. Examination of the original scaffolds shows 
the absence of key structural characteristics that could disrupt protein-protein interactions.  In 
recent years, compounds containing N-aryl-4-carboxamide cores have been developed as 
potential inhibitors of the interaction between LEDGF/p75 and IN proteins.  For instance, 
Cavalluzo and co-workers235 have designed, through pharmacophore modelling, and synthesized 
the 3-(1H-indol-3-ylthio)-N-(2-isopropoxy-6-methoxypyridin-3-yl)benzamide derivatives (known 
as CAB compounds) containing N-aryl-4-carboxamide moieties (framed in Figure 3.1) as 
potential inhibitors of the HIV-1 IN and host LEGDF/p75 co-factor interactions.  These 
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particular compounds have also been established to prevent the binding of LEDGF/p75 to its 
natural protein JPO2, the same site at which IN binds.  The data proved that the CAB 
compounds selectively bind to the cellular cofactor LEDGF/p75.  Furthermore, Serroa et al.180 
have also reported the design, via molecular docking, and synthesis of another class of 
compounds bearing N-aryl-4-carboxamide cores as inhibitors that targeted the LEDGF/p75-IN 
interaction.  These compounds were found to be non-toxic and exhibited submicromolar IC50 
values.   
 
 
 
Figure 3.1: Structure of compounds containing N-aryl-4-carboxamide moieties. 
 
On the basis of the above and our interest in the development of new potential anti-HIV-1 
drugs, attention was focused on exploring the effect of chemical structure variation by 
incorporating the N-aryl-4-carboxamide framework at the 4-position of the 5-aryl-1,3-oxazole 
scaffolds 96 (Scheme 3.3).  Our hypothesis was that this modification would increase the 
inhibition effect of this scaffold as well as providing insight into the structure activity 
relationships (SAR) for these types of compounds. Therefore, the work described here was 
aimed at integration of N-aryl-4-carboxamide cores at the 4-position of 5-aryl-1,3-oxazole 
derivatives 96 to obtain a set of N,5-diaryloxazole-4-carboxamides 100 as a second generation 
library. 
 
O
N
O
N
96
O
N
H
R'
R
R
100
Carboxamide 
moiety
 
 
Scheme 3.3: Integration of carboxamide moiety on the 5-aryl-1,3-oxazole fragments. 
 
90 
 
3.3.1. First retrosynthetic approach to target compounds  
The retrosynthetic analysis of the target N,5-diaryl-1,3-oxazole-4-carboxamides 100 is shown in 
Scheme 3.4. It was envisaged that the 1,3-oxazole ring system of the target scaffold 100 could be 
constructed through cycloaddition of commercially available benzoyl chloride 92 to 2-isocyano-
N-arylacetamide 101.   The key intermediate 101 in turn could obtained through a well-
established protocol  which could involve the dehydration of N-aryl-2-formamidoacetamide 
precursor 102, which could be derived by coupling of the aniline scaffold 74 with hydrazinyl 
formamide 103.  The precursor 103 could be the obtained from previously reported literature via 
a nucleophilic substitution reaction of N-formyl glycine methyl ester 104 with hydrazine 
monohydrate. The scaffold 104 could be obtained from two possible commercially available 
synthons; amino acid ester hydrochloride salts 105 and methyl formate 106.  
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Scheme 3.4: First retrosynthetic approach to the target compounds 100. 
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3.3.1.1. Synthesis of the 2-isocyano-N-aryl-acetamide  
The construction of the desired N,5-diaryl-1,3-oxazole-4-carboxamide derivatives 100 was then 
pursued and the key synthetic building blocks, 2-isocyano-N-arylacetamides 101, were first 
synthesized over 4 steps as illustrated in Scheme 3.5.  
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R
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O
NH2.HCl O
O
H
N
O
O
H
Et3N, rt, 3 d
O H2N
N
H
O
H
N O
NH2NH2.H2O (64%)
MeOH, rt, 4 h
105 104 81%
103 71%
i. 1N  HCl, NaNO2,
    H2O, 0
oC, 20 min
ii. NaHCO3, H2O
iii.
R
NH2
          R               Yields     
102a  4-Br               45%
102b  2,4-diOMe     68%
THF, 0oC, 5 h
           R                  Yields  
101a  4-Br                  34%
101b  2,4-diOMe        92%
106
74e R = 4-Br
74i R= 2,4-diOMe
Et3N, DCM, rt, 30 min
POCl3
 
 
Scheme 3.5: Synthesis of 2-isocyano-N-arylacetamides intermediates 101. 
 
Thus, the commercially available glycine ester hydrochloride 105 was reacted with excess methyl 
formate 106 in the presence of triethylamine catalyst at room temperature for 3 days.  Work-up 
furnished the desired ethyl 2-formamidoacetate 104 in a yield of 81%. The yield and NMR 
spectrum of the product 104 were comparable to those reported in literature.236,237,238,239 The N-
formyl glycine ethyl ester 104 was then subjected to a nucleophilic substitution reaction with 
hydrazine monohydrate in methanol at room temperature.238  After 4 hours, the resulting 
precipitate was then isolated by filtration and dried under high vacuum to afford pure N-(2-
hydrazinyl-2-oxoethyl)formamide 103 in a yield of 71%.  The identity of 103 was confirmed by 
the 1H NMR spectrum which showed the disappearance of the signals due to the ethyl protons 
and the appearance of an NH proton at 8.25 ppm, as well as the NH2 group at 4.26 ppm, while 
the 13C NMR spectrum further supported the loss of the carbon atoms of the ethyl group. 
The N-(2-hydrazinyl-2-oxoethyl)formamide 103 was then treated with 1N HCl and NaNO2, 
followed by addition of a solution of aniline 74 in THF at 0oC for 5 hours. Work up and 
 
92 
 
purification by column chromatography on silica afforded novel N-aryl-2-formamidoacetamide 
102a and 102b in yields of 45 and 68%. The 1H NMR spectrum of compound 102b confirmed 
the chemical structure of the N-aryl-2-formamidoacetamide products by exhibiting three 
downfield singlets at δ 9.09, 8.38 and 8.16 ppm, assigned to the two NH and 2-methine protons, 
while the signals in the aromatic region of δ 6.65-7.75 ppm correspond to the methine protons 
of the aryl ring.  
 
The N-aryl-2-formamidoacetamides 102a and 102b were then subjected to dehydration 
conditions by stirring with phosphoryl chloride and triethylamine in DCM at room temperature 
for 30 minutes.238   Work up and isolation by short column chromatography furnished the 
desired novel N-aryl-2-isocyanoacetamide intermediates 101a and 101b in yields of 34% and 
92%, respectively.  The identity of the product in each case was established by the disappearance 
of the N-formamide protons (NHCHO) in the 1H NMR spectrum for compound 101b and the 
formation of a new signal at δ 159.4 ppm in the 13C NMR spectrum, which corresponds to the 
divalent carbon ( ) of the isocyano group.  The FTIR spectroscopic data supported the 
formation of the N-aryl-2-isocyanoacetamides by exhibiting unique bands at 2157 cm-1 (for 101b) 
assigned to the isocyano group while the bands in the regions of 3291 and 1728 cm-1 were 
assigned to the NH and carboxyl groups (Table 3.6).   
 
Table 3.6: FTIR spectroscopic data of N-aryl-2-isocyanoacetamide intermediates 101a-b 
showing the N, C=O and isocyano bands. 
Compounds υNH(cm-1) υC=O(cm-1) υisocyano group (cm-1) 
101a 3291 1728 2157 
101b 3250 1702 2160 
 
 
3.3.1.2. Reaction of 101b with benzoyl chlorides  
As the final step in the synthesis of the target compounds, a set of benzoyl chlorides 92a-c were 
then reacted with N-aryl-2-isocyanoacetamide 101b in the presence of triethylamine in DCM at 
room temperature (Scheme 3.6, Route 1), but product formation could not be observed by 
TLC, even after prolonged stirring for 48 hours.  A change of solvent (THF for DCM) only 
afforded the recovery of starting material 101.  However, when the reaction was conducted in the 
presence of DBU instead of Et3N as catalyst (Scheme 3.6, Route 2), the hydration product 
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previously synthesized, N-(2,4-dimethoxyphenyl)-2-formamidoacetamide 102b, was obtained 
after 48 hours of stirring at room temperature in a yield of 85%.  It became clear then that the 
reactions between isocyanoacetamides bearing a secondary amide (such as 101b) with benzoyl 
chlorides do not proceed as expected.  A possible explanation for lack of reactivity of 
isocyanoacetamides might be the presence of an amide group, which tends to lower the acidity of 
the α-methylene protons adjacent to the isocyano group. Giustiniano and co-workers reported 
the lack of reactivity between acyl chloride and α-isocyanoacetamide containing a secondary 
amide, which is in agreement with the findings of this study.240  
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Scheme 3.6: Attempted synthesis of N,5-diaryl-1,3-oxazole-4-carboxamides. 
 
 
3.3.1.3. Reaction of compound 101b with benzaldehydes  
With the failure of the last step of the planned reaction path towards the target 100, an 
alternative route was envisaged and attention was turned to the reaction of benzaldehydes 7 with 
isocyanide 101b (Scheme 3.7) and subsequent oxidation of the resulting 4,5-dihydro-N,5-diaryl-
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1,3-oxazole-4-carboxamides 107 into target 100. Thus the benzaldehydes 7a-c and 7i were 
reacted with N-(2,4-dimethoxyphenyl)-2-isocyanoacetamide scaffold 101b in the presence of 
DBU in DCM at room temperature. TLC indicated the formation of a new spot and work up 
and purification using column chromatography gave (4R,5R)/(4S,5S)-4,5-dihydro-N,5-diaryl-1,3-
oxazole-4-carboxamide scaffolds 107 as a racemic mixture in good yield (Table 3.7). 
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Scheme 3.7:  Synthesis of the (4R,5R)/(4S,5S)-4,5-dihydro-N,5-diaryl-1,3-oxazole-4-
carboxamides 107. 
 
Table 3.7: Yields isolated (%) of (4R,5R)/(4S,5S)-4,5-dihydro-N,5-diaryl-1,3-oxazole-4-
carboxamide scaffolds 107. 
O
1
2
O
3
4 N
5
R
N
H
O
O
(rac)  
Compd R Yields (%) 
107a 4-F 70 
107b 2-Cl 60 
107c 3,4-diOMe 55 
107d H 70 
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The synthesis of the (4R,5R)/(4S,5S)-4,5-dihydro-N,5-diaryl-1,3-oxazole-4-carboxamide 
scaffolds was confirmed by NMR spectroscopy and the geometry reported here resembles that 
discussed in section 3.2.2. The 1H-NMR spectrum of compound 107a in deuterated chloroform 
(CDCl3) exhibited a singlet at 8.72 ppm, corresponding to the imine (NH) group, while another 
singlet at δ 7.18 ppm corresponds to the 2-methine proton of the 4,5-dihydro-1,3-oxazole ring. 
The two set of doublets at δ 5.72 and 4.62 ppm with J values of 7.6 Hz each correspond to the 
5- and 4-methine protons of the 4,5-dihydro-1,3-oxazole ring which are in vicinal coupling to 
each other. This splitting between 5- and 4- methine protons has been reported the (4R, 5R) / 
(4S, 5S) isomers.241  Furthermore, two singlets at δ 3.87 and 3.80 ppm were assigned to the six 
protons of two methoxy groups.  
 
3.3.1.4. Attempted oxidation of 5-aryl-4,5-dihydro-N-(3,5-dimethoxyphenyl)-1,3-oxazole-
4-carboxamides 
Encouraged by a reported approach where the oxidation of 2-aryl-4,5-dihydrooxazole-4-
carboxylates was accomplished using bromotrichloromethane (BrCCl3) and DBU under mild 
conditions, 242 we explored the oxidation of our dihydro-carboxamides 107 using this reported 
protocol in DCM at 0oC. Unfortunately, even after 48 hours none of the desired N,5-diaryl-4-
carboxamide-1,3-oxazole analogues 100 were obtained (Scheme 3.8).  
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Scheme 3.8: Attempted oxidation of 5-aryl-4,5-dihydro-N-(3,5-dimethoxyphenyl)-1,3-oxazole-4-
carboxamides. 
 
 
 
 
96 
 
Considering the number of steps required to synthesise the aryl-isocyanoacetamide synthetic 
intermediates and the failed final oxidation of 5-aryl-4,5-dihydro-N-(3,5-
dimethoxyphenyl)oxazole-4-carboxamides, attention was concentrated on designing a new 
retrosynthetic route towards the N,5-diaryl-1,3-oxazole-4-carboxamides 100. 
 
3.3.2. Second retrosynthetic approach to the target compounds  
A new retrosynthetic pathway for target 100 was then proposed (Scheme 3.9). The desired 
targeted 100 could be obtained from the coupling between aniline derivatives 74 and 5-aryl-1,3-
oxazole-4-carboxylic acids 108.  Scaffold 108 could arise from hydrolysis of ethyl 5-aryl-1,3-
oxazole-4-carboxylates 109, which in turn could be obtained from the condensation of 
commercially available reagents benzoyl chloride 92 and ethyl isocyanoacetate 89.  
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Scheme 3.9: Second retrosynthetic approach to the target compounds.  
 
3.3.2.1. Synthesis of 5-aryl-1,3-oxazole-4-carboxylic acids (108) 
As proposed in Scheme 3.10, the synthesis of 5-aryl-1,3-oxazole-4-carboxylic acids 108 was then 
pursued as a necessary step towards the target compounds 100.  Benzoyl chloride derivatives 92a 
and 92c were reacted with ethyl isocyanoacetate 89 in the presence of Et3N as a catalytic base 
using ethyl acetate solvent for 48 hours (Scheme 3.10).243,244,245  Work up and separation by 
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column chromatography on silica gel afforded the desired ethyl 5-aryl-1,3-oxazole-4-carboxylate 
derivatives 109a and 109c in good yields.  The better reactivity of ethyl isocyanoacetate 89 in 
comparison to the earlier scaffold, N-aryl-isocyanoacetamide 101, could be accredited to the 
presence of the ester group (R-CO2-), which tends to enhance the reactivity of the α-acidic 
protons adjacent to the carbonyl, while acidity of the methylene protons of N-aryl-
isocyanoacetamide 101 was reduced by the presence of the secondary amide.  
 
O
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N
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O
O
N
R
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92c R=  3-OMe
         R           Yields
109a:  F             72%  
109c:  3-OMe    67%
         R           Yields
108a:  F             89%  
108c:  3-OMe    82%
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Scheme 3.10: Synthesis of 5-aryl-1,3-oxazole-4-carboxylic acids. 
 
3.3.2.2. Mechanism for the formation of ethyl 5-aryl-1,3-oxazole-4-carboxylates 109 
A possible mechanism (Scheme 3.11) for formation of the ethyl 5-aryl-1,3-oxazole-4-carboxylates 
109 is believed to proceed via the deprotonation of the α-acidic proton of ethyl isocyanoacetate 
89 by a catalytic base to generate a highly reactive nucleophile 93, which then then attacks the 
benzoyl chloride 92, to give the alpha isocyano carbonyl intermediates 110, with displacement of 
the chlorine atom as the triethylamine hydrochloride salt.243 The intermediate 110, under basic 
conditions, exists in a dynamic equilibrium with α-isocyanoenolate 111, which then undergoes a 
ring closure upon work up to afford the desired ethyl 5-aryl-1,3-oxazole-4-carboxylates 109. 
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Scheme 3.11: Mechanism of the formation of ethyl 5-aryl-1,3-oxazole-4-carboxylates. 
 
The formation of the products 109 was confirmed by NMR spectroscopic analysis. The 1H NMR 
spectrum of compound 109a showed a singlet signal at 7.90 ppm corresponding to the methine 
proton of the oxazole moiety; while the 13C NMR spectrum revealed the methine carbon atom at 
148.8 ppm. Additionally, the 13C NMR further displays two signals at 161.9 and 154.7 ppm 
corresponding to the carbonyl carbon atom and the 5-carbon atom of the oxazole motif. 
 
The ethyl 5-aryl-1,3-oxazole-4-carboxylates 109a and 109c were then subjected to hydrolysis by 
refluxing in a mixture containing NaOH, methanol and water for 6 hours, followed by acidifying 
with HCl.246,247  Work up afforded the desired free carboxylic acid derivatives 108a and 108c in 
excellent yields of 82% and 89%.  The identity of the products was confirmed by means of 1D- 
and 2-D NMR spectroscopy. The 1H NMR spectrum of compound 108a was characterised by 
the loss of the signals arising from protons belonging to the ethyl group and the presence of a 
new signal downfield at 13.2 ppm corresponding to the proton of the carboxylic acid group. The 
loss of the ethyl group was also observed in the 13C NMR spectrum of the compound. In 
addition, the hydrolysis of the ester group was also evident in the FTIR spectra of 5-aryl-1,3-
oxazole-4-carboxylic acids 108, which displayed a broad signal at 2461 cm-1 (for 108a) and 2569 
cm-1 (for 108c) corresponding to the hydroxyl group, whilst the bands of the carbonyl (C=O) 
and the C=N group were observed in the region of 1709-1727 cm-1 and 1506-1596 cm-1. 
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3.3.2.3. Anilidation of 5-aryloxazole-4-carboxylic acid derivatives   
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Scheme 3.12: Synthesis of the target compounds 100. 
 
The 5-aryl-1,3-oxazole-4-carboxylic acids 108a and 108c were first converted to the more 
reactive 5-aryl-1,3-oxazole-4-carbonyl chloride intermediates 112a and 112c using SOCl2 under 
reflux for 8 hours (Scheme 3.12).248,249 These compounds are characterized by the absence of the 
hydroxyl group in the 1H NMR spectra.  
 
The final synthetic step was the nucleophilic attack of aniline derivatives 74 on the carbonyl 
chlorides 112a and 112c in the presence Et3N using ethyl acetate as a solvent for 48 hours. 
250,251 
Target compounds N,5-diaryl-4-carboxamide-1,3-oxazoles 100a-e and 100g-i were obtained 
after column chromatography, while the products 100f and 100j-k (with carboxylic substituent) 
were obtained as precipitates from DCM in good yields (Table 3.8).  Moreover, this 
transformation of the 5-aryl-1,3-oxazole-4-carboxylic acid scaffolds into the corresponding N,5-
diaryl-1,3-oxazole-4-carboxamide derivatives led to a total number of eleven novel compounds 
100a-k. Spectral analysis of the corresponding products with FTIR, 1D and 2D NMR, and 
LCMS confirmed the structures of the desired final products. 
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Table 3.8: Isolated yields (%) of the N,5-diaryl-1,3-oxazole-4-carboxamides 100a-k. 
O
O
N
R
N
H
R'
 
Compound R R’ Yields (%) 
100a 4-F 2-OH 84 
100b 4-F 2,4-diOMe 68 
100c 4-F 4-Br 73 
100d 4-F 2,4-diMe 70 
100e 4-F 2,4-diCl 72 
100f 4-F 2-COOH 64 
100g 3-OMe 2-OH 78 
100h 3-OMe 2,4-diOMe 72 
100i 3-OMe 4-Br 84 
100j 3-OMe 2-COOH 52 
100k 3-OMe 2-COOH,4-F 60 
 
 
3.3.2.5. FTIR and NMR spectroscopic analysis of N,5-diaryl-1,3-oxazole-4-carboxamides 
100 
The 1H NMR spectrum of N-(4-bromophenyl)-5-(3-methoxyphenyl)-1,3-oxazole-4-carboxamide 
100i is used as a representative of this compound class. This compound exhibited two singlets at 
9.12 and 8.00 ppm corresponding to the secondary amide group (NH) and the methine proton 
of the oxazole core. The eight methine protons of the two benzene ring systems resonate in the 
aromatic region of 7.00 ppm to 7.89 ppm, while the singlet signal at 3.90 ppm accounting for 
three protons corresponds to the methoxy group. The 13C NMR spectrum of compound 100i 
confirms the expected presence of 15 unique carbon environments with the carbonyl carbon 
atom resonating at 159.5 ppm, while the signals at 153.6 and 147.7 correspond to the 5-carbon 
and methine carbon atoms of the oxazole moiety, respectively. The FTIR spectra of target 
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compounds showed intense peaks in the region of 3200-3397 cm-1 corresponding to the NH 
stretch while the bands in the regions of 1660-1730 cm-1 and 1525-1591cm-1 correspond to the 
amide carbonyl group and C=N of the oxazole motif.  
 
3.3.2.6. Mass analysis of N,5-diaryl-1,3-oxazole-4-carboxamides 100 
Analysis of the compounds 100 by high-resolution mass spectrometry was done using an LC-MS 
system with an ESI (electrospray ionisation) probe. Calculated and experimental m/z values for 
the molecular ions of the parent compounds and their mSigma values are displayed in Table 3.9. 
Accurate formulae for the compounds were calculated using the Bruker SmartFormula3D® 
algorithm that associates within 5 mDa calculated isotopic patterns to the parent compound ion 
masses and their fragments (acceptable mSigma values ≤ 20). 
 
Table 3.9: HRMS results of the N,5-diaryl-1,3-oxazole-4-carboxamides 100a-k and their 
mSigma values. 
Compds 
Calculated 
m/z 
Chemical 
formula 
[M+1] 
Measured 
m/z 
Err 
ppm 
Err 
mDa 
mSigma 
values 
100a 299.0826 C16H12FN2O3 299.0841 -1.5. -2.9 0.6 
100b 343.1094 C16H16FN2O4 343.1116 -2.2 -6.3 1.2 
100c 360.9982 C16H1179BrFN2O2 361.0004 -2.2 -6.1 3.6 
100d 311.1190 C18H16FN2O4 311.1186 -0.4 -2.3 1.5 
100e 351.0098 C16H10Cl2FN2O2 351.0095 -0.3 -4.3 7.5 
100f 327.0781 C17H12FN2O4 327.0795 -1.9 -4.2 0.6 
100g 311.1026 C19H15N2O4 311.1036 -1.0 -1.3 9.4 
100h 355.1288 C19H19N2O5 355.1309 -2.1 -4.2 7.7 
100i 373.0182 C17H1479BrN2O3 373.0200 -1.8 -4.9 6.3 
100j 399.0975 C18H15N2O5 39.0977 -0.2 -0.6 8.8 
100k 357.0881 C18H14FN2O5 357.0906 -2.5 -6.9 3.2 
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3.3.2.6.1. MS/MS fragmentation 
Compound N-(2-hydroxylphenyl)-5-(4-fluorophenyl)-1,3-oxazole-4-carboxamide 100a was 
chosen as the model to discuss in detail the mass fragmentation patterns. As illustrated in Figure 
3.2, analysis of compound 100a by ESI-MS revealed a molecular ion peak at m/z 299.0841 
corresponding to the protonated parent ion, with a molecular formula C16H12FN2O3
+. The 
MS/MS spectrum of N-(2-hydroxylphenyl)-5-(4-fluorophenyl)-1,3-oxazole-4-carboxamide 100a 
at m/z 299.08 with the molecular formula C16H12FN2O3
+ exhibited a possible fragmentation 
pattern as depicted in Figure 3.3. The parent molecular ion decomposes by losing a neutral 
C6H5N group to give a fragment ion C10H7FNO3
+ at m/z 208.04. This ion further undergoes 
breakdown to provide two possible pathways: the first arises as a result of the loss of a water 
molecule to furnish a fragment ion at m/z 190.03 with chemical formula C10H5FNO2
+. This 
fragment then loses carbon monoxide (-CO) to provide the cation with formula C9H5FNO
+ at 
m/z 162.04, followed by further loss of another carbon monoxide (-CO) to afford a base peak at 
m/z 134.04 with chemical formula C8H5FN
+. This base peak may undergo the loss of hydrogen 
cyanide (-HCN) to form the fragment ion at m/z 107.03 with the formula C7H4F
+.  The second 
pathway involves the loss of carbon monoxide (-CO) to provide C9H7FNO2
+ at m/z 180.05, 
followed by further decomposition through loss of a neutral formaldehyde (-HCOH) to yield a 
fragment ion at m/z 150.04 with the formula C8H5FNO
+.  This ion then undergoes 
decomposition by losing hydrogen cyanide (-HCN) to give m/z 123.02 with the chemical 
formula C7H4FO
+. 
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a) 
 
b) 
Figure 3.2: Recorded spectra for compound 100a: (a) MS and b) MS/MS (col. energy 35 eV) 
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Figure 3.3: Fragmentation pathway of compound 100a 
 
 
 
105 
 
3.3.3. Biological evaluation in LEDGF/p75-IN inhibition assay 
A series of compounds containing a 5-aryl-1,3-oxazole core, were tested in an in vitro 
AlphaScreen assay to determine the percentage inhibition of the interaction between the host co-
factor LEDGF/p75 and HIV1 IN proteins. Due to the success seen in Chapter 2, and 
suggestions from the literature review regarding the screening of fragment libraries at higher 
concentration, we therefore wished to conduct the assessment of the second generation of 
oxazole-based compounds at 100 µM. 252,253,254,255   The experiments were run in triplicate and 
results are recorded in Table 3.10.  Re-evaluation of compounds 96a and 96d at a single dose of 
100 μM displayed lower percentage inhibition than at 10 μM concentration, which is attributed 
to the poor solubility of these compounds at higher concentration. Further evaluation of 
compounds containing a carboxylate ester group at the 4-position of the 5-aryl-1,3-oxazole ring 
showed these compounds displayed poor activity [109a (0%) and 109c (3%)].  However, the 
hydrolysis of these ethyl carboxylates into their corresponding free carboxylic acids slightly 
improved their percentage inhibition to 23% (108a) and 29% (108c).  These results point to the 
fact that the carboxylic acid functionality at the 4-position of the five-membered ring has some 
capacity to disrupt the interaction between LEDGF/p75 and IN proteins. In the set of target 
compounds, at least two compounds (100b and 100h) exceeded the pre-defined minimum cut-
off of 50%.  The compound bearing the electron withdrawing fluorine substituent at the para-
position of the phenyl ring directly linked to the oxazole moiety (compound 100b) exhibited the 
highest average percentage inhibition of 58% for the disruption of the LEDGF/p75-IN 
interaction, while the compound with the electron donating methoxy group at the meta-position 
of the benzene ring attached to the oxazole system (compound 100h) displayed an average 
percentage inhibition of 56%.  It is interesting to note that both of these compounds 100b and 
100h have electron-donating methoxy groups at the ortho- and para-positions of the aniline rings. 
The presence of the two methoxy groups may be significant due to their ability to participate in 
hydrogen bonding to the target protein.  Comparing compounds 100b and 100h versus 100a and 
100g (with the ortho-hydroxyl group), it is shows that the presence of a second electron-donating 
group at the para-position of the N-aryl ring is critical to accomplish better inhibition. However, 
the presence of an electron withdrawing chlorine atom at the ortho- and para-positions in 
compound 100e displayed lower inhibition (43%) compared to the percentage inhibition of 
compounds 100b and 100h, which could be attributed to the loss of the hydrogen bond of the 
methoxy group. Furthermore, the presence of the electron withdrawing bromine atom at the 
para-position in scaffolds 100c and 100i, as well as the presence of carboxylic substituents at the 
ortho-position didn‟t have major effects on the binding of the scaffolds. Further SAR revealed 
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that a large group occupying the ortho- and para-position of the aniline ring is favoured while the 
substitution of the other phenyl ring plays little role in inhibition. It is also noteworthy to 
mention that compounds 100b and 100h, showing the highest inhibition, contain similar 2,4-
dimethoxyaniline subunits in their structures to that found in the reported CAB compounds, 
which were active in disrupting the LEDGF/p75-IN interaction (see Figure 3.1).235   
 
Table 3.10: The HIV-1 IN-LEDGF/p75 inhibition activities of compounds 96a-d, 100a-k, 
107a-d, 108a-b and 109a-b at 100 μM. 
 
COMPOUD 
ENTRY 
 
HIV-1 IN – LEDGF 
(%) inhibition @ 100 
µM (AlphaScreen) 
 
O
O
N
R
N
H
R'
100a: R 4-F, R' 2-OH
100b: R 4-F, R' 2,4-diOMe
100c: R 4-F, R' 4-Br
100d: R 4-F, R' 2,4-diOMe
100e: R 4-F, R' 2,4-diCl
100f: R 4-F, R' 2-COOH
100g: R 3-OMe, R' 2-OH
100h: R 3-OMe, R'2,4-diOMe
100i: R 3-OMe, R' 4-Br
100j: R 3-OMe, R' 2-COOH
100k: R 3-OMe, R' 2-COOH,4F
O
O
N
R
HO
O
O
N
R
OEt
O
N
R
109a: R 4-F
109b: R 3-OMe
96a: R 4-F
96b: R 3-OMe
O
O
N
R
N
H
O
O
108a: R 4-F
108b: R 3-OMe
107a: R 4-F
107b: R 2-Cl
107c:  R 3,4-diOMe
107d: R H
TM
 
96a 4.04±1.08 
96d 3.63± 3.03 
100a 22.07±1.57 
100b 58.04±8.70 
100c 3.44±1.77 
100d 8.04±4.14 
100e 42.92±2.35 
100f 34.02±3.99 
100g 7.45±2.93 
100h 55.74±2.28 
100i 23.56±2.80 
100j 29.42±7.22 
100k 28.07±5.31 
107a 2.48.±7.28 
107b 0 
107c 2.53±5.26 
107d 4.13±10.36 
108a 22.84±1.20 
108c 28.71±7.29 
109a 0 
109c 3.37±3.31 
CX05168 91.37+-0.85 
HIV-1 IN and 
LEDGF with 
DMSO 
0 
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Analogues of the desired N,5-diaryl-4-carboxamide-1,3-oxazole products, the (4R,5R/4S,5R)-
4,5-dihydro-N-5-diaryl-1,3-oxazole-4 carboxylate derivatives 107, with no double bond between 
the 4- and 5-carbons of the oxazole ring, were inactive in the LEDGF/p75-IN assay.  This may 
be due to the lack of planarity resulting from the missing double bond in the oxazoline moiety.  
 
3.3.4. The prediction of ADME parameters of the synthesized compounds  
The ADME properties of the best two compounds were predicted using Discovery StudioTM and 
results are recorded in Table 3.11. 
 
Table 3.11: The ADME prediction for the synthesized compounds 100b and 100h obtained 
from Discovery Studio version 4.0. 
Compounds 
Aqueous 
Solubility  
Blood Brain 
Barrier 
Penetration 
Human Intestinal 
Absorption 
CYP2D6 
Inhibition 
100b 2 3 2 No 
100h 3 3 3 No 
 
 
The ADME prediction of compound 100h showed a good solubility level of 3 while the 
compound 100b had a low solubility level of 2. Furthermore, both compounds were predicted to 
be absorbed very poorly in the human intestine and were also found to be non-inhibitors of 
cytochrome p4502D6. Moreover, compound 100b was shown to be a medium penetrator of the 
BBB, while compound 100h exhibited a BBB penetration level of 3, representing low 
penetration. These results indicate the compounds warrant further modification to improve their 
ADME properties.   
 
3.3.5 Molecular modelling of the synthesized N,5-diaryl-1,3-oxazole-4-carboxamide 
derivatives 
Compounds 100b and 100h which displayed acceptable IN-LEDGF/p75 inhibition were 
subjected to a docking protocol in order to obtain details on the SARs and also to gain 
understanding of the binding patterns. The two best compounds were then docked into the same 
cavity where LEDGF/p75 binds to the HIV-1 IN dimer of the 2B4J crystal structure using the 
previously descried LibDock method in Section 2.3.4. The poses generated from LibDock were 
further subjected to scoring functions, analysed, in-situ energy minimized and then re-docked 
 
108 
 
using CDocker and flexible docking. Finally the binding energies of the flexible poses were then 
calculated and the results are recorded in Table 3.12. The predicted binding model indicated that 
the two compounds were binding at the interface between subunits A and B of the HIV-1 IN 
with compound 100b displaying the lowest binding energy of -66.956 Kcal/mol whilst 
compound 100h exhibited a binding energy of -53.8902Kcal/mol. 
 
Table 3.12:  A list of in silico interactions of compounds 100b and 100h and binding site amino 
acids according to order of  their binding energy.  
Compounds 
Binding energy 
Kcal/mol 
Amino acids 
interactions 
LibDocked 
Scoring functions 
100b -66.956 
Gln95, Ala128, 
THR124, Ala169, 
Glu170 
20.731 
100h -53.8902 
Gln95, Gln98, 
Ala169, 
23.336 
 
 
The predicted model for 100b (Figure 3.4, A and B) displayed the para-methoxy group of the 
aniline ring making a hydrogen bond to the Gln95 residue, while the fluorine atom and its phenyl 
ring occupy the hydrophobic pockets formed by the residues Thr124 and Ala128 of monomer A. 
Furthermore, the carbonyl oxygen atom was shown to make two hydrogen bonds with the 
Ala169 and Glu170 residues of subunit B of the HIV-1 IN.  
The projected binding model of compound 100h (Table 3.4, C and D) shows the para-methoxy 
of the aniline ring making two hydrogen bonds with the backbone Gln95 residue of monomer A 
whilst the meta-methoxy of the phenyl ring at the 5-position of the oxazole motif exhibited 
hydrogen bonding to the Glu170 of subunit B. Moreover, the phenyl at the 5-position of the 
oxazole ring is shown to occupy the hydrophobic pocket formed by the Ala169 amino acid 
residue while the NH adjacent to the carbonyl group shows a hydrogen bond to the oxygen of 
Gln98 residue. 
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A   B  
  
C  D  
Figure 3.4: Predicted binding models of compounds 100b (A and B), and 100h (C and D) 
docked in the LEDGF/p75 binding cavity at the HIV-1 IN dimer interface (with yellow 
CPK display sphere sized representing monomer A and green CPK display sphere sized 
for monomer B). 
 
The modelling results revealed that the para-methoxy group of the aniline is highly favoured 
through making a hydrogen bond with the Gln95 residue (as shown in Figures 3.4 and 3.5). 
Furthermore, compounds 100a and 100h were interacting with what are reported to be critical 
residues in the binding of the LEDGF/p75 protein.  
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Figure 3.5: Ovelaying projection model of compound 100b and 100h in the LEDGF/p75 
binding cavity at the HIV-1 IN dimer interface 
 
3.3.6. Conclusion 
A series of 5-aryl-1,3-oxazoles were successfully synthesized via the van Leusen approach by 
reacting TosMIC and substituted benzaldehydes in the presence of catalytic K2CO3 in MeOH in 
just 7 minutes under microwave conditions. The 5-aryl-1,3-oxazole products were obtained in 
good to high yields. However, attempts to prepare 5-aryl-1,3-oxazole scaffolds under the same 
microwave conditions in MeCN afforded instead the intermediates 5-aryl-4-tosyl-4,5-dihydro-
1,3-oxazoles, which were also obtained in high yields and could be converted easily to their 
respective oxazoles though an elimination step. The microwave assisted van Leusen approach 
used resulted in a time efficient method towards the preparation of both 5-aryl-1,3-oxazoles and 
5-aryl-4-tosyl-4,5-dihydro-1,3-oxazole scaffolds.  
Further investigations into the effect of reaction conditions on this synthesis under microwave 
irradiation may be interesting but time constraints did not allow this. The present fragment 
library, although not overly toxic to cells, showed no significant inhibitory activity on the 
LEDGF-IN interaction assay, nor on the Vpu binding assay, which may be attributed to their 
relatively small size. 
 
Based on the disappointing biological results obtained from the first fragment library, a second 
generation of compounds were prepared. Initial attempts were made to synthesise the N,5-diaryl-
1,3-oxazole-4-carboxamide derivatives via formation of N-aryl-2-isocyanoacetamide 
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intermediates. These key intermediates were successfully obtained by first converting the glycine 
ester hydrochloride with methyl formate into N-formyl glycine ethyl ester in good yield. This was 
followed by reaction with hydrazine monohydrate to afford the corresponding N-(2-hydrazinyl-
2-oxoethyl)formamide in excellent yield. Further treatment of the compound with 1M HCl and 
aqueous NaNO2 in water, followed by treatment with anilines in THF furnished the N-aryl-2-
formamidoacetamides in yields ranging from moderate to good. The N-aryl-2-
formamidoacetamides were then dehydrated using POCl3, Et3N in DCM to provide the 
corresponding N-aryl-2-isocyanoacetamide intermediates in yields of 84 and 92%.  Attempts to 
synthesize N,5-diaryl-1,3-oxazole-4-carboxamide derivatives by treatment of benzoyl chloride 
derivatives with these N-aryl-2-isocyanoacetamide intermediates using Et3N in DCM at room 
temperature for 24-48 hours were unsuccessful. Attempts to use DBU as a base didn‟t yield any 
desired products but instead resulted in an addition reaction to give the previously prepared N-
aryl-2-formamidoacetamide in 85% yield. Reaction of benzaldehydes with the N-aryl-2-
isocyanoacetamide intermediate in the presence of DBU afforded the corresponding 4,5-
dihydro-N,5-diaryl-1,3-oxazole-4-carboxamide scaffolds in good yields. Attempts to oxidize 
these (4R,5R/4S,5R)-4,5-dihydro-N,5-diaryl-1,3-oxazole-4-carboxamide scaffolds with BrCCl3 in 
DCM were unsuccessful. This prompted the search for a simple and effective route towards N,5-
aryl-1,3-oxazole-4-carboxamide derivatives. 
The N,5-aryl-1,3-oxazole-4-carboxamide derivatives were successfully constructed over three 
steps. Initial reaction of benzoyl chloride analogues with ethyl isocyanoacetate in the presence of 
DBU as base in THF afforded the ethyl 5-phenyl-1,3-oxazole-4-carboxylate products in good 
yields. These scaffolds were subjected to hydrolysis conditions with NaOH in water and MeOH, 
followed by acidification with 1M HCl to furnish the 5-phenyl-1,3-oxazole-4-carboxylic acid 
derivatives in high yields. Further treatment of 5-phenyl-1,3-oxazole-4-carboxylic acid 
compounds with thionyl chloride gave the more reactive 5-phenyl-1,3-oxazole-4-carbonyl 
chloride analogues, which were then reacted with aniline derivatives in the presence of Et3N at 
room temperature for 24 hours to obtain a series of novel N,5-aryloxazole-4-carboxamide 
derivatives in yields ranging from moderate to excellent.  
 
The synthesized novel N,5-aryl-1,3-oxazole-4-carboxamide derivatives, 5-aryloxazole-4-
carboxylic acids  and the ethyl 5-phenyloxazole-4-carboxylate compounds  were assessed for 
their ability to disrupt the interaction between HIV-1 IN and LEDGF/p75 proteins. In the IN-
LEDGF/p75 biochemical assay, inhibition by two compounds exceeded the pre-defined cut-off 
value of 50%.  These compounds contain electron donating methoxy groups at the ortho- and 
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para-positions of the aniline core that are similar to the CAB compounds described in the 
literature that exhibited inhibitory activity above 50%. These results indicate that the presence of 
electron donating methoxy substituents at the ortho- and para-positions of the aniline ring is 
highly favoured in compounds for disruption of the interaction between LEDGF/p75 and HIV-
1 IN proteins.  
 
From the ADME studies, compound 100b exhibited low solubility while compound 100h 
displayed a good solubility level. Both scaffolds were non-inhibitors of cytochrome enzymes and 
were found to be poorly absorbed in the human intestine. The ligand-protein docking study 
showed that both compounds 100b and 100h interact with some of critical residues within the 
HIV-1 IN dimer site. Furthermore, the para-methoxy group on the aniline ring was shown to be 
significant in the binding of these scaffolds. Their binding energies correlate with the percentage 
inhibition from AlphaScreen assay. 
 
Thus it appears that compounds containing the N-(2,4-dimethoxyphenyl)acetamide moiety can 
serve as templates for further modification to design more potent biologically active compounds 
that can specifically target the LEDGF/p75-IN interaction.  
 
3.4. Future work 
Further modification by varying the substituents on the phenyl group at the 5-position of the 
oxazole ring and their biological assessment as possible inhibitors of HIV-1 IN-LEDGF/p75 
interaction will form part of future work (Figure 3.6). Furthermore, screening of the oxazole-
based library in the HIV-1 Vpu-BST-2 ELISA assay, with the aim of possibly identifying hits to 
further modify and generate a next generation of compounds will be conducted in future.  
 
N
H
O
O
N
R
R'
varying 
the R group
 
 
Figure 3.6: Possible structural modifications of the oxazole based compounds. 
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CHAPTER 4 
 Synthesis of a family of 5-aryl-imidazol-1-yl acyl-based compounds as 
potential inhibitors of HIV-1 protein-host protein interactions using a van 
Leusen approach 
 
4.1. Introduction  
Amino acids play a significant role in many biological processes, hence they are often used as 
building blocks for designing new pharmacologically active compounds.256,257,258  Compounds 
with an amino acid backbone have displayed interesting biological activities like anti-HIV-1 and 
antimicrobial activities.259,260,261 On the basis of the above and aligned with our objectives defined 
in Chapter 1, we set out to incorporate a simple amino acid framework into the imidazole 
nucleus via the van Leusen reaction, anticipating the generation of a small family of 5-aryl-1H-
imidazol-1-yl acyl compounds 114 (Scheme 4.1).  We hoped that the screening of 5-aryl-1H-
imidazol-1-yl-based compounds could also provide viable hits that could be used as a template to 
design a second generation of  compounds that could act as possible inhibitors of  the HIV-1 IN-
host LEDGF/p75 and/or HIV-1 Vpu-Host BST-2 interactions.  This chapter will address 
synthetic challenges encountered in the incorporation of amino acids into the imidazole motif as 
well as the characterization of the synthesized compounds. Biological evaluation of the 
synthesized compounds in AlphaScreen and ELISA assays will also be discussed. 
 
H2N
R
O
OR' N
N
OR''
O
R
R''
TosMIC
113 114  
 
Scheme 4.1: The integration of  an amino acid into the imidazole motif  using the van Leusen 
reaction. 
 
4.2. Synthesis of 5-aryl-1H-imidazol-1-yl acyl derivatives using van Leusen reaction  
The key intermediates required for the van Leusen imidazole reaction were imines, prepared 
from amines and aldehydes. The amine components we required were derived from amino acids, 
while commercially available aldehydes were used. 
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4.2.1. Synthesis of free amino ethyl ester derivatives  
In order to generate van Leusen precursors from amino acids, the carboxylic acid groups 
required protection before conducting the condensation reactions with an aldehyde.  The 
carboxylic group is usually protected by converting the amino acid into the corresponding amino 
acid ester hydrochloride salt.  Convenient procedures for preparing the ester hydrochloride salts 
involve the addition of hydrochloric acid (HCl), 262 thionyl chloride (SOCl2)
263,264 or acetyl 
chloride (AcCl)265 to a solution of the amino acid in a protic solvent such as methanol or ethanol. 
Although, the ester hydrochloride salts can be obtained commercially, it was ideal to utilise the 
commercially available amino acids which were readily accessible in our laboratory. Therefore, 
the approach employing thionyl chloride was adopted and commercially available glycine 113a, 
L-alanine 113b and D-leucine 113c were chosen as synthons for the synthesis of van Leusen 
intermediates.   
 
HO
O
NH2
R
O
O
NH2.HCl
R
O
O
NH2
R
i. SOCl2, EtOH, 0
oC
ii. reflux, 5 h
i. Et3N, CHCl3, rt, 6 h
ii. reflux, 1 h
113a  R = H
113b  R =CH3 (S)
113c  R= CH2CH(CH3)2 (R)
105 115
93-98% 96-98%
 
Scheme 4.2: Synthesis of free amino acid ester 115. 
 
The synthesis commenced with the addition of SOCl2 to a mixture containing commercially 
available amino acids 113a-c in ethanol at 0oC, followed by refluxing for 5 hours as shown in 
Scheme 4.2. Work up afforded the corresponding amino ester hydrochloride salts 105a-c in 
excellent yields. The yields obtained were comparable to those values reported using a 
HCl/EtOH system (Table 4.1).266,267,268,269  The NMR spectra of the corresponding salts were in 
agreement with the data reported in literature while melting points of 144-147°C for compound 
105a and 76-78oC for compound 105b were comparable to the reported literature values. 263, 
269, 270, 271  
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Table 4.1: Isolated yields (%) of the amino ester hydrochloride salt 105. 
O
NH2.HCl
O
R  
Compounds R Yields (%) 
105a H 90 
105b CH3(S) 99 
105c CH2CH(CH3)2 (R) 95 
 
 
The esterified amino acid salts 105a-c were then treated with Et3N using CHCl3 as solvent at 
room temperature for 6 hours, followed by heating under reflux for 1 hour (Scheme 4.2). 
272,273 Work up furnished the free amino ethyl esters 115a-c in yields ranging from 96-98% 
(Table 4.2). 
 
Table 4.2: Isolated yields (%) of the free amino esters 115. 
 
Compounds R Yields (%) 
115a H 96 
115b CH3(S) 98 
115c CH2CH(CH3)2 (R) 98 
 
 
The chemical structures of free amino esters 115a-c were supported by NMR spectroscopic 
analysis and were consistent with reported literature. 274,275,276,277,278 The NMR spectra of L-alanine 
ethyl ester 115b will be discussed in detail as an illustration representing this compounds class. A 
distinguishing feature of compound 115b in the 1H NMR spectrum was the presence of two 
quartets: one at 4.01 ppm for the methylene protons of the ethyl group and one at 3.43 ppm for 
the methine proton at a chiral centre, with each having a coupling constant value of 7.2 Hz. 
Furthermore, a singlet corresponding to the two protons of the NH2 group appears at 1.59 ppm, 
whereas a doublet at 1.19 ppm with a J value of 7.4 Hz corresponds to the protons of the methyl 
group attached to the chiral centre. The upfield triplet at 1.13 ppm (J = 7.2 Hz) is assigned to the 
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protons of the methyl group, which are coupled with the methylene group (ethyl moiety). The 
13C NMR spectrum of compound 115b confirmed the presence of all five carbon atoms, with the 
carbonyl carbon atom signal appearing at 176.3 ppm, and signals at 60.5 and 49.8 ppm belonging 
to the methylene carbon atom of the ethyl group and methine carbon atom at a chiral centre. 
Furthermore, the signal at 20.4 ppm corresponds to the methyl carbon atom at a chiral centre, 
while the methyl carbon atom of the ethyl group resonates at 13.9 ppm. 
 
4.2.2. Condensation of amino ethyl ester derivatives with various benzaldehydes 
 
O
O
NH2
R
115a R = H
115b R= CH3 (S)
115c R= CH2CH(CH3)2 (R)
O
R'
MgSO4, DCM, rt, 16 h
N
R
O
O
R'
              R                                  Yields
116a-h   H                                  86-97%    
117a-d   CH3 (S)                        72-94%
118a-c   CH2CH(CH3)2 (R)         81-88%
115
7a R= 4-F
7b R= 2-Cl
7c R= 3-OMe
7d R= 2,4-diOMe
7e R=3,4-OCH2O-
7f R= 4-tBu
7g R= 3-OH,4-OMe
7j R= H
 
 
Scheme 4.3: Synthesis of ethyl 2-(arylideneamino)acyl intermediates. 
 
Walton et al. described the reaction of various aldehydes with esterified amino acid salts using 
Et3N as a base in the presence of MgSO4 in DCM at room temperature to afford the 
corresponding ethyl (E)-2-{(arylidene)amino}acetates in quantitative yields. 279 Inspired by this 
protocol, our free amino ethyl esters 115a-c were then exposed to the condensation reaction 
conditions by reacting with various benzaldehydes 7a-h in the presence of MgSO4 using DCM as 
solvent at room temperature for 16 hours (see Table 4.3). Work up furnished the desired ethyl 2- 
(arylideneamino)acyl intermediates (116a-h, 117a-d and 118a-c) in yields of up to 96%. The 
yields of the products obtained (96% for 116h and 92% for 117d) were considerable 
improvements over those reported by López-Pérez et al. (81% for 116h and 87% for 117d). 280 
Compounds 116a-h, 117a-d and 118a-c were used in the next stage without further purification. 
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Table 4.3: Isolated yields (%) of the ethyl 2-(arylideneamino)acyl intermediates. 
N
R
O
O
R'  
Compound R R’ Yields (%) 
116a H 4-F 91 
116b H 2-Cl 87 
116c H 3-OMe 90 
116d H 3,4-diOMe 93 
116e H 3,4-OCH2O 91 
116f H 4-tBu 88 
116g H 3-OH,4-OMe 86 
116h H H 96 
117a CH3 (S) 4-F 91 
117b CH3 (S) 3-OMe 72 
117c CH3 (S) 3,4-diOMe 83 
117d CH3 (S) H 92 
118a CH2CH(CH3)2 (R) 4-F 88 
118b CH2CH(CH3)2 (R) 3,4-diOMe 86 
118c CH2CH(CH3)2 (R) H 81 
 
 
The product structures were elucidated by NMR and FTIR spectroscopy, which verified that the 
compounds obtained were the desired ethyl 2-(arylideneamino)acyl intermediates 116, 117 and 
118. In solution, NMR spectroscopy indicates that compounds 116, 117 and 118 are present in 
each case as only one geometrical isomer, which by comparison with data reported in the 
literature is most likely the E- isomer.279,280,281, All 1H NMR spectra of the van Leusen 
intermediates 116, 117 and 118 showed a characteristic azomethine (N=CH) singlet in the region 
of δ 8.1-8.2 ppm, whilst the 13C NMR spectra for the same compounds exhibited the azomethine 
and carbonyl carbon atoms in the region of δ 163-165 and 170-171 ppm, respectively. The 1H 
NMR spectra of compounds 116a-h with no substituents at the carbon atom adjacent to the 
nitrogen atom and carbonyl group showed a singlet in the region of δ 4.3 to 4.4 ppm 
 
118 
 
corresponding to the methylene protons.  Signals from the methine protons at the chiral centre 
of the van Leusen intermediates 117a-d derived from L-alanine, can be observed as multiplets in 
the region of δ 4.0-4.2 ppm, due to overlapping with the quartet due to the 5-methylene protons 
of the ethyl group. Furthermore a doublet at 1.4 ppm (J = 7.2 Hz) and triplet at 1.2 ppm (J = 7.2 
Hz) correspond to the protons of the methyl group at the chiral centre and the methyl protons 
of the ethyl group, respectively. 
 
4.2.3. Optimization of conditions towards cycloaddition of TosMIC to the prepared ethyl 
2-(arylideneamino)acylate 
The cycloaddition of TosMIC 1 to the ethyl 2-(arylideneamino)acyls was initially attempted using 
our previously reported procedure described in Chapter 2. The (E)-ethyl-2-(3,4-
dimethoxybenzylideneamino)acetate 116d was then chosen as a precursor for the investigation. A 
mixture of ethyl-2-(3,4-dimethoxybenzylideneamino)acetate 116d and TosMIC 1 in MeCN using 
K2CO3 as a Lewis base was microwave-irradiated at a set temperature of 90
oC and a power of 
120 Watts under inert conditions, as depicted in Scheme 4.4 (Route 1). TLC indicated full 
consumption of 116d and little presence of TosMIC 1 after 5 hours. However, no new 
development of spots could be observed by TLC.  To further determine whether there was any 
product formed or not, the solvent was evaporated in vacuo and dried to afford a crude brown oil 
material.  The crude product was then analysed by NMR spectroscopy, however, 1H NMR 
revealed a complicated spectrum with none of the signals corresponding to the desired product 
present. A possible explanation for the failed conversion may be attributed to decomposition of 
the intermediate 116d under microwave irradiation, which implied that milder reaction 
conditions might be required in order to successfully afford the product. 
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Scheme 4.4: Effects of the reaction conditions on the formation of the desired products 120. 
 
With the failure of the above described reaction, an alternative route was envisaged and effort 
was then shifted to using 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) as a catalytic base towards 
the preparation of the van Leusen products.  We assumed that using a strong base under mild 
conditions, might promote the cycloaddition of TosMIC 1 to the ethyl 2-(5-aryl-1H-imidazoly-1-
yl)acyls, which could afford the desired van Leusen adducts. The reaction was then pursued by 
reacting ethyl 2-(3,4-dimethoxybenzylideneamino)acetate 116d and TosMIC 1, in the presence of 
DBU using DCM as a solvent of choice at room temperature as illustrated in Scheme 4.4 (Route 
2).  After 24 hours, TLC indicated complete consumption of TosMIC 1 and the formation of a 
new spot, suspected to be product. Isolation and purification of a newly formed spot by column 
chromatography afforded a pale yellow solid. However, analysis of the obtained product by 1H 
NMR spectroscopy (Figure 4.1) revealed that instead of the expected desired product, the ethyl 2-
[5-(3,4-dimethoxyphenyl)-4-tosyl-4,5-dihydro-1H-imidazol-1-yl)acetate 119d was obtained as a 
racemic mixture of 2 diastereomers in 55% yield.  This kind of product arises due to the 
unsuccessful elimination of the para-toluenesulfonyl group under certain reaction conditions.  
Further examination of the 1H NMR spectrum in Figure 4.1 revealed a 2:1 diastereomeric ratio 
(for trans-ethyl 2-{5-(3,4-dimethoxyphenyl)-4-tosyl-4,5-dihydro-1H-imidazol-1-yl]acetate A to cis-
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ethyl 2-[5-(3,4-dimethoxyphenyl)-4-tosyl-4,5-dihydro-1H-imidazol-1-yl]acetate B. The trans-1H-
imidazoline A was characterised by the presence of two doublets at 5.05 and 5.25 ppm with a 
coupling constant of 6.4 Hz corresponding to the two methine protons at the 4- and 5-positions 
of the oxazoline motif, while the two methine protons of cis-1H-imidazoline B resonate as a 
singlet at 4.77 ppm.  Furthermore, the methyl group of the imidazoline A resonates as a singlet at 
2.42 ppm, while for the imidazoline B the singlet appears at 2.04 ppm. The two doublets at the 
4- and 5-positions of the oxazoline ring arise as a result of the trans- geometry. These findings are 
supported by reported literature.282 
 
 
 
Figure 4.1: 400 MHz 1H NMR spectrum of mixture of trans-ethyl 2-[5-(3,4-dimethoxyphenyl)-4-
tosyl-4,5-dihydro-1H-imidazol-1-yl]acetate (A) and cis- ethyl 2-[5-(3,4-dimethoxyphenyl)-
4-tosyl-4,5-dihydro-1H-imidazol-1-yl]acetate imidazoline (B) as diastereomeric mixture. 
 
Inspired by our experience with the oxazole synthesis in section 3.2.2 and a reported protocol 
where the elimination of the para-toluenesulfonyl group was accomplished in toluene, we 
explored removal of this group in toluene under microwave irradiation.232  Thus, compound 119d 
was dissolved in toluene and subjected to microwave irradiation at a set temperature of 115oC 
for 10 minutes (observed by TLC). Work up and isolation by silica gel column chromatography 
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furnished the desired ethyl 2-[5-(3,4-dimethoxyphenyl)-1H-imidazol-1-yl]acetate 120d in a yield 
of 60%.  The synthesis of ethyl 2-[5-(3,4-dimethoxyphenyl)-1H-imidazol-1-yl]acetate 120d was 
also investigated without purification of compound 119d as illustrated in Scheme 4.4 ( Route 3).  
The reaction mixture was initially stirred under the conditions described for Route 2, followed by 
the removal of DCM in vacuo to obtain a crude brown product. The crude material was then re-
dissolved in toluene, microwaved under the conditions described above, and remarkably 
afforded ethyl 2-[5-(3,4-dimethoxyphenyl)-1H-imidazol-1-yl]acetate 120d in 74% yield after 
column chromatography, suggesting that the separation of intermediates is not necessary. 
Furthermore, the yield of formation of 120d without separation of intermediate 119d was better 
than the overall yield of the product in two steps via formation of 119d. 
 
4.2.4. Van Leusen reaction for the preparation of the ethyl 5-aryl-1H-imidazol-1-yl acyls  
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116 R= H
117 R= CH3 (S) 
118 R= CH2CH(CH3)3 (R)
        
120 R= H 
121 R= CH3 (S)
122 R= CH2CH(CH3)3 (R)  
 
Scheme 4.5: Synthesis of 2-(5-aryl-1H-imidazol-1-yl)acyls using optimized conditions. 
 
Under these optimized conditions, the generality and restrictions of the van Leusen reaction 
were investigated using other synthesized ethyl 2-(arylideneamino)acetate intermediates (Scheme 
4.5). Firstly, the ethyl 2-(arylideneamino)acetates 116a-h derived from glycine were used and 
successfully transformed into the corresponding novel ethyl 2-(5-aryl-1H-imidazol-1-yl)acetates 
120a-h in yields of between 26-74% (Scheme 4.5 and Table 4.4). The product yields were 
strongly influenced by the presence of substituents on the 5-aryl ring. However, attempted 
conversion of the other remaining intermediates 117a, c-d and 118a-c under similar conditions 
only afforded the corresponding novel (5-aryl-1H-imidazol-1-yl)acyls (121a, and 121c-d) derived 
from L-alanine 117a, c-d in yields ranging from 11 to 23% (Table 4.4). Products 122 derived from 
D-leucine 118a-c were, however, not obtained. From the observed results it is clear that the 
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yields of the products are strongly influenced by the substituents at the chiral centre and on the 
aryl ring. 
 
Table 4.4: Isolated yields (%) of the novel ethyl 2-(5-aryl-1H-imidazol-1-yl)acyls 120 and 121. 
1
N
2
3
N4
5
O
O
R
R'
 
Compounds R R’ Yields (%) 
120a H 4-F 52 
120b H 2-Cl 26 
120c H 3-OMe 38 
120d H 3,4-diOMe 74 
120e H 3,4-OCH2O 45 
120f H 4-tBu 35 
120g H 3-OH,4-OMe 51 
120h H H 33 
121a CH3 (S) 4-F 11 
121c CH3 (S) 3,4-diOMe 23 
121d CH3 (S) H 20 
 
 
In summary, we successfully incorporated simple amino acids into the imidazole nucleus via van 
Leusen reactions under mild conditions.  A total of eleven new ethyl 2-(5-aryl-1H-imidazol-1-
yl)acyl derivatives 120 and 121 were obtained using our novel van Leusen protocol described 
above. A mechanistic rationale for the formation of compounds 120 and 121 can be based on a 
similar mechanism to that outlined in Chapter 1, Scheme 1.6. However, in this case the 
elimination of the para-toluenesulfonyl group was accomplished by microwave irradiation in 
toluene.  
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4.2.4.1. Structure elucidation of newly synthesized 2-(5-aryl-1H-imidazol-1-yl)acyls by 
NMR and FTIR spectroscopy 
The characterization of these novel compounds 120 and 121 was assisted by 1H-NMR, 13C-NMR 
and FTIR spectral data. Compound 120d was chosen as the prototype representing this 
compound class. The presence of two singlets at δ 7.56 ppm and 7.03 ppm for the 2- and 4-
methine protons of the imidazole motif in the 1H NMR spectrum of compound 120d clearly 
indicate that the van Leusen product had been formed. Further evidence for the formation of 
compound 120d was a singlet at 4.61 ppm integrating for two protons corresponding to the 
methylene group adjacent to the carbonyl group. A quartet and a triplet at δ 4.13 ppm and 1.18 
ppm with J values of 7.2 Hz each, correspond to the methylene and methyl protons of the ethyl 
group, coupling with each other, while the six protons of the two methoxy groups appear at 3.87 
and 3.83 ppm as two singlets.  In the 13C NMR spectrum of compound 120d, the carbonyl 
carbon atom resonates as a signal at 167.8 ppm while the 2- and 4-methine carbon atoms emerge 
at 138.5 ppm and 121.5 ppm. The methylene carbon atom next to the carbonyl group appears as 
a signal at 46.3 ppm, whereas the methylene and methyl carbon atoms of the ethyl group 
resonate at 61.9 and 13.9 ppm. The two methoxy carbon atoms at the para- and meta-positions 
give rise to signals at 55.81 and 55.78 ppm. The FTIR spectra of novel ethyl 2-(5-aryl-1H-
imidazol-1-yl)acyls 120 and 121 showed the carbonyl (C=O) bands in the region of 1745-1755 
cm−1, whilst the bands in the region of 1306 cm-1  to 1380 cm-1  were assigned to the C-N group 
of the imidazole core (Table 4.5). 
 
Table 4.5: FTIR spectroscopic data of ethyl 2-(5-aryl-1H-imidazol-1-yl)acyl products showing 
the C=O and C=N bands.  
Compnds 120a 120b 120c 120d 120e 120f 120g 120h 121a 121c 
υC=O(cm-1) 1747 1748 1745 1748 1741 1755 1748 1736 1748 1750 
υC-N(cm-1) 1380 1356 1379 1356 1336 1363 1334 1376 1306 1324 
 
 
4.2.4.2.  Structure elucidation of newly synthesized ethyl 5-aryl-1H-imidazol-1-yl acyls by 
mass spectrometry 
Evidence of the successful incorporation of amino acids into the imidazole moiety was further 
provided by ESI-LCMS, which provides accurate identification of the compounds. The 
calculated and experimental molecular ions (m/z) of these novel scaffolds 120 and 121 as well as 
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their mSigma values are displayed in Table 4.6.  The accurate formula of the compounds was 
calculated using Bruker SmartFormula3D®, with a mass accuracy within 5 ppm (5 mDa).  The 
Bruker SmartFormula algorithm is used to associate the theoretical isotopic pattern of each 
potential accurate mass formula with the experimentally determined pattern.  Detailed 
elucidations of the fragments were carried out in positive ion mode and the parent molecular 
ions are presented as [M+H]+.  All eluted products from LC into mass spectrometry showed one 
peak on both detectors (UV before reaching the mass spectrometer and MS detector afterwards). 
The mass chromatograms single peak corresponds to the protonated molecular ion. 
 
Table 4.6: HRMS results of the ethyl 2-(5-aryl-1H-imidazol-1-yl)acyls (120 and 121) and their 
mSigma values.  
Compds 
Chemical 
formula 
[M+1] 
Calculated 
m/z 
Measured 
m/z 
Err 
(mDa) 
Err (ppm) 
mSigma 
value 
120a C13H14FN2O2+ 249.1034 249.1027 -0.7 10.8 2.0 
120b C13H14N2O2Cl+ 265.0738 265.0738 0.0 0.0 3.8 
120c C14H17N2O3+ 261.1234 261.1232 0.2 0.6 5.1 
120d C15H21N2O4+ 291.1339 291.1332 -0.7 -2.2 6.4 
120e C13H13N2O4+ 261.1183 261.1186 0.3 0.3 5.9 
120f C15H19N2O2+ 287.1754 287.1764 -1.0 -3.7 7.5 
120g C12H13N2O4+ 277.1183 277.1184 -0.1 -0.4 2.3 
120h C13H15N2O2+ 231.1128 231.1126 0.2 0.9 1.1 
121a C14H16FN2O2+ 263.1173 263.1190 -0.3 -1.1 4.4 
121c C16H21N2O4+ 305.1476 305.1503 -0.7 -2.4 3.1 
121d C14H17N2O2+ 245.1258 245.1279 -2.1 -1.1 5.0 
 
 
It was interesting to observe that variation on the 5-aryl ring had a significant influence on the 
fragmentation pattern of these ethyl 5-aryl-1H-imidazol-1-yl acyl scaffolds. These findings were 
observed in the MS/MS analysis supported by SmartFormula, which confirms possible formula 
for the fragment ions.  Compounds 120a and 120d were chosen as the models to discuss in detail 
the mass fragmentation patterns further. 
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4.2.4.2.1. Mass fragmentation of ethyl 2-[5-(4-fluorophenyl)-1H-imidazoyl]acetate 120a 
The mass spectrum in Figure 4.2 (a) of compound 120a revealed an intense molecular ion peak at 
m/z 249.1027, which was confirmed by SmartFormula as having the molecular formula 
C13H14FN2O2 [M + H]
+, consistent with the parent ion. 
 
 
 
Figure 4.2: Recorded spectra for compound 120a: (a) MS of [M+H]+ and b) MS/MS (collision 
energy of 35 eV). 
 
 
MS/MS fragmentation with 35eV N2 collision energy produced the spectrum depicted in Figure 
4.2 (b) of compound 120a, [M+H]+ peak m/z 249.10. A possible fragmentation pathway (Figure 
4.3) shows the compound undergoing disintegration to produce a base peak at m/z 221.07 with 
formula C11H10FN2O2
+ corresponding to the loss of a neutral ethene (CH2=CH2). The ion, 
C11H10FN2O2
+ then endures further fragmentation to give a peak at m/z 203.06 with a formula of 
a) 
 
b) 
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C11H8FN2O
+ relating to the loss of a H2O molecule, which defragments further and produces 
two fragmentation pathways. The first pathway involves a loss of carbon monoxide (CO) to 
form an ion at m/z 175.06 with formula C10H8FNO
+. Further breakdown of C10H8FNO
+ affords 
a peak at m/z 148.06 with formula C9H7FN
+ corresponding to the loss of hydrogen cyanide 
(CHN) through a ring opening of the imidazole moiety, followed by another loss of CHN to 
generate the ion at m/z 121 of formula C8H6FN
+. The second pathway from m/z 203.06 shows 
the loss of cyanic acid (HOCN) through ring opening of the imidazole moiety to afford 
C10H9FN
+ at m/z 162.07, which further loses a neutral ethylene molecule to give m/z at 136.06 
with formula C8H7FN
+. The molecular ion at 136.06 then loses an HCN molecule to yield a low 
fragment ion at m/z 109 with molecular formula C7H6F
+. 
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Figure 4.3: Possible fragmentation pathways of compound 120a. 
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4.2.4.2.2. Mass fragmentation of ethyl 2-[5-(3,4-dimethoxyphenyl)-1H-imidazoyl]acetate 
120d 
The measured spectrum of compound 120d (Figure 4.4 a) exhibited a peak at m/z 291.1332, 
which corresponds to the parent compound [M+H]+, with molecular formula C15H19N2O4. 
 
 
 
 
 
Figure 4.4:  Recorded spectra for compound 120d: (a) MS and b) MS/MS (col. energy 35eV). 
 
a) 
 
b) 
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Figure 4.5: Possible fragmentation pathways for compound 120d. 
 
The MS/MS spectrum (Figure 4.4b) shows a parent molecular ion exhibiting two fragmentation 
pathways as depicted Figure 4.5.  The first route shows the formation of a fragment ion at m/z 
275.10 with formula C14H15N2O4 due to a neutral loss of methane (-CH4); followed by a loss of 
ethene (C2H4) to provide molecular ion C12H11N2O4
+ at m/z 247.07. A further loss of carbon 
monoxide (-CO) from C12H11N2O4
+ gives rise to an ion at m/z 219.08 with formula 
C11H11N2O3
+, which further endures the loss of formaldehyde (HCOH) to produce fragment ion 
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C10H9N2O2
+ at m/z equal to 189.07. The ion at 189.07 then decomposes further to give two 
molecular ions at m/z 161.07 having formula C9H9N2O
+ attributed to the loss of carbon 
monoxide (-CO) and at m/z 145.0 with chemical formula C9H9N2
+, which arises due to loss of 
carbon dioxide (CO2). The second pathway involves a neutral loss of propan-2-one (C3H6O) to 
give a molecular ion at m/z 233.09 with formula C12H13N2O3
+. 
 
Having successfully established the structure of the novel ethyl 2-(5-aryl-1H-imidazol-1-yl) acyl 
derivatives 120 using FTIR and NMR spectroscopy and mass spectrometry, we thus wished to 
expand the existing library of imidazol-1-yl-based compounds by further transforming esters 120 
into two sets of compounds: 2-(5-aryl-1H-imidazol-1-yl)acetic acids and 2-(5-aryl-1H-imidazol-1-
yl)acetohydrazide derivatives.  
 
4.2.5. Synthesis of novel 2-(5-aryl-1H-imidazol-1-yl) acetic acids 123 
 
N
N
O
O
R'
N
N
OH
O
R'
Method A: NaOH, MeOH, H2O  reflux, 3 h
                  then 1N HCl
Method B: (MW) H2O, 200W, 105
oC, 3 h
120a R'= 4-F
120c R'= 3-OMe
120d R'= 3,4-diOMe, 
120e R'= 3,4-OCH2O
120f R'= 4-tBu
120g R'=  4-OH, 3-OMe
120h R'= H
123
Method A i: -
Method B ii: 56-72%
 
 
Scheme 4.6: Hydrolysis of ethyl 5-aryl-1H-imidazol-1-yl acylates. 
 
Initially, the hydrolysis of ethyl 5-aryl-1H-imidazolyl acylates 120a and 120c-h was carried out 
under reflux in the presence of NaOH using water and MeOH for 3 hours, followed by 
acidification with 1N HCl as illustrated in Scheme 4.6 (Method A).283 However, the isolation of 
the desired products from the water layer was challenging, which may be due to the existence of 
the desired products in zwitterionic form as indicated in Scheme 4.7. This may be attributed to 
the presence of both the basic imidazole ring and the carboxylic acid, which can tautomerise via 
internal hydrogen transfer from the carboxylic acid group to the nitrogen of the imidazole ring, 
resulting in compound 124 having both acidic and basic functionalities.284  
 
130 
 
N
N
OH
O
R'
123
N
NH
O
O
R'
124  
 
Scheme 4.7: Zwitterionic form of 2-(5-aryl-1H-imidazol-1-yl) acetic acids: neutral 123 and 
ionized form 124. 
 
Having failed to isolate the desired products, an alternative approach to hydrolysing the ethyl 2-
(5-aryl-1H-imidazol-1-yl)acetates using microwave irradiation was pursued. This was inspired by 
the fact that microwaves can enable water to act like a pseudo-organic solvent, thus speeding up 
the reactions in an aqueous medium.285  Therefore, a mixture of 2-(5-aryl-1H-imidazol-1-
yl)acetates 120a and 120c-h in water was microwave irradiated at a set power of 200 Watts and 
temperature of 105oC for 3 hours as indicated in Scheme 4.6 (Method B). Work up by washing 
with DCM and evaporating the water layer in vacuo afforded pure novel 2-(5-aryl-1H-imidazol-1-
yl) acetic acids 123 in yields ranging from 56 to 72% (Table 4.7). This method was better than the 
procedure described by Zhou et al.,283 because no removal of the acid or base catalyst at the end 
of the reaction was necessary.  
 
Table 4.7: Isolated yields (%) of the novel 2-(5-aryl-1H-imidazol-1-yl) acetic acids 123 via MW 
irradiation. 
N
N
OH
O
R'
 
Compounds R’ Yields (%) 
123a 4-F 72 
123c 3-OMe 56 
123d 3,4-diOMe 71 
123e 3,4-OCH2O 68 
123f 4-tBu 56 
123g 3-OH,4-OMe 58 
123h H 68 
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The formation of acetic acid products 123 was easily confirmed by the disappearance of signals 
due to the ethyl protons in their 1H NMR spectrum and the appearance of a quaternary 
ammonium proton due to the zwitterionic form (see Scheme 4.7) as a broad signal at 6.01 ppm 
for compound 123d, whilst the 13C NMR spectrum further confirmed the loss of the ethyl group. 
The FTIR spectra of 2-(5-aryl-1H-imidazol-1-yl) acetic acids 123a and 123c-h showed an 
absorption band in the region of 2434 to 2604 cm-1 that can be attributed to the NH+ of the 
zwitterionic form, which agrees with the observed 1H NMR spectroscopy. More evidence for the 
formation of the products 123 was found from their mass spectra, which confirmed the loss of 
an ethyl group with an acceptable tolerance of isotopic pattern fit factor (mSigma) lower than 20 
as recorded in Table 4.8. For example, compounds 123a and 123f with molecular formulae 
C11H10FN2O2
+ and C15H19N2O2
+ respectively, display the parent molecular ion peaks (M+1)+ at 
m/z 221.0720, and 259.1440, while their ester analogues 120a and 120f (see Table 4.6 ) with 
molecular formulae C13H14FN2O2
+ and C15H19N2O2
+exhibited the parent molecular ion peaks at 
m/z 249.1034 and 287.1764, respectively. The calculated difference of m/z 28.034 between the 
parent molecular ions of compounds 120 and 123 provides the proof that indeed the ethyl group 
was lost.  
 
Table 4.8: HRMS results of the 2-(5-aryl-1H-imidazol-1-yl) acetic acids 123 and their mSigma 
values. 
Compds 
Calculated 
m/z 
Chemical 
formula 
[M+1] 
Measured 
m/z 
Err 
(mDa) 
Err 
(ppm) 
mSigma 
value 
123a 221.0721 C11H10FN2O2+ 221.0720 0.1 0.5 2.3 
123c 233.0921 C12H13N2O3+ 233.0922 -0.1 -0.6 1.6 
123d 263.1040 C13H15N2O4+ 263.1017 2.3 8.5 4.3 
123e 247.0713 C12H11N2O4+ 247.0702 1.1 4.5 0.6 
123f 259.1441 C15H19N2O2+ 259.1440 0.3 1.2 1.0 
123g 249.2421 C12H13N2O4+ 263.2438 -1.7 11.1 8.4 
123h 203.0815 C11H11N2O2+ 203.0807 0.8 3.9 4.1 
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4.2.6. Synthesis of novel 2-(5-aryl-1H-imidazol-1-yl)acetohydrazide scaffolds 125 
 
 
 
Scheme 4.8: Synthesis of 2-(5-aryl-1H-imidazol-1-yl)acetohydrazide scaffolds 125. 
 
The selected ethyl 5-aryl-1H-imidazol-1-yl acyl derivatives 120 were also subjected to 
nucleophilic attack by hydrazine monohydrate in MeOH at room temperature for 24 hours 
(Scheme 4.8, Method C). Work up gave pure 2-(5-aryl-1H-imidazol-1-yl)acetohydrazide 
derivatives 125a and 125c-h in good yields (Table 4.9).  It was interesting to observe that the same 
scaffolds 125a and 125c-h were successfully obtained in excellent yields under microwave 
irradiation at a set temperature of 75oC in just 30 minutes as depicted in Scheme 4.8, method D 
(see Table 4.9 for the isolated yield). The microwave method has once again been shown to be a 
better synthetic option, with an increase in the reaction rate of 48-fold. 
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Table 4.9: Isolated yields (%) of the novel 2-(5-aryl-1H-imidazol-1-yl)acetic acids 125. 
N
N
HN
O
NH2
R'
 
Compounds R’ 
Conventional 
heating 
Yields (%) 
Microwave 
Yields (%) 
125a 4-F 86 92 
125c 3-OMe 72 86 
125d 3,4-diOMe 87 94 
125e 3,4-OCH2O 86 90 
125f 4-tBu 80 93 
125g 3-OH,4-OMe - 94 
125h H 74 90 
 
 
The formation of the desired products 125 was confirmed by means of FTIR and 1-D and 2D 
NMR spectroscopic analysis.  The FTIR spectra of these acetohydrazide derivatives 125 showed 
absorption bands in the region of 3104-3565 cm-1 corresponding to the NH2 of hydrazine while 
the bands in the region of 3026-3220 cm-1 were assigned to the NH group. Furthermore, the 
stretching bands of the amide carbonyl (C=O) group were found in the area of 1613-1747 cm-1 
(Table 4.10). This was a clear indication that the nucleophilic substitution reaction had occurred. 
 
Table 4.10:  FTIR spectroscopic data of the 2-(5-aryl-1H-imidazol-1-yl)acetohydrazides 125: 
showing the NH2, NH and C=O bands. 
Compounds 125a 125c 125d 125e 125f 125g 125h 
υNH2 (cm-1) 3104 3320 3565 3317 3335 3146 3321 
υNH (cm-1) 3026 3198 3209 3104 3220 3120 3197 
υC=O (cm-1) 1747 1677 1693 1655 1663 1613 1675 
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The NMR spectra of the synthesized 2-(5-aryl-1H-imidazol-1-yl)acetohydrazide scaffolds 125 
further validate the formation of the products. The 1H NMR spectrum of compound 125f (Figure 
4.6) reveals a singlet peak at δ 4.46 ppm integrating for two protons corresponding to an NH2 
group while an imine proton (NH) resonates as a singlet signal downfield at δ 9.28 ppm.  
 
 
Figure 4.6: 1H NMR spectrum of ethyl 2-[5-(4-tert-butylphenyl)-1H-imidazol-1-
yl]acetohydrazide 4.10f in DMSO-d6 at 30
oC citing major rotamer. 
 
Extra signals were observed on NMR spectroscopic analysis which could be the result of 
rotamers. Rotamers arise due to hindered rotation around the amide C-N bond caused by 
delocalization (Scheme 4.9).286,287 
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Scheme 4.9: Resonance of partial double bond in amide system. 
 
135 
 
To establish whether indeed the extra signals observed corresponded to rotamers, compound 
125f was studied at different temperatures by analysing the signals around the aromatic region in 
the 1H NMR spectrum.  At 30oC, the 1H NMR spectrum in DMSO-d6 of 125f (Figure 4.7) reveals 
that the relative ratio of the major and minor rotamers is 8:1.  When the temperature is increased 
to 70oC, the signals for the two rotamers begin to move closer to each other, but can still be 
observed.  Finally, at a temperature of 90oC, the two signals had coalesced into a single peak, this 
can be attributed to the fact that at these higher temperatures the rotation barrier between 
rotamers can be easily overcome, and the interconversion is fast enough when compared to the 
NMR spectroscopic time-scale. 
 
Figure 4.7: Effect of temperature on the aromatic signal markers in the 1 H-NMR spectrum of 
ethyl 2-[5-(4-tert-butylphenyl)-1H-imidazol-1-yl]acetohydrazide 125f in DMSO-d6. 
 
 
The 13C NMR spectrum (Figure 4.8 and 4.9) of compound 125f also showed the existence of 
rotamers. Changes in the spectrum around aromatic signals and the carbonyl carbon atom were 
also observed at different temperatures. At lower temperature, the carbonyl carbon atom of the 
major rotamer resonates at δ 166.6 ppm, while the minor rotamer emerges at δ 170.9 ppm. The 
signals of the minor rotamer broaden and then coalesce at temperatures of 70oC and 90oC.  
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Figure 4.8: 13C NMR spectrum of 2-[5-(4-tert-butylphenyl)-1H-imidazol-1-yl]acetohydrazide 125f 
in DMSO-d6 citing major rotamer. 
 
 
Figure 4.9: Effect of temperature on the aromatic signals markers in the 13C-NMR spectrum of 
ethyl 2-[5-(4-tert-butylphenyl)-1H-imidazol-1-yl]acetohydrazide 125f in DMSO-d6. 
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In summary, a total of 25 novel compounds belonging to ethyl 2-(5-aryl-1H-imidazol-1-yl)acyl 
(120 and 121),  2-(5-aryl-1H-imidazol-1-yl) acetic acid 123 and 2-(5-aryl-1H-imidazol-1-
yl)acetohydrazide 125 scaffolds were obtained from the above chemistry. These novel imidazol-
1-yl scaffolds were submitted for biological evaluation (direct assays). 
 
4.2.7. Biological evaluation of synthesized 1H-imidazoyl-1yl- based compounds 
A total of 25 compounds were submitted for testing in the IN-LEDGF/p75 AlphaScreen and 
the BST-2-Vpu ELISA assays for their ability to disrupt protein-protein interactions of interest: 
a) IN - LEDGF/p75 and b) BST-2 -Vpu.  All biological assays were conducted in house, at the 
Centre of Metal-based Drug Discovery laboratories, Advanced Material Division, Mintek 
(Randburg, South Africa).  Compounds with the highest inhibition (more than 50%) were 
further evaluated in a dose range assay for their IC50 values and in cell-based assay for their CC50 
values. 
 
4.2.7.1. Direct IN-LEDGF/p75 AlphaScreen assay 
Initially, 25 novel compounds were tested in an AlphaScreening assay to determine the 
percentage inhibition of disruption of the LEDGF-IN interaction at 100 µM. The tests were 
carried out in triplicate and average results are displayed in Table 4.11.  
Initial testing was carried out for 1H-imidazol-1-yl-based compounds (120 and 121). All ester 
derivatives, excluding compounds 120b and 121c exhibited a marginal ability of preventing 
LEDGF/p75-IN interaction. Compound 120h with no substituent on the 5-aryl ring was found 
to exhibit the highest inhibitory activity in this series (of only 26%). Furthermore, variation on 
the 5-aryl ring and at the stereogenic centre did not have a significant effect on the inhibition 
activities of these scaffolds. 
However, hydrolysis of ester derivatives 120 to the corresponding acetic acids 123 revealed one 
compound, 123g exceeding the 50% inhibition benchmark. This best inhibitor 123g, with a 
hydroxyl group and the methoxy group at the meta- and para-positions, exhibited 82% inhibition 
of the formation of the HIV-1 IN - LEDGF/p75 complex, and in a dose range assay produced 
an IC50 value of 19 µM.  Instead of the meta-OH group found in compound 123g, compound 
123d has a meta-methoxy group and shows a 10-fold reduced percentage inhibition activity, 
which implies that the presence of both OH and carboxylic acid (COOH) groups might be 
significant for the binding activity of the scaffold. In addition, the variation on the 5-aryl ring of 
the acetic acid derivatives 123 displayed a minimal inhibition activity ranging from 5-20%.  
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Table 4.11: The HIV-1 IN-LEDGF/p75 inhibition activities of the 5-aryl-1H-imidazol-1-yl 
compounds 120, 121, 123 and 125 at 100 µM. 
N
N
O
O
R'
N
N
HN
O
NH2
R'
120 R= H
121 R=Me
125
N
N
OH
O
R'
123
R
 
Compounds 
Entry  
R’ 
Biochemical target assays 
HIV-1 IN – LEDGF (%) inhibition @ 100 
µM  (AlphaScreen) 
120a 4-F 19 ±2.13 
120b 2-Cl 0 
120c 3-OMe 14±4.91 
120d 3,4-diOMe 7 ±3.94 
120e 3,4-OCH2O- 9 ±4.15 
120f 4-tBu 8 ±3.55 
120g 3-OH,4-OMe 11 ±3.84 
120h H 26 ±2.13 
121a 4-F 21 ±5.12 
121c 3-OMe 0 
121d 3,4-diOMe  21 ±3.02 
123a 4-F 26 ±1.67 
123c 3-OMe 5 ±4.18 
123d 3,4-diOMe 8 ±1.89 
123e 3,4-OCH2O- 30 ±6.67 
123f 4-tBu 0 
123g 3-OH,4-OMe 82 ±2.41 
123h H 31 ±3.42 
125a 4-F 40 ±5.02 
125c 3-OMe 23 ±4.52 
125d 3,4-diOMe 34 ±4.41 
125e 3,4-OCH2O- 33 ±8.46 
125f 4-tBu 40 ±4.62 
125g 3-OH,4-OMe 6 ±8.39 
125h H 10 ±3.96 
CX05168  91.37+-0.85 
HIV-1 IN and 
LEDGF with 
DMSO 
 
0 
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Transforming the ester derivatives 120 to the corresponding acetohydrazide scaffolds 125 also 
showed inhibition lower than the pre-defined 50% minimum benchmark. But their percentage 
inhibition values were slightly improved in comparison to the ester derivatives. For instance, 
compound 125a with no substituent on the 5-aryl ring and compound 125f with 4-tert-butyl 
group at the para-position of the 5-aryl ring exhibited 40% inhibition each, higher than that of 
the corresponding analogues 125a and 125f, which showed only 26% and 7% inhibition, 
respectively.  The rest of the compounds in the acetohydrazide set displayed marginal inhibition 
(ranging from 6% to 33%) of the formation of the IN-LEDGF/p75 complex.   
The best inhibitor 123g was further evaluated in an AlphaScreen Truhit counter assay to 
determine if it could have interfered with the interaction of the FLAG peptide with the anti-
FLAG acceptor beads. The compounds found to prevent the interactions of beads are regarded 
as false positives meaning that they are not disrupting the protein-protein interaction, but instead 
are absorbing the energy at the emission frequency, hence significantly diminishing the output 
signal for accurate reading. The best compound 123g was not a false positive.  
The cytotoxic effect of the best compound 123g was evaluated in the MT4-cell line at 100 µM 
concentration and was shown not to reduce the viability of the cell, hence it is considered as 
non-toxic. The antiviral activity was also carried out; however compound 123g did not inhibit 
HIV replication in cell culture. This is not of immediate concern given the fact that most of the 
compounds reported to be inhibitors of LEDGFp75 and IN interactions show lack of antiviral 
activity in cell based assays. 288  Furthermore, lack of antiviral activity may also be attributed to an 
inability of the compound to penetrate the cell or to not reaching the target. Besides the lack of 
antiviral activity, compound 123g can be considered a viable hit and warrants further 
investigation. 
 
4.2.7.2. Direct Vpu-BST-2 ELISA assay 
At the time of completion of the synthesis of the 5-aryl-1H-imidazoyl fragments, Mintek 
biochemists had finished developing and validating a BST-2-Vpu ELISA assay, which was then 
ready to screen a small batch of 25 compounds, namely: ethyl 5-aryl-1H-imidazol-1-yl acyls (120 
and 121), 2-(5-aryl-1H-imidazol-1-yl) acetic acids (123) and 2-(5-aryl-1H-imidazol-1-
yl)acetohydrazide scaffolds (125), alongside 6-aza-2-thiouridine (a compound that has previously 
been shown to inhibit Vpu mediated BST-2 degradation).288 The assay was carried out at 100 µM 
concentration (fragment screening) and the respective inhibition percentages were calculated; 
results are shown in Table 4.12.  
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Table 4.12:  HIV-1 Vpu-BST- inhibition activities of the 5-aryl-1H-imidazol-1-yl compounds 
120, 121, 123 and 125 at 100 µM. 
N
N
O
O
R'
N
N
HN
O
NH2
R'
120 R= H
121 R=Me
125
N
N
OH
O
R'
123
R
 
C
o
m
p
o
u
n
d
 
Biochemical target assays 
Cell-based assays (MT-
4 cells 
HIV-1 Vpu – BST-2 (%) 
inhibition @ 100 µM  
(ELISA) 
HIV-1 Vpu– BST-2 
inhibition IC50 (ELISA) 
(µM) 
 
CC50  
(µM) 
120a 54 - > 200 
120b 13 - - 
120c 51 - > 200 
120d 58 - 194 ± 0.6 
120e 33 - - 
120f 17 - - 
120g 30 - - 
120h 82 12 161 ± 0.8 
121a 63  103 ± 0.5 
121c 20 - - 
121d 22 - - 
123a 11 - - 
123c 30 - - 
123d 25 - - 
123e 9 - - 
123f 2 - - 
123g 0 - - 
123h 0 - - 
125a 48 - - 
125c 69 - > 200 
125d 28 - - 
125e 22 - - 
125f 45 - - 
125g 72 23 > 200 
125h 39 - - 
6-aza-2-thiouridine 54 - - 
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From the family of ester derivatives 120 and 121, five compounds showed more than 50% 
activity of disrupting the interactions between the HIV-1 Vpu and host BST-2 transmembrane 
domains at 100 µM. Compound 120h, with no substituent on the benzene ring, exhibited the 
highest percentage of 82%, followed by compound 121a (63% inhibition) with an electron-
withdrawing fluorine atom at the para-position on the 5-aryl ring and a methyl group at the chiral 
centre.  Compound 120d with the methoxy substituents at the para- and meta-positions and no 
chiral centre exhibited 58% inhibition of the Vpu- BST-2 interactions. The absence of the para-
methoxy substituent in scaffold 120c resulted in this compound showing 50% inhibitory activity. 
It was interesting to observe compound 120a, an analogue of 121a, with no chiral centre, also 
exhibited 54% inhibition in this ELISA assay. These data suggest that the presence of the para-
fluorine atom in scaffolds 120a and 121a as well as the presence of the methoxy substituent at 
the meta-position for 120c and 120d may be significant in preventing the interactions between 
HIV-1 Vpu and the host BST-2 protein.  
However, the potency observed for the five compounds belonging to ester series 120 was lost 
after hydrolysis into the corresponding acetic acids 123. These acetic acid scaffolds exhibited 
minimal inhibition activity (2-30%) with the exception of compounds 123g and 123h which were 
completely inactive. The results suggest that the family of 2-(5-aryl-1H-imidazol-1-yl) free acetic 
acids is not a suitable template for the design of potential inhibitors of the Vpu-BST-2 
interaction.  
The conversion of ester 120 into the corresponding acetohydrazide scaffolds 125 gave rise to two 
compounds, 125c and 125g, with more than 50% inhibition. Compound 125g with an OH and 
the methoxy group at the meta- and para-positions of the aryl ring displayed the highest 
imbibition percentage in this series (72%), whilst compound 125c with a methoxy substituent at 
the meta-position showed 69% inhibition.  Furthermore, it was interesting to note that both 
compounds 125c and 125g showed improved percentage inhibition in comparison with their 
ester analogues 120c and 120g. By contrast, an analogue of 120h (82%), compound 125h was 2-
times less potent. The results suggest that the presence of the electron donating groups at the 
meta- and para-positions of the 5-aryl ring are significant for the inhibition of these scaffolds. 
Additionally, compound 125a, a close analogue of 120a and 121a, exhibited 48% inhibition. 
Other compounds in the series of acetohydrazides displayed between 21-44% inhibitions.  
 
In summary, seven compounds from 25 screened imidazol-1-yl based compounds exceeded the 
pre-defined cut-off of 50%, and amongst them six surpassed the percentage inhibition of the 
standard 6-aza-2-thiouridine control compound in our BST-2–Vpu ELISA assay. It is 
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worthwhile to mention that the 6-aza-2-thiouridine does not directly disrupt the formation of 
Vpu-BST-2 complex, but it has been reported to act on the ion channel of the HIV-1 Vpu 
protein instead.288The results suggest that these best seven compounds may be unique Vpu-
BST inhibitors acting exclusively on the prevention of the Vpu-BST-2 complex formation.  
Compounds 120h and 125g, with the highest percentage inhibition were subjected to a dose 
response test and produced IC50 values of 12.42 and 23.36 µM, respectively (Table 4.12).   
In addition, the antiviral activity and cytotoxicity effects of the 7 best test compounds were 
determined in parallel using the MT-4 cell line. For the cytotoxicity assay the seven compounds 
were shown not to be overly toxic to the MT-4 cells and produced cytotoxic concentration 
(CC50) values ranging from 103 µM to greater than 200 µM in a dose response assay (Table 4.12). 
The activity of the virus in the presence of the test compounds was determined by detecting the 
p24 expression in HIV infected MT-4 cells. The compounds were tested at 10 and 100 µM 
doses; unfortunately none of the test compounds showed any significant inhibition at 10 and 100 
µM. The lack of antiviral activity could point to the fact that the compounds are not penetrating 
the cell or not reaching the desired target. These results indicate that a further modification in 
the structures of these compounds is necessary in order to improve their chemical and biological 
properties.   
 
4.2.8. In silico ADME profiling of novel 5-aryl-1H-imidazolyl- based compounds 
The ADME properties of the best seven compounds 120a, 120c, 120d, 120h, 121a, 125c and 
125g shown to exceed the 50% inhibition benchmark in the HIV-1 Vpu-BST-2 ELISA assay, 
and compound 123g which showed 82% disruption of the interaction between the HIV-1 IN 
and LEDGF/p75 were simulated using Biovia Discovery Studio TM with the aim of timeously 
evaluating and discarding unfavourable compounds.289, 290  The results are displayed in Table 4.13. 
All eight 2-(5-aryl-1H-imidazoyl) acyl derivative were predicted to have good or optimal aqueous 
solubility (level 3 and 4) and projected drug like properties with blood brain barrier (BBB) 
penetration levels medium to low, as shown in Table 4.13. By contrast, compounds, 120a, 120c, 
120d, 120h and 121a, from the ester family were predicted to have low intestinal absorption, 
while scaffolds 123g, 125c and 125g were predicted to have good human intestinal absorption. 
All eight analogues were projected to be non-inhibitors of CYP2D6, which means that these 
scaffolds are not expected to inhibit the CYP2D6 enzyme during metabolism through 
cytochrome p450 (CYP). These predictions suggest that these compounds merit further 
exploration as templates for possible inhibitors of the Vpu-BST-2 interaction. 
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Table 4.13: Predicted ADME profiles of eight 2-(5-aryl-1H-imidazoyl) acyl derivative using 
Discovery studio 4.0. 
compds 
Aqueous 
Solubility & 
Drug likeness 
Blood Brain 
Barrier 
Penetration 
Human 
Intestinal 
Absorption 
CYP2D6 
Inhibition 
120a 3 2 2 No 
120c 3 2 2 
No 
120d 3 3 2 
No 
120h 3 2 2 
No 
121a 3 2 2 
No 
123g 4 3 0 
No 
125c 3 3 0 
No 
125g 4 3 0 
No 
 
4.2.9. Molecular modelling of compound 123g at the IN dimer interface 
The potential binding modes of compound 123g (which showed more than 50% inhibition in 
the AlphaScreen assay) to the binding cavity of the HIV-1 IN dimer interface was simulated 
using BIOVIA Discovery Studio, making use of the crystal structure of HIV-1 IN (PDB code: 
2B4J). The best binding pose had a total binding energy of -150.388 kcal/mol.  The carboxylic 
group (-COOH) in the best pose of compound 123g (in Figure 4.10 A and B) made two 
hydrogen bonds with the main chain nitrogen atoms of the His171 residue of subunit B whilst 
the para-methoxy group is involved in a hydrogen bond with the Ala128 residue and its phenyl 
ring occupied the hydrophobic pocket of the same Ala128 amino side chain of monomer A. The 
meta-hydroxyl group exhibited three hydrogen bonds with the carbonyl group and a hydroxyl 
group as well as the hydrogen atom at a chiral centre of the Thr125 amino acid of subunit A. 
The docking results for compound 123g with HIV-1 IN dimer resemble the mode of interaction 
exhibited by the LEDGF/p75 protein with the dimer.291 The interactions between compound 
123g at the LEDGF/p75 binding site of the IN dimer interface were projected to be at relative 
distances of less than 3Å. 
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A     
B  
Figure 4.10:  A) 3D representation of molecular docking of the best pose of compound 123g in 
the LEDGF/p75 binding site at the IN dimer interface with hydrogen bonds provided in dashed 
lines at projected distances of less than 3Å; and B) 2D representation of compound 123g with 
critical residues within LEDGF/p75 binding site at the IN dimer interface. 
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4.3. The expansion on the 2-(5-aryl-1H-imidazoyl) acyl fragments to produce second 
generation compounds 
Encouraged by the biological results from the AlphaScreen assay, we wished to explore the 
second generation of compounds through a fragment growing method starting from the hit 
compound 123g. A literature survey revealed several compounds containing the hydrazine 
framework as potential inhibitors that prevent the formation of the LEDGF/p75-IN complex 
(outlined in Figure 4.11).292,293  For example, Tintori and co-workers292 identified a class of 
hydrazine compounds that prevent the binding of the LEDGF/p75 to the IN dimer interface 
through molecular docking while Sanchez et al. identified the hydrazine containing compounds 
through screening using LEDGF/p75 IBD-based pharmacophore models as potential inhibitors 
of the LEDGF/p75 – IN interaction (Figure 4.11).293  
 
  
 
  
 
Figure 4.11: Examples of reported hydrazine-based compounds as potential inhibitors of 
LEDGF/p75-IN interaction. 
 
On the basis of the above and our interest in the development of possible inhibitors that can 
prevent the formation of the HIV-1 IN and host LEDGF/p75 protein complex, attention was 
shifted to exploring the effects of structure variation by fragment expansion on the hit 
compound 123g through incorporating the hydrazine framework. Our proposition was that the 
hydrazine incorporation would increase percentage inhibition of the scaffolds as well as probing 
the structure activity relationship of these types of compounds. Thus, the work described here 
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was aimed at insertion of a hydrazine motif through a fragment expansion method to give a set 
of N'-arylidene-based compounds as second generation of these compounds.  
 
4.3.1. Synthesis of N'-arylidene-2-(5-aryl-1H-imidazol-1-yl)acetohydrazide and N,5-
diaryl-2-(1H-imidazol-1-yl)acetamide derivatives 
An analogue of identified hit compound 123g, 2-(5-aryl-1H-imidazol-1-yl)acetohydrazide 125g 
was used as the starting point, as it was readily available.   In addition, other selected 2-(5-aryl-
1H-imidazol-1-yl)acetohydrazide scaffolds were also included, which would assist in probing the 
SAR of the compounds. Therefore, 2-(5-aryl-1H-imidazol-1-yl)acetohydrazide scaffolds 125a, 
125d, 125f and 125g were then heated under reflux in the presence of benzaldehydes 7a-f using 
MeOH as solvent for about 8 hours as shown in Scheme 4.10.294  Work up furnished the desired 
fifteen novel N'-arylidene-2-(5-aryl-1H-imidazol-1-yl)acetohydrazide derivatives 127a-o. The 
yields of the products obtained were in the range of 63 to 86% as recorded in Table 4.14.  
 
125a R= 4-F 
125d R= 3,4-DioMe
125f R= 4-tBU
125g R= 3-OH-4-OMe
N
N
O
HN
R
O
R'
MeOH. reflux, 8 h
7a R' = 4-F, 
7b R'= 2-Cl
7d R'= 3,4-diOMe
7f R'= 4-tBu
7g R'= 3-OH,4-OMe
7h R'= H
127
N
N
O
HN
R
N
R'
NH2
 
 
Scheme 4.10: Synthesis of (E)-N'-arylidene-2-(5-aryl-1H-imidazol-1-yl)acetohydrazide 127. 
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Table 4.14: Isolated yields (%) of the novel (E)-N'-arylidene-2-(5-aryl-1H-imidazol-1-
yl)acetohydrazide 127a-o. 
N
N
O
HN
N
R
R'
 
Compounds R R’ Yield (%) 
127a 3-OH, 4-OMe 4-F 73 
127b 3-OH, 4-OMe 2-Cl 64 
127c 3-OH, 4-OMe 3,4-diOMe 75 
127d 3-OH, 4-OMe 4-tBu 70 
127e 3-OH, 4-OMe 3-OH, 4-OMe 76 
127f 3-OH, 4-OMe H 63 
127g 4-F 4-F 54 
127h 4-F 2-Cl 68 
127i 4-F 3,4-diOMe 86 
127j 4-F 4-tBu 76 
127k 4-F 3-OH, 4-OMe 81 
127l 4-F H 72 
127m 3,4-diOMe 4-F 83 
127n 3,4-diOMe 4-tBU 71 
127o 4-tBu H 81 
 
 
4.3.1.1. Structure elucidation of N'-arylidene-2-(5-aryl-1H-imidazol-1-yl)acetohydrazide 
127a-o 
The formation of the desired N'-arylidene-2-(5-aryl-1H-imidazol-1-yl)acetohydrazide compounds 
127a-o were characterised by FTIR and NMR spectroscopy and ESI-MS.  The FTIR spectra of 
N'-arylidene-2-(5-aryl-1H-imidazol-1-yl)acetohydrazides 127a-o showed  the disappearance of 
NH2 bands while the NH band was still observed in the region of 3061 cm
-1 to 3216 cm-1.  
Moreover, the hydrazide C=O stretching bands were observed in the region of 1672 cm -1 to 
1698 cm-1, whilst  the two bands in the region of 1503cm-1 to 1564cm-1 correspond to the N=CH 
stretch of the azomethine group and the imidazole moiety.   
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The NMR spectra of the compounds 127 determined in DMSO-d6 confirmed the loss of NH2 
and the appearance of the azomethine proton (-N=CH) with signals in the region of 8.00-8.63 
ppm, whilst the signals in the region of δ 11.57-11.89 ppm correspond to an NH proton.   Both 
1H and 13C NMR spectra of compounds 127 presented additional signals due to the restricted 
rotation around the carbonyl amide bond.  The 13C NMR spectra of the fluorinated compounds 
127a, g-l showed the corresponding fluorine splittings. 
The parent molecular ion peaks in the ESI-MS spectra ([M+H]+.) further validate their chemical 
structures (Table 4.15). 
 
Table 4.15: HRMS results of the (E)-N'-arylidene-2-(5-aryl-1H-imidazol-1-yl)acetohydrazide 
127a-o and their mSigma values. 
C
o
m
p
d
s Chemical 
formula 
[M+1] 
Calculated 
m/z 
Measured 
m/z 
mSigma 
value 
Err 
(mDa) 
Err 
(ppm) 
127a C19H18FN4O3+ 369.1357 369.1366 -0.9 -2.4 1.8 
127b C19H18ClN4O3+ 385.1062 385.1062 -0.0 -0.0 0.8 
127c C23H27N4O3+ 407.2078 407.2083 -0.5 -1.2 0.4 
127d C21H23N4O5+ 411.1663 411.1674 -1.1 -2.7 4.3 
127e C20H21N4O5+ 397.1506 397.1510 -0.4 -2.7 5.2 
127f C19H19N4O3+ 351.1452 351.1455 -0.3 -0.8 3.6 
127g C18H15F2N4O+ 341.1208 341.1217 -0.8 -2.4 6.5 
127h C18H15FClN4O+ 357.0913 357.0918 -0.5 -1.5 7.0 
127i C20H20FN4O3+ 383.1514 383.1521 -0.7 -0.7 6.2 
127j C22H24FN4O+ 379.1929 379.1933 -0.4 -1.1 4.4 
127k C19H18FN4O3+ 369.1357 359.1363 -0.5 -1.4 5.5 
127l C18H16FN4O+ 323.1303 359.1304 -0.1 -0.6 1.6 
127m C20H20FN4O3+ 383.1514 383.1522 -0.8 -2.0 6.2 
127n C18H16FN4O+ 421.2234 421.2238 0.4 1.2 5.4 
127o C22H25N4O+ 361.2023 361.2025 -0.2 -0.7 9.1 
 
 
4.3.2. Synthesis of N,5-diaryl-2-(1H-imidazol-1-yl)acetamide derivatives 
It was of further interest to extend the existing library by converting the ethyl 2-(5-aryl-1H-
imidazol-1-yl) acyl derivatives 120 into the corresponding N,5-diaryl-2-(1H-imidazol-1-
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yl)acetamides 128 in accordance with the previously reported protocols.238 We were hoping that 
the inclusion of the carboxamide group in scaffolds 120 might increase the inhibition activities of 
the compounds. Due to time contraints, only ethyl 2-[5-(4-fluorophenyl)-1H-imidazol-1-
yl]acylate 127a was reacted with NaNO2 in 1M HCl at 0
oC, followed by addition of a solution of 
aniline derivatives 74 in THF and further stirring at the same temperature for 16 hours (Scheme 
4.11). Work up and isolation by column chromatography afforded two novel N,5-diaryl-2-(1H-
imidazol-1-yl)acetamide derivatives 128a-b bearing electron-donating groups at the N-aryl ring in 
yields of 58 and 68%, respectively. However, when the N-aryl group contained dihalide groups at 
the ortho- and para-positions, no products were isolated under the tested reaction conditions. This 
may be attributed to the electron-withdrawing effects of the substituents at those positions 
reducing the nucleophilicity of the aniline nitrogen. 
 
N
N
O
NH
NH2
R'
i) NaNO2, 1N HCl, 0
oC, 20 min
ii)                          ,THF, 0oC, 16 h RF
            R'                        Yields
        
128a   2,3-diOMe              63%
128b   2,3-diMe                 58%
N
N
O
O
120a
F
74f R'=2,4-diCl
74i R'= 2,4-diOMe
74j R'= 2,4-diMe
74k R'=  2,4-diF
 
 
Scheme 4.11: Synthesis of N,5-diaryl-2-(5-aryl-1H-imidazol-1-yl)acetamide derivatives 128. 
 
4.3.2.1. Structure elucidation of the N,5-diaryl-2-(1H-imidazol-1-yl)acetamides 128 
In this section, by way of example, FTIR and NMR spectra of compound 128a will be discussed 
in detail below as representative of this compound class. The FTIR spectrum of compound 128a 
showed the absorption band at 3241 cm-1 relating to an NH group whilst the band at 1742 cm-1 
corresponded to an amide carbonyl group.   
A characteristic feature of compound 128a in the proton NMR spectrum was the presence of an 
NH singlet at 8.01 ppm while another two singlets at 7.76 and 7.16 ppm correspond to the two 
methine protons of the imidazole motif. A singlet signal at 4.74 ppm was assigned to the 
methylene protons adjacent to the carbonyl group while two characteristic methoxy singlets 
resonate at 3.78 and 3.72 ppm. The 13C NMR spectrum for compound 128a displayed signals at 
164.2 ppm and 162.9 ppm which correspond to the carbonyl carbon atom and the carbon atom 
(1JC,F= 253 Hz) directly attached to the fluorine atom. Furthermore, the carbon signals of the aryl 
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ring directly attached to fluorine at the para-position appears as a doublet due to fluorine 
splitting. 
 
4.3.3. Biological evaluation of the synthesized (E)-N'-arylidene-2-(5-aryl-1H-imidazol-1 
yl)acetohydrazides 127a-o and N,5-diaryl-2-(1H-imidazol-1-yl)acetamides 128a-b 
The newly synthesized seventeen compounds belonging to a families of novel (E)-N'-arylidene-
2-(5-aryl-1H-imidazol-1-yl)acetohydrazides 127a-o and N,5-diaryl-2-(1H-imidazol-1-
yl)acetamides 128a-b were submitted to be evaluated for inhibition of LEDGF/p75-IN 
interactions using the AlphaScreen assay at 100µM. The tests were carried out in triplicate and 
average results are recorded in Table 4.16.  
 
Table 4.16: The HIV-1 IN-LEDGF/p75 inhibition activities of N'-arylidene-2-(5-aryl-1H-
imidazol-1-yl)acetohydrazides 127 and N,5-diaryl-2-(1H-imidazol-1-yl)acetamides 128. 
Compounds entry 
Biochemical target assays 
HIV-1 IN – LEDGF (%) inhibition @ 100 µM 
(AlphaScreen) 
127a 0 
127b 19 ± 3.31 
127c 24 ± 9.03 
127d 49 ± 6.06 
127e 20 ± 2.53 
127f 0 
127g 37 ± 6.67 
127h 48 ± 5.06 
127i 19 ± 5.74 
127j 75 ± 4.47 
127k 13 ± 8.40 
127l 13 ± 9.44 
127m 6 ± 3.02 
127n 64 ± 2.22 
127o 83 ± 1.40 
128a 31 ± 7.07 
128b 0 
CX05168 91.37+-0.85 
HIV-1 IN and LEDGF with 
DMSO 
0 
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Of the seventeen screened compounds, at least three arylidene-based compounds (127j, 127n 
and 127o) exceeded the 50% benchmark at a single dose concentration of 100 μM. These best 
three inhibitors of the IN-LEDGF/p75 interaction contained the 4-tert-butylphenyl group.  
Compound 127o with no substituent on the aryl ring directly linked to the hydrazine motif 
exhibited the highest inhibition percentage of 83%, followed by compound 127j with a para-
fluorine atom on the 5-aryl ring with 75% inhibition. Compound 127n, with the methoxy groups 
at the meta- and para-positions on the 5-aryl ring displayed 64% inhibition of the LEDGF/p75-
IN interaction. It was interesting to observe that another compound 127d with a 4-tert-
butylphenyl group on the aryl ring linked to the hydrazine motif exhibited 49% inhibition, which 
proves further the significance of a tert-butyl moiety in the disrupting activity of the compounds.  
Compound 127h with a chlorine atom at the ortho-position of the aryl ring linked to the 
hydrazine motif and fluorine atom at the para-position on the 5-aryl ring yielded inhibition 
activity of 48%, while a close analogue, compound 127b, containing a hydroxyl and a methoxy 
group at the meta- and para-position showed a significant decrease in activity with an inhibition of 
19%. Other hydrazine scaffolds exhibited minimal inhibition activity (6-37%) with the exception 
of compounds 127a and 127f which were entirely inactive. Amongst the acetamide family, 
compounds 128a with two methoxy group at the ortho- and para-positions of the N-arylacetamide 
motif exhibited only 31% inhibition of the formation of the IN-LEDGF/p75 complex, while 
compound 128b with two methyl group at the ortho- and para-positions of the N-arylacetamide 
moiety was inactive. 
The best three compounds were further assessed in the Truhit assay and they were found not to 
be false positives. The two LEDGF/p75-IN inhibitors 127j and 127o showing highest inhibition 
were further evaluated in a dose range assay and they produced IC50 values of 27μM and 32 μM, 
respectively. In a cell based assay, these compounds were found not to reduce the viability of the 
MT-cell and no antiviral activities were observed for the best three compounds, which may point 
to poor solubility or that they are only disrupting the protein-protein interaction and not causing 
multimerization. The inhibition activity observed for the best three N-arylidene-based 
compounds reported here provides groundwork for further investigations. 
 
4.3.4. In silico ADME studies of novel (E)-N'-arylidene-2-(5-aryl-1H-imidazol-1-
yl)acetohydrazide compounds 
The ADME and Lipinski‟s “rule of five” or Veber‟s rule, of the best three compounds were 
determined in order to filter compounds which do not adhere with these properties using 
BIOVIA Discovery StudioTM.289,295 The best three compounds were found to have less than 5 
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hydrogen donors, 5 to 7 hydrogen acceptors and their molecular weights were established to be 
less than 500 (360.45 > MW < 420.20), which falls within the Lipinski rule (Table 4.17). These 
compounds did not violate Lipinski‟s or Veber‟s rules, which indicate good drug-likeness 
properties whilst the polar surface area of the best four compounds were established to be below 
140Å displaying good lipophilicity. 
 
Table 4.17:  The predicted Lipinski properties of the best four (E)-N'-arylidene-2-(5-aryl-1H-
imidazol-1-yl)acetohydrazides 127j and 127n-o. 
Compounds 
Molecular 
Weight 
(g/mol) 
Lipinski’s 
Number of 
hydrogen 
donor 
Lipinski’s 
Number of 
hydrogen 
acceptor 
Number of 
rotational 
bond 
Polar Surface 
Area 
(PSA_2D) 
127j 378.443 1 5 6 58.043 
127n 420.504 1 7 8 75.903 
127o 360.452 1 5 6 58.043 
Note: ideal ranges for druggability; Mw <500; H donors <5; H acceptors from 5-7; PSA <140. 
 
ADME properties of the best three compounds 127j and 127n-o were also performed by means 
of Discovery StudioTM to determine their BBB penetration, aqueous solubility and human 
intestinal absorption, and cytochrome p450 2D6 protein inhibition (Table 4.18).289,290 The three 
compounds were predicted to have low solubility (level 2) which implies that the compounds 
slightly dissolve in water, and all were projected to have good absorption levels, which indicate 
that they can be absorbed very well by the human intestine after oral dosage. Compounds 127j 
and 127o were predicted to be high BBB penetrators indicating that they might cause central 
nervous system side effects, whilst compound 127n was a medium penetrator which suggests 
that it might have low chances of causing side effects in the central nervous system. 
Furthermore, compound 127n was predicted to be a non-inhibitor of the CYP2D6 enzymes, 
which are responsible for metabolism of many drugs in the human body.  
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Table 4.18: Predicted ADME profiles of four (E)-N'-arylidene-2-(5-aryl-1H-imidazol-1-
yl)acetohydrazides 127j and 127n-o. 
Compounds 
Aqueous 
Solubility & 
Blood Brain 
Barrier 
Penetration 
Human 
Intestinal 
Absorption 
CYP2D6 
Inhibition 
127j 2 1 0 Yes 
127n 2 2 0 No 
127o 2 1 0 Yes 
 
 
4.3.5.  Molecular modelling of the synthesized (E)-N'-arylidene-2-(5-aryl-1H-imidazol-1-
yl)acetohydrazides 127j and 127n-o at the HIV-1 IN dimer interface 
The best three N'-arylidene compounds which were found to be active by exhibiting more than 
50% inhibition of the LEDGF/p75 -IN protein-protein interaction were docked in the 
LEDGF/p75 binding site of the HIV-IN dimer-dimer interface ( PDB code: 2B4J). The docking 
studies were carried out using Discovery Studio software. The best three compounds were 
docked at the dimer cavity of the HIV-IN where the LEDGF/p75 binds using LibDock scoring, 
and following energy minimizations until achieving the lowest binding energy poses. The scoring 
results and their calculated binding energy are recorded in Table 4.19. The docking study showed 
that the best three compounds were binding in the LEDGF/p75 binding cavity of the IN dimer 
interface with compound 127n displaying a total binding energy of -61.1730Kcal/mol (lowest 
binding energy), followed by 127j with a total binding energy of -59.624 Kcal/mol whilst 
compound 127o exhibited a total binding energy of -53.8902 Kcal/mol. The lowest binding 
energy exhibited by compound 127n could be attributed to the methoxy group which could form 
a hydrogen bond with residues within the binding site causing the stabilisation of the interaction 
between HIV-1 IN and the compound. 
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Table 4.19:  A list of in silico interaction of compounds (127j, 127n and 127o) and their binding 
energy.  
Compounds 
Binding energy 
Kcal/mol 
LibDock 
Score 
Jain 
score  
Amino acids 
interactions 
127j 
-53.8902 30.9486 3.52 
Ala98, Leu102 
Ala128, Ala129, 
Ala169, Glu170, 
Thr174 
 
127n 
-61.1730 36.8581 2.38 
Ala98, Leu102 
Ala128, Ala129, 
Gln168, Trp131, 
Glu170, His171 
 
127o 
-53.8902  44.8739 1.46 
Ala98, Leu102 
Ala128, Gln168, 
Glu170, His171 
 
 
The predicted binding model of compound 127j shown in Figure 12 A and B displayed the 
carbonyl oxygen forming two hydrogen bonds with an NH of Gln168 and Glu170 residues while 
the 4-tert-butylphenyl group at the 5-position of the imidazole motif occupies the hydrophobic 
pockets of the Ala98 residue. The phenyl ring directly attached to the hydrazine group is shown 
to pack in a hydrophobic cavity of His171, whilst the imidazole moiety falls in the hydrophobic 
cavity of Ala98 and Leu102 residues.  
The para-methoxy group in 127n (Figure 4.12, C and D) exhibited a hydrogen bond to the His171 
residue, while its imidazole moiety interacts in a similar mode to compound 127j. Moreover, the 
azomethine and an NH group of the hydrazine motif display two hydrogen bonds to the Gln168 
residue while the 4-tert-butylphenyl ring is packed into the hydrophobic pockets of Trp131. 
The model of compound 127o (Figure 4.12, E and F) shows the imidazole core packed into 
hydrophobic pockets of the Ala98 and Leu102 residues while the 4-tert-butylphenyl ring is 
packed into the hydrophobic cavity of Ala128. Furthermore, the oxygen atoms of the carbonyl 
group display two hydrogen bonds to the Gln98 and Glu170 amino acids whilst the phenyl ring 
directly attached to the hydrazine group packs into the hydrophobic His171 residue. 
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A   B  
C    D   
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E    F    
 
Figure 4.12: Predicted binding models of compounds 127j (A and B), 127n (C and D) and 127o 
(E and F) docked in the LEDGF/p75 binding cavity at the HIV-1 IN dimer interface 
(with yellow CPK display sphere sized representing monomer A and green CPK display 
sphere sized for monomer B). 
 
In summary, the binding model shows that the three compounds with the best activity in the 
AlphaScreen interact with the amino acids in the HIV-1 IN binding cavity, with compound 127n 
exhibiting the lowest binding energy. The study reveals that the imidazole motif of the best 
compounds occupies the hydrophobic pockets of amino acid residues known to interact with 
LEDGF/p75. Furthermore, these compounds occupy the same binding cavity of the HIV-1 IN 
as occupied by LEDGF/p75. 
 
4.4. Conclusion 
A novel family of 5-aryl-imidazol-1-yl-based compounds were successfully synthesized by 
incorporation of simple amino acids via a van Leusen approach.  Firstly, glycine, L-alanine and 
D-leucine were converted to the corresponding amino acid ethyl ester hydrochloride salts in 
excellent yields, followed by treatment with Et3N in CHCl3 to afford free amino esters in good 
yields. These free amino esters were further subjected to condensation reactions with various 
benzaldehydes to furnish the ethyl 2-(arylideneamino)acyl intermediates in excellent yields. An 
initial attempt to react TosMIC with ethyl 2-(arylideneamino)acyl intermediates using previously 
established protocols, under microwave irradiation was unsuccessful. This was attributed to 
possible decomposition of the intermediate under MW heating. However, the problem was 
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overcome by reacting TosMIC with ethyl 2-(arylideneamino)acyl intermediates induced by DBU 
in DCM at room temperature for 24 hours, followed by removal of DCM and further subjecting 
the crude material to microwave heating under toluene at a set temperature of 115oC for 10 
minutes to afford the ethyl 2-(5-aryl-1H-imidazol-1-yl)acyls in poor to good yield. The yields of 
the products were strongly influenced by the substituents at the chiral centre and on the aryl ring.  
Initial attempts to isolate the hydrolysed 2-(5-aryl-1H-imidazol-1-yl) acetic acids from reaction of 
selected ethyl 2-(5-aryl-1H-imidazol-1-yl)acylates with NaOH in MeOH proved to be 
challenging, which may be due to the existence of these compounds in ionized form. However, 
the hydrolysis of ethyl 2-(5-aryl-1H-imidazol-1-yl)acylates to the corresponding 2-(5-aryl-1H-
imidazol-1-yl) acetic acids was successfully achieved in good yield by microwave irradiation in 
water at a set power of 200 Watts and temperature of 105oC for 3 hours. Furthermore, selected 
ethyl 2-(5-aryl-1H-imidazol-1-yl)acylates were subjected to nucleophilic attack by hydrazine 
monohydrate using both conventional heating and microwave methods to afford 2-(5-aryl-1H-
imidazol-1-yl)acetohydrazide scaffolds in various yields. A total of 26 novel 5-aryl-imidazol-1-yl-
based scaffolds were obtained and submitted for biological evaluation.  
 
IN-LEDGF/p75 AlphaScreen assay: The 26 novel 5-aryl-imidazol-1-yl-based compounds were 
screened for direct inhibition of HIV-1 IN-LEDGF/p75 interaction. Only compound 123g 
from a family of 2-(5-aryl-1H-imidazol-1-yl)acetic acids displayed inhibition above 50% with an 
IC50 value of 19 μM. The best scaffold was non-toxic to the MT-4 cell at 100 μM but 
unfortunately, it did not inhibit HIV-1 replication in the cell.  
Compound 123g was then modelled and subjected to docking simulations in order to understand 
the probable binding modes at molecular level. This scaffold was projected to have a good 
probability of interacting with important amino acids in the HIV-1 dimer interface in a 
comparable mode of action to the LEDGF/p75 protein.  Furthermore, the best scaffold 123g is 
predicted to have good ADME properties. The results indicated that compound 123g has 
significant ability to prevent the formation of the LEDGF/p75-IN complex and is considered a 
promising hit to design the next generation of compounds.  
 
Vpu-BST-2 ELISA assay: Seven out of 26 5-aryl-imidazol-1-yl-based compounds were found to 
exceed the 50% benchmark value at 100 μM. Compound 120h exhibiting the highest percentage 
inhibition of 82% with an IC50 of 12.42 µM, followed by compound 125g with 72% inhibition 
and an IC50 value of 23.36 µM for preventing the Vpu-BST-2 interaction. The seven best 
compounds were further evaluated in MT-4 cells in order to determine the CC50 values and 
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produced CC50 values between 102 µM to greater than 200 µM. None of the compounds showed 
any antiviral activity in the cell-based assay. The best compounds could be used as viable hits to 
design compounds with improved inhibition and IC50 values. 
The predicted ADME properties of the best seven inhibitors of the Vpu -BST-2 interactions 
showed good to optimal aqueous solubility with medium to low blood brain barrier (BBB) 
penetration levels. Furthermore, five compounds 120a, 120c, 120d, 120h and 121a showed low 
predicted intestinal absorption while scaffolds 123g, 125c and 125g were shown to have good 
human intestinal absorption. The best seven compounds were predicted to be non-inhibitors of 
the cytochrome P450 enzyme. These data reveal that these compounds merit further exploration 
as viable hits to design the next generation inhibitors of the Vpu-BST-2 interaction. 
 
A series of new N'-arylidene-2-(5-aryl-1H-imidazol-1-yl)acetohydrazide compounds and N,5-
diaryl-2-(1H-imidazol-1-yl)acetamide derivatives were designed and synthesized as second 
generation compounds. Initially, a small family of N'-arylidene-2-(5-aryl-1H-imidazol-1-
yl)acetohydrazide derivatives was successfully synthesized by reacting acetohydrazide derivatives 
with various benzaldehydes in MeOH under reflux.  The products were obtained in excellent 
yields as rotamers due to the restricted rotation around the amide bond.  
To further increase the number of compounds in the existing library, ethyl 2-[5-(4-fluorophenyl)-
1H-imidazol-1-yl]acylate was then reacted with NaNO2 in 1N HCl at 0
oC, followed by addition 
of aniline derivatives in THF to afford the two novel N,5-diaryl-2-(1H-imidazol-1-yl)acetamide 
derivatives bearing electron-donating groups at the N-aryl ring in good yields. When aniline with 
dihalides at the ortho- and para-positions were used, none of the desired compounds were 
isolated, which could be attributed to the electron-withdrawing effects of the halides. 
Having successfully synthesized the desired target compounds, seventeen novel compounds 
were sent for biological testing for their ability to disrupt LEDGF/p75-IN complex formation in 
an AlphaScreen assay. Three compounds showed inhibition that exceeded the 50% inhibition 
benchmark at 100 μM concentration and both contained the 4-tert-butylphenyl group. The top 
two LEDGF/p75-IN inhibitors 127j and 127o with the highest percentage inhibition in the 
AlphaScreen assay produced IC50 values of 27μM and 32 μM. 
 
Molecular docking was performed to give the probable binding mode of the best three 
compounds at the binding cavity of the HIV-1 dimer. The best three compounds were binding 
in the HIV-1 dimer interface in a mode of action similar to the LEDGF/p75 protein. The 
imidazole moiety was found to be packed into the hydrophobic cavities of important residues 
 
159 
 
known to interact with LEDGF/p75. Furthermore, the ADME predictions conducted on the 
best three compounds (127j, 127n and 127o) indicate that these compounds have low solubility 
(level 2) but good absorption levels. However, only compound 127n was predicted as a non-
inhibitor of the CYP2D6 protein. 
These results suggest that compound 127n could be selected for further optimization for 
improvement in anti-HIV-1 activity and aqueous solubility. The studies described in the present 
chapter demonstrate the usefulness of  TosMIC chemistry towards development of  nitrogen 
containing heterocycles. It also provides credence to the belief  that such progress can be 
accomplished in the academic domain. Furthermore, the compounds described have not been 
previously described for targeting the interaction between LEDGF/p75-HIV-1 IN proteins. 
 
4.5. Future Work 
Future work will involve insertion of  a second aryl ring at the 4-position of  the imidazole motif  
of  the 2-(5-aryl-1H-imidazol-1-yl) acetic acids, hoping that the modification will increase the 
percentage inhibition as well as the IC50 values of  the compounds in the HIV-1 IN-LEDGF/p75 
AlphaScreen assay (Figure 4.13). Evaluation of  the N'-arylidene-2-(5-aryl-1H-imidazol-1-
yl)acetohydrazides and N,5-diaryl-2-(1H-imidazol-1-yl)acetamides in the HIV-1 Vpu-BST-2 assay 
will also form part of  future work. 
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Figure 4.13: Possible structural modification of the 2-(5-aryl-1H-imidazol-1-yl) acetic acids.  
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CHAPTER 5 
Synthesis of 3-aryl-N-arylisoxazol-5-amine scaffolds using aryl isocyanides 
and their usefulness as for possible inhibitors of HIV-1 protein- host protein 
interactions 
 
5.1 Introduction  
Compounds containing the isoxazole motif have been reported to possess significant biological 
activity.296,297,298,299,300,301  To date no compounds with the isoxazole moiety have been reported as 
potential inhibitors that could disrupt the HIV-1 IN- LEDGF/p75 interactions, which made this 
moiety more interesting for this project. Keeping this in mind and considering our interest in 
extending the existing library of aryl-linked five-membered nitrogen containing heterocyclic 
fragments, we pursued the synthesis of a series of 3-aryl-N-arylisoxazol-5-amine fragments by 
employing aryl isocyanide as a synthon. We hoped that evaluation of these compounds could 
also offer a starting point to design a second generation of compounds, which could have anti-
HIV-1 activity through inhibiting the HIV-1 IN-LEDGF/p75 interactions.  
 
5.2. Synthesis of 3-aryl-N-arylisoxazol-5-amine based compounds 
The synthesis of 3-aryl-N-arylisoxazol-5-amines 131 requires the preparation of two essential 
intermediates; namely: the 2-halo-1-arylketone oximes 129 and aryl isocyanides 130 (Scheme 
5.1). The synthesis of these key intermediates was then pursued en-route to the final products. 
This chapter will discuss the synthetic challenges encountered in the preparation of isoxazoles, as 
well as characterization of compounds, reaction mechanisms and biological data of the isoxazole 
products.  
N C
N
Cl
+ Base
N
O
NH
solvent
HO
R'
R
R
R'
129 130 131  
 
Scheme 5.1: Synthetic strategy towards isoxazoles. 
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 5.2.1. Synthesis of key 2-halo-1-arylketoneoxime intermediates  
Our first efforts were towards the synthesis of the 2-halo-1-arylethanone oxime intermediates 
129, which were obtained over three steps via formation of 2-halo-1-arylethenone intermediate 
133 starting from aldehyde 7 as proposed in Scheme 5.2.   
 
O OH
Cl
Cl
Cl
O
Cl
NHOH
Cl
R R R R
7 132 133 129  
Scheme 5.2: Proposed synthetic strategy for the formation of 2-halo-1-arylethanone oximes. 
 
5.2.1.1. Synthesis of the 2,2,2-trichloro-1-aryl-ethanol 
The starting point of the synthesis was conversion of the aldehyde into the corresponding 
trihalocarbinols. These trihalocarbinols are routinely prepared through a base promoted addition 
of chloroform to the carbonyl group of the aldehyde using relatively strong base at mild 
temperatures to avoid the Cannizzaro reaction.302,303  In addition, cyclic amidines such as 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN) and guanidine 
have been described to stimulate the addition of chloroform to aldehyde under mild 
conditions.304  DBU was chosen as a catalytic base to induce the addition of chloroform to the 
aldehyde. Specifically, selected benzaldehydes 7 were reacted with dry chloroform 134 in the 
presence of DBU at room temperature under inert conditions for 4-48 hours as shown in 
Scheme 5.3. Work up furnished the desired 2,2,2-trichloro-1-aryl-ethanol products 132a-d as 
racemates in yields of up to 96% (Table 5.1). The yield of products was comparable to those 
values described in literature.304  
132a-d: 88-96%
Cl
H
134
DBU,  0oC-rt, 4-48h
7a R = 4-F 
7e R= 3,4-OCH2O
7j R= H
7k R= 4-Cl
H
O
R R
OH
Cl
Cl
Cl
Cl
Cl
 
 
Scheme 5.3: Synthesis of 2,2,2-trichloro-1-aryl-ethanol derivatives 132. 
Table 5.1: Isolated yields (%) of the 2,2,2-trichloro-1-arylethanol products 132. 
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R
OH
Cl
Cl
Cl
 
Compd R Yields (%) 
132a 4-F 94 
132b 3,4-OCH2O- 96 
132c H 93 
132d 4-Cl 88 
 
 
A probable mechanism for the formation of the 2,2,2-trichloro-1-arylethanol derivatives 132 is 
shown in Scheme 5.4 and is thought to involve deprotonation of chloroform 134 by the 
catalytic DBU to generate a reactive chloroform carbanion 135. This carbanion 135 then attacks 
the carbonyl carbon of aldehyde 7 to generate 2,2,2-trichloro-1-arylethan-1-olate intermediate 
136, followed by subsequent protonation to give 2,2,2-trichloro-1-arylethanol product 132.304 
 
Cl
Cl
Cl
H
DBU Cl
Cl
Cl
O
H
R
O
Cl
Cl
Cl
H+
OH
Cl
Cl
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135 136 132134
7
R
R
 
 
Scheme 5.4: Mechanistic pathway for the formation of 2,2,2-trichloro-1-arylethanols 132. 
 
The structures of 2,2,2-trichloro-1-arylethanol derivatives 132 were confirmed by NMR and 
FTIR spectroscopic analysis and were consistent with reported values.304  Compounds 132a-d 
were obtained as racemates.304 By way of example, compound 132c is discussed in detail and the 
key features of the proton NMR spectrum for this compound was the presence of a signal for 
the hydroxyl group which resonates as a singlet at δ 3.45 ppm and the methine proton at the 
chiral centre resonating as a signal at δ 5.21 ppm. The signals in the aromatic region were 
integrated and correspond to the five methine protons of the benzene ring. The 13C NMR 
spectrum of compound 132c exhibited all the expected carbon signals with the methine carbon 
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atom at the chiral centre resonating at δ 84.4 ppm whilst the carbon atom directly attached to the 
three chlorine atoms emerged at 103.0 ppm.   
The FTIR spectra of the compounds 132a-d confirmed the presence of an OH group as a broad 
signal appearing between 3326 and 3500 cm-1 as recorded in Table 5.2. 
 
Table 5.2: FTIR spectroscopic data of 2,2,2-trichloro-1-arylethanol derivatives 132 showing the 
OH bands.  
Compounds 132a 132b 132c 132d 
υOH (cm-1) 3447 3326 3426 3500 
 
5.2.1.2. Oxidation of 2,2,2-trichloro-1-aryl-ethanol derivatives  
 
OH
Cl
Cl
Cl CuCl, bipyridine
132a R= 4-F
132b R= 3,4-OCH2O
132c R= H
132d R= 4-Cl
O
Cl
133a-d 24-66%
DCE, reflux, 8h
R
R
 
 
Scheme 5.5: Synthesis of 2-chloro-1-aryl-ethanone derivatives 133 
 
A series of 2,2,2-trichloro-1-arylethanol derivatives 132a-d were then subjected to an oxidation 
reaction in accordance with a protocol reported in the literature.305 Thus, 2,2,2-trichloro-1-aryl-
ethanol derivatives 133a-d were heated under reflux in the presence of CuCl and bipyridine using 
1,2-dichloroethane (DCE) as solvent under oxygen free conditions for 8 hours (Scheme 5.5).  
Separation by short column chromatography gave 2-chloro-1-aryl-ethanone scaffolds 133a-d in 
yields ranging between 24 -66% (see Table 5.3). In our hands the yields of the products 133c and 
133d obtained were significantly lower than yields previously reported by Ram and co-workers 
(i.e. 96% for 133c and 90% for 133d).305  Compound 133a and 133b were not reported in the 
study conducted by Ram et al.,305 but they have been previously prepared using different starting 
materials.  
 
Table 5.3: Isolated yields (%) of the 2-chloro-1-aryl-ethanone products 133. 
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O
Cl
R  
Compound R Yields (%) 
133a 4-F 66 
133b 3,4-OCH2O- 24 
133c H 54 
133d 4-Cl 60 
 
 
The proposed mechanistic pathway for the oxidation of 2,2,2-trichloro-1-arylethanols 132 by 
CuCl/bipyridine is depicted in Scheme 5.6 and is similar to the previously reported by Ram et 
al.305  The initial step is considered to involve the reduction of one carbon-chlorine bond to 
generate copper-chlorocarbenoid intermediate 137, followed by removal of the CuCl/bipyridine 
complex, to produce enol 138 via a hydride shift. This compound 138 tautomerises to give 2-
chloro-1-aryl-ethanone 133.305 
OH
Cl
Cl
Cl
R
132
OH
CuCl/bipyr
Cl
R
3CuCl/bipyr
-2CuCl/bipyr
137
H
OH
Cl
R
1,2-H shift
-CuCl/bipyr
H
138
O
Cl
R
tautomerization
133
 
Scheme 5.6: Proposed mechanism of formation of 2-chloro-1-aryl-ethanones 133. 305 
 
The 2-chloro-1-aryl-ethanone products 133a-d were characterized by FTIR, and 1D and 2D 
NMR spectroscopy, and were in agreement with reported literature values.305  The main 
characteristic in the 1H NMR spectrum of compound 133b was the presence of a singlet at δ 
4.66 ppm integrating for two protons of the methylene group adjacent to the carbonyl group, 
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whilst the 13C NMR spectrum revealed the presence of a carbonyl carbon atom at 189.0 ppm and 
a methylene carbon atom adjacent to the carbonyl group at 45.6 ppm. The existence of the 
methylene carbon atom was evident in the DEPT 135 spectrum, where it resonated as a negative 
signal.  The FTIR spectra further confirmed the presence of the carbonyl group by showing 
stretch bands in the region of 1686-1701 cm-1 as shown in Table 5.4. 
 
Table 5.4: FTIR spectroscopic data of 2-chloro-1-aryl-ethanone products 133 showing the C=O 
bands.  
Compounds 133a 133b 133c 133d 
υC=O (cm-1) 1706 1736 1701 1686 
 
 
5.2.1.3. Synthesis of 2-chloro-1-aryl-ethanone oxime intermediates 
Zhang et al. had earlier reported a synthetic procedure for 2-chloro-1-phenylethanone oxime. 306 
To explore this route to 2-chloro-1-aryl-ethanone oxime intermediates, compounds 133a-d were 
subjected to condensation reaction conditions by reacting with hydroxylamine hydrochloride in 
the presence of water and MeOH as solvent at room temperature for 16 hours as indicated in 
Scheme 5.7. Work up by addition of more water, furnished the key 2-chloro-1-aryl-ethanone 
oxime intermediates 129a-d as precipitates in excellent yields (Table 5.5). The yield of the product 
129c obtained was as good as that reported by Zhang (i.e. 83%).306 
 
133a R= 4-F
133b R= 3,4-OCH2O
133c R= H
133d R= 4-Cl
O
Cl
R
N
Cl
R
129a-d: 88-94%
NH2OH.HCl, H2O, MeOH, rt, 16 h
OH
 
 
Scheme 5.7: Synthesis of 2-chloro-1-aryl-ethanone oxime intermediates. 
 
 
 
Table 5.5: Isolated yields (%) of the 2-chloro-1-aryl-ethanone oxime products 129. 
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N
Cl
R
OH
 
Compound R Yields (%) 
129a 4-F 94 
129b 4-Cl 93 
129c H 88 
129d 3,4-OCH2O- 94 
 
The structures of the products obtained were elucidated by NMR spectroscopy and values were 
in agreement with those found in the literature.306 ,307,314,315  NMR spectroscopic  analysis revealed 
that the 2-chloro-1-aryl-ethanone oxime products 129 were obtained as a mixture of geometric 
isomers in a ratio of 8:1 and assignment of the NMR spectra was based on previously reported 
literature values.314,315 The 1H NMR spectrum of compound 129b in chloroform revealed two 
singlets at 4.59 and 4.44 ppm corresponding to the methylene proton adjacent to a chlorine atom 
of both isomers, while hydroxylic protons for the two isomers were registered at 9.41 and 9.11 
ppm.  However, the 1H NMR spectrum of compound 129d in DMSO-d6 exhibited the OH 
groups of the two isomers as peaks at 11.9 and 11.8 ppm whilst the methine protons adjacent to 
the chlorine atom resonated as signals at 4.67 and 4.61 ppm, respectively.  The 13C NMR 
spectrum of compound 129b revealed the signal of the carbon atom double bonded to nitrogen 
of both isomers at 153.5 and 152.9 ppm while the methylene carbon atoms emerged at 44.5 and 
32.1 ppm. The FTIR spectra of these scaffolds revealed the presence of an OH group in the 
frequency region between 3226 and 3369 cm-1 whilst the C=N signal resonates in range of 1604-
1701cm-1 (Table 5.6). Furthermore, the frequencies in a region of 956 to 998 cm-1 were assigned 
to the stretching vibration of the N-O group. 
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Table 5.6: FTIR spectroscopic data of 22-chloro-1-aryl-ethanone oxime products 129 showing 
the OH, C=N and N-O bands. 
compounds 129a 129b 129c 129d 
υOH (cm-1) 3295 3360 3226 3269 
υC=N (cm-1) 1701 1686 1700 1717 
υN-O (cm-1) 836 833 960 953 
 
With the 2-chloro-1-aryl-ethanone oxime intermediates in hand, the focus was then shifted to 
the preparation of aryl isocyanide intermediates, making use of readily commercially available 
anilines. 
 
5.2.2. Synthesis of aryl isocyanide derivatives 
N-formylated compounds are very valuable intermediates in the preparation of isocyanide 
compounds.  They are readily generated by formylation of primary amines using various reagents 
such as acetic formic anhydride,308,309 silica sulfuric acid,310 zinc oxide,311 formic acid,312 
ammonium formate,313 ethyl formate,314 and other reagents. However, recently, a protocol 
involving the N-formylation of amines using ultrasound irradiation under solvent- and catalyst-
free conditions at 110oC has been cited.315  Encouraged by this observation, we pursued the 
synthesis of N-formylated anilines under microwave irradiation utilising the same temperatures 
reported for the ultrasound irradiation approach. Thus, a series of aniline derivatives 74e-f, i and 
j were microwave irradiated neat with formic acid at a set temperature of 110oC for 1 hour (as 
monitored by TLC), as illustrated in Scheme 5.8. Work up afforded the corresponding N-aryl-
formamide products 139a-d in yields similar to those reported under ultrasound irradiation and 
acetic formic anhydride methods (Table 5.7).312-315  
 
74e R'= 4-Br
74f R'= 2,4-diCl
74i R'= 2,4-diOMe
74j R'= 2,4-diMe
NH2
R'
NHCHO
R'
N
R'
C
MW: 110oC, 1 h
HCOOH
139a-d: 74-94% 130a-d: 71-91%
Et3N, DCM, rt,16 h
POCl3
 
 
Scheme 5.8: Synthesis of aryl isocyanides 130a-d. 
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Table 5.7: Isolated yields (%) of the N-aryl-formamide products 139a-d. 
NHCHO
R'  
Compounds R’ Yields (%) 
139a 4-Br 92 
139b 2,5-diCl 83 
139c 2,4-diOMe 74 
139d 2,4-diMe 79 
 
 
The structures of the N-aryl-formamide products 139a-d were confirmed by NMR spectroscopic 
analysis as rotamers which resulted due to the restricted rotation about the amide bond.  By way 
of example the structure of N-(2,4-dimethylphenyl) formamide 139d will be discussed in detail.  
The 1H NMR spectrum of N-(2,4-dimethylphenyl) formamide 139d showed a doublet at 8.54 
ppm with a J value of 12 Hz, corresponding to the presence of the major rotamer while the 
minor rotamer appears as a singlet at 8.39 ppm. Furthermore, the NH proton of the major 
rotamer resonates as a signal at 7.96 ppm whilst the signal at 7.17 ppm corresponds to the 
existence of the NH proton of the minor rotamer. The 13C NMR spectrum of compound 139d 
showed the aldehyde carbon atom of the major rotamer at 163.5 ppm, while the aldehyde carbon 
atom of the minor rotamer emerged as a signal at 159.2 ppm.  
 
The N-aryl-formamide derivatives 139a-d were then subjected to dehydration conditions with 
POCl3 in the presence of triethylamine in DCM at room temperature for 2 hours as depicted in 
Scheme 5.6.316,317,318 Work up and purification by column chromatography afforded the 
corresponding aryl isocyanides 130a-d in good yields (Table 5.8). The aryl isocyanide products 
130a-d isolated had an extremely distressing odour, which is associated with the majority of 
members of the isocyanide class of compounds.319 
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Table 5.8: Isolated yields (%) of the aryl-isocyanide products 130a-d. 
N
R'
C
 
Compd R Yields (%) 
130a 4-Br 71 
130b 2,5-diCl 78 
130c 2,4-diOMe 91 
130d 2,4-diMe 75 
 
 
Due to their strong odour, the synthesized aryl isocyanides 130a-d were only analysed by NMR 
spectroscopy and values were compared to those reported in literature.319 The unique 
characteristics were observed in their 1H NMR spectra which showed the loss of signals due to 
both amine and aldehyde protons. Further evidence was observed in the 13C NMR spectra which 
exhibited the disappearance of the signal for the aldehyde carbon atom and the appearance of a 
signal arising from an isocyano carbon atom. The isocyano carbon atom in compounds 130a and 
130c was observed as a triplet with J values of 6 Hz each at 164.8 and 165.8 ppm, respectively, 
whilst compounds 130b and 130d displayed the same carbon atom as a singlet signal at 165.9 and 
170.9 ppm, respectively. Furthermore, the carbon atom of the aryl ring directly linked to the 
isocyano group in compounds 130a and 130c resonated as triplets at 123.9 and 125.5 ppm with a 
coupling constant of 13 Hz each, whilst 13C NMR spectra of 130b and 130d showed the same 
carbon atoms as singlets at 129.4 and 109.5 ppm. The appearance of signals due to the isocyano 
carbon atom and the carbon atom of the aryl ring directly attached to isocyano group as triplets 
could be attributed to 13C-14N coupling.320  
 
5.2.3. Synthesis of 3-aryl-N-isoxazol-5-amine derivatives   
With all the necessary intermediates in hand, attention was concentrated on the synthesis of a 
series of 3-aryl-N-arylisoxazol-5-amine derivatives in accordance with the methodology described 
by Buron and co-workers.164 However, only a few examples that involve reaction between the α-
haloacetophenoneoxime with aryl isocyanide catalysed by Na2CO3 in DCM as solvent to produce 
the corresponding 3-aryl-N-arylisoxazol-5-amines have been reported thus far. 
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 5.2.3.1. Control experiment between 2-chloro-1-aryl-ethanone oxime and aryl isocyanides 
The reaction of 2-chloro-1-(2,4-dimethoxyphenyl)ethanone oxime 129c and 1-isocyano-2,4-
dimethoxybenzene 130c was chosen as a model system to test the reaction conditions. Initial 
attempts were carried out without any base, thus 2-chloroacetophenoneoxime 129c and 1-
isocyano-2,4-dimethoxybenzene 130c were reacted in DCM at room temperature as depicted in 
Scheme 5.9 (Table 5.9, entry 1). After seven days TLC still indicated the presence of both 
starting materials with no formation of products.  However, the addition of Na2CO3 to the above 
described reaction conditions showed that the 2-chloroacetophenoneoxime 129c was fully 
consumed after 24 hours and showed the presence of a new spot, although the smell of 
isocyanide was still present (Table 5.9, entry 2). Work up and purification of the new spot by 
column chromatography afforded the N-(2,4-dimethoxyphenyl)-3-phenylisoxazol-5-amine 
product 131a in a yield of 12%.  Due to the low yield isolated, we decided to explore several 
other bases as shown in Table 5.9 using conditions similar to those described above. When a 
similar reaction was conducted in the presence of NaOAc.3H2O (entry 3), the yield of the 
desired product 131a didn‟t improve even after 7 days, while the yield of the product was worse 
in the presence of K2CO3 (entry 4). Furthermore, the use of Cs2CO3 (entry 5) attained the 
desired product in just an hour with no improvement in terms of the product yields (11% yield 
obtained).  Attempts to carry out the reaction at lower temperature didn‟t have any significant 
effect on the yields of the reaction (entry 6).   
 
N
C
N
Cl
+ Base
N
O
O
O
O
O
129c 130c
131a
DCM, rt
NH
OH
 
 
Scheme 5.9: Experimental control reaction. 
 
Table 5.9: Effects on the yield of different reaction conditions. 
Entry Base Time Yields (%) 
1 - 7 d No reaction 
2 Na2CO3 24 h 12 
3 NaOAc.3H2O 7 d 13 
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Entry Base Time Yields (%) 
4 K2CO3 5 d 11 
5 CS2CO3 1 h 11 
6 Na2CO3 at-10oC 24 h 12 
 
 
5.2.3.2. Determination of the effects of substituents and isocyanide reactivity on the 
reaction  
With the above reactions giving low yields of the title compound, attention was focused on 
exploring the reactivity other synthesized aryl isocyanides 130a and 130b with 2-
chloroacetophenoneoximes 129a and 129d in order to determine the effects of the aryl 
substituents on the reaction, using Na2CO3 as catalytic base (Scheme 5.10). 
 
N
Cl
Na2CO3, DCM, rt, 2 h
N
O
N
NH
O
O
Na2CO3, DCM, rt, 2 h
O
N
O
C
OH
R'
129a R= 4-F
129c R= H
129d R= 4-Cl
130a R' = 4-Br
130c R' = 2,4-diOMe
130d R' = 2,4-diMe
141
R
9-20% yields
35-42% yields
R
ON
NH
R R'
131
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Route 1
Route 2
 
 
Scheme 5.10: Reaction of 2-chloro-1-aryl-ethanone oxime with isocyanides. 
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Therefore, 2-chloro-1-aryl-ethanone oximes 129a and 129d and aryl isocyanides 130a and 130d 
were reacted in the presence of Na2CO3 with DCM as solvent at room temperature, as shown in 
Scheme 5.10 (Route 1). After 24 hours, TLC indicated complete consumption of 2-chloro-1-
aryl-ethanone oximes 129a and 129d and two spots, one corresponding to aryl isocyanides and 
the other to suspected product. The suspected product spot was then isolated by column 
chromatography to afford the desired products, 131b-e with yields ranging from 9-20% as 
indicated in Table 5.10. These results indicate that the substituents of both aryl rings didn‟t have 
much influence on the product yields. To determine certainly if the aryl isocyanide reactivity was 
the problem, a commercially available methyl isocyanide 140 was used under similar conditions 
(Scheme 8, Route 2). Work up and column chromatography gave the desired methyl 2-(3-
phenylisoxazol-5-ylamino)acetate product 141a-b in yields of 35 and 42%, respectively (Table 
5.10). The yield was much improved as compared to the yields obtained when aryl isocyanide 
was used, which implies that the low yields of these products could be attributed to the low 
reactivity of aryl isocyanide and the short life span of the unstable nitrosoalkene species 
generated in situ. 
 
Table 5.10: Isolated yields (%) of 5-amino-3-arylisoxazole 131b-g and 141a-b.  
ON
NH
R
R'
 
Compounds R R’ Yields (%) 
131b H 2,4-dimethylphenyl 20 
131c 4-F 2.4-dimethylphenyl 9 
131d H 4-Brphenyl 11 
131e 4-F 4-Brphenyl 9 
141a 4-F CH2COOMe 35 
141b 4-Cl CH2COOMe 42 
 
5.2.3.3. Plausible mechanism for the formation of 5-amino-3-arylisoxazole 
The suggested mechanism shown in Scheme 5.11 involves a base induced removal of HCl from 
2-chloro-1-aryl-ethanone oxime 129 to generate an unstable reactive nitroalkene species 142 in 
situ, which is followed by rapid attack by the isocyanide 130 resulting in the generation of 143, 
which then tautomerises to give desired product 131. 164 
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Scheme 5.11: Plausible mechanism for the formation of 5-amino-3-arylisoxazole 131. 
 
5.2.4. Synthesis of 3-aryl-N-isoxazol-5-amine derivatives 
To increase the diversity of the synthesized series of 5-amino-3-arylisoxazoles described above, it 
was decided to convert the 2-chloro-1-aryl-ethanone oxime derivatives 129 into the 
corresponding 5-amino-3-arylisoxazole derivatives 144 with no substituent on the amine position 
in accordance with a previously described protocol by Kong el at.321  Therefore, the scaffolds 
129a-c in MeOH were added slowly to a suspension of potassium cyanide in MeOH at room 
temperature, followed by stirring of the resulting mixture for 30 minutes as depicted in Scheme 
5.12 . Work up and separation by column chromatography furnished 3-arylisoxazol-5-amine 
derivatives 144a-c in reasonable yields similar to those obtained by Kong and co-workers (Table 
5.11).321  
 
N
Cl
OH
129a R= 4-F
129c R= H
129d R= 4-Cl
R
ON
NH2
R
144
53-68%
KCN
MeOH, rt, 30 min
 
 
Scheme 5.12: Reaction between 2-chloroacetophenoneoximes with KCN. 
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Table 5.11: Isolated yields (%) of the 5-amino-3-arylisoxazole 144a-c from KCN reaction.  
1
2
3
O
4
N
5
NH2
R  
Compounds R Yields (%) 
144a 4-F 68 
144b 4-Cl 63 
144c H 53 
 
 
5.2.5. Structure elucidation of isoxazole-based compounds 
The synthesized compounds were characterised by NMR spectroscopy and their data were in 
agreement with the expected chemical structures. The important aspects of the 1H NMR 
spectrum for compound 131b was a singlet signal at 6.56 ppm corresponding to an NH proton, 
whilst in compounds 141b, an NH proton resonates as a triplet at 5.34 ppm with a J value of 5.0 
Hz due to coupling with the adjacent two protons of the methylene group (which resonates at 
4.00 ppm as a doublet with a J value of 5.5 Hz). On other hand, evidence of formation of 
compound 144c in the 1H NMR spectrum was a broad signal at 4.50 ppm corresponding to the 
NH2 protons. Furthermore, more evidence for the formation of the desired compounds was the 
presence of the 4-methine of the isoxazole moiety, which emerges as a singlet at 5.83 ppm for 
131b, 5.28 ppm for 141a and 5.42 ppm for 144c. Additionally, 13C NMR spectra of the 
compounds displayed signals of the 5-carbon atom at 167.1 ppm (for 131b), 169.3 (for 141a) and 
168.9 ppm for 144c; while the 3-carbon atom resonating at 163.6 ppm (for 131b), 162.7 ppm (for 
141a) and 163.8 ppm for 144c. The 4-methine carbon atom of an isoxazole moiety on these 
scaffolds resonates at 78.4 ppm (for 131b), 77.3 for 141a and 78.2 for 144c. The FTIR spectra of 
the compounds 131a-e and 141a-b showed the presence of the NH stretching band between 
3263-3407 cm-1 whilst the compounds 144a-c show the presence of the NH2 stretch in the 
region of 3321-3454 cm-1 (Table 5.12). Moreover, the FTIR spectra of compounds 141a-b further 
exhibited an amide carbonyl signal at 1742-1743 cm-1. 
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Table 5.12:  FTIR spectroscopic data of of-arylisoxazol-5-amines showing the NH, C=O and 
NH2 bands 
Compound 131a 131b 131c 131d 131e 141a 141b 144a 144b 144c 
υNH (cm-1) 3314 3268 3267 3291 3281 3407 3381 - - - 
υC=O (cm-1) - - - - - 1742 1743 - - - 
υNH2 (cm-1) - - - - - - - 3454 3433 3433 
 
 
In summary the reactivity of aryl isocyanides and the short life span of the in situ generated 
nitroalkene species were found to be major drawbacks towards generation 3-aryl-N-arylisoxazol-
5-amine derivatives. Therefore, effective reaction conditions that can activate the aryl isocyanide 
130 prior to reaction with 2-chloro-1-aryl-ethanone oximes 129 were required; however time 
constraints did not allow this study. Thus investigation into such reaction conditions will form 
part of future work. However, a total of 10 target 5-amino-3-arylisoxazole compounds were 
obtained from the above described chemistry and five of these (131a-e) were found to be novel 
compounds. These 10 compounds were submitted for biological testing. 
 
5.3. Biological evaluation of isoxazole based compounds 
5.3.1. Direct HIV-1 –LEDGF/p5 assay 
The synthesized isoxazole based fragments 131, 141 and 144 were sent for evaluation using a 
well-established AlphaScreen assay at a single concentration of 100 µM in order to determine the 
inhibitory percentage by interrupting the interaction between HIV-1 IN and host LEDGF/p75 
proteins. The screening results were carried out in triplicate and the results are reported in Table 
5.14. 
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Table 5.14: The HIV-1 IN-LEDGF/p75 inhibition activities of the 3-arylisoxazol-5-amines at 
100 µM. 
 
Compounds Entry 
Biochemical target assays 
HIV-1 IN – LEDGF (%) 
inhibition @ 100µM 
(AlphaScreen) 
 
Standard Deviations 
131a 27.83 ± 1.24 
131b 18.02 ±0.27 
131c 26.65 ±2.57 
131d 0 ±1.50 
131e 29.60 ±1.78 
141a 43.05 ± 1.99 
141b 15.03 ± 4.17 
144a 29.84 ± 0.77 
144b 0 ± 2.46 
144c 29.94 ± 0.36 
CX05168 91.37 +-0.85 
HIV-1 IN and LEDGF 
with DMSO 
0  
 
 
The biological data obtained showed that the synthesized isoxazole-based fragments with the 
exception of 131d and 144b displayed low inhibitory activities at a single concentration of 100 
µM, with a percentages ranging from 15 to 43%. The compound 141a exhibited the highest 
percentage in the series with 43%. Based on the results, it was decided that this library would not 
be pursued further.  
 
5.4. Conclusion 
The title isoxazole based-compounds were successfully synthesized. Initially, two essential 
intermediates; 2-halo-1-arylketone oximes and aryl isocyanides were prepared in accordance with 
literature reported protocols. The 2-halo-1-arylketone oximes were achieved over three steps; by 
firstly reacting a series of selected benzaldehydes with chloroform under inert atmosphere at 
room temperature for 4-48 hours to afford 2,2,2-trichloro-aryl-ethanols with excellent yields. 
These trihaloarylethanols were further subjected to oxidative conditions by treatment with CuCl 
and bipyridine in DCE to furnish 2-chloro-1-arylethanone derivative in lower yields in 
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comparison to the yield obtained in literature. The 2-chloro-1-arylethanone derivatives were 
treated with hydroxylamine hydrochloride in MeOH at room temperature to give 2-chloro-1-
aryl-ethanone oximes as geometric isomers in good yields. The second intermediates were 
obtained over two steps by initial microwave irradiation of a mixture of anilines with formic acid 
to afford N-aryl-formamide, followed by dehydration with POCl3 in the presence of 
triethylamine to afford aryl isocyanide scaffolds in excellent yields. The 2-halo-1-arylketone 
oximes and aryl isocyanides were reacted in the presence of Na2CO3 using DCM as solvent at 
room temperature to afford the desired 3-aryl-N-arylisoxazol-5-amine products in poor yields.  
Several other bases were also screened, however, none of the bases was able to exceed the initial 
result obtained with Na2CO3 even lowering the temperature to -10
oC didn‟t have a significant 
effect on the formation of the products. These low yields were attributed to the low reactivity of 
aryl isocyanides and the short life span of the unstable reactive nitroalkene species, which is 
generated in situ through elimination of HCl. However, when commercially available methyl 
isocyanoacetate was used, the desired methyl 2-(3-phenylisoxazol-5-ylamino)acetate products 
were isolated in much improved yields. These data support the theory discussed above. In order 
to extend the library, 2-halo-1-arylketone oximes were then treated with KCN in MeOH to 
furnish 3-arylisoxazol-5-amine derivatives with a free amine group. Compounds 131, 141 and 144 
were submitted for biological evaluation in the HIV-1 IN-LEDGF/p75 AlphaScreen assay at 
100 µM. Unfortunately, none of the fragments exceeded the 50% inhibition benchmark. 
 
 
 
5.5. Future work 
 
1. Investigate the effective reaction conditions that can activate the aryl isocyanides prior to 
reaction with 2-chloro-1-aryl-ethanone oximes. 
2. Screening of isoxazole-based compounds in BST-2 Vpu ELISA assay to identify possible 
hits. 
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CHAPTER 6  
Antimicrobial activities of synthesized compounds 
 
6.1 Introduction 
Infectious diseases caused by bacterial pathogens continue to be a major threat to public health 
in both developing and developed countries.322,323,324 Although many species of bacteria are 
beneficial, several harmful gram positive and gram negative bacteria are responsible for 
infectious diseases like pneumonia325,326 and tuberculosis (TB)327,328 to point out a few.  Much 
therapeutic progress has been made to protect against infections caused by bacterial pathogens 
through the use of immunization and antimicrobial agents such as antibiotics. Natural isolated 
antibiotics like ampicillin,329 chlortetracycline,330 and demeclocycline331,332 (Figure 6.1) can act by 
either killing or preventing the growth of the bacterial pathogens. In addition, chemical synthesis 
also plays its role in the development of the antibacterial drugs such as ciprofloxacin,333,334 and 
cefamandole335 to mention a few (Figure 6.1). 
 
OH
Cl
O
H2N
O
N
H
OH
H
OH O
demeclocycline
OH
HO
O
N
F
N
NH
O
HO
ciprofloxacin
H
H2N
HN
O
N
O
S
O
HO
H
Ampicillin
OH
Cl
OH
H2N
O
O
N
H
OH
H
O OH
OH
chlortetracycline
N
N
N
N
cefamandole
S
S
N
HO O
O
N
H
O
HO  
 
Figure 6.1: Representive examples of antibacterial agents. 
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Although the current antibiotics have managed to improve clinical outcomes over the past 
decades, evolving bacterial strains have hampered the treatment of bacterial infections, resulting 
in higher morbidity and mortality rates. The overuse and misuse of antibiotics in people and 
animals as well as genetic mutation of bacterial proteins are some factors which have contributed 
to an increase in antimicrobial resistance.  According to WHO in 2016, an estimated 480 000 
people worldwide had developed multi-drug resistance to the two most powerful anti-TB 
agents.336 Furthermore, the resistance to artemisinin-based combination therapies (ACTs), which 
are used for the treatment of Plasmodium falciparum malaria, has also been detected all over the 
world.337,338 The development of drug resistance has already posed many therapeutic challenges 
like affecting the battle against HIV and malaria as well as medical procedures such as diabetes 
management, cancer chemotherapy and organ transplantation. The efficacy of current 
antimicrobial agents is compromised because of the emergence of new drug resistance and as 
such the need for development of small molecules with novel modes of action is high. 
 
This chapter therefore focuses on the antimicrobial assessment of the synthesized 5-aryl-1H-
imidazole, 5-aryl-oxazole, 5-aryl-1H-imidazol-1-yl and 3-aryl-isoxazole based families of 
compounds. We hypothesised that screening of synthesized libraries of compounds may provide 
an important starting point for the development of the next generation of antimicrobial agents. 
 
6.2. Antimicrobial activities of the synthesized libraries of five membered nitrogen 
containing heterocyclic compounds 
The libraries of synthesized 5-aryl-1H-imidazole, 5-aryl-oxazole, 5-aryl-1H-imidazol-1-yl and 3-
aryl-isoxazole based compounds were evaluated in the same way for their antimicrobial activities 
against two Gram-positive bacterial species (Staphylococcus aureus ATCC 25923 and Bacillus cereus 
ATCC 11779), two Gram negative bacterial species (Escherichia coli ATCC 8739 and Pseudomonas 
aeruginosa ATCC 27858) and one yeast (Candica tropicalis ATCC 750) using the Minimum 
Inhibitory Concentration (MIC) assay determined by the iodonitrotetrazolium (INT) chloride 
method. The MIC assay was conducted at the University of the Witwatersrand, Department of 
Pharmacy and Pharmacology in the School of Therapeutic Science under the guidance of 
Professor Sandy van Vuuren. Ciprofloxacin and nystatin were used as positive controls for 
bacteria and yeast, respectively. Compounds which exhibit an MIC value of 15.6 μg/ml are 
considered to be good antibacterials, while MIC values of 31.3, 65.5 and 125 μg/ml are 
considered to represent moderate, marginal and low/weak activity, respectively. The compounds 
were tested in duplicate and their results recorded.  
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6.2.1. Antimicrobial activities of synthesized 5-aryl-1H-imidazole-based compounds 
The antimicrobial activities of the twenty three novel 5-aryl-1H-imidazole based compounds 
(Figure 6.1) were investigated and results are documented in Table 6.1. Antimicrobial testing (Table 
6.1) revealed that some of the compounds exhibited significant antimicrobial activities against 
bacterial strains.  
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Figure 6.1: Representation of the 5-aryl-1H-imidazole based compounds as possible 
antimicrobial agents. 
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Table 6.1: Minimum inhibitory concentrations (MIC, μg/ml) of synthesized 5-aryl-1H-imidazole 
based compounds  
C
o
m
p
o
u
n
d
s 
 
 
Gram positive bacteria Gram negative bacteria Yeast 
S. aureus 
ATCC 
2592 
B. cereus 
ATCC 11779 
E.coli 
ATCC 8739 
P.aeruginosa 
ATCC 27858 
C. tropicalis 
ATCC 750 
79a 125 125 250 205 125 
79c > 250 62.5 125 >250 62.5 
79d > 250 > 250 250 250 250 
79e - 31.3 >250 >250 - 
79f 15.6 31.3 250 250 31.3 
79g  250 250 250 250 125 
80a 125 125 250 250 125 
80b 250 250 >250 >250 250 
80c 62.5 62.5 >250 >250 62.5 
80d 62.5 250 >250 >250 125 
80e 125 250 >250 >250 250 
80f 62.5 15.6 >250 >250 31.3 
81a > 250 > 250 > 250 > 250 - 
81d 250 250 250 250 125 
82a 62.5 125 >250 >250 >250 
82d 62.5 125 >250 >250 250 
82e 250 250 125 250 > 250 
83a > 250 > 250 > 250 > 250 > 250 
87a > 250 > 250 > 250 > 250 31.3 
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Gram positive bacteria Gram negative bacteria Yeast 
S. aureus 
ATCC 
2592 
B. cereus 
ATCC 11779 
E.coli 
ATCC 8739 
P.aeruginosa 
ATCC 27858 
C. tropicalis 
ATCC 750 
87b > 250 > 250 > 250 > 250 > 250 
88a > 250 > 250 > 250 > 250 > 250 
88b > 250 > 250 > 250 > 250 > 250 
Ciprofloxacin 1.25 0.156 0.313 0.313 - 
Nystatin - - - - 0.156 
 
 
The most potent compound 79f with an n-butyl group attached to a nitrogen atom and the tert-
butyl substituent at the para-position on the 5-aryl ring exhibited a remarkably good MIC value 
of 15.6 μg/ml against S. aureus and a moderate MIC value of 31.3 μg/ml against B. cereus and C. 
tropicalis. These values correspond to the 60 µM (i.e. against S. aureus and 112 µM (i.e. 122 µM 
against B. cereus) concentration for 79f. Compound 80f, with a cyclohexyl group instead of the n-
butyl group of 79f, showed a good MIC value of 15.6 μg/ml (i.e. 55 µM) against B. cereus, while 
against C. tropicalis it displayed a comparable MIC value to that of compound 79f. Both 
compounds 79f and 80f were inactive against the two Gram negative bacterial strains.  
Introduction of an electron donating group (-OCH2O-) at the meta- and para-positions in the 5-
aryl ring in compound 79f gave compound 80e, which displayed a moderate MIC value of 31.3 
μg/ml (i.e. 116 µM) against B. cereus, while against gram-negative strains no activity was observed. 
However, compound 79e showed a weak MIC value of 125 μg/ml against C. tropicalis while no 
activity was observed against two gram-positive and negative strains. Furthermore, compound 
80c with the methoxy group at the meta-position exhibited a marginal MIC value of 62.5 μg/ml 
against S. aureus, B. cereus and C. tropicalis, while its analogue compound 79c also showed a 
marginal MIC value of 62.5 μg/ml against B. cereus and C. tropicalis. Compound 80d bearing two 
methoxy groups at the meta- and para-positions of the 5-aryl ring displayed a marginal MIC value 
of 62.5 μg/ml against S. aureus, while against B. cereus, E.coli, P.aeruginosa and C. tropicalis it was 
inactive. Furthermore, an analogue of 80d, compound 79d exhibited no activity against any of 
the four bacterial and one yeast strain.  Compound 82a and 82d, with a benzyl group attached to 
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a nitrogen atom, both exhibited MIC values of 62.5 μg/ml against S. aureus and displayed a low 
MIC activity of 125 μg/ml against B. cereus. Compound 87a with a para-fluorine atom on the 5 
aryl ring and 4-bromophenyl group linked to the nitrogen atom exhibited a moderate MIC value 
of 31.3 μg/ml against C. tropicalis, while the rest of the compounds with a 4-bromophenyl group 
were inactive against all strains tested. The rest of the compounds did not exhibit any activity 
against any of the tested bacterial and yeast strains. Although some imidazole compounds 
exhibited good antimicrobial activities, their MIC values were much higher than those of the 
ciprofloxacin and nystatin positive controls. MIC values of the evaluated imidazole-based 
compounds indicated that they were more active against Gram-positive bacteria and yeast strains 
than against gram negative bacteria. The results suggest that compound 79f and 80f could be 
viable hits to design a next generation of antimicrobial agents targeting S. aureus and B. cereus 
strains. 
 
6.2.2. Antimicrobial activities of synthesized 5-aryl-oxazole based compounds 
Nineteen synthesized 5-aryl-oxazole- and oxazoline-based compounds (Figure 6.2) were assessed 
for their antimicrobial effects and results are detailed in Table 6.2. Analysis of the obtained results 
showed that compounds 108a-b and 109a-b were inactive against all four bacterial and the one 
yeast strain. However, compound 100e, which contains a chlorine atom at the ortho- and para- 
positions on the 5-aryl ring showed moderate antibacterial activity against S. aureus and against 
yeast C. tropicalis, with MIC values of 31.3 μg/ml (89 µM), whereas against B. cereus it exhibited a 
marginal MIC value of 62.5μg/ml. Moreover, compound 100c exhibited good antibacterial 
activity against P.aeruginosa, with an MIC value of 31.3 μg/ml (87 µm), and marginal antimicrobial 
activity against S. aureus and B. cereus with MIC values of 62.5 μg/ml. Compound 100j displayed 
marginal antibacterial effects against S. aureus and C. tropicalis, with MIC values of 62.5 μg/ml, 
and against B. cereus with an MIC value of 125 μg/ml. Compound 100b and 100k only showed 
marginal antimicrobial activities against B. cereus, with MIC values of 62.5 μg/ml and 125 μg/ml, 
respectively. All these synthesized compounds exhibited marginal MIC values as compared to 
the bacterial positive control, ciprofloxacin with an MIC value of 1.25 μg/ml and yeast control, 
nystatin with an MIC of 0.156 μg/ml.  
The 4,5-dihydro-N,5-diaryl-1,3-oxazole-4-carboxamide scaffolds 107 were shown to be inactive 
against all four bacterial and one yeast strain. Halogenated N-(2,4-dichlorophenyl)-5-(4-
fluorophenyl)oxazole-4-carboxamide (100e) showed some antimicrobial activity and could be 
selected for further development at a later stage, if deemed necessary. 
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Figure 6.2: Representation of the 5-aryl-oxazole and oxazoline-based compounds as possible 
antimicrobial agents. 
 
 
Table 6.2: Minimum inhibitory concentrations (MIC, μg/ml) of synthesized 5-aryl-oxazole-
based compounds  
C
o
m
p
o
u
n
d
s 
 
 
Gram positive bacteria Gram negative bacteria Yeast 
S. aureus 
ATCC 
2592 
B. cereus 
ATCC 
11779 
E.coli 
ATCC 
8739 
P.aeruginosa 
ATCC 27858 
C. tropicalis 
ATCC 750 
100a > 250 > 250 >250 - - 
100b > 250 62.5 >250 - > 250 
100c 62.5 62.5 >250 31.3 - 
100d > 250 > 250 >250 > 250 - 
100e 31.3 62.5 250 > 250 31.3 
100f 250 62.5 >250 - 125 
100g > 250 > 250 >250 > 250 - 
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Gram positive bacteria Gram negative bacteria Yeast 
S. aureus 
ATCC 
2592 
B. cereus 
ATCC 
11779 
E.coli 
ATCC 
8739 
P.aeruginosa 
ATCC 27858 
C. tropicalis 
ATCC 750 
100h > 250 > 250 >250 > 250 > 250 
100i > 250 > 250 >250 > 250 > 250 
100j 62.5 125 >250 > 250 62.5 
100k 250 125 >250 > 250 > 250 
107a > 250 > 250 >250 > 250 > 250 
107b > 250 > 250 >250 > 250 > 250 
107c > 250 > 250 >250 > 250 > 250 
107d > 250 > 250 >250 > 250 > 250 
108a > 250 > 250 >250 > 250 > 250 
108b > 250 > 250 >250 > 250 > 250 
109a > 250 > 250 >250 > 250 > 250 
109b > 250 > 250 >250 > 250 > 250 
Ciprofloxacin 1.25 0.156 0.313 0.313 - 
Nystatin - - - - 0.156 
 
 
6.2.3. Antimicrobial activities of synthesized 5-aryl-1H-imidazol-1-yl based compounds  
The antimicrobial activity of the twenty three novel 5-aryl-imidazol-1-yl compounds (Figure 6.3) 
was determined using the MIC assay and results are recorded in Table 6.3.   
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Figure 6.3: Representation of the 5-aryl-imidazol-1-yl compounds as possible antimicrobial 
agents. 
 
Table 6.3: Minimum inhibitory concentrations (MIC, μg/ml) of synthesized imidazol-1-yl-based 
compounds  
C
o
m
p
o
u
n
d
s 
 
Gram positive bacteria Gram negative bacteria Yeast 
S. aureus 
ATCC 2592 
B. cereus 
ATCC 11779 
E.coli 
ATCC 8739 
P.aeruginosa 
ATCC 27858 
C. tropicalis 
ATCC 750 
120a > 250 > 250 > 250 > 250 > 250 
120c > 250 > 250 > 250 > 250 > 250 
120d > 250 > 250 > 250 > 250 > 250 
120e > 250 > 250 > 250 > 250 > 250 
120f 125 >250 > 250 > 250 > 250 
120h > 250 > 250 > 250 > 250 > 250 
120g > 250 > 250 > 250 > 250 > 250 
121a > 250 > 250 > 250 > 250 > 250 
121c > 250 > 250 > 250 > 250 > 250 
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Gram positive bacteria Gram negative bacteria Yeast 
S. aureus 
ATCC 2592 
B. cereus 
ATCC 11779 
E.coli 
ATCC 8739 
P.aeruginosa 
ATCC 27858 
C. tropicalis 
ATCC 750 
123a > 250 > 250 > 250 > 250 > 250 
123c 125 > 250 62.5 > 250 > 250 
123d > 250 > 250 > 250 > 250 > 250 
123e > 250 > 250 > 250 > 250 > 250 
123f > 250 > 250 > 250 > 250 > 250 
123g 125 > 250 62.5 > 250 15.6 
123h > 250 > 250 > 250 > 250 > 250 
125a 125 250 250 > 250 250 
125c > 250 250 250 > 250 250 
125d 125 250 250 > 250 250 
125e > 250 > 250 > 250 > 250 > 250 
125f > 250 > 250 > 250 > 250 > 250 
125g 250 > 250 > 250 > 250 > 250 
125h > 250 > 250 > 250 > 250 > 250 
Ciprofloxacin 1.25 0.156 0.313 0.313 - 
Nystatin - - - - 0.156 
 
 
The results of antimicrobial testing indicated that only compound 120f from a set of ester 
derivatives 120 exhibited a marginal antimicrobial activity at an MIC value of 125 μg/ml against 
the S. aureus strain, while the rest of the compounds in the series were found to be inactive 
against all four bacterial and one yeast strain.   
The tested compound 123g with a hydroxyl and methoxy group at the meta- and para-positions 
of the 5-aryl ring from the series of acetic acids scaffolds 123 exhibited the highest MIC activity 
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of 15.6 μg/ml (63 µM) against the C. tropicalis, but moderate MIC activity against E.coli of 65.2 
μg/ml, whereas against S. aureus strain it only showed an MIC value of 125 μg/ml. Furthermore, 
compound 123d with the electron-donating methoxy group at the meta-position of the 5-aryl ring 
displayed weak antimicrobial activity against S. aureus, at an MIC value of 125 μg/ml, while an 
MIC value of 62.5 μg/ml against E. coli was observed. The rest of the acetic acid derivatives did 
not show any activity against the four bacterial and one yeast strain.  
 
Compounds 125a (with the para-fluorine atom) and 125d (with methoxy groups at the meta- and 
para-positions) exhibited a weak MIC value of 125 μg/ml each against S. aureus while other 
scaffolds within the acetohydrazide series 125 were found to have no activity against any strains. 
Unfortunately, the active imidazol-1-yl compounds mentioned above demonstrated marginal 
MIC values as compared to positive controls for both bacterial and yeast strains.  In general, 
results suggest that only compound 123g could be used as a template to design next generation 
antimicrobial agents. 
 
6.2.4. Antimicrobial activities of synthesized 3-aryl-isoxazole based compounds  
The antimicrobial effects of the 10 synthesized isoxazole-based compounds (Figure 6.4) were 
investigated and results are detailed in Table 6.4. The results of antimicrobial testing indicated 
that none of the isoxazole based compounds were active against any of the four bacterial and 
yeast strains. 
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Figure 6.4: Representation of the isoxazole-based compounds as possible antimicrobial agents. 
 
189 
 
Table 6.4: Evaluation of in vitro antimicrobial activity of the synthesized isoxazole based 
compounds  
Compounds 
Tested 
Gram Positive bacteria Gram Negative bacteria Yeast 
S. aureus 
ATCC 2592 
B. cereus 
ATCC 11779 
E. coli 
ATCC 8739 
P. aeruginosa 
ATCC 27858 
C. tropicalis 
ATCC 750 
131a > 250 > 250 > 250 > 250 > 250 
131b > 250 > 250 > 250 > 250 > 250 
131c > 250 > 250 > 250 > 250 > 250 
131d > 250 > 250 > 250 > 250 > 250 
131e > 250 > 250 > 250 > 250 > 250 
141a > 250 > 250 > 250 > 250 > 250 
141b > 250 > 250 > 250 > 250 > 250 
144a > 250 > 250 > 250 > 250 > 250 
144b > 250 > 250 > 250 > 250 > 250 
144c > 250 > 250 > 250 > 250 > 250 
Ciprofloxacin 1.25 0.156 0.313 0.313 - 
Nystatin - - - - 0.156 
 
 
6.3. Conclusion 
The antimicrobial activities of the synthesized 5-aryl-1H-imidazole, 5-aryl-oxazole, 5-aryl-1H-
imidazol-1-yl and 3-aryl-isoxazole based compounds were assessed in an MIC assay using the 
INT method against Staphylococcus aureus ATCC 25923 and Bacillus cereus ATCC 11779 (gram-
positive bacteria strains) and Escherichia coli ATCC 8739 and Pseudomonas aeruginosa ATCC 27858 
(gram negative bacteria strains) as well as against Candica tropicalis ATCC 750 (yeast strain). 
Although some of the synthesized compounds were found to display promising antimicrobial 
activities with good MIC values, their values were marginal compared to those of ciprofloxacin 
for bacteria and nystatin for yeast standard controls. Among the tested compounds 79f, 80g, 
123g and 100e were found to be the most potent antibacterial hits and it can be concluded that 
these scaffolds could act as a framework for further development through synthetic modification 
to obtain more potent biologically active compounds. 
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CHAPTER 7 
General Conclusion 
 
Isocyanides have been widely applied in organic synthesis, due to the ease of manipulating 
different reaction conditions to provide different nitrogen-containing heterocyclic compounds. 
In this dissertation, we have explored the application of two isocyanide precursors, TosMIC and 
aryl isocyanide, to generate small diverse libraries of five membered nitrogen containing 
heterocycles and evaluated them for their ability to disrupt HIV-1 IN-LEDGF/p75 interactions; 
binding of Vpu to CD4/CD74; and/ or HIV-1 Vpu-BST-2 protein interactions. Hit compounds 
were identified from biological screening, and these were used in the design of second generation 
compounds which were synthesised with additional structural diversity at several positions. 
Second generation compounds were subsequently screened for their ability to inhibit HIV-1 
protein-protein interactions. 
 
7.1. Synthesis of small families of five-membered nitrogen containing heterocycles. First 
generation 
In Chapter 2, the utility of TosMIC was successfully demonstrated in the synthesis of a small 
library of twenty six substituted imidazoles 79-83 using both conventional and microwave 
irradiation approaches (see Figure 7.1). The microwave strategy described represents a significant 
improvement over the conventional method using MeCN as solvent.  
Yields of these 1H-imidazole based products were found to be influenced by two factors, 
namely: 
1) The nature of the substituents on the 5-aryl ring (derived from an aldehyde) and the 
primary amine used. For example, when both the ortho- and para-positions of the 5-aryl 
ring were occupied by electron donating methoxy groups (79d, 80d and 81d) the highest 
yields were obtained, while the presence of electron-withdrawing substituents at the ortho- 
or para-position of the 5-aryl ring gave rise to low yields (i.e. 20% for 79b, 38% for 79a, 
and 23% for 80b). When substituted anilines were used in the reaction, the 4-
bromoaniline 74e gave the best results, while anilines with halides at the ortho- and para-
positions did not give rise to any desired product.  
2) The choice of solvent; with the use of MeCN being favoured.  The use of MeOH was 
less favourable because of the inherent preference of TosMIC to react with MeOH and 
afford products such as E and Z- HOCH2N=CH(OMe).   
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Of the 27 imidazole-based compounds synthesised (79-83), 26 compounds were found to be 
new, with only 82e having been previously reported, although it was obtained under different 
conditions using sodium cyanide in a protic solvent under heating using tBuNH2 and K2CO3 as 
catalytic base.204 
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79a R= 4-F
79b R= 2-Cl
79c R= 3-OMe
79d R= 2,4-diOMe
79e R= 3,4-OCH2O-
79f  R= 4-tBu
79g R= 3,4-OCH2CH2O
-
79h 2-NO2
79i  4-NO2
80a R= 4-F
80b R= 2-Cl
80c R= 3-OMe
80d R= 2,4-diOMe
80e R= 3,4-OCH2O-
80f  R= 4-tBu
80h R= 2-NO2
80i  R = 4-NO2
81a R= 4-F
81c R= 3-OMe
81e R= 2,4-diOMe
82a R= 4-F
82d R= 2,4-diOMe
82e R= 3,4-OCH2O-
N
N
R
Br83a R= 4-F
83d R= 2,4-diOMe
83e R= 3,4-OCH2O-
R
 
 
Figure 7.1: Representation of the first generation of synthesised imidazole based compounds 
 
Having successfully established the usefulness of TosMIC under microwave irradiation 
conditions in Chapter 2, we then set out to expand the scope of the study towards the synthesis 
of 5-aryl-1,3-oxazoles 96 and 5-aryl-4-tosyl-2,4-dihydro-1,3-oxazoles 97 (Figure 7.2), which was 
successfully achieved (Chapter 3). Although the compounds obtained have previously been 
reported, the use of microwave irradiation was found to be a novel synthetic approach. The 
microwave assisted van Leusen approach used resulted in a time efficient method towards the 
preparation of both 5-aryl-1,3-oxazoles 96 and 5-aryl-4-tosyl-4,5-dihydro-1,3-oxazole 97 
scaffolds. The substituents on the 5-aryl ring were shown to have little effect on the yield of the 
products, while the choice of the solvent had a marked influence on product formation. When 
MeOH was used, the desired 5-aryl-1,3-oxazoles 96a-h were obtained, but in MeCN the 
intermediate 5-aryl-4-tosyl-4,5-dihydro-1,3-oxazoles 97 were obtained instead. 
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96c R= 3-OMe
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Figure 7.2: Representation of the first generation of synthesised oxazole and oxazoline-based 
compounds 
 
The exciting success achieved using a microwave assisted van Leusen reaction to access the 
imidazole and oxazole derivatives, led to the third main objective of the project (Chapter 4). An 
attempt was made to achieve a direct route for the incorporation of simple amino acids to 
generate a library of novel 5-aryl-1H-imidazoyl acyl derivatives using a microwave assisted van 
Leusen reaction. Unfortunately we were unable to obtain ethyl 2-(5-aryl-1H-imidazol-1-
yl)acetates 120, which may be attributed to decomposition of the intermediates under microwave 
irradiation. An alternative approach using DBU as a catalytic base to promote the addition of 
TosMIC to ethyl 2-(arylideneamino)acetates intermediates 116 and 117 (derived from aldehydes 
and simple amino acids) under milder reaction conditions was developed. This method led to the 
isolation of the novel ethyl 2-(5-aryl-1H-imidazol-1-yl)acetates 120-121 (Figure 7.3) derived from 
glycine and L-alanine in various yields; while the products derived from D-leucine 118a-c were, 
however, not obtained. From the observed results it was clear that the yields of the products 
were strongly influenced by the substituents at the chiral centre and on the aryl ring. For 
example, when a methyl group was present at the chiral centre and the electron-donating 
methoxy group was at the meta- and para-positions (compound 121c), a 23% yield was obtained 
which is low when compared to that of compound 120c (74 %) without a substituent at the 
chiral centre. These 5-aryl-1H-imidazoyl-acylate derivatives 120 were further transformed into 
two novel sets of 5-aryl-1H-imidazoyl-acetic acids 123 and 5-aryl-1H-imidazoyl-acetohydrazides 
125. In this way, a total of 25 novel compounds belonging to the 1H-imidazol-1-yl-based 
scaffold were obtained.  
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125c R'= 3-OMe
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116 R= H
117 R= CH3 (S) 
118 R= CH2CH(CH3)3 (R)
        
120 R= H 
121 R= CH3 (S)
122 R= CH2CH(CH3)3 
(R)
 
 
Figure 7.3: Representation of the first generation of synthesised imidazol-1-yl based compounds 
 
Our final synthetic objective is described in Chapter 5, where we successfully synthesised 3-aryl-
5-amino-isoxazole derivatives 131 (Figure 7.4) using aryl isocyanides 130, although in poor yields. 
However, when commercially available methyl isocyanoacetate 140 was used, the desired methyl 
2-(3-phenylisoxazol-5-ylamino)acetate products 141 were isolated in much improved yields. A 
total of 10 compounds were obtained, with five found to be new. The methodology employed in 
the synthesis of these scaffolds has been previously described, with a single example involving 
the reaction of an aryl isocyanide with an oxime being reported by Buron et al.164  
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Figure 7.4: Representation of the synthesised isoxazole-based compounds 131 and 141 
 
From a synthetic point of view, it can be concluded that the success of the van Leusen reaction, 
independent of the energy source applied, was strongly influenced by the nature of the imine 
intermediates (mainly towards the imidazole moiety) and the choice of the solvent, while in case 
of aryl isocyanides, the formation of the products was affected by the low reactivity of aryl 
isocyanides and the short life span of the unstable reactive nitroalkene species, which is 
generated in situ through elimination of HCl. Undoubtedly, isocyanide chemistry, in particular the 
use of TosMIC, is an essential tool in the synthesis of five membered nitrogen containing 
fragments with distinctive properties for medicinal chemistry.  
 
7.2. Biological evaluation and hit identification  
The libraries of the synthesised diverse nitrogen containing heterocycles were then evaluated for 
their ability to disrupt HIV-1 IN-LEDGF/p75 interactions; binding of Vpu to CD4/CD74; 
and/ or HIV-1 Vpu-BST-2 protein interactions. Based on the assays conducted, the compounds 
tested did not effectively bind to HIV-1 Vpu and as a result, a decision was made not to pursue 
this avenue further. Several of the compounds, however, inhibited the HIV-1 IN-LEDGF/p75 
and HIV-1 Vpu-BST-2 protein interactions at micromolar concentration. The compounds tested 
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were not overtly toxic in the MT-4 cell line. Despite having inhibitory activity within the 
biochemical assay, none of the compounds inhibited viral replication within their respective cell 
based assays. As the compounds display varying levels of toxicity, it is unlikely that the 
compounds have poor permeability. The results could suggest an inability of the compounds to 
reach the target or possibly point to poor compound solubility. Considering all possible factors, 
compound 83d (52% inhibition and an IC50 value of 25 µM) and 123g (82% inhibition and an 
IC50 value of 19 µM) were selected as suitable hits to produce a family of closely-related 
compounds, which specifically target interactions between HIV-1 IN and LEDGF/p75 proteins,  
while compound 125g (72% inhibition and an IC50 value of 23 µM) was identified as viable hit 
that could  be used as a template to design the next generation of possible HIV-1 Vpu-BST-2 
inhibitors.  
 
7.3. Synthesis of Second Generation Compounds and their Biological Evaluation 
Starting from the identified HIV-1 IN-LEDGF/p75 hits, sets of second generation compounds 
were designed and synthesized through introduction of structural diversity at several positions, 
with the hope of improving the potency of the original hits. Based on the chosen hit 83d, a 
carboxylic group was inserted at the 4-position of the imidazole moiety to generate 1,5-diaryl-
1H-imidazole-4-carboxylic acids 87 as second generation compounds (Figure 7.5) 
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O
HO
83a
-COOH
R
87a R= 4-F
87b R= 3-F
87c R= 3-OMe
87d R= 3-Me
87e R= H  
 
Figure 7.5: Integration of -COOH group on the hit 83a to give 1,5-diaryl-1H-imidazole-4-
carboxylic acids 87. 
 
N'-arylidene and carboxamide groups were introduced onto the scaffold of hit compound 123g 
and other selected compounds (120a, 125a, 125d and 125f), which resulted in the generation of 
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two sets of novel (E)-N'-arylidene-2-(5-aryl-1H-imidazol-1-yl)acetohydrazides 127 and N,5-
diaryl-2-(1H-imidazol-1-yl)acetamide compounds 128 (Figure 7.6).  
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125d R= 3,4-diOMe
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R''F
128a R''= 2,3-diOMe         
128b R''= 2,3-diMe
120a R= F
R' = OCH2CH3
           R                      R'
127a  3-OH, 4-OMe     4-F
127b  3-OH, 4-OMe    2-Cl
127c  3-OH, 4-OMe    3,4-diOMe
127d  3-OH, 4-OMe    4-tBu
127e  3-OH, 4-OMe    3-OH, 4-OMe
127    3-OH, 4-OMe     H
127g  4-F                    4-F
127     4-F                    2-Cl
127i    4-F                    3,4-diOMe
127j    4-F                    4-tBu
127k   4-F                    3-OH, 4-OMe
127l    4-F                     H
127m  3,4-diOMe         4-F
127n   3,4-diOMe         4-tBu
127      4-tBu                 H
carboxamide
moieties
N'-arylidene group
 
 
Figure 7.6:Integration of N'-arylidene and carboxamide groups on compound 120 and 125 to 
give (E)-N'-arylidene-2-(5-aryl-1H-imidazol-1-yl)acetohydrazides 127 and N,5-diaryl-2-(1H-
imidazol-1-yl)acetamide compounds 128. 
 
For second generation oxazole derivatives, an N-aryl-carboxamide was inserted at the 4-position 
of the oxazole moiety, resulting in a series of novel N,5-diaryl-4-carboxamide-1,3-oxazoles 100 
(Figure 7.7).  
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100g: R 3-OMe, R' 2-OH
100h: R 3-OMe, R'2,4-diOMe
100i:  R 3-OMe, R' 4-Br
100j:  R 3-OMe, R' 2-COOH
100k: R 3-OMe, R' 2-COOH,4-F  
 
Figure 7.7: Integration of N'-arylidene and carboxamide groups on compound 96 to give N,5-
diaryl-4-carboxamide-1,3-oxazoles 100. 
 
These second generation compounds were biologically evaluated in an HIV-1–IN LEDGF/p75 
AlphaScreen assay. Biological assessment of the 1,5-diaryl-1H-imidazole-4-carboxylic acids 87a-e 
identified four compounds surpassing the percentage inhibition of the original hit compound, 
83d, while at least two compounds from the N,5-diaryl-4-carboxamide-1,3-oxazoles scaffold 100 
exhibited improved percentage inhibition of the LEDGF/p75-IN interactions (Figure 7.8). 
Furthermore, three compounds with the 4-tert-butylphenyl motif from the set of N'-arylidene 
derivatives 127 were found to be disruptors of HIV-1 IN and LEDGF/p75 interactions (Figure 
7.8).   In the dose response assay, the best inhibitors produced micromolar inhibition values but, 
unfortunately, these compounds did not effectively exhibit antiviral activity. This is not of 
immediate concern given the fact that most of the compounds reported to be inhibitors of 
LEDGFp75 and IN interactions show lack of antiviral activity in cell based assays. It was 
interesting to observe that our active compounds 87a-e, like most of the previously reported 
HIV-1-LEDGF inhibitors such as ALLINI (Figure 1.8), and CX05168 (Figure 8.1), have aryl rings 
substituted with a halide, while compounds 100b and 100h, like the CAB compounds (Figure 3.1), 
have electron donating methoxy groups at the ortho- and para-positions on the phenyl ring.  
Furthermore, the synthesized compounds 87a-e also contain a carboxylic moiety, which is found 
in the HIV-1 IN-LEDGF inhibitors shown in Figure 1.7.  These results seem to indicate that our 
synthesised compounds have certain essential core elements present in their structures, which 
play a role in preventing the HIV-1 IN –LEDGF/p75 interactions. Hence these compounds 
have potential for development into the next generation IN inhibitors.  
A total of eleven inhibitors were identified that were able to inhibit the HIV-1 IN-LEDGF/p75 
interaction (Figure 7.8). 
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Figure 7.8: Representation of the eleven identified inhibitors of HIV-1 IN-LEDGF/p5 
including their percentage inhibition at 100 µM. 
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Seven compounds from the imidazolyl family (Figure 7.9) were identified as viable hits that could 
be further modified by introducing various groups to generate a possible second generation of 
HIV-1 Vpu-BST-2 inhibitors. None of these compounds have previously been synthesised nor 
have similar compounds been reported as inhibitors of this interaction.  
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Figure 7.9: Representation of the seven identified inhibitors of HIV-1 Vpu-BST-2 interactions 
including their percentage inhibition at 100 µM. 
 
The synthesized libraries of five membered nitrogen containing heterocycles were assessed for 
their antimicrobial activities using MIC methods (Chapter 6). At least four compounds 79f, 80g, 
123g and 100e exhibited moderate antimicrobial activity in various concentrations ranging from 
55 to 122 µM against gram positive bacterial strains and one yeast strain.  
 
7.4. Modelling Results  
The predicted binding model at the HIV-1 interface reveals that these active compounds in 
Figure 7.8 are able to form several hydrogen bonds and hydrophobic interactions with important 
allosteric site amino acids residues, such as Gln95, Ala98, Leu102, Ala128, Trp132, Glu170, 
His171 and Thr174, consequently, preventing the HIV-1 IN-LEDGF/p75 interactions. These 
residues have been previously described to be critical to the binding of the LEDGF/p75 protein.  
In addition, compound 87c was found to have the lowest binding energy among the active 
compounds. This implies that this compound might bind more strongly than the others at the 
HIV-1 IN binding cavity.  An overlay of the modelled binding poses for compounds 87a, b, c 
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and d and 127j and n is shown in Figure 7.9. This shows that the imidazole moiety of compound 
87c in red , as well as that of compounds 127j and 127n in light blue falls in the hydrophobic 
cavity of Ala128 and Ala129, while for compounds 87a, 87b, 87d and 87e the imidazole moiety 
projects towards the hydrophobic pockets formed by the Glu170 residue.  Overlaying of the 
acetic acid scaffolds 87 (Figure 7.10) shows that they interact via hydrogen bonding interactions 
with the backbone of His171. The exception to this compound 87c which is shown to form 
hydrogen bonds with the Gln95 and the Tyr99 residues. 
 
 
Figure 7.9: Overlaying projection model of compound 87c (in red), 87a, 87b, 87d, 87e in yellow  
and 120j, 120n and 120o in light blue in the LEDGF/p75 binding cavity at the HIV-1 
IN dimer interface. 
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Figure 7.10: Overlaying projection model of compound 87c (in red), 87a, 87b, 87d, 87e (in 
grey) in the LEDGF/p75 binding cavity at the HIV-1 IN dimer interface. 
 
The eighteen identified inhibitors (Figure 7.8) exhibited different ADME properties, these 
parameters are essential factors in determining whether the compounds can be taken further for 
drug development. Amongst the active inhibitors, the following compounds exhibited an 
ADME solubility level of 2 (implying that the compounds have poor oral absorption) ,namely: 5-
aryl-1H-imidazole-4-carboxylic 87a-e, compounds 100b, 127j, 127n and 127o, , while 
compounds 100h, 120a, 120c, 120d, 121a and 125c exhibited an ADME level of 3 (good oral 
absorption), which is comparable to the control raltegravir.  Furthermore, compounds 123g and 
125g are predicted to have optimal solubility, indicating that they might be completely absorbed 
by the human intestine after oral dosage. Of the eighteen identified active inhibitors, compounds 
87b, 127j and 127o were predicted to have a BBB level of 1, which indicates that they might be 
able to penetrate the blood brain barrier, hence the probability of central nervous system side 
effects is very high, while compounds 87a, 87c, 87d, 87e, 120a, 120c, 120h, 121aand 127n are 
predicted to have level 2 BBB properties and compounds 100a, 100b, 120g, 120c and 120g are 
predicted to have a small chance of causing side effects in the central nervous system. All 
eighteen active inhibitors, excluding compounds 127j and 127n, are predicted to have a fasle 
CYP2D6, which suggests these compounds do not inhibit CYP2D6 enzymes of the cytochrome 
p450 (CYP) enzyme system. 
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7.5. Final Remarks 
Besides a lack of antiviral activity in a cell-based assay, the data acquired in this dissertation is 
very encouraging. The newly synthesised second generation of compounds have not been 
previously reported as targeting the interaction between host LEDGF/p75 and HIV-1 IN 
proteins. This provides new structures that could be potential leads in the development of HIV-
1IN-LEDGF/p75 inhibitors, which hold great promise for future therapy.  
 
Of the eighteen active compounds, the most promising set appears to be the family of 1,5-diaryl-
1H-imidazole-4-carboxylic acids 87 for the following reasons: 
1) They possess the COOH functional group which is known to be critical to the binding 
of other reported HIV-1 IN LEDGF/p75 inhibitors.  
2) These compounds can theoretically form the necessary hydrogen bonds and 
hydrophobic interactions with important allosteric site residues, such as Gln95, Ala128, 
Trp132, Glu170, His171 and Thr174. 
3) Their ADME parameters could be easily improved because of their relatively small size. 
4) Their chemical structure permits the introduction of structural diversity at the carboxylic 
acid group, which could enhance their biological properties. 
5) The SAR at the 1-position of the imidazole ring can be further exploited by development 
of new synthetic methodology to allow other anilines to be incorporated.  
6) They have not been previously reported and could be considered as lead compounds to 
be further developed as potential HIV-1 IN LEDGF/p75 inhibitors. 
 
The success in the generation of diverse five membered nitrogen containing heterocycles in the 
present study was made possible by the versatility of the isocyanide synthons. The usefulness of 
TosMIC further allows for the exploration of structure activity relationships of closely related 
analogues, which is critical in the fragment drug discovery approach. The study presented further 
provides evidence that synthetic efforts and a fragment screening approach are complementary 
approaches in drug discovery that enable the identification of valuable hit compounds against 
new targets.   
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CHAPTER 8 
EXPERIMENTAL PROCEDURES 
 
8.1 General Experimental Procedures 
8.1.1. Purification of solvents and reagents 
All commercially available reagents were supplied by Sigma Aldrich and used without further 
purification. Dry solvents were used directly from an LC-Tech SP-1 Solvent Purification System 
stored under argon gas. The microwave-assisted reactions were performed in a CEM Discover 
reactor (Dynamic Temperature and Power set, with 250 psi maximum pressure allowed). All 
solvents used for chromatographic purposes were supplied by Sigma Aldrich and/or RadChem 
and were used without further distillation.  
 
8.1.2. Chromatography 
Column chromatography was performed using Merck Silica gel 60 [particle size 0.040-0.063 mm 
(230-400 mesh)] and MN Kieselgel 60 (particle size 0.063-0.200 mm) employing different types 
of solvents. TLC was performed on pre-coated Merck silica gel F254 plates and viewed under 
UV light (254 nm) or following exposure to iodine vapour.   
 
8.1.3. Spectroscopic and physical data 
NMR spectra were recorded on a 400 MHz Bruker Avance Spectrometer at 298 K equipped 
with a BBI 5 mm probe. Chemical shifts are reported in ppm, and are referenced internally to 
residual solvent resonances and calibrated using solvent signals [7.26 (CDCl3) and 2.50 (DMSO-
d6) for 
1H NMR; 77.0 (CDCl3) 39.52 (DMSO-d6) for 
13C NMR].  
High-resolution mass spectra were obtained on an LC-MS system consisting of a Dionex 
Ultimate 3000 Rapid Separation LC system equipped with a C-18 pre-coated column and 
coupled to a MicrOTOF QII Bruker mass spectrometer fitted with an electrospray source and 
operating in positive mode. Sodium formate clusters were used as internal calibration. LC-MS 
grade acetonitrile and methanol were obtained from Sigma Aldrich and water from a Milli-Q 
integral system. The MicrOTOF QII source parameters source were as follows: ESI source type; 
autoMSMS mode; mass range: 50-3000 Da; on positive polarity; end plate offset -500 V; capillary 
voltage 4500 V; nebulizer N2 1.2 bar; dry heater 200°C; drying N2 flow 8.0 l/min. The mass 
analyses were performed using DatAnalysis software (Bruker Daltonics, Germany).  
Fast Fourier Infrared spectra (FTIR) were recorded using a Thermo Nicolet 5700 spectrometer, 
from 4000 to 400 cm-1, with the following collecting parameters: Number of sample scans: 128; 
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Number of background scans: 64; Resolution: 4.000; Sample gain: 8.0; Mirror velocity: 0.1581; 
Aperture: 100.00; Detector: DTGS KBr; Beam splitter: XT-KBr. Samples were prepared in a 
mortar as KBr mixtures.  All signals are reported on the wavenumber scale (ν/cm-1). 
All melting points were obtained using a Stuart SMP10 melting point apparatus and are 
uncorrected. 
 
8.1.3. Nomenclature and Compound Numbering  
The compound numbering system used for purposes of discussion are not meant to reflect the 
systematic numbering of these compounds. Nomenclature is based on the IUPAC system. 
 
8.1.4. Biological Evaluation Experiments 
The screening of compounds by means of HIV binding assays was conducted in-house within 
the Centre of Metal Drug Discovery group (CMDD), Advanced Material Division, Mintek, 
Randburg. 
 
8.1.4.1. HIV-1 IN-LEDGF/p75 AlphaScreen Assay 
For the HIV-1 IN-LEDGF/p75 AlphaScreen assay, 206 HIV-1 IN was incubated with 10 μM 
/100 μM of each compound for 30 minutes at 26°C with slight shaking and subsequently 0.3 μM 
LEDGF/p75 was added and incubated for an hour. Nickel chelating acceptor beads (Perkin 
Elmer, USA) and Nickel chelating donor beads (Perkin Elmer, USA) were added to a final 
concentration of 10 μg/ml and incubated at 30°C in the dark with gentle shaking. Once 
incubation was complete the plate was read between 520-620nm on the EnSpire® plate reader 
(Perkin Elmer, USA). Controls included: HIV-1 IN and LEDGF/p75 protein and CX05168; 
which is a known HIV-1 IN-LEDGF/p75 inhibitor was used as the control compound to 
validate the assay. Compounds displaying inhibition of above 50% were analyzed and were 
subsequently tested in ten serially diluted doses ranging from 0.39μM to 200 μM to determine an 
IC50 for each compound. This was carried out in duplicate on the plate and in three separate 
experiments.  
 
8.1.4.2. HIV-1 Vpu binding Assay  
In the HIV-1 Vpu binding ELISA assay,339, 340 the Vpu: GFP fusion protein (400 ng per well) was 
plated in coating buffer (0.05 M Na2CO3 [Sigma Aldrich, USA], 0.05 M NaHCO3 [Saarchem, 
Merck Chemicals (Pty) Ltd, USA] and 0.1 % NaN3 [Sigma Aldrich, USA], pH 9.6), and incubated 
overnight at 4 °C. After washing three times with 1 X tris-buffered saline (TBS) and blocking 
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with 5 % casein peptone (Conda Pronadisa Molecular Biology, Spain) for 2 hours at room 
temperature, plates were washed again and incubated with 1000 x diluted anti-Vpu antibody 
(NIH catalogue number 969) for 2 hours at room temperature. Plates were then washed three 
times with TBST (a mixture of tris-buffered TBS and Tween 20) and incubated with 2000 x 
diluted goat anti-rabbit IgG peroxidase labelled antibody (KPL, USA) for 90 minutes at room 
temperature before visualizing with the substrate, 3,3‟,5,5‟-tetramethylbenzidine liquid (TMB; 
Life Technologies, USA). Controls were included in all plates. 
 
8.1.4.3. HIV-1 Vpu- BST-2 ELISA Assay 
For this assay, 5 ng/mL of Vpu was incubated with 100 μM of each compound for 30 minutes 
at 37 °C with slight shaking; and BST-2, to a final concentration of 5 ng/mL, was coated on a 
96-well polysorp plate that was pre-coated with an anti-BST-2 antibody. Following the 
incubation period, the BTS-2 was aspirated and the wells were washed three times with wash 
buffer. The Vpu/compound complexes were introduced, and the plates were incubated at 37 °C 
for an hour, washed, and a biotin-conjugated anti-BST-2 antibody was added and incubated at 37 
°C for another hour. Streptavidin conjugated to HRP was added and the plates were incubated at 
37 °C for 30 minutes. HRP activity was detected using the TMB substrate, the enzyme-substrate 
reaction was terminated by addition of sulphuric acid, and the colour change was measured 
spectrophotometrically at 490 nm using the xMark microplate reader. A total of 24 compounds 
were tested alongside 6-aza-2-thiouridine, which has previously been shown to inhibit the 
Vpu/BST-2 interaction, and was thus used as a positive control.  
 
8.1.4.4. Antiviral for HIV-1 LEDGF/p75 interatcion  
MT-4 cells (obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, 
NIH: MT-4 catalogue number 120) were seeded the day before antiviral testing at 3 x 105 cells 
per ml. The following day the viability was checked and 2 x 105 cells per ml were placed into a 50 
ml conical tube and HIV-1NL4-3 stock added. The cells were spinoculated (O‟Doherty et al., 2000) 
at 3000 x g for 90 minutes. Cells were subsequently washed four times with 0.01 M PBS to 
remove any unbound virus. A control set of cells were spinoculated without virus and washed 
four times with 0.01 M PBS to replicate the test cells. A total of 10 ml 10 % RPMI media was 
then added to the cells and 100 µl of cells were added to each well of a Corning® Costar® 96-
Well Cell Culture Plates (Sigma Aldrich, USA). The plate was placed into the 37°C, 5 % CO2 
incubator to equilibrate for one hour. During the incubation compounds were made up in RPMI 
media containing 10 % heat inactivated FCS. The compounds were serially diluted from 100 µM 
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to 1.56 µM. A total of 100 µl of compound solution was added to the wells containing cells and 
mixed to ensure they were homogeneous. The plate was placed into a 37°C, 5 % CO2 incubator 
for five days. 
 
A Biomerieux Vironostika HIV-1 Ab/Ag micro ELISA system was used to test for p24. All 
buffers were prepared according to manufacturer‟s specifications and the manufacturer‟s 
protocol was followed. Briefly, 145 µl of disruption buffer was added to each well including 
control wells and incubated at 37°C for one hour. A total volume of 5 µl of each test specimen 
was added to the disruption buffer and control samples were added. The plate was then 
incubated at 37°C for 60 minutes and wells were then washed with 1x wash buffer for 30 
seconds. Washing was repeated six times. Once washed 100 µl of 3,3',5,5'-tetramethylbenzidine 
(TMB) substrate mix (1:1 ratio of TMB substrate A and B) was added and incubated for 5-30 
minutes in the dark until sufficient colour had developed. The reaction was stopped by the 
addition of 100 µl 1 M sulphuric acid. The plates were then read on a multiplate reader at 450nm 
(xMARKTM, Bio-Rad, USA).  
 
8.1.4.5. Cellular Toxicity assay 
The day of cytotoxicity testing, cells were counted and seeded at 1 x 106 cells per ml. A total of 
100 µl of cells were added to each well of a 96 well cell culture plate for testing. The plate was 
placed into the incubator to equilibrate to 37°C and 5 % CO2. During this time, test compounds 
were made up in 10% RPMI solution in a serial dilution from 100 µM to 1.56 µM.  A total of 100 
µl compound was added to wells containing cells and mixed to ensure the solution was 
homogeneous with the cells. The plate was placed into the 37°C incubator for 5 days. On the 5th 
day 10 µl of MTS was added and mixed. The plates were then incubated for a further four hours, 
and read at 490 nm (xMARKTM, Bio-Rad, USA.) The data analysis was completed on Origin 8.1 
with the log value of the concentration plotted against the absorbance level to determine a dose 
curve. From the curve, a half maximal cytotoxicity CC50 for compounds was determined. 
Controls used included auranofin, raltegravir and CX05168. 
 
8.1.4.6. Minimum inhibitory concentration using p-iodonitrotetrazolium (INT) chloride 
method 
The antimicrobial minimum inhibition concentration (MIC) using the p-iodonitrotetrazolium 
chloride method was conducted at the University of  the Witwatersrand, Department of 
 
207 
 
Pharmacy and Pharmacology in the School of Therapeutic Science under guidance of Professor 
Sandy van Vuuren. 
8.1.4.6.1. Preparation of stock solution for antimicrobial testing 
The stock of solutions the synthesized compounds used for the minimum inhibitory 
concentration (MIC) assays were prepared by dissolving the sample in 10% dimethyl sulfoxide 
(DMSO), followed by dilution with sterile water in order to make a concentration of 1 mg/ml. 
In cases where the synthesized compounds were insoluble in 10% DMSO, 100% acetone was 
used to create the same concentration of 1mg/ml. The concentration of 0.01 mg/ml of 
ciprofloxacin and 0.01 mg/ml nystatin were also prepared and were used as positive controls for 
bacteria and yeast, respectively, while the 10% DMSO in water and 100% acetone were used as 
the negative controls. A solution of p-iodonitrotetrazolium (INT) chloride (0.08 g) in 200 ml of 
sterile water was prepared as the indicator. 
 
8.1.4.6.2 Screening of synthesized compounds against pathogens 
The synthesized compounds were assessed for their antimicrobial effects against two Gram-
positive bacterial species (Staphylococcus aureus ATCC 25923 and Bacillus cereus ATCC 11779), two 
Gram-negative bacterial species (Escherichia coli ATCC 8739 and Pseudomonas aeruginosa ATCC 
27858) and one yeast (Candica tropicalis ATCC 750) in tryptone soya broth using the MIC assay. 
Tryptone soya broth (100 μl) was added into each of the 96 well microtiter plates, followed by 
the addition 100 μl of each tested compound solution including positive and negative controls. 
Serial dilutions were performed by pipetting 100 μl into next well and the last 100 μl of dilution 
was discarded. The serial dilution provided the following nine concentrations: 250, 125, 62.5, 
31.25, 15.6, 7.8, 3.91, 1.95, and 0.98 μg/ml. Prior to the addition of culture to the microtiter 
plates, 1 ml of each culture was sub-cultured in 100 μl tryptone soya broth to obtain a 0.5 
McFarland standard. Sub-culture volume of 100 μl was then added to all wells of microtiter 
plates, which contained the compounds and broth. Each plate was sealed with a sterile adhesive 
sealing film to avoid evaporation of test samples, followed by incubation at 37°C for 24 hours 
for bacteria species and for 48 hours for the yeast. After incubation, 40 μl of p-
iodonitrotetrazolium (INT) chloride was added to each well of the microtiter plates. 341, 342 Each 
plate was read to determine the minimum inhibitory concentration. The wells with clear or no 
visible bacterial growth determined the lowest concentration. The assessments were carried out 
in duplicate. 
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8.1.5. Computer Modeling 
8.1.5.1. Ligand preparation 
Prior to docking, the selected compounds were energy minimized using a CHARMM based 
force field function under Small Molecules‟ Prepare and Filter Ligands function to generate all 
possible combinations of stereoisomers and conformers.  
 
8.1.5.2. Preparation of HIV IN-1 protein  
The HIV-1 IN protein used in the modeling was prepared by a previous member of the group, 
Dr Telisha Traut,343 using a BIOVIA Discovery Studio 4.0 package. The PDB code 2B4J model 
(IN-LEDGF/p75) was retrieved (http://www.rcsb.org/pdb) and LEDGF/p75 was removed 
from the HIV-1 IN-LEDGF/p75 complex and prepared by building missing loops, addition of 
hydrogen atoms, bond order assignment, and optimization of bond lengths, bond angles, torsion 
angles and non-bonded interactions. Known HIV-1 IN-LEDGF/p75 inhibitors (27) identified 
by Bruno Simoneau et al. 344 consisting of known IC50, EC50, CC50 and KD values were used to 
train the model. The sphere had the following xyz coordinates: 7.175, -17.325, -17.502 and radius 
of 14Å.  
 
8.1.5.3 Docking of selected compound into HIV IN binding cavity  
Molecular docking studies were performed using the BIOVIA Discovery Studio software 
package, version 4.0 in the allosteric site (LEDGF/p75-binding site) of HIV-1 IN protein (PDB 
code: 2B4J). The selected compounds were primarily positioned in the same site where 
LEDGF/p75 binds to the HIV-1 IN dimer using the LibDock protocol, which resulted in the 
generation of hundreds for poses of each compound. These poses were exposed to Jain, PLP2 
and LibDock scoring protocols, and then analysed, followed by the further optimised by in-situ-
energy-minimisation and flexible docking. The binding energies of the best poses generated from 
flexible docking were then calculated. 
 
8.1.5.4. ADME properties 
The absorption, distribution, metabolism and excretion (ADME) of synthesized compounds was 
determined theoretically using the ADMET Descriptors application in the BIOVIA Discovery 
StudioTM, version 4.0. The ADME determinations were carried out in order to analyse solubility, 
intestinal absorption, blood-brain barrier (BBB) penetration and cytochrome P450 inhibition. 
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8.1.6. Isothermal titration calorimetry  
The proteins was purified in house within the Centre of Metal Drug Discovery group (CMDD), 
Advanced Material Division, Mintek, Randburg. The ITC experiments were conducted at the 
University of the Witwatersrand, Department of Protein Structure-Function Research Unit in the 
School of Molecular and Cell Biology under guidance of Professor Yasien Sayed. 
 
8.1.6.1. Buffer exchange 
A total of 2.5 ml HIV-1 IN sub B protein with a final concentration of 25 µM was loaded into a 
cellulose dialysis membrane with a 10 kDa cut-off. The dialysis membrane was submerged in 
dialysis buffer (1M NaCl, 20 mM Hepes pH 7.4 , 1 mM DTT, 2.5 mM β-mercaptoethanol, 5% 
glycerol) and buffer exchanged for 5 hours at 4°C. After 5 hours the buffer was changed to a 
fresh buffer and exchanged for a further 5 hours. A final change of buffer was performed 
overnight and the buffer kept for use in the ITC experiment. 
 
8.1.6.2. Compound preparation  
CX05168 (Figure 8.1) which is known to be a HIV-1 IN-LEDGF/p75 inhibitor was used as a 
control in an attempt to establish the ITC protocol.53 Control compound was made up to a stock 
solution of 20 mg/ml in DMSO. For a final concentration of 1 mM CX05168 for use in the ITC 
experiment, 8.84 µl of 20mg/ml CX05168 was added to 491.136 µl of ITC buffer. Other 
concentrations were prepared in a similar manner. 
N
O
OH
CX05168
Cl
 
 
Figure 8.1: Structure of the control compound CX05168.  
 
8.1.6.3. ITC experiment settings 
ITC experiments were conducted using a VP-ITC MicroCalorimeter TM. The cell temperature 
was set at 20oC and experiments were programmed to run 35 injections at 300-second intervals 
with stirring speed of 750 revolutions per minute (rpm). The initial default volume of injection 
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was set at 3 μl while other the 34 injections were 8 μl.  The preliminary ITC data fitting was 
carried out using NITPIC and ITCsy software. 
 
8.2. Chapter 2 experimental procedure 
8.2.1. Synthesis of N-arylidene alkylamines 
The following general synthetic procedures for the preparation of N-arylidene alkylamines were 
performed and the yields obtained are indicated for each compound: 
 
8.2.1.1. Synthetic Procedure A: Conventional Method 
To a solution of aldehyde (1 molar equivalent) in DCM (5 ml) was added primary amine (1.2 
molar equivalent) and MgSO4 (0.14 mg). The resulting reaction mixture was then allowed to stir 
at room temperature for 16 hours (monitored by TLC). At the end of the reaction time, the 
solution was filtered to remove the MgSO4 and washed with DCM (2 x 5 ml).  The combined 
DCM fractions were then concentrated in vacuo and dried under high vacuum to give pure N-
arylidene alkylamine. 345 
 
8.2.1.2. Synthetic Procedure B: Microwave Irradiation 
A mixture of aldehyde (1 molar equivalent) and primary amine (1.2 molar equivalents) in a 10 ml 
microwave vessel was irradiated neat at 60oC for 4 minutes using the standard MW method (in 
the CEM microwave standard control method, the specified set temperature is held over a set 
time period, while the power applied is controlled by the instrument default settings). At the end 
of the reaction time (monitored by TLC), DCM was added and reaction mixture was transferred 
into round bottom flask and the vessel was then rinsed with DCM. The combined DCM 
fractions were then concentrated in vacuo to give pure N-arylidene alkylamine.  
 
8.2.1.3. (E)-N-(4-Fluorobenzylidene)butan-1-amine 75a 
1
F
N
2
3
4
5
6
  
(E)-N-(4-Fluorobenzylidene)butan-1-amine 75a was successfully synthesized as described by 
synthetic procedure A {4-fluorobenzaldehyde (0.596 g, 4.80 mmol) and n-butylamine (421 mg, 
5.76 mmol)} and synthetic procedure B {4-fluorobenzaldehyde (338 mg, 2.72 mmol) and n-
butylamine (239 mg, 4.08 mmol)}; Physical characteristics: pale brown oil; Yields: 748 mg, 
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87% for synthetic procedure A and 478 mg, 98% for synthetic procedure B; 1H NMR (400 
MHz, CDCl3) δ 8.21 (1H, s, N=CH), 7.12 (2H, m, Hz, ArH), 7.02 (2H, t, J = 8.8 Hz, ArH ), 3.57 
(2H, t, J = 7.0 Hz, 2-CH2), 1.63-1.70 (2H, m, 3-CH2), 1.33-1.42 (2H, m, 4-CH2), 0.92 (3H t, J = 7 
.4 Hz, 5-CH3); 
13C NMR (101 MHz, CDCl3) δ 164.1 (d, 
1JCF = 250 Hz, para-CF), 159.1 (6-C) 
132.6 (d, 4JCF = 3 Hz, 1‟-C), 129.8 (d, 
3JCF = 9 Hz, ortho-C), 115.5 (d, 
2JCF = 22 Hz, meta-C), 61.3 
(2-C), 32.9 (3-C), 20.4 (4-C), 13.8 (5-C). 
 
8.2.1.4. (E)-N-(2-Chlorobenzylidene)butan-1-amine 75b 
1
N
2
3
4
5
6
Cl
 
(E)-N-(2-Chlorobenzylidene)butan-1-amine 75b was successfully synthesized as described by 
synthetic procedure A {2-chlorobenzaldehyde (550 mg, 3.91 mmol) and n-butylamine (343 mg, 
4.69 mmol)} and synthetic procedure B {2-chlorobenzaldehyde (351 mg, 2.50 mmol) and n-
butylamine (219 mg, 3.00 mmol)}; Physical characteristics:  colourless oil; Yields: 719 mg, 
94% for synthetic procedure A and 484 mg, 99% for synthetic procedure B: 1H NMR (400 
MHz, CDCl3) δ 8.61 (1H, s, N=CH), 7.92 (1H, d, J = 8.4 Hz, ArH), 7.17-7.28 (3H, m, ArH), 
3.56 (2H, t, J = 7.0 Hz, 2-CH2), 1.58-1.65 (2H, m, 3-CH2), 1.29-1.34 (2H, m, 4-CH2), 0.85 (3H, t, 
J = 7.4 Hz, 5-CH3); 
13C NMR (101 MHz, CDCl3) δ 157.4 (N=CH), 134.9, 133.3, 131.2, 129.7, 
128.2, 126.9 (ArC), 61.5 (2-C), 32.8 (3-C), 20.4 (4-C), 13.8 (5-C). 
 
8.2.1.5. (E)-N-(3-Methoxybenzylidene)butan-1-amine 75c 
1
N
2
3
4
5
6O
 
(E)-N-(3-Methoxybenzylidene)butan-1-amine 75c was successfully synthesized as described by 
synthetic procedure B using 3-methoxybenzaldehyde (313 mg, 2.30 mmol) and n-butylamine 
(202 mg, 2.76 mmol); Physical characteristics:  colourless oil; Yields: 428 mg, 97% for 
synthetic procedure B; 1H NMR (400 MHz, CDCl3) δ 8.26 (1H, s, N=CH), 7.28-7.37 (3H, m, 
ArH), 6.98 (1H, d, J = 8.4 Hz, ArH), 3.87 (3H, s, ArOCH3), 3.62 (2H, t, J = 7.0 Hz, 2-CH2), 1.70-
1.75 (2H, m, 3-CH2), 1.39-1.50 (2H, m, 4-CH2), 0.96 (3H, t, J = 7.4 Hz, 5-CH3);  
13C NMR (101 
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MHz, CDCl3) δ 160.5 (ArCOCH3), 159.8 (N=CH), 137.8, 129.4, 121.2, 117.1, 111.4 (ArC), 61.3 
(2-C), 55.2 (ArCOCH3), 32.9 (3-C), 20.4 (4-C), 13.8 (5-C). 
 
 
 
8.2.1.6. (E)-N-(2,4-Dimethoxybenzylidene)butan-1-amine 75d 
1
N
2
3
4
5
6
O
O
 
(E)-N-(2,4-Dimethoxybenzylidene)butan-1-amine 75d was successfully synthesized as described 
by synthetic procedure A {2,4-dimethoxybenzaldehyde (1.01 g, 6.10 mmol) and n-butylamine 
(535 mg, 7.32 mmol) and synthetic procedure B {2,4-dimethoxybenzaldehyde (332 mg, 2.00 
mmol) and n-butylamine (210 mg, .40 mmol)}; Physical characteristics: light brown oil; 
Yields: 1.13 g, 84% for synthetic procedure A and 434 mg, 98% for synthetic procedure B; 1H 
NMR (400 MHz, CDCl3) δ 8.48 (1H, s, N=CH ), 7.77 (1H, d, J = 8.8 Hz, ArH), 6.37 (1H, d, J = 
8.8 Hz, ArH), 6.28 (1H, s, ArH), 3.66 and 3.68 (6H, 2 x s, 2 x ArOCH3), 3.44 (2H, t, J = 7.0 Hz, 
2-CH2), 1.51-1.57 (2H, m, 3-CH2), 1.24-1.30 (2H, m, 4-CH2), 0.81 (3H, t, J = 7.4 Hz, 5-CH3); 
13C 
NMR (101 MHz, CDCl3) δ 162.5 and 159.6 (2 x ArCOCH3), 155.8 (N=CH), 128.1, 117.9, 105.0, 
97.6 (ArC), 61.4 (2-C), 55.0 and 54.9 (2 x ArCOCH3), 33.0 (3-C), 20.2 (4-C), 13.7 (5-C). 
 
8.2.1.7. (E)-N-(Benzo[d][1,3]dioxol-5-ylmethylene)butan-1-amine 75e 
1
N
2
3
4
5
6O
O  
(E)-N-(Benzo[d][1,3]dioxol-5-ylmethylene)butan-1-amine 75e was successfully synthesized as 
described by synthetic procedure A {piperonal (2.07 g, 13.87 mmol) and n-butylamine (1.21 g, 
16.55 mmol) and synthetic procedure B {piperonal (330 mg, 2.20 mmol) and n-butylamine (193 
mg, 2.64 mmol)}; Physical characteristics: brown oil; Yields: 2.73 g, 96% for synthetic 
procedure A and 451 mg, 100% for synthetic procedure B; 1H NMR (400 MHz, CDCl3) δ 8.11 
(1H, s, N=CH), 7.32 (1H, s, ArH), 7.05 (1H, d, J = 7.6 Hz, ArH), 6.77 (1H, d, J = 8.0 Hz, ArH), 
5.94 (2H, s, ArOCH2O-), 3.52 (2H, t, J = 7.0 Hz, 2-CH2), 1.60-1.67 (2H, m, 3-CH2), 1.33-1.39 
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(2H, m, 4-CH2), 0.90 (3H, t, J = 7.4 Hz, 5-CH3); 
13C NMR (101 MHz, CDCl3) δ 159.6 (N=CH), 
149.5, 148.1, 131.1, 123.9, 107.8, 106.4 (ArC), 101.2 (ArOCH2O), 61.0 (2-C), 33.0 (3-C), 20.3 (4-
C), 13.8 (5-C). 
 
8.2.1.8. (E)-N-(4-tert-butylbenzylidene)butan-1-amine 75f 
1
N
2
3
4
5
6
 
(E)-N-(4-tert-Butylbenzylidene)butan-1-amine 75f was successfully synthesized as described by 
synthetic procedure A {4-tert-butylbenzaldehyde (600 mg, 3.70 mmol) and n-butylamine (325 mg, 
4.44 mmol)} and synthetic procedure B {4-tert-butylbenzaldehyde (339 mg, 2.09 mmol) and n-
butylamine (183 mg, 2.51 mmol)}; Physical characteristics: pale brown oil; Yields: 676 mg, 
84% for synthetic procedure A and 423 mg, 93% for synthetic procedure B; 1H NMR (400 
MHz, CDCl3) δ 8.30 (1H, s, N=CH), 7.65-7.68 (2H, m, ArH), 7.41-7.43 (2H, m, ArH), 3.15 (2H, 
t, J = 7.0 Hz, 2-CH2), 1.60-1.77 (2H, m, 3-CH2), 1.31-1.33 [11H, m, 4-CH2 and ArC(CH3)3], 0.98 
(3H, t, J = 7.4 Hz, 5-CH3); 
13C NMR (101 MHz, CDCl3) δ 158.4 (N=CH), 153.7, 134.0, 127.9 , 
125.5 (ArC), 70.1 (2-C), 34.9 [ArCC(CH3)], 33.0 (3-C), 20.3 (4-C), 13.8 (5-C), 25.4 [ArCC(CH3)3]. 
 
8.2.1.8. (E)-N-(2,3-Dihydrobenzo[b][1,4]dioxin-6 yl)methylene)butan-1-amine 75g 
1
N
2
3
4
5
6O
O  
(E)-N-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methylene)butan-1-amine 75g was successfully 
synthesized as described by synthetic procedure A using 1,4-benzodioxan-6-carboxaldehyde (506 
mg, 3.08 mmol) and n-butylamine (271 mg, 3.70 mmol); Physical characteristics: pale brown 
oil; Yield: 567 mg, 84 %; 1H NMR (400 MHz, CDCl3) δ 8.03 (1H, s, N=CH), 7.18 (1H, s, ArH) 
7.10 (1H, d, J = 8.4 Hz, ArH), 6.77 (1H, d, J = 8.0 Hz, ArH), 4.16 (4H, s, ArOCH2CH2O), 3.45-
3.49 (2H, t, J = 7.0 Hz, 2-CH2), 1.55-159 (2H, m, 3-CH2), 1.26-1.31 (2H, m, 4-CH2), 0.83 (3H, t, 
J = 7.4 Hz, 5-CH3); 
13C NMR (101 MHz, CDCl3) δ 159.7 (N=CH), 145.5 and 143.5 
(ArCOCH2CH2O), 130.1, 121.5, 117.2, 116.5 (ArC), 64.4 and 64.0 (ArCOCH2CH2O-), 61.3 (2-
C), 32.9 (3-C), 20.3 (4-C), 13.8 (5-C). 
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8.2.1.9. (E)-N-(2-Nitrobenzylidene)butan-1-amine 75h 
1
N
2
3
4
5
6
NO2
 
(E)-N-(2-Nitrobenzylidene)butan-1-amine 75h was successfully synthesized as described by 
synthetic procedure B using 4-nitrobenzaldehyde (227 mg, 1.50 mmol) and n-butylamine (133 
mg, 1.80 mmol); Physical characteristics: yellow oil; Yield: 226 mg, 73%; 1H NMR (400 
MHz, CDCl3): δ 8.66 (1H, s, N=CH), 7.97-8.03 (2H, m, ArH), 7.51-7.66 (2H, m, ArH), 3.65 (2H, 
t, J = 7.0 Hz, 2-CH2), 1.66-1.73 (2H, m, 3-CH2), 1.35-1.44 (2H, m, 4-CH2), 0.92 (3H, t, J = 7.4 
Hz, 5-CH3); 
13C NMR (101 MHz, CDCl3) δ 156.6 (N=CH), 148.7, 133.4, 131.3, 130.4, 129.6, 
124.2 (ArC), 61.4 (2-C), 32.6 (3-C), 20.3(4-C), 13.8 (5-C). 
 
8.2.1.9. (E)-N-(4-Nitrobenzylidene)butan-1-amine 75i 
1
N
2
3
4
5
6
O2N  
(E)-N-(4-Nitrobenzylidene)butan-1-amine 75i was successfully synthesized as described by 
synthetic procedure B using 4-nitrobenzaldehyde (197 mg, 1.30 mmol) and n-butylamine (114 
mg, .55 mmol); Physical characteristics: yellow oil; Yield: 244 mg, 91%; 1H NMR (400 MHz, 
CDCl3) δ 8.34 (1H, s, N=CH), 8.22-8.25 (2H, m, ArH), 7.86-7.90 (2H, m, ArH), 3.64 (2H, t, J = 
7.0 Hz, 2-CH2), 1.65-1.73 (2H, m, 3-CH2), 1.38-1.43 (2H, m, 4-CH2), 0.92-0.96 (3H, t, J = 7.4 Hz, 
5-CH3); 
13C NMR (101 MHz, CDCl3) δ 158.3 (N=CH), 148.8, 141.8, 128.6, 123.8 (ArC), 61.6 (2-
C), 32.7 (3-C), 20.4 (4-C), 13.8 (5-C). 
 
8.2.1.11. (E)-N-(4-Fluorobenzylidene)cyclohexanamine 76a 
1
N
2
3
4
5
6
7
8
F  
 
215 
 
(E)-N-(4-Fluorobenzylidene)cyclohexanamine 76a was successfully synthesized as described by 
synthetic procedure A {4-fluorobenzaldehyde (545 mg, 4.39 mmol) and cyclohexylamine (523 
mg, 5.27 mmol)} and synthetic procedure B {4-fluorobenzaldehyde (347 mg, 2.80 mmol) and 
cyclohexylamine (333, mg, 3.36 mmol)}; Physical characteristics: pale yellow oil; Yields: 766 
mg, 85% for synthetic procedure A and 506 mg, 88% for synthetic procedure B: 1H NMR (400 
MHz, CDCl3) δ 8.26 (1H, s, N=CH), 7.69 (2H, m, ArH), 7.04 (2H, t, J = 8.8 Hz, ArH), 3.14 (1H, 
m, 2-CH), 1.38-1.85 (10H, m, 3-, 4-, 5-, 6- & 7-CH2); 
13C NMR (101 MHz, CDCl3) δ 164.0 (d, 
1JC,F =249.6 Hz, para-CF), 157.0 (8-C), 132.9 (d, 
4JC,F =3.0 Hz 1‟-C), 129.8 (d, 
3JC,F = 8.1 Hz,  ortho-
C), 115.6 (d, 2JC,F = 22.0 Hz, meta-C), 69.8 (2-C), 34.3 (3- & 7-C), 25.6 (4- & 6-C), 24.7 (5-C). 
 
8.2.1.12. (E)-N-(2-Chlorobenzylidene)cyclohexanamine 76b 
1
N
2
3
4
5
6
7
8
Cl
 
(E)-N-(2-Chlorobenzylidene)cyclohexanamine 76b was successfully synthesized as described by 
synthetic procedure A {2-chlorobenzaldehyde (593 mg, 4.23 mmol) and cyclohexylamine (504 
mg, 5.08 mmol)} and synthetic procedure B {2-chlorobenzaldehyde (336 mg, 2.39 mmol) and 
cyclohexylamine (285 mg, 2.87 mmol)}; Physical characteristics: pale yellow solid; Yields: 807 
mg, 86% for synthetic procedure A and  472 mg, 89% for synthetic procedure B; 1H NMR (400 
MHz, CDCl3) δ 8.71 (1H, s, N=CH), 7.99 (1H, d, J = 7.6 Hz, ArH), 7.23-7.34 (3H, m, ArH), 
3.22-3.28 (1H, m, 2-CH), 1.38-1.83 (10H, m, 3-, 4-, 5-, 6- & 7-CH2); 
13C NMR (101 MHz, 
CDCl3) δ 155.4 (N=CH), 134.9, 133.6, 131.1, 129.6, 128.4, 126.9 (ArC), 70.0 (2-C), 34.3 (3- & 7-
C), 25.6 (4- & 6-C), 24.7 (5-C).  
 
8.2.1.13. (E)-N-(3-Methoxybenzylidene)cyclohexanamine 76c 
1
N
2
3
4
5
6
7
O
 
(E)-N-(3-Methoxybenzylidene)cyclohexanamine 76c was successfully synthesized  as described 
by synthetic procedure A {3-methoxybenzaldehyde (515 mg, 3.78 mmol) and cyclohexylamine 
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(450 mg, 4.54 mmol)} and synthetic procedure B {3-methoxybenzaldehyde (354 mg, 2.60 mmol) 
and cyclohexylamine (309 mg, 3.12 mmol)}; Physical characteristics: white solid; Yields: 591 
mg, 72% for synthetic procedure A and 497 mg, 88% for synthetic procedure B; Melting point: 
58-61oC; 1H NMR (400 MHz, CDCl3) δ 8.30 (1H, s, N=CH), 7.28-7.34 (3H, m, ArH), 6.95 (1H, 
dd, J = 8.0 Hz, 1.2 Hz, ArH), 3.86 (3H, s, ArOCH3), 3.17-3.25 (1H, m, 2-CH), 1.38-1.88 (10H, 
m, 3-, 4-, 5-, 6- & 7-CH2); 
13C NMR (101 MHz, CDCl3) δ 159.8 (ArCOCH3), 158.4 (N=CH), 
138.1, 129.4, 121.2, 116.9, 111.7 (ArC), 69.9 (2-C), 55.3 (ArCOCH3), 34.2 (3- & 7-C), 25.6 (4- & 
6-C), 24.8 (5-C). 
 
8.2.1.14. (E)-N-(2,4-Dimethoxybenzylidene)cyclohexanamine 76d 
1
N
2
3
4
5
6
7
8
O
O
 
(E)-N-(2,4-Dimethoxybenzylidene)cyclohexanamine 76d was successfully synthesized as 
described by synthetic procedure A {2,4-dimethoxybenzaldehyde (589 mg, 3.55 mmol) and 
cyclohexylamine (422 mg, 4.25 mmol)} and synthetic procedure B {2,4-dimethoxybenzaldehyde 
(330 mg, 1.99 mmol) and cyclohexylamine (236 mg, 2.38 mmol)}; Physical characteristics: pale 
yellow solid; Yields: 711 mg, 81% for synthetic procedure A and 487 mg, 99% for synthetic 
procedure B; Melting point: 55-58oC; 1H NMR (400 MHz, CDCl3) δ 8.63 (1H, s, N=CH), 7.87 
(1H, d, J = 8.8 Hz, ArH), 6.47 (1H, d, J = 6.8 Hz, ArH), 6.40 (1H, s, ArH), 3.81 (6H 2 x s, 2 x 
ArOCH3), 3.11-3.80 (1H, m, 2-CH), 1.20-1.82 (10H, m, 3-, 4-, 5-, 6- & 7- CH2); 
13C NMR (101 
MHz, CDCl3) δ 162.7 and 159.8 (2 x ArCOCH3), 154.1 (N=CH), 127.5, 118.4, 105.2, 98.0 (ArC), 
70.2 (2-C), 55.4 and 55.3 (2 x ArCOCH3), 34.6 (3- & 7-C), 25.7 (2- & 6-C), 25.0 (5-C). 
 
8.2.1.15. (E)-N-(Benzo[d][1,3]dioxol-5-ylmethylene)cyclohexanamine 76e 
1
N
2
3
4
5
6
7
8O
O  
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(E)-N-(Benzo[d][1,3]dioxol-5-ylmethylene)cyclohexanamine 76e was successfully synthesized as 
described by synthetic procedure A {piperonal (583 mg, 3.88 mmol) and cyclohexylamine (462 
mg, 4.66 mmol)} and synthetic procedure B {piperonal (339 mg, 2.26 mmol) and 
cyclohexylamine (269 mg, 2.71 mmol)}; Physical characteristics: pale yellow solid; Yields: 807 
mg, 90% for synthetic procedure A and 507 mg, 97% for synthetic procedure B; Melting point: 
64-67oC (lit346,347); 1H NMR (400 MHz, CDCl3) δ 8.18 (1H, s, N=CH), 7.34 (1H, s, ArH) 7.07 
(1H, d, J = 6.8 Hz, ArH), 6.79 (1H, d, J = 8.0 Hz, ArH), 5.96 (2H, s, ArOCH2O), 3.10-3.16 (1H, 
m, 2-CH), 1.36-1.84 (10H, m, 3-, 4-, 5-, 6- & 7- CH2); 
13C NMR (101 MHz, CDCl3) δ 157.6 
(N=CH), 149.4 and 148.1 (ArCOCH2O), 131.4, 123.9, 107.9 (ArC), 101.3 (ArCOCH2O), 61.0 (2-
C), 34.3 (3- & 7-C), 25.6 (4- & 6-C), 24.8 (5-C). 
 
8.2.1.16. (E)-N-(4-tert-Butylbenzylidene)cyclohexanamine 76f 
1
N
2
3
4
5
6
7
8
 
(E)-N-(4-tert-Butylbenzylidene)cyclohexanamine 76f was successfully synthesized as described by 
synthetic procedure A {4-tert-butylbenzaldehyde (550 mg, 3.39 mmol) and cyclohexylamine (404 
mg, 4.07 mmol)} and synthetic procedure B {4-tert-butylbenzaldehyde (357 mg, 2.20 mmol) and 
cyclohexylamine (2.64 mmol)}; Physical characteristics: white solid; Yields: 767 mg, 93% for 
synthetic procedure A and 530 mg, 99% for synthetic procedure B; Melting point:45-48oC; 1H 
NMR (400 MHz, CDCl3) δ 8.30 (1H, s, N=CH), 7.65 (2H, d, J = 8.4 Hz, ArH), 7.41 (2H, d, J 
=8.4 Hz, ArH), 3.15.-3.20 (1H, m, 2-CH), 1.33-1.86 [19H, m, 3-, 4-, 5-, 6- & 7- CH2 and 
ArC(CH3)]; 
13C NMR (101 MHz, CDCl3) δ 158.4 (N=CH), 153.7 [ArCC(CH3)3], 134.0, 127.9, 
125.5 (ArC), 70.1 (2-C), 34.9 [ArCC(CH3)3], 34.4 (3- & 7-C), 31.3 [ArCC(CH3)3], 25.7 (4- & 6-C) 
24.9 (5-C). 
8.2.1.17. (E)-N-(2-Nitrobenzylidene)cyclohexanamine 76h 
1
NNO2
2
3
4
5
6
7
8
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(E)-N-(2-Nitrobenzylidene)cyclohexanamine 76h was successfully synthesized as described by 
synthetic procedure B using 2-nitrobenzaldehyde (190 mg, 1.26 mmol) and cyclohexylamine 
(1.51 mmol); Physical characteristics: yellow oil; Yield: 278 mg, 95%; 1H NMR (400 MHz, 
CDCl3) δ 8.70 (1H, s, N=CH), 7.97-8.03 (2H, m, ArH), 7.61-7.65 (1H, m, ArH), 7.49 (1H, m, 
ArH), 3.28-3.33 (1H, m, 2-CH), 1.23-1.85 (10H, m, 3-, 4-, 5-, 6- & 7- CH2); 
13C NMR (101 MHz, 
CDCl3) δ 154.6 (N=CH), 148.7 (ArCNO2), 133.4, 131.6, 130.3, 12.7, 124.1 (ArC), 70.0 (2-C), 34.0 
(3- & 7-C), 25.5 (4- & 6-C), 24.5 (5-C). 
 
8.2.1.17. (E)-N-(4-Nitrobenzylidene)cyclohexanamine 76i 
8
N1
2
3
4
5
6
7
O2N  
(E)-N-(4-Nitrobenzylidene)cyclohexanamine 76i was successfully synthesized as described by 
synthetic procedure B using 4-nitrobenzaldehyde (230 mg, 1.52 mmol) and cyclohexylamine (181 
mg, 1.82 mmol); Physical characteristics: yellow oil; Yield: 321 mg, 91%; 1H NMR (400 
MHz, CDCl3) δ 8.38 (1H, s, N=CH), 8.23-8.25 (2H, m, ArH), 7.86-7.89 (2H, m, ArH), 3.25-3.30 
(1H, m, 2-CH), 1.25-1.87 (10H, m, 3-, 4-, 5-, 6- & 7- CH2); 
13C NMR (101 MHz, CDCl3) δ 156.2 
(N=CH), 148.8 (ArCNO2), 142.1, 128.7, 128.8 (ArC), 70.1 (2-C), 34.1 (3- & 7-C), 25.5 (4-& 6-C), 
24.6 (5-C). 
 
8.2.1.19. (E)-N -(4-Fluorobenzylidene)cyclopropanamine 77a 
1
5
N
2
F
3
4
 
(E)-N-(4-Fluorobenzylidene)cyclopropanamine 77a was successfully synthesized as described by 
synthetic procedure A using 4-fluorobenzaldehyde (424 mg, 3.42 mmol) and cyclopropylamine 
(234 mg, 4.10 mmol; Physical characteristics: brown oil; Yield: 430 mg, 77%; 1H NMR (400 
MHz, CDCl3) δ 8.40 (1H, s, N=CH), 7.64 (2H, d, J = 8.6 Hz, ArH), 7.04 (2H, t, J = 8.6 Hz, 
ArH), 2.98-3.02 (1H, m, 2-CH), 0.89-0.99 (4H, m, 3- & 4-CH2); 
13C NMR (101 MHz, CDCl3) δ 
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163.9 (d, 1JF,C = 249.6 Hz, para-CF), 156.9 (N=CH), 132.8 (d, 
4JF,C = 3.0 Hz, 1‟-C), 129.8 (d, 
3JF,C = 
8.1 Hz, ortho-C), 115.5 (d, 2JF,C = 21.1 Hz, meta-C), 41.8 (2-C), 8.70 (3- & 4-C).. 
 
8.2.1.20. (E)-N -(3-Methoxybenzylidene)cyclopropanamine  77c 
1
5
N
2
3
4
O
 
(E)-N-(3-Methoxybenzylidene)cyclopropanamine 77c was successfully synthesized as described 
by synthetic procedure A using 3-methoxybenzaldehyde (483 mg, 3.55 mmol) and 
cyclopropylamine (243 mg, 4.26 mmol); Physical characteristics: brown oil; Yield: 572 mg, 
92%; 1H NMR (400 MHz, CDCl3) δ 8.47 (1H, s, N=CH), 7.28-7.37 (3H, m, ArH), 6.98 (1H, dd, 
J = 3.5 Hz, ArH), 3.89 (3H, s, ArOCH3), 3.07-3.10 (1H, m, 2-CH), 0.98-1.05 (4H, m, 3- & 4-
CH2); 
13C NMR (101 MHz, CDCl3): δ 159.8 (ArCOCH3), 158.2 (N=CH), 137.9, 129.5, 120.7, 
116.6, 111.2 (ArC), 55.3 (ArCOCH3), 41.8 (2-C), 8.77 (3- & 4-C). 
 
8.2.1.21. (E)-N-(2,4-Dimethoxybenzylidene)cyclopropanamine 77d  
1
5
N
2
3
4
O
O
 
(E)-N-(3-dimethoxybenzylidene)cyclopropanamine 77d was successfully synthesized as 
described by synthetic procedure A using 2.4-dimethoxybenzaldehyde (450 mg, 2.71 mmol) and 
cyclopropylamine (186 mg, 3.25 mmol); Physical characteristics: pale yellow solid; Yield: 484 
mg, 87% for synthetic procedure A; 1H NMR (400 MHz, CDCl3) δ 8.77 (1H, s, N=CH), 7.79 
(1H, d, J = 8.4 Hz, ArH), 6.47 (1H, d, J = 8.4 Hz, ArH), 6.42 (1H, s, ArH), 3.81 and 3.84 (6H 2 x 
s, 2 x ArOCH3), 2.99-3.02 (1H, m, 2-CH), 0.85-0.93 (4H, m, 3- & 4-CH2); 
13C NMR (101 MHz, 
CDCl3): δ 162.7 and 159.8 (2 x ArCOCH3), 158.6 (N=CH), 129.5, 116.6, 111.2, 98.0 (ArC), 55.4 
and 55.3 (2 x ArCOCH3), 41.8 (1-C), 8.77 (2- & 3-C). 
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8.2.1.22. (E)-N-(4-Fluorobenzylidene)-1-phenylmethanamine 78a 
1
N
2
3
F  
 
(E)-N-(4-Fluorobenzylidene)-1-phenylmethanamine 78a was successfully synthesized as 
described by synthetic procedure B using 4-fluorobenzaldehyde (161 mg, 1.30 mmol) and benzyl 
amine (167 mg, 1.55 mmol); Physical characteristics: orange solid; Yield: 255 mg, 92%; 1H 
NMR (400 MHz, CDCl3) δ 8.37 (1H, s, CH=N), 7.78-7.82 (2H, m, ArH) 7.05 (7H, m, ArH), 
4.83 (2H, s, CH=NCH2); 
13C NMR (101 MHz, CDCl3) δ  165.5 (d, 
1JC,F = 250 Hz, para-CF), 
160.4 (CH=N), 139.1 (ArC), 132.4 (d, 1JC,F = 3 Hz, 1’-C ), 130.1 , 130.0, 128.5 (d, 
3JC,F = 8 Hz, 
ortho-C) 127.9 (ArC), 115.6 (d, 1JC,F = 22 Hz, meta-C),  64.9 (CH=NCH2). 
 
8.2.1.23. (E)-N -(2-Chlorobenzylidene)-1-phenylmethanamine 78b 
1
N
3
2
Cl
 
(E)-N-(2-chlorobenzylidene)-1-phenylmethanamine 78b was successfully synthesized as 
described by synthetic procedure B using 2-chlorobenzaldehyde (163 mg, 1.16 mmol) and 
benzylamine (149 mg, 1.39 mmol); Physical characteristics: pale yellow oil; Yield: 248 mg, 
93%; 1H NMR (400 MHz, CDCl3) δ 8.86 (1H, s, CH=N), 8.01 (1H, dd, J = 6 Hz, 1.2 Hz, ArH) 
7.05 (8H, m, ArH), 4.89 (2H, s, CH=NCH2); 
13C NMR (101 MHz, CDCl3) δ 158.7 (CH=N), 
139.0, 135.2, 133.1, 131.6, 129.7, 128.6, 128.3, 128.0, 127.1, 127.0 (ArC); 65.3 (CH=NCH2). 
 
8.2.1.24. (E)-N-(3-Methoxybenzylidene)-1-phenylmethanamine 78c 
1
N
2
3
O
 
(E)-N-(3-Methoxybenzylidene)-1-phenylmethanamine 78c was successfully synthesized as 
described by synthetic procedure B using 3-methoxybenzaldehyde (127 mg, 0.93 mmol) and 
benzylamine (120 mg, 1.12 mmol); Physical characteristics: pale yellow oil; Yield: 205 mg, 
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98%; 1H NMR (400 MHz, CDCl3) δ 8.29 (1H, s, CH=N), 7.31 (1H, d, J = 8.4 Hz, ArH), 6.91-
7.29 (8H, m, ArH), 4.72 (2H, s, CH=NCH2), 3.76 (3H, s, ArOCH3); 
13C NMR (101 MHz, 
CDCl3) δ 161.9 (CH=N), 159.8 (ArCOCH3), 139.1, 137.5, 129.5, 128.4, 127.9, 126.9, 121.9, 
117.5, 115.6 (ArC), 64.9 (C=NCH2), 55.3 (ArCOCH3). 
 
8.2.1.25. (E)-N -(2,4-Dimethoxybenzylidene)-1-phenylmethanamine 78d 
1
N
2
3
O
O
 
(E)-N-(2,4-Dimethoxybenzylidene)-1-phenylmethanamine 78d was successfully synthesized as 
described by synthetic procedure B using 2,4-dimethoxybenzaldehyde (170 mg, 1.02 mmol) and 
benzylamine (132 mg, 1.23 mmol); Physical characteristics: yellow oil; Yield: 234 mg, 90%; 1H 
NMR (400 MHz, CDCl3) δ 8.89 (1H, s, CH=N), 8.11 (1H, d, J = 8.4 Hz, ArH), 7.36-7.47 (5H, 
m, ArH), 6.5-6.66 (2H, m, ArH), 4.97 (2H, s, CH=NCH2), 3.95 and 3.97 (6H, 2 x s, 2 x 
ArOCH3); 
13C NMR (101 MHz, CDCl3) δ 163.0 and 160.1 (2 x ArCOCH3), 157.4 (CH=N), 
139.9, 128.6, 128.5, 128.3, 127.9, 117.9, 105.3, 98.0 (ArC), 65.5 (C=NCH2), 55.4 and 55.3 (2 x 
ArCOCH3). 
 
8.2.1.26. (E)-N-(Benzo[d][1,3]dioxol-5-ylmethylene)-1-phenylmethanamine 78e 
1
N
2
3O
O  
(E)-N-(Benzo[d][1,3]dioxol-5-ylmethylene)-1-phenylmethanamine 78e was successfully 
synthesized as described by synthetic procedure B using piperonal (141 mg, 0.94 mmol) and 
benzylamine (121 mg, 1.13 mmol); Physical characteristics: white solid; Yield: 214 mg, 95%; 
Melting point: 64-70oC (lit.348); 1H NMR (400 MHz, CDCl3) δ 8.18 (1H, s, CH=N), 7.04-7.34 
(8H, m, ArH), 6.73 (1H, d, J  = 8.8 Hz, ArH), 5.90 (2H, s, ArOCH2O), 4.96 (2H, s, C=NCH2); 
13C NMR (101 MHz, CDCl3) δ 161.0 (C=N), 149.9 and 148.2 (2 x ArCOCH2O), 139.4, 131.0, 
128.4, 127.9, 126.9, 124.5, 108.0, 106.7 (ArC), 101.4 (ArCOCH2O), 64.7 (C=NCH2). 
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8.2.2. Synthesis of 1-substituted-5-aryl-1H-imidazole  
8.2.2.1. Stepwise van Leusen general synthetic procedure C  
In a 100 ml three-necked flask equipped with a magnetic stirrer bar was introduced N-arylidene 
alkylamine (1 molar equivalent), TosMIC (1.5 molar equivalents) and K2CO3 (1.3 molar 
equivalents). An inert atmosphere was then created by degassing through evacuating and refilling 
with argon three times, followed by introduction of dry acetonitrile (5 ml). The resulting reaction 
mixture was then refluxed for 72 hours (monitored by TLC) under argon. Upon completion of 
the reaction, the solvent was evaporated in vacuo to afford brown oily crude material which was 
then purified by  column chromatography [on silica; elution with hexane-EtOAc (1:2), followed 
by 100% ethyl acetate] to afford the desired pure 1-substituted-5-aryl-1H-imidazoles with Rf 
values of between 0.78-0.8 
 
8.2.2.2. Microwave assisted van Leusen general synthetic procedure D 
In a 10 ml microwave reaction vessel equipped with a magnetic stirrer bar was introduced N-
arylidene alkylamine (1 molar equivalent), TosMIC (1.5 molar equivalents), K2CO3 (1.2 molar 
equivalents). An inert atmosphere was created by degassing through evacuating and refilling with 
argon three times, followed by addition of dry acetonitrile (5 ml). The resulting reaction mixture 
was then microwave irradiated at a set temperature of 90oC and a power of 120 Watts for 7 
hours in a sealed vessel. The progress of the reaction was monitored by TLC. After cooling to 
room temperature, the solvent was concentrated in vacuo to give brown oily crude material which 
was then purified by column chromatography on silica gel as described in synthetic procedure C 
to furnish the desired 1-substituted-5-aryl-1H-imidazoles. 
 
8.2.2.3. Three -component van Leusen reaction general synthetic procedure E 
In order to generate the N-arylidene alkylamine in situ, aryl aldehyde (1 molar equivalent) and an 
aliphatic amine (1.1 molar equivalents) were introduced into a 10 ml microwave reaction vessel 
equipped with magnetic stirrer bar. The resulting reaction mixture was then microwave irradiated 
at a set temperature of 60oC using standard method for 4 minutes. After cooling to room 
temperature, TosMIC (1.5 molar equivalents) and K2CO3 (1.3 molar equivalent) were then 
added. An inert atmosphere was created by degassing through evacuating and refilling with argon 
three times, followed by addition of dry MeCN (5 ml). The resulting reaction mixture was then 
irradiated at a set temperature of 90oC and a power of 120 Watts for 7 hours in a sealed vessel. 
The progress of the reaction was monitored by TLC. After cooling to room temperature, the 
solvent was concentrated in vacuo to give a brown oily residue which was then purified by column 
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chromatography on silica gel as described in synthetic procedure C to furnish the desired 1-
substituted-5-aryl-1H-imidazoles. (N.B: in cases where aniline derivatives were used, the reaction 
mixture was irradiated for 1 hour prior to addition of TosMIC and K2CO3). 
 
8.2.2.4. Three -component van Leusen reaction general synthetic procedure F 
In order to generate the N-arylidene alkylamine in situ appropriate aryl aldehyde (1 molar 
equivalent) and an aliphatic amine (1.1 molar equivalents) were introduced into a 10 ml 
microwave reaction vessel equipped with a magnetic stirrer bar. The resulting reaction mixture 
was then microwave irradiated at a set temperature of 60oC using standard method for 4 
minutes. After cooling to room temperature, K2CO3 (1.3 molar equivalent) and TosMIC (1.5 
molar equivalent) were then introduced. An inert atmosphere was created by degassing through 
evacuating and refilling with argon three times, followed by introduction of anhydrous MeOH (5 
ml). The resulting reaction mixture was then irradiated at set temperature of 90oC and a power of 
120 Watts for 7 hours in a sealed vessel. The progress of the reaction was monitored by TLC. 
After cooling to room temperature, the solvent was concentrated in vacuo gave brown oily residue 
which was then purified by column chromatography on silica gel as described in synthetic 
procedure C. 
 
8.2.2.5. 1-Butyl-5-(4-fluorophenyl)-1H-imidazole 79a 
1
N
2
3
N4
5
6
7
8
F
9  
1-Butyl-5-(4-fluorophenyl)-1H-imidazole 79a was successfully synthesized according to 
procedure C {N-(4-fluorobenzylidene)butan-1-amine 75a (345 mg, 1.93 mmol), TosMIC (565 
mg, 2.89 mmol) and K2CO3 (346 mg, 2.51 mmol)} and synthetic procedure D {N-(4-
fluorobenzylidene)butan-1-amine (317 mg, 1.77 mmol), TosMIC (518 mg, 2.66 mmol) and 
K2CO3 (318 mg, 2.30 mmol)}; Physical characteristics: brown oil; Yields: 160 mg, 38% for 
synthetic procedure C and 213 mg, 55% for synthetic procedure D; 1H NMR (400 MHz, 
CDCl3) δ 7.55 (1H, s, 2-CH), 7.30-7.34 (2H, m, ArH), 7.10-7.14 (2H, m, ArH), 7.01 (1H, s, 4-
CH) 3.89 (2H, t, J =7.0 Hz, NCH2), 1.56-160 (2H, m, 7-CH2), 1.19-1.24 (2H, m, 8-CH2), 0.81 
(3H, t, J = 7.4 Hz, 9-CH3); 
13C NMR (101 MHz, CDCl3) δ 163.9 (d, JC,F= 246.9 Hz, para-CF),  
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138.0 (2-CH), 130.7 (d, 4JF,C = 3.0 Hz, 1‟-C), 130.6 (d, 
3JF,C = 8.1 Hz, ortho-C), 128.0 (4-C), 115.9 (d, 
2JF,C = 21.1 Hz, meta-C), 45.0 (6-C), 32.8 (7-C), 19.6 (8-C), 13.4 (9-C); FTIR νmax/cm
-1 (KBr): 
3388, 3104, 2960, 2873, 1682, 1599, 1516, 1456, 1448, 1221, 1110, 1023, 915, 853, 755, 695, 658, 
603, 537; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C13H16FN2 219.1292, found 219.1294. 
 
8.2.2.6. 1-Butyl-5-(2-chlorophenyl)-1H-imidazole 79b 
1
N
2
3
N4
5
6
7
8 9
Cl
 
1-Butyl-5-(2-chlorophenyl)-1H-imidazole 79b was successfully synthesized according to 
procedure C {N-(2-chlorobenzylidene)butan-1-amine 75b (313 mg, 1.60 mmol), TosMIC (469 
mg, 2.40 mmol) and K2CO3 (288 mg, 208 mmol)} and  synthetic procedure D {N-(2-
chlorobenzylidene)butan-1-amine (266 mg, 1.36 mmol), TosMIC (398 mg, 2.04 mmol) and 
K2CO3 (244 mg, 1.77 mmol)}; Physical characteristics: brown oil; Yields: 75 mg, 20% for 
synthetic procedure C and 83 mg, 26% for synthetic procedure D; 1H NMR (400 MHz, CDCl3) 
δ 7.58 (1H, s, 2-CH), 7.32-7.50 (4H, m, ArH), 7.02 (1H, s, 4-CH), 3.78 (2H, t, J  =7.2 Hz, 
NCH2), 1.50-1.57 (2H, m, 7-CH2), 1.15-1.22 (2H, m, 8-CH2), 0.77 (3H, t, J = 7.2 Hz, 9-CH3); 
13C 
NMR (101 MHz, CDCl3) δ 137.5 (2-CH), 135.0 (5-C), 132.8, 130.2, 129.8, 129.7, 129.3 (ArC), 
128.9 (4-C), 115.6 (ArC), 45.1 (6-C), 32.7 (7-C), 19.5 (8-C), 13.4 (9-C); FTIR νmax/cm
-1 (KBr): 
3401, 2959, 2873, 1727, 1633, 1557, 1458, 1367, 1285, 1220, 1145, 1114, 1035, 916, 767, 659, 
537; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C13H16ClN2 235.0995, found 235.1002. 
 
8.2.2.7. 1-Butyl-5-(3-methoxyphenyl)-1H-imidazole 79c 
1
N
2
3
N4
5
6
7
8 9
O
 
1-Butyl-5-(3-methoxyphenyl)-1H-imidazole 79c was successfully synthesized according to 
procedure D using N-(3-methoxybenzylidene)butan-1-amine 75c (176 mg, 0.92 mmol), TosMIC 
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(407 mg, 1.38 mmol) and K2CO3 (171 mg, .24 mmol); Physical characteristics: yellow oil; 
Yield: 127 mg, 60%; 1H NMR (400 MHz, CDCl3) δ 7.54 (1H, s, 2-CH), 7.31 (1H, t, J = 6.8 Hz, 
ArH), 7.04 (1H, s, 4-CH), 6.89-6.94 (3H, m, ArH), 3.83 (2H, t, J  = 7.4 Hz, NCH2), 3.83 (3H, s, 
ArOCH3), 1.57-1.65 (2H, m, 7-CH2), 1.18-1.27 (2H. m, 8-CH2), 0.81 (3H, t, J = 7.4 Hz, 9-CH3); 
13C NMR (101 MHz, CDCl3) δ 159.7 (ArCOCH3), 138.0 (2-C), 132.8 (5-C), 131.5, 129.7 (ArC), 
128.1 (4-C), 121.1, 114.5, 113.3 (ArC), 55.3 (ArCOCH3), 45.1 (6-C), 32.8 (7-C), 19.6 (8-C), 13.4 
(9-C); FTIR νmax/cm
-1 (KBr): 3383, 2958, 2873, 1682, 1610, 1580, 1489, 1290, 1212, 1169, 1116, 
1050, 1029, 919, 845, 785, 698, 656, 570; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C14H19N2O 
231.1492, found 231.1498. 
 
8.2.2.8. 1-Butyl-5-(2,4-dimethoxyphenyl)-1H-imidazole 79d 
1
N
2
3
N4
5
6
7
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O
O
 
1-Butyl-5-(2,4-dimethoxyphenyl)-1H-imidazole 79d was successfully synthesized according to 
procedure C {N-(2,4-dimethoxybenzylidene)butan-1-amine 75d (107 mg, 0.55 mmol), TosMIC 
(245 mg, 0.83 mmol) and K2CO3 (100 mg, 0.72 mmol)}; synthetic procedure D {N-(2,4-
dimethoxybenzylidene)butan-1-amine (137 mg, 0.71 mmol), TosMIC (209 mg, 1.07 mmol) and 
K2CO3 (127 mg, 0.92 mmol)} and synthetic procedure E {2,4-dimethoxybenzaldehyde (81 mg, 
0.49 mmol) and n-butylamine (43 mg, 0.59 mmol) TosMIC (144 mg, 0.74 mmol) and K2CO3 (88 
mg, 0.64 mmol); Physical characteristics: brown oil; Yields: 115 mg, 80 % for synthetic 
procedure C and 161 mg, 87% synthetic procedure D, 103 mg, 81% for synthetic procedure E; 
1H NMR (400 MHz, CDCl3) δ 7.50 (1H, s, 2-CH), 7.09 (1H, d, J=8.8 Hz, ArH), 6.88 (1H, s, 4-
CH), 6.52 (2H, d, J = 7.6 Hz, ArH), 3.84 and 3.75 (6H, 2 x s, 2 x ArOCH3), 3.72 (2H, t, J  =7.2 
Hz, NCH2), 1.51-1.58 (2H, m, 7-CH2), 1.15 (2H, m, 8-CH2), 0.78 (3H, t, J = 7.2 Hz, 9-CH3); 
13C 
NMR (101 MHz, CDCl3) δ 161.4 and 158.3 (2 x ArCOCH3), 137.0 (4-CH), 132.8 (ArC), 129.5 
(5-C), 128.0 (4-CH), 111.5, 104.4, 98.6 (Ar-C), 55.3 and 55.2 (2 x ArCOCH3), 45.0 (6-C), 32.5 (7-
C), 19.5 (8-C), 13.3 (9-C); FTIR νmax/cm
-1 (KBr): 3383, 2958,2875, 1722, 1678, 1616, 1578, 1459, 
1416, 1364, 1305, 1283, 1208, 1160, 1132, 1030, 92, 1030, 922, 834, 660, 618; HRMS (ESI-TOF) 
m/z: [M+H]+ Calcd for C15H21N2O2 261.1598, found 261.1587. 
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8.2.2.9. 5-(Benzo[d][1,3]dioxol-5-yl)-1-butyl-1H-imidazole 79e 
1
N
2
3
N4
5
6
7
8 9
O
O
 
5-(Benzo[d][1,3]dioxol-5-yl)-1-butyl-1H-imidazole 79e was successfully synthesized according to 
procedure C {N-(benzo[d][1,3]dioxol-5-ylmethylene)butan-1-amine 75e (320 mg, 1.56 mmol), 
TosMIC (459 mg, 2.34 mmol) and K2CO3 (281 mg, 2.03 mmol)}; synthetic procedure D { N-
(benzo[d][1,3]dioxol-5-ylmethylene)butan-1-amine (372 mg, 1.81 mmol), TosMIC (531 mg, 2.72 
mmol) and K2CO3 (325 mg, 2.35 mmol)} and synthetic procedure E {piperonal (96 mg, 0.63 
mmol) and n-butylamine (55 mg, 0.76 mmol), TosMIC (186 mg, 0.95 mmol) and K2CO3 (113 
mg, 0.82 mmol)}; Physical characteristics: brown oil; Yields: 164 mg, 43% synthetic 
procedure C, 212 mg, 48% for synthetic procedure D and 84 mg, 55% for synthetic procedure 
E; 1H NMR (400 MHz, CDCl3) δ 7.48 (1H, s, 2-CH), 6.94 (1H, s, 4-CH), 6.77-6.84 (3H, m, 
ArH), 5.97 (2H, s, ArOCH2O), 3.87 (2H, t, J = 7.2 Hz, NCH2), 1.53-1.60 (2H, m, 7-CH2), 1.15-
1.24 (2H, m, 8-CH2), 0.79 (3H, t, J = 7.2 Hz, 9-CH3); 
13C NMR (101 MHz, CDCl3) δ 147.7 and 
147.4 (2 x ArCOCH2O ), 137.6 (2-C), 132.5 (5-C), 127.7 (4-C), 123.7, 122.6, 109.2, 108.4 (ArC), 
101.2 (ArCOCH2O), 44.8 (6-C), 32.7 (7-C), 19.5 (8-C), 13.3 (9-C); FTIR νmax/cm
-1 (KBr): 3378, 
2959, 2931, 2873, 1721, 1683, 1609, 1558, 1478, 1379, 1331, 1237, 1113, 1038, 933, 879, 812, 
660; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C17H25N2O2 245.1285, found 245.1276. 
 
8.2.2.10. 1-Butyl-5-(4-tert-butylphenyl)-1H-imidazole 79f 
1
N
2
3
N4
5
6
7
8 9  
1-Butyl-5-(4-tert-butylphenyl)-1H-imidazole 79f was successfully synthesized according to 
procedure C {N-(4-tert-butylbenzylidene)butan-1-amine 75f (322 mg, 1.48 mmol), TosMIC (433 
mg, 2.22 mmol) and K2CO3 (265 mg, 1.92 mmol)} and synthetic procedure D {N-(4-tert-
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butylbenzylidene)butan-1-amine (382 mg, 1.76 mmol), TosMIC (515 mg, 2.64 mmol) and K2CO3 
(317 mg, 2.29 mmol)}; Physical characteristics: brown oil; Yields: 167 mg, 44% for synthetic 
procedure C and 235 mg, 52% for synthetic procedure D; 1H NMR (400 MHz, CDCl3) δ 7.55 
(1H, s, 4-CH), 7.43 (2H, J = 8.4 Hz, ArH), 7.28 (2H, J = 8.4 Hz, ArH), 7.03 (1H, s, 4-CH), 3.93 
(2H, t, J =7.2 Hz, NCH2), 1.60-1.67 (2H, m, 7-CH2), 1.35 [9H, s, C(CH3)3], 1.24-1.30 (2H, m, 8-
CH2), 0.83 (3H, t, J= 7.4 Hz, 9-CH3); 
13C NMR (101 MHz, CDCl3) δ 151.0 [ArCC(CH3)3], 137.8 
(2-C), 132.9 (5-C), 128.5 (ArC), 127.8 (4-C), 127.2, 125.9, 45.0 (6-C), 34.6 [ArCC(CH3)3], 32.9 (7-
C), 31.6, [ArCC(CH3)3], 19.7 (8-C), 13.5 (9-C); FTIR νmax/cm
-1 (KBr): 3373, 2960, 2931, 2865, 
1717, 1682, 1614, 1556, 1463, 1363, 1269, 1220, 1114, 1033, 916, 839, 659, 571; HRMS (ESI-
TOF) m/z: [M+H]+ Calcd for C17H25N2 257.2012, found 257.2008. 
 
8.2.2.11. 1-Butyl-5-(2,3-dihydro-1,4-benzodioxin-6-yl)-1H-imidazole 79g 
1
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1-Butyl-5-(2,3-dihydro-1,4-benzodioxin-6-yl)-1H-imidazole 79g was successfully synthesized 
according to procedure C using N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methylene)butan-1-
amine 75g (112 mg, 0.51 mmol), TosMIC (150 mg, 0.77mmol) and K2CO3 (91 mg, 0.66 mmol); 
Physical characteristics: brown oil; Yield: 71 mg, 54%; 1H NMR (400 MHz, CDCl3) δ 7.49 
(1H, s, 2-CH), 6.96 (1H, s, 4-CH), 6.79-6.90 (3H, m, ArH), 4.27 (4H, s, ArOCH2CH2O), 3.89 
(2H, t, J =7.2 Hz, NCH2), 1.55-1.63 (2H, m, 7-CH2), 1.90-1.25 (2H, m, 8-CH2), 0.81 (3H, t, J = 
7.2 Hz, 9-CH3); 
13C NMR (101 MHz, CDCl3) δ 143.5 and 143.4 (ArCOCH2CH2O), 137.6 (2-C), 
132.4 (5-C), 127.7 (4-C), 123.3, 122.0, 117.7, 117.3 (ArC), 64.3 and 64.2 (ArCOCH2CH2O), 44.9 
(6-C), 32.8 (7-C), 19.6 (8-C), 13.4 (9-C); FTIR νmax/cm
-1 (KBr): 3374, 2962, 2931, 2874, 1720, 
1584, 1503, 1460, 1362, 1286, 1250, 1123, 1067, 921, 893, 815, 749, 658; HRMS (ESI-TOF) 
m/z: [M+H]+ Calcd for C15H19N2O2 259.1441, found 259.1434. 
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8.2.2.12. 1-Butyl-5-(2-nitrophenyl)-1H-imidazole 79h 
1
N
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1-Butyl-5-(2-nitrophenyl)-1H-imidazole 79h was successfully synthesized according to the 
described general procedure D using N-(2-nitrobenzylidene)butan-1-amine 75h (361 mg, 1.75 
mmol), TosMIC (513 mg, 2.63 mmol) and K2CO3 (315 mg, 2.28 mmol); Physical 
characteristics: brown oil; Yield: 56 mg, 13%; 1H NMR (400 MHz, CDCl3) δ 8.01-8.03 (1H, 
m, ArH), 7.67 (1H, s, 2-CH), 7.41-7.69 (3H, m, ArH), 6.96 (1H, s, 4-CH), 3.71 (2H, t, J =7.2 Hz, 
NCH2), 1.51-1.57 (2H, m, 7-CH2), 1.15-1.23 (2H, m, 8-CH2), 0.77 (3H, t, J = 7.2 Hz, 9-CH3); 
13C 
NMR (101 MHz, CDCl3) δ 149.5 (ArCNO2), 138.0 (2-C), 133.6 (5-C), 132.7, 130.4 (ArC), 129.9 
(4-C), 128.6, 127.9, 124.6, 45.1 (6-C), 32.4 (7-C), 19.5 (8-C), 13.0 (9-C); FTIR νmax/cm
-1 (KBr): 
3400, 3108, 2959, 2873, 1727, 1633, 1557, 1456, 1367, 1367, 1284, 1219, 1146, 1114, 1083, 1035, 
916, 812, 768, 659, 537; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C13H16N3O2 246.1237, 
found 246.1240. 
 
8.2.2.13. 1-Butyl-5-(4-nitrophenyl)-1H-imidazole 79i 
1
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1-Butyl-5-(4-nitrophenyl)-1H-imidazole 79i was successfully synthesized according to the 
described general procedure D using N-(4-nitrobenzylidene)butan-1-amine 75i (379 mg, 1.84 
mmol), TosMIC (539 mg, 2.76 mmol) and K2CO3 (330 mg, 2.39 mmol); Physical 
characteristics: brown oil; Yield: 66 mg, 15%; 1H NMR (400 MHz, CDCl3) δ 8.28-8.31 (2H, 
m, ArH), 7.63 (1H, s, 2-CH), 7.26-7.56 (2H, m, ArH), 7.20 (1H, s, 4-CH), 4.01 (2H, t, J =7.4 Hz, 
6-CH2), 1.61-1.66 (2H, m, 7-CH2), 1.21-1.29 (2H, m, 8-CH2), 0.83 (3H, t, J  = 7.4 Hz, 9-CH3); 
13C 
NMR (101 MHz, CDCl3) δ 147.03 (ArCNO2), 139.8 (2-C), 136.7 (5-C), 130.8, 130.2 (ArC), 128.6 
(4-C), 126.8 (ArC), 45.6 (6-C), 32.8 (7-C), 19.6 (8-C), 13.4 (9-C); FTIR νmax/cm
-1 (KBr):): 3388, 
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3103, 2960, 2873, 1682, 1599, 1516, 1456, 1368, 1221, 1110, 1023, 916, 854, 755, 696, 658, 536; 
HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C13H16N3O2 246.1237, found 246.1238. 
 
8.2.2.14. 1-Cyclohexyl-5-(4-fluorophenyl)-1H-imidazole 80a 
1
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1-Cyclohexyl-5-(4-fluorophenyl)-1H-imidazole 80a was successfully synthesized according to the 
described general procedure C {N-(4-fluorobenzylidene)cyclohexanamine 76a (129 mg, 0.63 
mmol), TosMIC (186 mg, 0.95 mmol) and K2CO3 (116 mg, 0.84 mmol)} and synthetic 
procedure D {N-(4-fluorobenzylidene)cyclohexanamine (172 mg, 0.84 mmol), TosMIC (246 mg, 
1.26 mmol) and K2CO3 (140 mg, 1.01 mmol)}; Physical characteristics: pale yellow solid; 
Yields: 71 mg, 46% for synthetic procedure C, 105 mg, 51% for synthetic procedure D; Melting 
point: 111-114oC; 1H NMR (400 MHz, CDCl3) δ 7.64 (1H, s, 2-CH), 7.27-7.7.30 (2H, m, ArH), 
7.01-7.13 (2H, m, ArH), 6.69 (1H, s, 4-CH) 3.79-3.87 (1H, m, NCH), 1.18-2.01 (10H, m, 7-, 8-, 
9-, 10 and 11-CH2); 
13C NMR (101 MHz, CDCl3) δ 163.7 (d, 
1JC,F= 246.9 Hz, para-CF), 134.9 (2-
C), 131.4 (5-C), 130.8 (d, 4JF,C = 3.0 Hz, 1‟-C), 127.5 (4-C), 126.3 (d, 
3JF,C = 8.1 Hz, ortho-C), 115.6 
(d, 2JF,C = 21 Hz, meta-C), 54.5 (6-C), 34.7 (7- & 11-C), 25.6 (8-& 10-C), 25.0 (9-C); FTIR νmax/cm
-
1 (KBr): 3109, 3091, 3070, 2942, 2857, 1665, 1630, 1609, 1557, 1491, 1470, 1455, 1357, 1265, 
814, 664, 604, 565, 504; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C15H18FN2 245.1449, found 
245.1475. 
 
8.2.2.15. 1-Cyclohexyl-5-(2-chlorophenyl)-1H-imidazole 80b  
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1-Cyclohexyl-5-(2-chlorophenyl)-1H-imidazole 80b was successfully synthesized according to 
procedure C {N-(2-chlorobenzylidene)cyclohexanamine 76b (337 mg, 1.52 mmol), TosMIC (445 
mg, 2.28 mmol) and K2CO3 (274 mg, 1.98 mmol)} and synthetic procedure D {N-(2-
chlorobenzylidene)cyclohexanamine (195 mg, 0.88 mmol), TosMIC (256 mg, 1.31 mmol) and 
K2CO3 (145 mg, 1.05 mmol)}; Physical characteristics: pale yellow solid; Yields: 91 mg, 23% 
for synthetic procedure C and 67 mg, 29% for procedure D; Melting point: 131-134oC; 1H 
NMR (400 MHz, CDCl3) δ 7.70 (1H, s, 2-CH), 7.29-7.51 (4H, m, ArH), 6.99 (1H, s, 4-CH), 
3.55-3.63 (1H, m, NCH), 1.18-2.03 (10H, m, 7-, 8-, 9- , 10- and 11-CH2); 
13C NMR (101 MHz, 
CDCl3) δ 135.2 (2-C), 134.7 (5-C), 133.0, 130.2, 129.8, 129.4, 129.3 (ArC), 128.1 (4-C), 126.8 
(ArC), 55.2 (6-C), 34.5 (7 and 11-C), 25.7 (8- and 10-C), 25.2 (9-C); FTIR νmax/cm
-1 (KBr): 3095, 
2934, 2855, 1704, 1661, 1566, 1477, 1453, 1272, 1231, 1113, 1074, 1034, 923, 916, 830, 754, 666; 
HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C15H18ClN2 261.1153, found 261.1155. 
 
8.2.2.16. 1-Cyclohexyl-5-(3-methoxyphenyl)-1H-imidazole 80c 
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1-Cyclohexyl-5-(3-methoxyphenyl)-1H-imidazole 80c was successfully synthesized according to 
procedure C {N-(3-methoxybenzylidene)cyclohexanamine 76c (341 mg, 1.57 mmol), TosMIC 
(461 mg, 2.36 mmol) and K2CO3 (282 mg, 2.04 mmol)} and synthetic procedure D {N-(3-
methoxybenzylidene)cyclohexanamine (380 mg, 1.75 mmol), TosMIC (514 mg, 2.63 mmol) and 
K2CO3 (315 mg, 2.28 mmol)}; Physical characteristics: pale yellow oil; Yields: 189 mg, 47% 
for synthetic procedure C, 238 mg, 53% for procedure D; 1H NMR (400 MHz, CDCl3) δ 7.64 
(1H, s, 2-CH), 7.29-7.34 (1H, m, ArH), 7.00 (1H, s, 4-CH), 6.86-6.89 (3H, m, ArH), 3.93-3.99 
(1H, m, NCH), 3.78 (3H, s, ArOCH3), 1.22-2.04 (10H, m, 7-, 8-, 9-, 10- and 11-CH2); 
13C NMR 
(101 MHz, CDCl3) δ 159.6 (ArCOCH3), 135.0 (2-C), 132.4 (5-C), 131.6, 129.6, 127.5 (4-C), 121.3, 
114.7, 113.3 (ArC), 55.2 (ArCOCH3), 54.5 (6-C), 34.8 (7- and 11-C), 25.6 (8- and 10-C), 25.1 (9-
C); FTIR νmax/cm
-1 (KBr): 2934, 2856, 1679, 1605, 1580, 1482, 1450, 1352, 1318, 1225, 1117, 
1168, 1087, 1052, 1036, 998, 860, 844, 814, 699, 659; HRMS (ESI-TOF) m/z: [M+H]+ Calcd 
for C16H21N2O
 257.1648, found 257.1668. 
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8.2.2.17. 1-Cyclohexyl-5-(2,4-dimethoxyphenyl)-1H-imidazole 80d 
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1-Cyclohexyl-5-(2.4-dimethoxyphenyl)-1H-imidazole 80d was successfully synthesized according 
to procedure C {N-(2,4-dimethoxybenzylidene)cyclohexanamine 76d (138 mg, 0.56 mmol), 
TosMIC (164 mg, 0.84 mmol) and K2CO3 (239 mg, 1.73 mmol)}; synthetic procedure D {N-
(2,4-dimethoxybenzylidene)cyclohexanamine (151 mg, 0.61 mmol), TosMIC (180 mg, 0.92 
mmol) and K2CO3 (101 mg, 0.73 mmol)} and synthetic procedure E {2,4-
dimethoxybenzaldehyde (85 mg, 0.51 mmol) and cyclohexylamine (61 mg, 0.61 mmol), TosMIC 
(150 mg, 0.77 mmol) and K2CO3 (93 mg, 0.67 mmol)}; Physical characteristics: pale yellow 
solid; Yields: 103 mg, 64% for synthetic procedure C, 129 mg, 74% for procedure D and 107 
mg, 73% for Procedure F; Melting point: 99-102oC; 1H NMR (400 MHz, CDCl3) δ 7.60 (1H, s, 
2-CH), 7.09 (1H, d, J = 8.8 Hz, ArH), 6.84 (1H, s, 4-CH), 6.49-6.51 (2H, m, ArH), 3.80 and 3.70 
(6H, 2 x s, 2 x ArOCH3), 3.51-3.59 (1H, m, NCH ), 1.15-1.99 (10H, m, 7-, 8-, 9-,10- and 11-
CH2); 
13C NMR (101 MHz, CDCl3) δ 161.4 and 158.2 (2 x ArCOCH3), 134.2 (2-C), 132.9 (5-C), 
128.9 (ArC), 127.1 (4-C), 111.4, 104.4, 98.5 (ArC), 55.0 and 55.1 (2 x ArCOCH3), 55.2 (6-CH), 
34.6 (7- and 11-C), 25.7 (8- and 10-C), 25.1 (9-C); FTIR νmax/cm
-1 (KBr): 3096, 3002, 2957, 2932, 
2857, 1614, 1581, 1553, 1495, 1435, 1307, 1289, 1265, 1211, 1161, 1136, 1055, 1028, 925, 817, 
796; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C17H23N2O2 287.1754, found 287.1770. 
  
8.2.2.18. 5-(Benzo[d][1,3]dioxol-5-yl)-1-cyclohexyl-1H-imidazole 80e 
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5-(benzo[d][1,3]dioxol-6-yl)-1-cyclohexyl-1H-imidazole 80e was successfully synthesized 
according to procedure C {N-(benzo[d][1,3]dioxol-5-ylmethylene)cyclohexanamine 76e (206 mg, 
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0.89 mmol), TosMIC (262 mg, 1.34 mmol) and K2CO3 (216 mg, 1.56 mmol)}; synthetic 
procedure D {N-(benzo[d][1,3]dioxol-5-ylmethylene)cyclohexanamine (409 mg, 1.77 mmol), 
TosMIC (519 mg, 2.66 mmol) and K2CO3 (318 mg, 2.30 mmol)} and synthetic procedure E 
{piperonal (102 mg, 0.68 mmol) and cyclohexylamine (81 mg, 0.82 mmol), TosMIC (1.02 mmol) 
and K2CO3 (0.88 mmol)}; Physical characteristics: pale yellow solid; Yields: 84 mg, 35% for 
synthetic procedure C, 258 mg, 54% for synthetic procedure D and 92 mg, 50% for synthetic 
procedure E; Melting point.: 85-88oC; 1H NMR (400 MHz, CDCl3) δ 7.58 (1H, s, 2-CH), 6.90 
(1H, s, 4-CH), 6.72-6.83 (3H, m, ArH), 5.96 (2H, s, ArOCH2O), 3.81-3.87 (1H, m, NCH), 1.15-
1.98 (6H, m, 7-, 8-, 9-, 10- and 11-CH2); 
13C NMR (101 MHz, CDCl3) δ 147.6 and 147.4 
(ArCOCH2O), 134.6 (2-C), 132.0 (5-C), 127.2 (4-C), 123.8, 122.8, 109.5, 108.4 (ArC), 101.1 
(ArCOCH2O), 54.3 (6-C), 34.6 (7- and 11-C), 25.5 (8- and 10-C), 25.0 (9-C); FTIR νmax/cm
-1 
(KBr): 3126, 3100, 3070, 2944, 2894, 2848, 2783, 1670, 1556, 1501, 1475, 1445, 1265, 1232, 
1118, 1099, 1042, 943, 862, 878, 808, 659, 626; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for 
C16H19N2O2 271.1481, found 271.1464. 
 
8.2.2.19. 1-Cyclohexyl-5-(4-tert-butylphenyl)-1H-imidazole 80f 
1
N
2
3
N4
5
6
7
8
9
10
11
 
1-Cyclohexyl-5-(4-tert-butylphenyl)-1H-imidazole 80f was successfully synthesized according to 
procedure C {N-(4-tert-butylbenzylidene)cyclohexanamine 76f (306 mg, 1.49 mmol), TosMIC 
(437 mg, 2.24 mmol) and K2CO3 (241 mg, 1.74 mmol)} and synthetic procedure D {N-(4-tert-
butylbenzylidene)cyclohexanamine (339 mg, 1.65 mmol), TosMIC (484 mg, 2.48 mmol) and 
K2CO3 (297 mg, 2.15 mmol)}; Physical characteristics: pale orange solid; Yields: (122 mg, 
29% for synthetic procedure C and 233 mg, 50% for synthetic procedure D); Melting point: 
113-116oC; 1H NMR (400 MHz, CDCl3) δ 7.65 (1H, s, 2-CH), 7.44-7.46 (2H, m, ArH), 7.24-
7.25 (2H, m, ArH), 6.99 (1H, s, 4-CH) 3.92-4.00 (2H, m, 6-CH), 1.20-2.07 [19H, m, 7-, 8-, 9-, 10-
, 11-CH2 and C(CH3)3]; 
13C NMR (101 MHz, CDCl3) δ 150.9 [ArCC(CH3)], 134.9 (2-C), 132.5 (5-
C), 128.7 (ArC), 127.3 (4-C), 125.6 (ArC), 54.4 (6-C), 34.9 (7- and 11-C), 34.6 [ArCC(CH3)3], 31.6 
[ArCC(CH3)3], 25.7 (8- and 10-C), 25.2 (9-C); FTIR νmax/cm
-1 (KBr): 3130, 3065, 3035, 2931, 
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2860, 1669, 1613, 1548, 1474, 1463, 1454, 1403, 1360, 1268, 1218, 1117, 993, 917, 956, 817, 808, 
665, 579; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C17H27N2 283.2169, found 283.2190. 
 
8.2.2.22. 1-Cyclohexyl-5-(2-nitrophenyl)-1H-imidazole 80h 
1
N
2
3
N4
5
6
7
8
9
10
11
NO2
  
1-Cyclohexyl-5-(2-nitrophenyl)-1H-imidazole 80h was successfully synthesized according to 
procedure C using N-(2-nitrobenzylidene)cyclohexanamine 76h (369 mg, 1.59 mmol),  TosMIC 
(554 mg, 2.84 mmol) and K2CO3 (286 mg, 2.07 mmol) C; Physical characteristics: brown oil; 
Yield: 52  mg, 12%; 1H NMR (400 MHz, CDCl3) δ 7.74 (1H, s, 2-CH), 7.33-7.64 (4H, m, ArH), 
7.03 (1H, s, 4-CH), 3.58-3.69 (1H, m, NCH), 1.21-1.21 (10H, m, 7-, 8, 9-, 10 and 11-CH2);
13C 
NMR (101 MHz, CDCl3) δ 137.5 (2-C), 135.0 (5-C), 132.8, 130.2, 129.8, 129.3 (ArC), 128.9 (4-
C), 115.6 (ArC), 45.1 (6-C), 32.7 (7- and 11-C), 19.5 (8- and 10-C), 13.4 (9-C); HRMS (ESI-
TOF) m/z: [M+H]+ Calcd for C15H18N3O2 272.1394, found 272.1393. 
 
8.2.2.23. 1-Butyl-5-(4-nitrophenyl)-1H-imidazole 80i 
1
N
2
3
N4
5
6
O2N 7
8
9
10
11
 
1-Cyclohexyl-5-(4-nitrophenyl)-1H-imidazole 80h was successfully synthesized according to 
procedure C using N-(4-nitrobenzylidene)cyclohexanamine 76i (386 mg, 1.66 mmol), TosMIC 
(469 mg, 2.40 mmol) and K2CO3 (299 mg, 2.16 mmol); Physical characteristics: brown oil; 
Yield: 45 mg, 10%; 1H NMR (400 MHz, CDCl3) δ 8.30 (2H, d, J =8.4 Hz, ArH), 7.77 (1H, s, 2-
CH), 7.49 (2H, 8.8 Hz, ArH), 7.15 (1H, s, 4-CH), 3.92-3.98 (1H, m, 6-CH), 1.63-2.07 (4H, m, 7- 
and 11-CH2), 1.22-1.32 (6H, m, 8-, 9- and 10-CH2); 
13C NMR (101 MHz, CDCl3) δ 147.2 
(ArCNO2), 136.7 (2-C), 136.6 (5-C), 130.6 (ArC), 129.1 (4-C), 126.3, 115.7 (ArC), 55.5 (6-C), 34.8 
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(7- and 11-C), 25.6 (8-, and 10-C), 25.0 (9-C); HRMS (ESI-TOF) m/z: [M+H]+ Calcd for 
C15H18N3O2 272.1394, found 272.1382. 
 
8.2.2.24. 1-Cyclopropyl-5-(4-fluorophenyl)-1H-imidazole 81a 
1
N
2
3
N4
5
6
7
8F
 
1-Cyclopropyl-5-(4-fluorophenyl)-1H-imidazole 81a was successfully synthesized according to 
procedure D using N-(4-fluorobenzylidene)cyclopropanamine 77a (250 mg, 1.53 mmol), 
TosMIC (447 mg, 2.29 mmol) and K2CO3 (275 mg, 1.99 mmol); Physical characteristics: 
brown oil; Yield: 71 mg, 23 %; 1H NMR (400 MHz, CDCl3) δ 7.58 (1H, s, 2-CH), 7.46-7.50 
(2H, m, ArH), 7.09-7.13 (2H, m, ArH), 7.03 (1H, s, 4-CH), 3.28-3.34 (H, m, 6-CH), 0.83-0.97 
(4H, m, 7-and 8- CH2); 
13C NMR (101 MHz, CDCl3) δ 162.4 (
1JF,C = 245.9 Hz, para-CF), 138.6 
(2-C), 133.4 (5-C), 129.8 (d, 4JF,C = 3.0 Hz, 1‟-C), 127.6 (4-C), 126.2 (d, 
3JF,C = 8.1 Hz, ortho-C), 
115.6 (d, 2JF,C = 21.1 Hz, meta-C), 27.3 (6-C), 7.48 (7- and 8-C); HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd for C12H12FN2 203.0974, found 203.0979. 
 
8.2.2.25. 1-Cyclopropyl-5-(3-methoxyphenyl)-1H-imidazole 81c 
1
N
2
3
N4
5
6
7
8
O
 
1-Cyclopropyl-5-(3-methoxyphenyl)-1H-imidazole 81c was successfully synthesized according to 
the described general procedure D using N-(3-methoxybenzylidene)cyclopropanamine 77c (405 
mg, 2.31 mmol), TosMIC (678 mg, 3.47 mmol) and K2CO3 (415 mg, 3.00 mmol); Physical 
characteristics: pale yellow oil; Yield: 198 mg, 40%; 1H NMR (400 MHz, CDCl3) δ 7.58 (1H, s, 
2-CH), 7.31-7.35 (1H, m, ArH), 6.88-7.13 (5H, overlapping multiplets and singlet, ArH and 4-
CH), 3.84 (3H, s, ArOCH3), 3.33-3.39 (1H, m, 6-CH), 0.85-1.01 (4H, m, 7- and 8-CH2); 
13C 
NMR (101 MHz, CDCl3) δ 159.5 (ArCOCH3), 138.7 (2-C), 134.2 (5-C), 131.3, 129.5 (ArC), 
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127.9 (4-C), 120.5, 113.8, 112.9 (ArC), 55.1 (ArCOCH3), 27.5 (6-C), 7.56 (7-and 8-C); HRMS 
(ESI-TOF) m/z: [M+H]+ Calcd for C13H15N2O 215.1179, found 215.1188. 
 
8.2.2.26. 1-Cyclopropyl-5-(2,4-dimethoxyphenyl)-1H-imidazole 81d 
1
N
2
3
N4
5
6
7
8
O
O
 
1-Cyclopropyl-5-(2,4-dimethoxyphenyl)-1H-imidazole 81d was successfully synthesized 
according to procedure D using N-(2,4-dimethoxybenzylidene)cyclopropanamine 78d (302 mg, 
1.47 mmol), TosMIC (429 mg, 2.20 mmol) and K2CO3 (264 mg, 1.91 mmol); Physical 
characteristics: brown oil; Yield: 244 mg, 68%; 1H NMR (400 MHz, CDCl3) δ 7.49 (1H, s, 2-
CH), 7.10 (1H, d, J = 8.8 Hz, ArH), 6.87 (1H, s, 4-CH), 6.47 (2H, J = 6.8 Hz, ArH), 3.73 and 
3.80 (6H, 2 x s, 2 xArOCH3), 3.18-3.22 (1H, m, NCH), 0.66-0.70 (4H, m, 7- and 8- CH2); 
13C 
NMR (101 MHz, CDCl3) δ 161.2 and 158.3 (2 x ArCOCH3), 137.6 (2-C), 132.0 (5-C), 131.0 
(ArC), 127.9 (4-C), 111.9, 104.1, 98.4 (ArC), 55.2 and 55.1 (2 x ArCOCH3), 26.6 (6-C), 5.84 (7- 
and 8-C); HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C14H17N2O2 245.1285, found 245.1290. 
 
8.2.2.27. 1-Benzyl-5-(4-fluorophenyl)-1H-imidazole 82a 
1
N
2
3
N4
5
6
F
 
1-Benzyl-5-(4-fluorophenyl)-1H-imidazole 82a was successfully synthesized according to 
procedure D using N-(4-fluorobenzylidene)-1-phenylmethanamine 78a (226 mg, 1.06 mmol), 
TosMIC (308 mg, 1.58 mmol) and K2CO3 (189 mg, 1.37 mmol); Physical characteristics: 
brown oil; Yield: 70 mg, 26%; 1H NMR (400 MHz, CDCl3) δ 7.57 (1H, s, 2-CH), 7.20-7.32 (5H, 
m, ArH), 7.09 (1H, s, 4-CH), 6.97-7.05 (4H, m, ArH), 5.10 (2H, s, NCH2); 
13C NMR (101 MHz, 
CDCl3) δ 163.8 (d, 
1JC,F = 247Hz, para-CF), 138.6 (2-C), 136.5 (5-C), 132.4 130.8, 130.7 (ArC), 
128.8 (d, 4JF,C = 3.0 Hz, 1‟-C), 128.2 (4-C) 128.0 (ArC), 126.5 (d, 
3JF,C = 8.1 Hz, ortho-C), 115.6 (d, 
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2JF,C = 21.1 Hz, meta-C), 48.6 (NCH2); HRMS (ESI-TOF) m/z: [M+H]
+ Calcd for C16H14FN2 
253.1136, found 253.1138. 
 
8.2.2.28. 1-Benzyl-5-(3-methoxyphenyl)-1H-imidazole 82c 
1
N
2
3
N4
5
6
O
 
1-Benzyl-5-(3-methoxyphenyl)-1H-imidazole 82c was successfully synthesized according to 
procedure D using N-(3-methoxybenzylidene)-1-phenylmethanamine 78c (327  mg, 1.45 mmol), 
TosMIC (439 mg, 2.25 mmol) and K2CO3 (261 mg, 1.89 mmol); Physical characteristics: 
brown oil; Yield: 92 mg, 24 %; 1H NMR (400 MHz, CDCl3) δ 7.58 (1H, s, 2-CH), 7.27-7.35 
(4H, m, ArH), 6.87-7.15 (5H, m, ArH), 6.79 (1H, s, 4-CH), 5.17 (2H, s, NCH2) 3.69 (3H, s, 
ArOCH3); 
13C NMR (101 MHz, CDCl3) δ 159.6 (ArCOCH3), 138.7 (2-C), 136.8(5-C), 133.3, 
130.8 (ArC), 129.7 (4-C), 128.9, 128.1, 127.9, 126.6, 121.2, 114.1, 113.9 (ArC), 55.1 (ArCOCH3), 
48.7 (NCH2); HRMS (ESI-TOF) m/z: [M+H]
+ Calcd for C17H17N2O2  265.1335, Found 
265.1329. 
 
8.2.2.29. 1-Benzyl-5-(2,4-dimethoxyphenyl)-1H-imidazole 82d 
1
N
2
3
N4
5
6
O
O
 
1-Benzyl-5-(2,4-dimethoxyphenyl)-1H-imidazole 82d was successfully synthesized according to 
procedure D using N-(2,4-dimethoxybenzylidene)-1-phenylmethanamine 78d (391 mg, 1.53 
mmol), TosMIC (449 mg, 2.30 mmol) and K2CO3 (275 mg, 1.99 mmol); Physical 
characteristics: brown oil; Yield: 333 mg, 74%; 1H NMR (400 MHz, CDCl3) δ 7.55 (1H, s, 2-
CH), 7.28-7.31 (3H, m, ArH), 7.03-7.12 (4H, m, ArH and 4-CH), 6.50-6.53 (2H, m, ArH), 4.98 
(2H, s, NCH2), 3.86 and 3.71 (6H, 2 x s, 2 x ArOCH3);
 13C NMR (101 MHz, CDCl3) δ 161.5 and 
158.3 (2 x ArCOCH3), 137.6 (2-C), 136.7 (5-C), 133.0, 130.0 (ArC), 128.5 (4-C), 128.2, 127.6 
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,127.2, 111.1, 104.4, 98.6 (ArC), 55.3 and 55.2 (2 x ArCOCH3), 48.8 (NCH2); HRMS (ESI-TOF) 
m/z: [M+H]+ Calcd for C18H19N2O2 295.1441, found 295.1408. 
 
8.2.2.30. 5-(Benzo[d][1,3]dioxol-5-yl)-1-benzyl-1H-imidazole 82e 
1
N
2
3
N4
5
6
O
O
 
5-(Benzo[d][1,3]dioxol-5-yl)-1-benzyl-1H-imidazole 82e was successfully synthesized according 
to procedure D using N-(benzo[d][1,3]dioxol5-ylmethylene)-1-phenylmethanamine 78e (122 mg, 
0.51 mmol), TosMIC (149 mg, 0.77 mmol) and K2CO3 (91 mg, 0.66 mmol); Physical 
characteristics: pale yellow solid; Yields: 31 mg, 22%; Melting point: 84-87oC; 1H NMR (400 
MHz, CDCl3) δ 7.53 (1H, s, 2-CH), 7.29-7.33 (3H, m, ArH), 6.74-7.06 (5H, m, ArH), 6.72 (1H, s, 
4-CH), 5.97 (2H, s, ArOCH2O), 5.11 (2H, s, NCH2); 
13C NMR (101 MHz, CDCl3) δ 147.8 and 
147.6 (ArCOCH2O), 138.3 (2-C), 136.7 (5-C), 130.7, 133.1 (ArC), 127 (4-C) 123.2, 127.9, 126.6, 
122.9, 109.4, 108.5 (ArC), 101.2 (ArCOCH2O), 48.6 (NCH2); HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd for C17H15N2O2 279.1128, found 279.1143. 
 
8.2.2.31. 1-(4-Bromophenyl)-5-(4-fluorophenyl)-1H-imidazole 83a 
1
N
2
3
N4
5
F
Br  
1-(4-Bromophenyl)-5-(4-fluorophenyl)-1H-imidazole 83a was successfully synthesized according 
to procedure E using 4-fluorobenzaldehyde (99 mg, 0.80 mmol), 4-bromoaniline (151 mg, 0.88 
mmol), TosMIC (234 mg, 1.2 mmol)  and K2CO3 (144 mg, 1.04 mmol); Physical 
characteristics: pale yellow solid; Yield: 173 mg, 68%; Melting Point:130-133oC; 1H NMR 
(400 MHz, CDCl3) δ 7.70 (1H, s, 2-CH), 7.51 (2H, m, ArH), 7.23 (1H, s, 4-CH), 6.69-7.11 (6H, 
m, ArH); 13C NMR (101 MHz, CDCl3) δ 161.1 (d, JC,F = 247Hz, para-CF), 138.5 (2-C), 135.4 (5-
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C), 132.8 136.1, 130.0, 128.8, (ArC), 127.0 (4-C), 122.1 (ArC),125.0 (d, 3JC,F = 10 Hz, ortho-C) 
115.7 (d, 2JF,C = 21 Hz, meta-C); HRMS (ESI-TOF) m/z: [M+H]
+ Calcd for C15H11
79BrFN2 
317.0090, found 317.0115 
 
8.2.2.32. 1-(4-Bromophenyl)-5-(2,4-dimethoxyphenyl)-1H-imidazole 83d 
1
N
2
3
N4
5
O
Br
O
 
1-(4-Bromophenyl)-5-(2,4-dimethoxyphenyl)-1H-imidazole 83d was successfully synthesized 
according to procedure E using 2,4-dimethoxybenzaldehyde (143 mg, 0.86 mmol), 4-
bromoaniline (163 mg, 0.95 mmol), TosMIC (252 mg, 1.29 mmol) and K2CO3 (155 mg, 1.12 
mmol); Physical characteristics: pale yellow oil; Yield: 117 mg, 38%; 1H NMR (400 MHz, 
CDCl3) δ 7.62 (1H, s, 2-CH), 7.43-7.45 (2H, m, ArH), 7.13-7.18 (1H, d, J =12 Hz, ArH), 7.12 
(1H, s, 4-CH), 6.98-7.00 (2H, m, ArH), 6.31-6.50 (2H,m, ArH), 3.80 and 3.34 (3H, 2 x s, 2 x 
ArOCH3); 
13C NMR (101 MHz, CDCl3) δ 161.5 and 157.5 (2 x ArCOCH3), 137.2 (2-C), 136.8 
(5-C), 134.5, 132.1, 132.0 (ArC), 129.8 (4-C), 125.6, 120.9, 111.0, 104.6, 98.7 (ArC), 55.3 and 54.7 
(2 x ArCOCH3); HRMS (ESI-TOF) m/z: [M+H]
+ Calcd for C17H16
79BrN2O2 359.0395, found 
359.0394. 
 
8.2.2.33. 5-(Benzo[d][1,3]dioxol-5-yl)-1-(4-bromophenyl)-1H-imidazole 83e 
1
N
2
3
N4
5
Br
O
O
 
5-(Benzo[d][1,3]dioxol-5-yl)-1-(4-bromophenyl)-1H-imidazole 83e was successfully synthesized 
according to procedure E using piperonal (110 mg, 0.73 mmol), 4-bromoaniline (139 mg, 0.81 
mmol), TosMIC (215 mg, 1.10 mmol) and K2CO3 (130 mg, 0.94 mmol); Physical 
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characteristics: pale yellow solid; Yield: 155 mg, 62%; Melting point: 115-118oC; 1H NMR 
(400 MHz, CDCl3) δ 7.69 (1H, s, 2-CH), 7.2-7.54 (2H, m, ArH), 7.18 (4-CH), 7.051-7.07 (2H, m, 
ArH), 6.57-6.74 (3H, m, ArH), 5.92 (2H, s, ArOCH2O);
 13C NMR (101 MHz, CDCl3) δ 147.7 
and 147.5 (ArCOCH2O), 138.1 (2-C), 135.4 (5-C), 132.7 ArC), 128.3 (4-C), 127.0, 122.6, 122.4, 
122.1, 108.7, 108.5, (ArC), 101.3 (ArCOCH2O); HRMS (ESI-TOF) m/z: [M+H]
+ Calcd for 
C16H12
79BrN2O2 343.0082, found 343.0099. 
 
8.2.3. Synthesis of N-aryl benzamide derivatives 
8.2.3.1. General synthetic procedure 
To a stirred solution containing aniline (1.0 molar equivalent), triethylamine (1.05 molar 
equivalents) in EtOAc (30 ml) was added benzoyl chloride (1.05 molar equivalents) at 0°C. After 
addition, the resulting reaction mixture was stirred at room temperature for 16 hours (monitored 
by TLC).  Upon completion, EtOAc (20 ml) was then added, followed by washing with 1M HCl, 
saturated NaHCO3 and water. The organic layer was dried over MgSO4 and concentrated in vacuo 
to afford the pure N-aryl-benzamide derivatives.211 
 
8.2.3.2. N-(4-Bromophenyl)-4-fluorobenzamide 91a 
1'
2 N
H
1
O
F
Br
 
N-(4-Bromophenyl)-4-fluorobenzamide 91a was successfully synthesized according to general 
procedure using 4-fluorobenzoyl chloride (2.39 g, 15.1 mmol) and 4-bromoaniline (2.6 g, 14.4 
mmol); Physical characteristics: pale yellow solids; Yield: 3.85 g, 91%); Melting point: 167-
169 °C (lit349); 1H NMR (400 MHz, DMSO-d6) δ 10.4 (1H, s, NH), 8.01-8.06 (2H, m, ArH), 7.75 
(2H, m, ArH), 7.51 (2H, d, J = 8.0 Hz, ArH), 7.34 (2H, d, J = 8.0 Hz, ArH); 13C NMR (101 
MHz, DMSO-d6) δ 164.2 (d, 
1JC,F  = 248 Hz, para-CF), 164.5 (C=O), 138.5 (ArC), 131.2 (d, 
4JC,F  = 
3 Hz, 1‟-C), 130.5  (d, 3JC,F  = 9 Hz, ortho-C), 122.26 (ArC), 115.5 (d , 
4JC,F  = 21 Hz, meta-C), 115.4 
(ArCBr); FTIR νmax/cm
-1 (KBr): 3345, 3089, 3070, 1904, 1713, 1642, 1591, 1525, 1505, 1395, 
1316, 1299, 1236, 1106,1098, 1076, 1013, 901, 858, 821, 762, 659, 625, 516, 501. 
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8.2.3.3. N-(4-Bromophenyl)-3-fluorobenzamide 91b 
1'
2 N
H
1
O
Br
F
 
N-(4-Bromophenyl)-3-fluorobenzamide 91b was successfully synthesized according to general 
procedure using 3-fluorobenzoyl chloride (3.30 g, 20.8 mmol) and 4-bromoaniline (3.41 g, 19.8 
mmol); Physical characteristics: pale yellow solid; Yield: 5.30 g, 91%; Melting point: 169-
171°C; 1H NMR (400 MHz, DMSO-d6) δ 10.5 (1H, s, NH), 7.79-7.86 (4H, m, ArH), 7.56-7.65 
(3H, m, ArH) 7.46-7.51 (1H, m, ArH); 13C NMR (101 MHz, DMSO-d6) δ 164.3 (C=O), 162.0 
(d, 1J C,F = 247 Hz, 3‟-CF), 136.9 (d, 
4JC,F = 4 Hz, 6‟-C), 135.6, 131.5 (ArC), 130.6 (d, 
3JC,F  = 8 Hz, 
1‟-C), 123.9 (d, 3JC,F = 3 Hz, 5‟-C), 122.3 (ArC), 118.5 (d, 
2J C,F  = 24 Hz, 4‟-C), 115.7 (ArCBr); 
114.6 (d, 2J C,F  = 22.1 Hz, 2‟-C); FTIR νmax/cm
-1 (KBr): 3315, 3178, 3100, 3065, 1900, 1656, 1585, 
1517, 1491, 1435, 1397, 1313, 1267, 1198, 1083, 1007, 948, 885, 823, 802, 750, 678, 504. 
 
8.2.3.4. N-(4-Bromophenyl)-3-methoxybenzamide 91c 
1'
2 N
H
1
O
Br
O
 
N-(4-Bromophenyl)-3-methoxybenzamide 91c was successfully synthesized according to general 
procedure using 3-methoxybenzoyl chloride (2.08 g, 12.2 mmol) and 4-bromoaniline (2.00 g, 
11.6 mmol); Physical characteristics: pale yellow solid; Yield: 3.20 g, 90%; Melting point: 
161-163°C; 1H NMR (400 MHz, DMSO-d6) δ 10.6 (1H, s, NH), 7.41-7.52 (5H, m, ArH), 7.33 
(1H, d, J = 6.8 Hz, ArH), 7.03 (2H, d, J = 6.8 Hz, ArH), 3.88 (3H, s, ArOCH3); 
13C NMR (101 
MHz, DMSO-d6) δ 164.3 (C=O), 157.6 (ArCOCH3), 136.5, 133.5, 131.9, 129.4, 122.2, 122.1, 
118.7, 118.3 (ArCBr), 113.9 (ArC), 55.5 (ArCOCH3) ; FTIR νmax/cm
-1 (KBr): 3329, 3100, 3057, 
3028, 1896, 1658, 1591, 1513, 1491, 1393, 1312, 1235, 1078, 1007, 920, 909, 883, 745, 688, 661, 
509. 
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8.2.3.5. N-(4-Bromophenyl)-3-methylbenzamide 91d 
1'
2 N
H
1
O
Br
 
N-(4-Bromophenyl)-3-methylbenzamide 91d was successfully synthesized according to the 
general procedure using 3-methylbenzoyl chloride (1.78 g, 11.5 mmol) and 4-bromoaniline (1.88 
g, 10.9 mmol); Physical characteristics: pale yellow solid; Yield: 2.81 g, 89%; Melting point: 
161-163°C; 1H NMR(400 MHz, DMSO-d6) δ 10.5 (1H, s, NH), 7.53-7.76 (4H, m, ArH), 7.31-
7.45 (4H, m, ArH), 2.23 (3H, s, ArCH3); 
13C NMR (101 MHz, DMSO-d6) δ 164.4 (C=O), 134.6, 
134.2, 131.1, 129.9, 129.1, 128.4, 126.0, 124.8, 121.3 (ArC), 24.1 (ArCCH3); FTIR νmax/cm
-1 
(KBr): 3329, 3174, 3096, 3061, 1948, 1900, 1658, 1587, 1512, 1491, 1393, 1357, 1312, 1291, 
1244, 1183, 1074, 1012, 8200, 809, 744, 701, 688, 669, 502. 
 
8.2.3.6. N-(4-Bromophenyl)benzamide 91e 
1'
2 N
H
1
O
Br
 
N-(4-Bromophenyl)benzamide 91e was successfully synthesized according to general procedure 
using benzoyl chloride (2.09 mg, 14.9 mmol) and 4-bromoaniline (2.44 g, 14.2 mmol); Physical 
characteristics: pale yellow solid; Yield: 3.37 g, 86%; Melting point: 203-205°C (lit350); 1H 
NMR (400 MHz, DMSO-d6) δ 10.4 (1H, s, 1-NH), 7.94 (2H d, J= 6.8 Hz)ArH), 7.76 (2H, d, J = 
7.6 Hz, ArH), 7.48-7.64 (5H, m, ArH); 13C NMR (101 MHz, DMSO-d6) δ 172.7 (C=O), 138.4, 
137.1, 136.8, 134.7, 134.0, 133.8, 133.1, 127.6 (ArC); FTIR νmax/cm
-1 (KBr): 3332, 3174, 3096, 
3055, 1656, 1540, 1512, 1452, 1346, 1322, 1440, 1096, 989, 845, 760, 512. 
 
8.2.3.7. N-(2,4-Dimethoxyphenyl)-4-fluorobenzamide 91f 
1'
2 N
H
1
O
O
O
F  
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N-(2,4-Dimethoxyphenyl)-4-fluorobenzamide 91f was successfully synthesized according to the 
general procedure using 4-fluorobenzoyl chloride (1.68 g, 10.6 mmol) and 2,4-dimethoxyaniline 
(1.55 g, 10.1 mmol); Physical characteristics: grey solid; Yield: 2.31 g, 83%; Melting point: 
172-175 °C; 1H NMR (400 MHz, DMSO-d6) δ 9.57 (1H, s, NH), 7.63-7.82 (3H, m, ArH), 7.46-
7.62 (4H, m, ArH), 3.87 and 3.90 (6H, 2 x s, ArOCH3); 
13C NMR (101 MHz, DMSO-d6) δ 163.8 
(C=O), 162.1 (d, 1JC,F  = 245 Hz, para-FC), 158.2 and 153.8 (2 x ArCOCH3), 137.0 (d,
 4JC,F =3 Hz, 
1‟-C), 130.6 (d,  3JC,F = 8 Hz, ortho-C), 126.2, 123.7 (ArC), 118.3 (d, 
2JC,F = 23 Hz, meta-C), 114.2, 
99.0 (ArC), 55.7 and 55.4 (2 x ArCOCH3); FTIR νmax/cm
-1 (KBr): 3286, 2660, 2922, 2839, 1900, 
1650, 1602, 1497, 1394, 1313, 1224, 1158, 1025, 853, 822, 765, 679, 694, 606, 507.  
 
8.2.3.8. N-(2,4-Dimethylphenyl)-4-fluorobenzamide 91g 
1'
2 N
H
1
O
F  
N-(2,4-dimethylphenyl)-4-fluorobenzamide 91g was successfully synthesized according to the 
general procedure using 4-fluorobenzoyl chloride (2.25 g, 14.2 mmol) and 2.4 dimethylaniline 
(1.64 g, 13.5 mmol); Physical characteristics: light grey solid; Yield: 2.89 g, 88%; Melting 
point: 179-181 °C; 1H NMR (400 MHz, DMSO-d6) δ 9.93 (1H, s, NH), 8.09-8.13 (2H, dd, J = 
5.6 Hz, 3.2 Hz, ArH), 7.32 (2H, t, J = 8.8 Hz, ArH), 7.21 (1H, d, J = 7.6 Hz, ArH), 7.06 (1H, s, 
ArH), 7.00 ( 1H, d, J = 7.6 Hz, ArH), 2.22 and 2.28 (6H, 2 x s, 2 x ArCH3); 
13C NMR (101 MHz, 
DMSO-d6) δ 164.4 (C=O), 164.2 (d, 
1JC,F  = 249 Hz, para-CF), 135.2 and 133.0 (2 x ArCCH3), 
131.1 (d, 4JC,F  = 3.0 Hz, 1‟-C), 130.9 (d, 
3JC,F  = 9 Hz, ortho-C), 126.7, 115.4 (ArC), 115.2 (d, 
2JC,F  = 
21 Hz, meta-C), 20.6 and 17.9 (2 x ArCCH3); FTIR νmax/cm
-1 (KBr): 3286, 3078, 3017, 2922, 
1896, 1652, 1602, 1522, 1497, 1313, 1297, 1223, 1276, 1158, 1091, 1013, 855, 809, 765, 606, 539, 
506. 
 
8.2.3.9. N-(2,4-Dimethylphenyl)-3-methoxy-benzamide 91h 
1'
2 N
H
1
O
O
 
N-(2,4-Dimethylphenyl)-3-methoxybenzamide 91h was successfully synthesized according to the 
general procedure using 3-methoxybenzoyl chloride (1.98 g, 12.8 mmol) and 2.4 dimethylaniline 
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(1.48 g, 12.2 mmol); Physical characteristics: light grey solid; Yield: 2.80 g, 90%; Melting 
point: 156-159°C; 1H NMR (400 MHz, CDCl3) δ 7.80 (1H, s, NH), 7.62 (1H, d, J = 7.6 Hz, 
ArH), 7.39 (1H, s, ArH), 7.32-7.38 (2H, m, ArH), 7.01-7.08 (3H, m, ArH), 3.83 (3H, s, ArOCH3), 
2.31 and 2.25 (6H, 2 x s, 2 x ArCH3); 
13C NMR (101 MHz, CDCl3) δ 165.6 (C=O), 159.8 
(ArCOCH3), 153.8 and 136.3 (2 x ArCCH3), 135.2, 132.9, 131.1, 130.1, 129.6, 123.7, 118.7, 117.7, 
112.5 (ArC), 55.3 (ArCOCH3) 20.8 and 17.7 (2 x ArCCH3); FTIR νmax/cm
-1 (KBr): 3226, 3013, 
2965, 1934, 1752, 1648, 1586, 1512, 1311, 1253, 1239, 1219, 1188, 1129, 1033, 986, 878, 822, 
761, 688, 607, 506. 
 
8.2.3.10. N-(2,4-Dichlorophenyl)-4-fluorobenzamide 91i 
1'
2 N
H
1
O
Cl
Cl
F  
N-(2,4-Dichlorophenyl)-4-fluorobenzamide 91i was successfully synthesized according to the 
described general procedure using 4-fluorobenzoyl chloride (2.55 g, 16.1 mmol) and 2.4-
dichloroaniline (2.48 g, 15.3 mmol); Physical characteristics: white solid; Yield: 4.04 g, 93%; 
Melting point: 134-136°C (lit.351); 1H NMR (400 MHz, DMSO-d6) δ 10.2 (1H, s, NH), 8.07-
8.11 (2H, m, ArH), 7.68 (1H, s, ArH), 7.62 (1H, d, J = 8.8 Hz, ArH), 7.34 -7.47 (3H, m, ArH); 13 
CNMR (100 MHz, DMSO-d6) δ 164.4 (d, 
1J C,F  = 250 Hz, para-CF), 164.4 (C=O), 134.2, 133.2, 
130.9, 130.6 (d, 3J C,F  = 9 Hz, ortho-C), 130.5 (d, 
4JC,F  = 3 Hz, 1‟-C) 129.5, 129.1, 127.6 (ArC), 
115.5 (d, 2JC,F  = 22 Hz, meta-C); FTIR νmax/cm
-1 (KBr): 3369, 3282, 3060, 1909, 1783, 1696, 
1660, 1581, 1507, 1406, 1292, 1275, 1440, 1096, 989, 849, 807, 652, 626, 608, 556, 507. 
 
 
8.2.3.11. N-(2,4-Dichlorophenyl)-3-methoxybenzamide 91j 
1'
2 N
H
1
O
Cl
Cl
O
 
N-(2,4-Dichlorophenyl)-3-methoxybenzamide 91j was successfully synthesized according to the 
general procedure using 3-methoxybenzyl chloride (2.12 g, 12.4 mmol) and 2.4-dichloroaniline 
(1.91 g, 11.8 mmol); Physical characteristics: white solid; Yield: 3.15 g, 90%; Melting point: 
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177-180 °C; 1H NMR (400 MHz, DMSO-d6) δ 10.4 (1H, s, NH), 7.71 (2H, d, J = 7.6 Hz, ArH), 
7.49 (1H, s, ArH), 7.31-7.33 (3H, m, ArH), 7.23 (1H, d, J = 7.6 Hz, ArH), 387 (3H, s, ArOCH3); 
13C NMR (101 MHz, DMSO-d6) δ 164.3 (C=O), 157.8 (ArCOCH3), 145.2, 144.8, 132.0, 130.6, 
129.6, 128.2, 128.1, 126.0, 124.9, 122.6, 120.9, (ArC), 55.8 (ArCOCH3); FTIR νmax/cm
-1 (KBr): 
3369, 3438, 2154, 1660, 1601, 1539, 1499, 1438, 1328,1220, 1016, 691, 667.  
 
8.2.4. Synthesis of N-aryl benzimidoyl chloride intermediates  
8.2.4.1. General Procedure  
A mixture N-Aryl-benzamide (1.0 molar equivalent) and thionyl chloride (6.0 molar equivalents) 
was refluxed for 16 hours (monitored by TLC). Upon reaction completion, excess of thionyl 
chloride was removed by co-evaporation with toluene under rotavapour to afford (E)-N-aryl-
benzimidoyl chloride after drying under high vacuum.212  
 
8.2.4.2. (E)-N-(4-Bromophenyl)-4-fluorobenzimidoyl chloride 90a 
Cl
1
2 N
1'
Br
F
 
(E)-N-(4-Bromophenyl)-4-fluorobenzimidoyl chloride 90a was successfully synthesized 
according to the general procedure using N-(4-bromophenyl)-4-fluorobenzamide 90a (2.08 g, 
7.07 mmol) and SOCl2 (5.04 g, 42.4 mmol); Physical characteristics: pale yellow solid; Yield: 
2.01 g, 96%; 1H NMR (400 MHz, CDCl3) δ 8.15-8.19 (2H, m, ArH), 7.52 (2H, d, J = 7.6 Hz, 
ArH), 7.14 (2H, d, J = 7.6 Hz, ArH), 6.89 (2H, d, J = 5.6 Hz, ArH); 13C NMR (101 MHz, 
CDCl3) δ 164.8 (d, 
1JC,F  = 252 Hz, para-CF), 146.3 (ArCCCl), 142.7, 131.9 (ArC), 131.7 (d, 
3JC,F  = 
9 Hz, ortho-C), 130.2 (d, 4J C,F = 3 Hz, 1‟-C), 122.3 (ArC), 118.4 (ArCBr), 115.5 (d, 
2J C,F  = 22 Hz, 
meta-C). 
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8.2.4.3. (E)-N-(4-Bromophenyl)-4-fluorobenzimidoyl chloride 90b 
Cl
1
2 N
1'
Br
F
 
(E)-N-(4-Bromophenyl)-3-fluorobenzimidoyl chloride 90b was successfully synthesized 
according to the general procedure using N-(4-bromophenyl)-3-fluorobenzamide 90b (1.93g, 
6.55 mmol) and SOCl2 (4.68 g, 39.3 mmol); Physical characteristics: pale yellow solid; Yield: 
1.84 g, 95%; 1H NMR (400 MHz, CDCl3) δ 7.75-7.87 (2H, m, ArH), 7.42-7.45 (2H, m, ArH), 
7.32-7.39 (2H, m, ArH), 6.80-6.84 (2H, m, ArH); 13C NMR (101 MHz, CDCl3) δ 162.5 (d, 
1J C,F 
= 247.4 Hz, 3‟-CF), 146.1 (ArCCCl), 142.2 (d, 4JC,F = 4 Hz, 6‟-C), 137.2 (d, 
3JC,F  = 8 Hz, 1‟-C), 
132.0 (ArC), 130.5, 129.93 (ArC), 125.1 (d, 3JC,F = 3 Hz, 5‟-C), 122.3 (ArC), 119.2 (d, 
2J C,F = 22 
Hz, 2‟-C), 116.3 (d, 2J C,F  = 24 Hz, 4‟-C).  
 
8.2.4.4. (E)-N-(4-Bromophenyl)-3-methoxybenzimidoyl chloride 90c 
Cl
1
2 N
1'
Br
O
 
(E)-N-(4-Bromophenyl)-3-methoxybenzimidoyl chloride 90c was successfully synthesized 
according to the general procedure using N-(4-bromophenyl)-3-methoxybenzamide 90c (3.12 g, 
10.2 mmol) and SOCl2 (7.28 g, 61.2 mmol); Physical characteristics: pale yellow solid; Yield: 
3.24 g, 98%; 1H NMR (400 MHz, CDCl3) δ 7.74 (1H, d, J = 7.6 Hz, ArH), 7.68 (1H, s, ArH), 
7.52 (2H, d, J = 7.6 Hz, ArH), 6.80 (1H, t, J = 8.2 Hz, ArH), 7.11 (1H, d, J = 7.6 Hz , ArH), 6.89 
(2H, d, J = 7.6 Hz , ArH), 3.88 (3H, s, ArOCH3); 
13C NMR (101 MHz, CDCl3) δ 159.6 
(ArCOCH3), 146.5 (ArCCCl), 143.9, 136.5, 131.9, 129.4, 122.2, 122.1, 118.7, 118.3 (ArCBr), 
113.9 (ArC), 55.5 (ArCOCH3). 
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8.2.4.5. (E)-N-(4-Bromophenyl)-3-methylbenzimidoyl chloride 90d 
Cl
1
2 N
1'
Br  
(E)-N-(4-Bromophenyl)-3-methylbenzimidoyl chloride 90d was successfully synthesized 
according to the general procedure using N-(4-bromophenyl)-3-methxylbenzamide 91d (2.56 g, 
8.85 mmol) and  SOCl2 (6.32 g, 53.1 mmol);  Physical characteristics: pale yellow solid; Yield: 
2.68 g, 98%; 1H NMR (400 MHz, CDCl3) δ 7.74 (2H, d, J = 7.6 Hz, ArH), 7.01-7.56 (4H, m, 
ArH), 6.89 (2H, d, J = 7.6 Hz, ArH), 2.22 (3H, s, ArCH3); 
13C NMR (101 MHz, CDCl3) δ 154.3, 
146.5 (ArCCCl), 138.6, 133.2, 131.1, 129.9, 129.1, 128.4, 126.0, 124.8 (ArC), 121.3 (ArCBr), 24.1 
(ArCCH3). 
 
8.2.4.6. (E)-N-(4-Bromophenyl)benzimidoyl chloride 90e 
Cl
1
2 N
1'
Br  
(E)-N-(4-Bromophenyl)benzimidoyl chloride 90e was successfully synthesized according to the 
described general procedure using N-(4-bromophenyl)benzamide 91e (2.50 g, 9.05 mmol) and 
SOCl2 (6.46 g, 54.3 mmol); Physical characteristics: pale yellow solid; Yield: 2.56 g, 96%; 
1H 
NMR (400 MHz, CDCl3) δ 8.20 (2H, d, J = 7.6 Hz, ArH), 7.51-7.62 (5H, m, ArH), 6.95 (2H, d, J 
= 8.8 Hz , ArH); 13C NMR (101 MHz, CDCl3) δ 146.5 (ArCCCl), 144.0, 135.2, 132.0, 131.9, 
129.4, 128.5, 122.3, 118.3 (ArC). 
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8.2.4.7. (E)-N-(2.4-Dimethoxyphenyl)-4-fluorobenzimidoyl chloride 90f 
Cl
1
2 N
1'
O
O
F
 
(E)-N-(2.4-Dimethoxyphenyl)-4-fluorobenzimidoyl chloride 90f was successfully synthesized 
according to the general procedure using 4-fluoro-N-(2,4-dimethoxyphenyl)benzamide 91f (2.14 
g, 7.66 mmol) with SOCl2 (5.47 g, 46.0 mmol); Physical characteristics: grey solid; Yield: 2.14 
g, 95%; 1H NMR (400 MHz, CDCl3) δ 7.74-7.76 (2H, m, ArH), 7.51 (2H, t, J = 7.6 Hz, ArH), 
6.90-7.42 (3H, m, ArH), 3.88 and 3.92 (6H, 2 x s, ArOCH3); 
13C NMR (101 MHz, CDCl3) δ 
162.1 (d, 1JC,F = 245 Hz, para-CF), 158.2 and 153.8 ( 2 x ArCOCH3), 143.5 (ArCCl), 137.0 (d,
 4JC,F 
=6 Hz, 1‟-C), 130.6 (d,  3JC,F = 8 Hz, meta-C), 126.2, 123.7, 119.4 (ArC), 118.3 (d, 
2J C,F = 23 Hz, 
meta-C), 114.2 and 99.0 (ArC), 55.7 and 55.4 ( 2 x ArCOCH3).  
 
8.2.4.8. (E)-N-(2.4-Dimethylphenyl)-4-fluorobenzimidoyl chloride 90g 
Cl
1
2 N
1'
F
 
(E)-N-(2.4-Dimethylphenyl)-4-fluorobenzimidoyl chloride 90g was successfully synthesized 
according to the general procedure using 4-fluoro-N-(2,4-dimethylphenyl)benzamide 91g (1.77 g, 
7.26 mmol) and SOCl2 (5.19 g, 43.6 mmol); Physical characteristics: pale grey solid; Yield: 
1.86 g, 98%; 1H NMR (400 MHz, CDCl3) δ 8.21-8.24 (2H, m, ArH), 7.10-7.20 (4H, m, ArH), 
6.8 (1H, d, J = 8.2 Hz, ArH), 2.37 and 2.20 (2 x ArCCH3); 
13C NMR (101 MHz, CDCl3) δ 164.2 
(d, 1JC,F  = 253 Hz, para-CF), 143.9 (ArCCCl), 141.6, 134.7, 131.7 (d, 
3JC,F  = 9 Hz, ortho-C), 131.1, 
128.4, 126.8, 119.2 9 (ArC), 115.9 (d, 2JC,F  = 22 Hz, meta-C), 20.9 and 17.8 (2 x ArCCH3). 
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8.2.4.9. (E)-N-(2.4-Dimethylphenyl)-3-methoxybenzimidoyl chloride 90h  
Cl
1
2 N
1'
O
 
(E)-N-(2.4-Dimethylphenyl)-3-methoxybenzimidoyl chloride  90h was successfully synthesized 
according to the described general procedure using N-(2,4-dimethylphenyl)-3-
methoxybenzamide 91h (2.18 g, 8.53 mmol) with SOCl2 (6.09 g, 51.2 mmol); Physical 
characteristics: white solid; Yield: 2.24 g, 96%; 1H NMR (400 MHz, CDCl3) δ 7.80 (1H, d, J = 
8.2 Hz, ArH), 7.76 (1H, t, J = 5.6 Hz, ArH), 7.39 (1H, t, J = 5.6 Hz, ArH), 7.07-7.14 (3H, m, 
ArH), 6.82 (1H, d, J = 7.6 Hz, ArH), 3.91 (3H, s, ArOCH3), 2.37 and 2.20 (6H, 2 x s, 2 x 
ArCH3); 
13C NMR (101 MHz,): δ 159.6 (ArCOCH3), 143.9 ( ArCCCl), 143.0 and 136.6, 
(ArCCH3), 134.6, 131.0, 129.3, 128.3, 126.8, 122.0, 119.2, 118.3, 114.0, 55.4 (ArCOCH3), 20.9 
and 17.7 (2 x ArCCH3).  
 
8.2.5. Synthesis of ethyl 1,5-diaryl-1H-imidazoyl carboxylates 
8.2.5.1. General synthetic procedure A 
A mixture of ethyl isocyanoacetate (1 molar equivalent) and DBU (1.0 molar equivalent) in 
anhydrous THF was cooled to -78oC under a continuous flow of argon. N-aryl benzimidoyl 
chloride (1.0 molar equivalent) was then added. The resulting reaction mixture was allowed to 
warm to room temperature and was stirred for 48 hours (monitored by TLC) under inert 
atmosphere. Upon completion, the solvent was concentrated in vacuo to give a brown oily residue 
which was then purified by column chromatography on silica gel [eluting first with EtOAc/ 
Hexane (1:4), followed by 100% EtOAc] to afford the desired ethyl 1,5-diaryl-1H-imidazole 
carboxylate. 
 
8.2.5.2. General synthetic procedure B 
Potassium t-butoxide (1.1 molar equivalent) was added to a solution of the N-aryl-benzamide 
(1.0 molar equivalent) in anhydrous THF (20 ml) at 0 °C under argon. After stirring the mixture 
at 0 °C for 20 min, the reaction mixture was again cooled to -35°C and diethylchlorophosphate 
(1.3 molar equivalents) was added slowly. After stirring this mixture at 0 °C for 30 min, the 
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reaction flask was cooled to -35 °C and ethyl isocyanoacetate (1.1 molar equivalent) was added, 
followed by potassium t butoxide (1.1 molar equivalent). The mixture was stirred at room 
temperature for 8-16 hours with TLC monitoring. Unfortunately no formation of products was 
observed.  
 
8.2.5.3. Ethyl 1-(4-bromophenyl)-5-(4-fluorophenyl)-1H-imidazole-4-carboxylate 88a 
1 2
N
34 N
5
1'
Br
O
O
7
8
F
 
Ethyl 1-(4-bromophenyl)-5-(4-fluorophenyl)-1H-imidazole-4-carboxylate 88a was successfully 
synthesized according to procedure A using N-(4-bromophenyl)-4-fluorobenzimidoyl chloride 
90a (592 mg, 2.00 mmol), ethyl isocyanoacetate (226 mg, 2.00 mmol) and DBU (305 mg, 2.00 
mmol) in anhydrous THF (20 ml); Physical characteristics: pale yellow solid; Yield: 497 mg, 
64%; Melting point: 145-147oC;  1H NMR (400 MHz, CDCl3) δ 7.70 (1H, s, 2-CH), 7.46 (2H, 
d, J = 8.4 Hz, ArH), 7.19 (2H, m, ArH), 6.93-7.02 (4H, m, ArH), 4.26 (2H, q,  J = 7.2 Hz, 
OCH2CH3), 1.26 (3H, t, J = 7.2 Hz, OCH2CH3); 
13C NMR (101 MHz, CDCl3) δ 162.9 (d, 
1J C,F  = 
251 Hz, para-CF), 162.6 (C=O), 137.3 (2-C), 136.9, 134.4, 132.7 (d, 4JC,F  = 3 Hz, 1‟-C), 132.6, 
127.2, 125.3, 123.8 (d, 3J C,F  = 8 Hz, ortho-C), 122.8 (ArCBr), 115.2 (d, 
2JC,F = 22.1 Hz, meta-C ), 
60.5 (7-C), 14.2 (8-C); FTIR νmax/cm
-1 (KBr): 3104, 3096, 2987, 1904, 1716, 1609, 1591, 1560, 
1497, 1375, 1348, 1279, 1256, 1185, 1090, 1070, 1028, 963, 845, 830, 665, 617, 515; HRMS 
(ESI-TOF) m/z: [M+H]+ Calcd for C18H15
79BrFN2O2 389.0295, found 389.0301. 
 
8.2.5.4. Ethyl 1-(4-bromophenyl)-5-(3-fluorophenyl)-1H-imidazole-4-carboxylate 88b 
1 2
N
34 N
5
1'
Br
O
O
7
8
F
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Ethyl 1-(4-bromophenyl)-5-(3-fluorophenyl)-1H-imidazole-4-carboxylate 88b was successfully 
synthesized according to general procedure A using N-(4-bromophenyl)-3-fluorobenzimidoyl 
chloride 90b (625 mg, 2.11 mmol), ethyl isocyanoacetate (239 mg, 2.11 mmol) and DBU (321 
mg, 2.11 mmol) in anhydrous THF (20 ml); Physical characteristics: yellow solid; Yield: 475 
mg, 58%; Melting point: 129-131oC;  1H NMR (400 MHz, CDCl3) δ 7.74 (1H, s, 2-CH), 7.48 
(2H, d,  J = 8.2 Hz, ArH), 7.27-7.32 (1H, m, ArH), 6.96-7.08 (5H, m, ArH), 4.28 (2H, q,  J = 7.2 
Hz, OCH2CH3), 1.28 (3H, t, J = 7.2 Hz, OCH2CH3); 
 13C NMR (101 MHz, CDCl3) δ 162.1 (d, 
1J 
C,F  = 247 Hz, meta-CF),  162.4 (C=O), 137.6 (C-2), 136.4, 132.8, 131.0 (ArC), 129.9 (d, 
3JC,F  = 8 
Hz, 1‟-C), 127.1 (ArC), 126.5 (d, 4JC,F  = 3 Hz, 6‟-C), 122.8 (ArCBr), 117.8 (d, 
2JC,F  = 22 Hz, 2‟-C), 
116.1 (d, 2J C,F  = 21 Hz, 4‟-C), 60.7 (7-C), 14.1 (8-C); FTIR νmax/cm
-1 (KBr): 3093, 2991, 2978, 
1900,  1708, 1617, 1582, 1561, 1498, 1372, 1343, 1297, 1259, 1236, 1192, 1178, 1092, 1073, 1032, 
964, 830, 799, 601, 517; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C18H15
79BrFN2O2 389.0295, 
found 389.0301. 
 
8.2.5.5. Ethyl 1-(4-bromophenyl)-5-(3-methoxyphenyl)-1H-imidazole-4-carboxylate 88c 
1 2
N
34 N
5
1'
Br
O
O
7
8
O
 
Ethyl 1-(4-bromophenyl)-5-(3-methoxyphenyl)-1H-imidazole-4-carboxylate 88c was successfully 
synthesized according to procedure A using N-(4-bromophenyl)-3-methoxybenzimidoyl chloride 
90c (1.88 g, 5.79 mmol), ethyl isocyanoacetate (655 mg, 5.79 mmol) and DBU (882 mg, 5.79 
mmol) in anhydrous THF (20 ml); Physical characteristics: yellow solid; Yield: 418 mg, 18%; 
1H NMR (400 MHz, CDCl3) δ 7.61 (1H, s, 2-CH), 7.37 (2H, d, 
 J = 8.4 Hz, ArH), 7.10 (1H, t, J 
= 8.0 Hz, ArH), 6.88 (2H, d, J = 8.4 Hz, ArH), 6.70-6.80 (3H, m, ArH), 4.19 (2H, q,  J = 7.2 Hz, 
OCH2CH3), 3.63 (3H, s, ArOCH3), 1.18 (3H, t, J = 7.0 Hz, OCH2CH3); 
 13C NMR (101 MHz, 
CDCl3) δ 162.6 (C=O), 159.0 (ArCOCH3), 137.6 (2-C), 137.2, 134.7, 132.6, 130.9, 129.1, 127.1, 
123.1, 122.5, 119.3, 116.5, 114.5 (ArC), 60.4 (7-C), 55.1 (ArCOCH3), 14.1 (8-C); FTIR νmax/cm
-1 
(KBr): 3097, 3000, 2978, 2930, 1891, 1715, 1587, 1552, 1496, 1449, 1374, 1344, 1321, 1261, 
1207, 1187, 1097, 1070, 1042, 1029, 961, 829, 661, 569, 517; HRMS (ESI-TOF) m/z: [M+H]+ 
Calcd. for C19H18
79BrN2O3 401.0495, found 401.0487. 
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8.2.5.6. Ethyl 1-(4-bromophenyl)-5-(3-methylphenyl)-1H-imidazole-4-carboxylate 88d 
1 2
N
34 N
5
1'
Br
O
O
7
8
 
Ethyl 1-(4-bromophenyl)-5-(3-methylphenyl)-1H-imidazole-4-carboxylate 88d was successfully 
synthesized according to general procedure A using N-(4-bromophenyl)-3-methylbenzimidoyl 
chloride 90d (1.93 g, 6.25 mmol), ethyl isocyanoacetate (707 mg, 6.25 mmol) and DBU (952 mg, 
6.25 mmol) in anhydrous THF (20 ml); Physical characteristics: white solid; Yield: 722 mg 
30%; Melting point: 185-187oC; 1H NMR (400 MHz, CDCl3) δ 7.69 (1H, s, 2-CH), 7.43 (2H, d, 
 
J = 8.4 Hz, ArH), 7.13-7.19 (2H, m, ArH), 7.05 (1H, s, ArH), 6.93-6.98 (3H, m, ArH), 4.25 (2H, 
q,  J = 7.2 Hz, OCH2CH3), 2.27 (3H, s, ArCH3), 1.24 (3H, t, J = 7 Hz, OCH2CH3); 
 13C NMR 
(101 MHz, CDCl3) δ 162.6 (C=O), 138.0, 137.6 (2-C), 137.2, 134.6, 132.5, 131.3, 130.7, 129.7, 
127.8, 127.1, 122.4 (ArC), 60.4 (7-C), 21.3 (ArCCH3), 14.1 (8-C); FTIR νmax/cm
-1 (KBr): 3100, 
2987, 1896, 1713, 1591, 1552, 1497, 1372, 1279, 1258, 1194, 1177, 1101, 1070, 1039, 962, 830, 
819, 652, 621, 522; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C19H18
79BrN2O2 385.0546, found 
385.0557. 
 
8.2.5.7. Ethyl 1-(4-bromophenyl)-5-phenyl-1H-imidazole-4-carboxylate 88e 
1 2
N
34 N
5
1'
Br
O
O
7
8
 
Ethyl 1-(4-bromophenyl)-5-phenyl-1H-imidazole-4-carboxylate 88e was successfully synthesized 
according to procedure A using N-(4-bromophenyl)-benzimidoyl chloride 90e (1.48 g, 5.03 
mmol ), ethyl isocyanoacetate (569 mg, 5.03 mmol) and DBU (766 mg, 5.03 mmol) in anhydrous 
THF (20 ml); Physical characteristics: white solid; Yield: 411 mg, 22%; Melting point: 138-
140oC;  1H NMR (400 MHz, CDCl3) δ 7.70 (1H, s, 2-CH), 7.44 (2H, d, 
 J = 8.4 Hz, ArH), 7.28-
7.33 (3H, m, ArH), 7.21-7.22 (2H, m, ArH), 6.93 (2H, d, J = 8.4 Hz, ArH), 4.26 (2H, q,  J = 7.2 
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Hz, OCH2CH3), 1.25 (3H, t, J = 7.2 Hz, OCH2CH3); 
 13C NMR (101 MHz, CDCl3) δ 162.7 
(C=O), 137.9 (2-C), 137.3, 134.6, 132.6, 130.8, 129.0, 128.0, 127.8, 127.2, 125.3, 122.5 (ArC), 
60.5 (7-C), 14.2 (8-C); FTIR νmax/cm
-1 (KBr): 3096, 2974, 1900, 1709, 1604, 1586, 1556, 1498, 
1373, 1295, 1280, 1181, 1091, 1073, 993, 828, 765, 661, 517; HRMS (ESI-TOF) m/z: [M+H]+ 
Calcd for C16H16
79BrN2O2 371.0390, found 371.0398. 
 
8.2.6. Hydrolysis of ethyl 1,5-diaryl-1H-imidazole-4-carboxylates 
8.2.6.1. General synthetic procedure  
NaOH (2 molar equivalent) was added to a solution of ethyl 1,5-diaryl-1H-imidazoyl 
carboxylate (1 molar equivalent) in MeOH (5 ml) and H2O (5 ml). The resulting reaction 
mixture was refluxed until disappearance of the starting material (monitored by TLC).  MeOH 
solvent was then removed in vacuo and the remaining aqueous crude material was slowly 
neutralized with 1M HCl, followed by extraction with EtOAc (2 x 20 ml). The organic layer was 
then washed with brine, dried over MgSO4, and the solvent was removed in vacuo to produce the 
desired novel 1,5-diaryl-1H-imidazole-4-carboxylic acids. 
 
8.2.6.2. 1-(4-Bromophenyl)-5-(4-fluorophenyl)-1H-imidazole-4-carboxylic acid 87a 
1 2
N
34 N
51'
F
Br
O
HO
 
1-(4-Bromophenyl)-5-(4-fluorophenyl)-1H-imidazole-4-carboxylic acid 87a was successfully 
synthesized according to the general procedure using ethyl 1-(4-bromophenyl)-5-(4-
fluorophenyl)-1H-imidazole-4-carboxylate 88a (404 mg, 1.04 mmol) and NaOH (83 mg, 2.08 
mmol) in MeOH (5 ml) and water (5 ml); Physical characteristics: pale yellow solid; Yield: 255 
mg, 68%; Melting point: 189-192oC; 1H NMR (400 MHz, DMSO-d6) δ 12.4 (1H, br, COOH), 
8.06 (1H, s, 2-CH), 7.59 (2H, d, J = 8.4 Hz, ArH), 7.13-7.32 (6H, m, ArH); 13C NMR (100 MHz, 
DMSO-d6) δ 163.7 (C=O), 161.3 (d, 
1JC,F = 246.1 Hz, para-CF), 138.2 (2-C), 136.2, 134.5 (ArC), 
133.1 (d, 3JC,F = 8.0 Hz, ortho-C),132.3 128.4 (ArC), 125.0 (d, 
4JC,F = 3.1 Hz, 1‟-C); 121.7 (ArCBr), 
114.8 (d, 2JC,F = 22.1 Hz, meta-C); FTIR νmax/cm
-1 (KBr): 3124, 2831, 2511 (OH), 1697, 1603, 
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1594, 1503, 1351, 1292, 1258, 1227, 1195, 1186, 1160, 1070, 1001, 974, 840, 817, 769, 730, 577, 
501; HRMS (ESI-TOF) m/z: [M+H]+ Calcd, for C16H11
79BrFN2O2 360.9982, found 360.9991. 
 
8.2.6.3. 1-(4-Bromophenyl)-5-(3-fluorophenyl)-1H-imidazole-4-carboxylic acid 87b 
1 2
N
34 N
5
1'
Br
O
HO
F
 
1-(4-Bromophenyl)-5-(3-fluorophenyl)-1H-imidazole-4-carboxylic acid 87b was successfully 
synthesized according to the general procedure using ethyl 1-(4-bromophenyl)-5-(3-
fluorophenyl)-1H-imidazole-4-carboxylate 88b (342 mg, 0.88 mmol) and NaOH (70 mg, 1.76 
mmol) in MeOH (5 ml) and water (5 ml); Physical characteristics: pale yellow solid; Yield: 229 
mg, 72%; 1H NMR (400 MHz, DMSO-d6): δ 12.3 (1H, br, COOH), 8.08 (1H, s, 2-CH), 7.60 
(2H, d, J = 8.8 Hz, ArH), 7.31 (1H, d, J = 6.8 Hz, , ArH), 7.15-7.22 (4H, t, J = 10.4 ArH), 7.01 
(1H, d, J = 7.6 Hz, ArH); 13C NMR (101 MHz, DMSO-d6) δ 163.7 (C=O), 161.2 (d, 
1J C,F  = 244 
Hz, meta-FC), 138.4 (2-C), 135.7, 134.6, 131.6 (d, 3JC,F = 3 Hz, 1‟-C), 130.8 (d, 
3JC,F = 9 Hz, 6‟-C), 
129.7 (d, 4JC,F = 8 Hz, 5‟-C), 129.6, 128.7, 127.0 (ArC), 121.7 (ArCBr), 118.0 (d, 
2JC,F = 23 Hz, 2‟-
C), 115.5 (d, 2JC,F = 21.1 Hz, 4‟-C); FTIR νmax/cm
-1 (KBr): 3117, 3065, 2917, 2855, 2487(OH), 
1895, 1687, 1613, 1583, 1566, 1496, 1479, 1442, 1378, 1338, 1285, 1250, 1204, 1183, 1070, 972, 
866, 819, 807, 764, 573, 501; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C16H11
79BrFN2O2 
360.9982, found 360.9987. 
 
8.2.6.4. 1-(4-Bromophenyl)-5-(3-methoxyphenyl)-1H-imidazole-4-carboxylic acid 87c 
1 2
N
34 N
5
1'
Br
O
HO
O
 
1-(4-Bromophenyl)-5-(3-methoxyphenyl)-1H-imidazole-4-carboxylic acid 87c was successfully 
synthesized according to the general procedure using ethyl 1-(4-bromophenyl)-5-(3-
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methoxyphenyl)-1H-imidazole-4-carboxylate 88c (385 mg, 0.96 mmol) and NaOH (77 mg, 1.92 
mmol) in MeOH (5 ml) and water (5 ml); Physical characteristics: pale yellow solid; Yield: 280 
mg, 78%; 1H NMR (400 MHz, DMSO-d6) δ 12.3 (1H, br, COOH), 8.05 (1H, s, 2-CH), 7.59 
(2H, d, J = 8.0 Hz, ArH), 7.18 (2H, t, J = 6.6 Hz, ArH), 6.87 (2H, d, J = 10.0 Hz, ArH), 6.75 
(2H, d, J = 7.6 Hz, ArH) 3.65 (3H, s, ArOCH3); 
13C NMR (101 MHz, DMSO-d6) δ 163.7 
(C=O), 158.4 (ArCOCH3), 138.1 (2-C), 136.9, 134.9, 132.2, 130.5, 129.8, 128.9, 128.3, 123.1, 
121.6, 116.8, 144.0, (ArC), 55.0 (ArCOCH3); FTIR νmax/cm
-1 (KBr): 3117, 3061, 3004, 2969, 
2830, 2565 (OH), 1909, 1704, 1674, 1909, 1704, 1674, 1601, 1548, 1496, 1465, 1421, 1355, 1343, 
1254, 1217, 1172, 1040, 977, 852, 726, 539, 504; H.RMS (ESI-TOF) m/z: [M+H]+ Calcd for 
C17H14
79BrN2O3 373.0182,
 Found 373.0201 
 
8.2.6.5. 1-(4-Bromophenyl)-5-(3-methylphenyl)-1H-imidazole-4-carboxylic acid 87d 
1 2
N
34 N
5
1'
Br
O
HO
 
1-(4-Bromophenyl)-5-(3-methylphenyl)-1H-imidazole-4-carboxylic acid 87d was successfully 
synthesized according to the general procedure using ethyl 1-(4-bromophenyl)-5-(3-
methylphenyl)-1H-imidazole-4-carboxylate 88d (420 mg, 1.09 mmol) and NaOH (87 mg, 2.18 
mmol) in MeOH (5 ml) and water (5 ml); Physical characteristics: white solid; Yield: 292 mg, 
75%; 1H NMR (400 MHz, DMSO-d6) δ 12.2 (1H, br, COOH), 8.04 (1H, s, 2-CH), 7.58 (2H, d, J 
= 8.4 Hz, ArH), 7.10-7.19 (5H, m, ArH), 6.97 (1H, d, J = 7.2 Hz, ArH), 2.22 (3H, s, ArCH3); 
13C 
NMR (101 MHz, DMSO-d6) δ 163.7 (C=O), 138.1 (2-C), 137.2, 136.8, 134.8, 132.2, 131.4, 
130.5, 129.2, 128.5, 128.3, 127.8, 127.6, (ArC), 121.5 (ArCBr), 20.9 (ArCCH3); FTIR νmax/cm
-1 
(KBr): 3134, 2923, 2848, 2498 (OH), 1895, 1705, 1613, 1591, 1547, 1495, 1351, 1261, 1218, 
1184, 1066, 1026, 974, 852, 727, 539, 501; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for 
C17H14
79BrN2O2
 357.0233, found 357.0244.  
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8.6.5.6.1-(4-Bromophenyl)-5-phenyl-1H-imidazole-4-carboxylic acid 87e 
1 2
N
34 N
5
1'
Br
O
HO
 
1-(4-Bromophenyl)-5-phenyl-1H-imidazole-4-carboxylic acid 87e was successfully synthesized 
according to the general procedure using ethyl 1-(4-bromophenyl)-5-phenyl-1H-imidazole-4-
carboxylate 88e (427 mg, 1.15 mmol) and NaOH (92 mg, 2.30 mmol) in MeOH (5 ml) and water 
(5 ml); Physical characteristics: white solid; Yield: 249 mg, 63%; 1H NMR (400 MHz, 
DMSO-d6): δ 12.2 (1H, br, COOH), 8.06 (1H, s, 2-CH), 7.57 (2H, d, J = 8.0 Hz, ArH), 7.15-7.31 
(7H, m, ArH); 13C NMR (101 MHz, DMSO-d6) δ 163.7 (C=O), 138.2 (2-C), 137.1, 134.8, 132.2, 
130.8, 130.5, 125.9, 128.5, 128.3, 127.8 (ArC), 121.5 (ArCBr); FTIR νmax/cm
-1 (KBr): 3117, 3096, 
2969, 2848, 2470 (OH), 1930, 1721, 1683, 1609, 1558, 1494, 1388, 1356, 1257, 1169, 1070, 1012, 
975, 846, 780, 696, 521; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C16H12
79BrN2O2 343.0077, 
found 343.0089. 
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8.3. Chapter 3 experimental procedures 
8.3.1. . Synthesis of 5-aryl-1,3-oxazole 
8.3.1.1. Microwave assisted van Leusen general synthetic procedure A 
To a 10 ml microwave reaction vessel equipped with a magnetic stirrer bar was introduced aryl 
aldehyde (1 molar equivalent), TosMIC (1.1 molar equivalents) and K2CO3 (2 molar equivalents). 
An inert atmosphere was then created by degassing through evacuating and refilling with argon 
three times, followed by addition of anhydrous MeOH (10 ml). The resulting capped reaction 
mixture was then microwave irradiated at a set temperature of 90oC and a power of 120 Watts 
for 7 min (monitored by TLC and conditions maintained until consumption of the TosMIC 
reagent). Upon completion of the reaction, the solvent was evaporated in vacuo. The crude 
material was purified by flash column chromatography [elution with ethyl acetate and hexane 
ratio (1:4)] to afford 5-aryl-1,3-oxazole derivatives with Rf values of between 0.51-0.65.  
 
8.3.1.2. Microwave assisted van Leusen general synthetic procedure B 
To a 10 ml microwave reaction vessel equipped with a magnetic stirrer bar was introduced aryl 
aldehyde (1 molar equivalent), TosMIC (1.1 molar equivalents) K2CO3 (2 molar equivalents). An 
inert atmosphere was then created by degassing through evacuating and refilling with argon three 
times, followed by introduction of anhydrous MeCN (5 ml). The resulting reaction mixture was 
capped and microwave irradiated at a set temperature of 90oC and a power of 120 Watts for 12 
min. Upon completion of the reaction (monitored by TLC and conditions maintained until 
consumption of the TosMIC reagent), the solvent was then evaporated in vacuo. The crude 
material was then stirred at 0oC in a mixture containing MeOH (4 ml) and water (0.5 ml) until a 
precipitate formed. The precipitate was collected, washed with water and dried under high 
vacuum to give 5-aryl-4-tosyl-4,5-dihydro-1,3-oxazoles with Rf values between 0.64-0.72. 
 
8.3.1.3. Aromatization general synthetic procedure C 
A mixture of 5-aryl-4-tosyl-4,5-dihydro-1,3-oxazole (1 molar equivalent) in toluene (5 ml) was 
refluxed for 1 hour. After completion of the reaction, toluene was concentrated in vacuo and the 
crude material was purified by column chromatography [eluting with hexane and ethyl acetate 
(4:1)] to furnish 5-aryl-1,3-oxazoles after drying under high vacuum (with Rf values of between 
0.51-0.65). 
 
 
 
 
257 
 
8.3.1.4. 5-(4-Fluorophenyl)-1,3-oxazole 96a 
1
2
O
34 N
51'
F  
5-(4-Fluorophenyl)-1,3-oxazole 96a was successfully synthesized from reaction of 4-
fluorobenzaldehyde (166 mg, 1.34 mmol), TosMIC (287 mg, 1.47 mmol) and K2CO3 (370 mg, 
2.68 mmol) in dry MeOH as described in synthetic procedure A; Physical characteristics: 
brown oil; Yield: 184 mg, 84%; 1H NMR (400 MHz,CDCl3) δ 7.89 (1H, s, 2-CH), 7.61-7.64 
(2H, m, ArH), 7.29 (1H, s, 4-CH), 7.10 (2H, t, J = 7.6 Hz, ArH); 13C NMR (101 MHz, CDCl3)
 δ 
162.7 (d, 1JC,F= 249.9 Hz, para-CF), 150.72 (5-C), 150.4 (2-C), 126.2 (d, 
3JC,F= 8.1 Hz, ortho-C), 
124.0 (d, 4JC,F= 4.0 Hz, 1-C), 121.1 (4-C), 116.1 (22.1 Hz, meta-C); HRMS (ESI-TOF) m/z: 
[M+H]+ Calcd for C9H7FNO 164.0506, found 164.0508. 
 
8.3. 1.5. 5-(2-Chlorophenyl)-1,3-oxazole 96b 
1
2
O
34 N
51'
Cl
 
5-(2-Chlorophenyl)-1,3-oxazole 96b was successfully synthesized from reaction of 2-
chlorobenzaldehyde (170 mg, 1.21 mmol), TosMIC (260 mg, 1.33 mmol) and K2CO3 (333 mg. 
2.41 mmol) in dry MeOH as described in synthetic procedure A; Physical characteristics: pale 
yellow solid; Yield: 161 mg, 74%; Melting point: 44-46oC (lit.233); 1H NMR (400 MHz,CDCl3) δ 
7.87 (1H, s, 2-CH), 7.72 (1H, s, ArH), 7.71 (1H, s, 4-CH) 7.28-7.39 (1H, m, ArH), 7.24-7.25 (1H, 
m, ArH), 7.16-7.20 (1H, m, ArH); 13C NMR (101 MHz, CDCl3)
 δ 150.3 (2-C), 148.0 (5-C), 130.7, 
130.6, 129.1, 127.8, 127.0, 126.5 (ArC), 126.3 (4-C); HRMS (ESI-TOF) m/z: [M+H]+ Calcd for 
C9H7ClNO 180.0211, found 180.0245. 
 
8.3.1.6. 5-(3-Methoxyphenyl)-1,3-oxazole 96c 
1
2
O
34 N
51'
O
 
5-(2-Methoxyphenyl)-1,3-oxazole 96c was successfully synthesized from reaction of 3-
methoxybenzaldehyde (163 mg, 1.20 mmol), TosMIC (258 mg, 1.32 mmol) and K2CO3 (330 mg, 
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2.39 mmol) in dry MeOH as described in synthetic procedure A; Physical characteristics: pale 
yellow oil; Yield: 126 mg, 60%; 1H NMR (400 MHz,CDCl3) δ 7.84 (1H, s, 2-CH), 7.55 (1H, dd, 
J = 4.8 Hz, 2 Hz, ArH), 7.21 (1H, s, 4-CH and 6.92 (2H, d, J = 8.8 Hz, ArH), 3.81 (3H, s, 
ArOCH3); 
13C NMR (101 MHz, CDCl3)
 δ 159.8 (ArCOCH3), 151.5 (5-C), 149.8 (2-C), 125.8, 
120.5, 119.8, 114.3 (ArC), 55.2 (ArCOCH3); HRMS (ESI-TOF) m/z: [M+H]
+ Calcd for 
C10H10NO2 176.0706, found 176.0736. 
 
8.3.1.7. 5-(2,4-Dimethoxyphenyl)-1,3-oxazole 96d 
1
2
O
34 N
51'
O
O  
5-(2,4-Dimethoxyphenyl)-1,3-oxazole 96d was successfully synthesized from reaction of 2,4-
dimethoxybenzaldehyde (160 mg, 0.96 mmol), TosMIC (207 mg, 1.06 mmol) and K2CO3 (267 
mg, 1.93 mmol) in dry MeOH as described in general synthetic procedure A; Physical 
characteristics: pale yellow solid; Yield: 87 mg, 44%; Melting point: 104-106oC; 1H NMR 
(400 MHz,CDCl3) δ 7.85 (1H, s, 2-CH), 7.66 (1H, J = 8.8 Hz, ArH), 7.42 (1H, s, 4-CH), 6.53-
6.59 (2H, m, ArH), 3.83 and 3.92 (6H, 2 x s, 2 x ArOCH3); 
13C NMR (101 MHz, CDCl3)
 δ 160.9 
and 156.9 (2 x ArCOCH3), 148.9 (2-C), 148.0 (5-C), 126.9 (ArC), 123.5 (4-C), 110.3, 104.9, 98.5 
(ArC), 55.4 and 55.8 (2 x ArCOCH3); HRMS (ESI-TOF) m/z: [M+H]
+ Calcd for C11H12NO3 
206.0812, found 206.0839. 
 
8.3.1.8. 5-(Benzo[d][1,3]dioxol-5-yl)-1,3-oxazole 96e 
1
2
O
34 N
51'
O
O  
5-(Benzo[d][1,3]dioxol-5-yl)-1,3-oxazole 96e was successfully synthesized from reaction of 
piperonal (140 mg, 0.93 mmol), TosMIC (199 mg, 1.02 mmol) and K2CO3 (257 mg, 1.86 mmol) 
in dry MeOH as described in a synthetic procedure A and from refluxing of (4R,5R)/(4S,5S)-5-
(benzo[d][1,3]dioxol-5-yl)-4-tosyl-4,5-dihydrooxazole 97e (200 mg, 0.60 mmol) in toluene as 
describe in a general synthetic procedure C; Physical characteristics: yellow solid; Yield: 470 
mg, 76 mg, 43% for synthetic procedure A and 78 mg, 69% for synthetic procedure C; Melting 
Point: 44-46oC (lit352); 1H NMR (400 MHz,CDCl3) δ 7.86 (1H, s, 2-CH), 7.21 (1H, s, 4-CH), 
7.10-7.18 (2H, m, ArH), 6.85 (1H, d, J = 7.6 Hz, ArH), 6.00 (ArOCH2O); 
13C NMR (101 MHz, 
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CDCl3)
 δ 148.9 (2-C), 148.0 (5-C), 148.2 and 148.0 (2 x ArCOCH2O), 132.5 (ArC), 121.9 (4-C), 
118.6, 108.8, 105.0 (ArC), 101.4 (ArCOCH2O); HRMS (ESI-TOF) m/z: [M+H]
+ Calcd for 
C10H8NO3 190.0499, found 190.0528. 
 
8.3.1.9. 5-(4-tert-Butylphenyl)-1,3-oxazole 96f 
1
2
O
34 N
51'
 
5-(4-tert-Butylphenyl)-1,3-oxazole 96f was successfully synthesized from reaction of 4-tert-
butylbenzaldehyde (149 mg, 0.92 mmol), TosMIC (197 mg, 1.01 mmol) and K2CO3 (254 mg, 
1.84 mmol) in dry MeOH as described in synthetic procedure A; Physical characteristics: 
sticky brown material; Yield: 109 mg, 59%; 1H NMR (400 MHz,CDCl3) δ 7.55 (1H, s, 2-CH), 
7.58-7.60 (2H, d, J = 8.4 Hz, ArH), 7.44-7.47 (2H, d, J= 8.4 Hz, ArH), 7.31(1H, s, 4-CH) 1.34 
[9H, s, ArC(CH3)3]; 
13C NMR (101 MHz, CDCl3)
 δ 151.9 (2-C), 150.2 (5-C),134.6, 125.9, 125.0, 
124.2 (ArC), 120.9 (4-C), 34.7 [ArCC(CH3)3], 31.2, {ArC(CH3)3}; HRMS (ESI-TOF) m/z: 
[M+H]+ Calcd for C13H16NO 202.1242, found 202.1234. 
 
8.3.1.10. 5-(4-Nitrophenyl)-1,-3-oxazole 96g 
1
2
O
34 N
51'
O2N  
5-(4-Nitrophenyl)-1,3-oxazole 96g was successfully synthesized from reaction of 4-
nitrobenzaldehyde (165 mg, 1.09 mmol), TosMIC (234 mg, 1.2 mmol) and K2CO3 (301 mg, 2.18 
mmol) in dry MeOH as described in synthetic procedure A; Physical characteristics: yellow 
solid; Yield:207 mg, 73%; Melting point: 137-139 °C (lit.353), 1H NMR (400 MHz,CDCl3) δ 
8.28-8.31 (2H, m, ArH), 8.02 (1H, s, 2-CH), 7.80-7.83 (2H, m, ArH), 7.56 (1H, s, 4-CH); 13C 
NMR (101 MHz, CDCl3)
 δ 151.8 (2-C), 149.5 (5-C), 147.4 (ArCNO2), 133.4, 124.8, 124.7 (ArC), 
124.5 (4-C); HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C9H7N2O3 191.0451, found 191.0458. 
 
 
 
 
 
260 
 
8.3.1. 11. 5-(2-Nitrophenyl)-1,3-oxazole 96h 
1
2
O
34 N
51'
NO2
 
5-(2-Nitrophenyl)-1,3-oxazole 96h was successfully synthesized from reaction of 2-
nitrobenzaldehyde (177 mg, 1.17 mmol), TosMIC (252 mg, 1.29 mmol) and K2CO3 (254 mg, 
1.84 mmol) in dry MeOH as described in general synthetic procedure A and from refluxing of 5-
(2-nitrophenyl)-4-tosyl-4,5-dihydrooxazole 97h (339 mg, 0.98 mmol) in toluene as described in 
general synthetic procedure C; Physical characteristics: pale yellow solid; Yield: 151 mg, 68% 
for synthetic procedure A and 117 mg, 63% for general synthetic procedure C; Melting point: 
70-72oC (lit.354); 1H NMR (400 MHz,CDCl3) δ 7.97 (1H, s, 2-CH), 7.84-7.85 (1H, m, ArH), 7.64-
7.72 (2H, m, ArH), 7.51-7.55 (1H, m, ArH), 7.39 (1H, s, 4-CH); 13C NMR (101 MHz, CDCl3)
 δ 
151.6 (2-C), 147.5 (5-C), 146.5 (ArCNO2), 132.5, 129.8, 129.6, 125.8, 124.4 (ArC), 121.6 (4-C); 
HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C9H7N2O3 191.0451, found 191.0475. 
 
8.3.1.12. 5-Phenyl-1,3-oxazole 96i 
1
2
O
3
4 N
51'
 
5-Phenyl-1,3-oxazole 96i was successfully synthesized from refluxing of (4R,5R)/(4S,5S)-5-
phenyl-4-tosyl-4,5-dihydrooxazole 97i (319 mg, 1.06 mmol) in toluene as described in general 
synthetic procedure C; Physical characteristics: pale yellow solid; Yield: 105 mg, 68%; 
Melting point: 38-41oC (lit.231); 1H NMR (400 MHz,CDCl3) δ 7.96 (1H, s, 2-CH), 7.66-7.70 
(2H, m, ArH), 7.43-7.49 (2H, m, ArH), 7.38-7.40 (2H, m, 4-CH and ArH); 13C NMR (101 MHz, 
CDCl3)
 δ 151.5 (2-C), 150.4 (5-C), 128.9, 128.6, 127.7, 124.3 (ArC), 121.3 (4-C); HRMS (ESI-
TOF) m/z: [M+H]+ Calcd for C9H7NO 145.0528, found 145.0521. 
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8.3.1.13. (4R,5R)/(4S,5S)-5-(Benzo[d][1,3]dioxol-5-yl))-4-tosyl-4,5-dihydrooxazole 97e 
1
2
O
34 N
51'
(rac)
S
O
O
O
O
 
(4R,5R)/(4S,5S)-5-(Benzo[d][1,3]dioxol-5-yl))-4-tosyl-4,5-dihydrooxazole 97e was successfully 
synthesized from reaction of piperonal (162 mg, 1.08 mmol), TosMIC (232 mg, 1.19 mmol) and 
K2CO3 (299 mg, 2.16 mmol) in MeCN as described in synthetic procedure B; Physical 
characteristics: white solid; Yield: 298 mg, 80%; 1H NMR (400 MHz,CDCl3) δ 7.83(2H, d, J = 
8.8 Hz, ArH), 7.37(2H, d, J = 8.8 Hz, ArH), 7.18 (1H, d, J = 1.2 Hz, 2-CH), 6.74-6.81 (3H, m, 
ArH), 597 (2H, s, ArOCH2O), 5.94 (1H, d, J = 6.0 Hz, 5-CH), 4.99 (1H, dd, J =4.4 Hz, 1.6 Hz, 
4-CH), 2.45 (3H, s, ArCH3); 
13C NMR (101 MHz, CDCl3)
 δ 159.3 (2-C), 148.4 and 148.3 (2 x 
ArCOCH2O), 145.7, 133.1, 131.4, 129.9, 129.5, 119.5, 108.6, 105.6 (ArC), 101.4 (ArCOCH2O), 
92.4 (4-C), 79.4 (5-C), 21.7 (ArCCH3); FTIR νmax/cm
-1 (KBr): 3314, 1675, 1596, 1503, 1447, 
1303, 1257, 1141, 1062, 1039, 938, 816. 
 
8.3.1.14. (4R,5R)/(4S,5S)-5-(2-Nitrophenyl)-4-tosyl-4,5-dihydrooxazole 97h 
1
2
O
34 N
51'
(rac)
S
O
O
NO2
 
(4R,5R)/(4S,5S)-5-(2-Nitrophenyl)-4-tosyl-4,5-dihydrooxazole 97h was successfully synthesized 
from reaction of 2-nitrobenzaldehyde (281 mg, 1.86 mmol), TosMIC (400 mg, 2.05 mmol) and 
K2CO3 (514 mg, 3.72 mmol) in dry MeCN as described in synthetic procedure B; Physical 
characteristics: orange solid; Yield: 419 mg, 65%; 1H NMR (400 MHz,CDCl3) δ 7.90-7.93 (1H, 
m, ArH), 7.85 (2H, d, J = 8.8 Hz, ArH), 7.52-7.69 (3H, m, ArH and 2-CH), 7.38 (2H, d, J = 8.8 
Hz, ArH), 6.39 (1H, d, J = 7.2 Hz, ArH), 5.32 (1H, J = 6 Hz, 5-CH), 5.30 (1H, J = 2\6.0 Hz, 4-
CH), 2.46 (3H, s, ArCH3); 
13C NMR (101 MHz, CDCl3)
 δ 159.0 (2-C), 148.2, 145.9, 133.4, 132.9, 
130.8, 130.4, 129.9, 129.7, 129.6, 125.2 (ArC), 91.8 (4-C), 77.03 (5-C), 21.8 (ArCCH3); FTIR 
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νmax/cm
-1 (KBr): 2922, 2868, 1702, 1672, 1599, 1524, 1347, 1317, 1224, 1133, 1036, 1011, 855, 
815, 687, 569. 
 
8.3.1.15. (4R,5R)/(4S,5S)-5-Phenyl-4-tosyl-4,5-dihydrooxazole 97i 
1
2
O
34 N
51'
(rac)
S
O
O
 
(4R,5R)/(4S,5S)-5-Phenyl-4-tosyl-4,5-dihydrooxazole 97i was successfully synthesized from 
reaction of benzaldehyde (152 mg, 1.43 mmol), TosMIC (307 mg, 1.57 mmol) and K2CO3 (395 
mg, 2.86 mmol) in MeCN as described in synthetic procedure B; Physical characteristics: 
white solid; Yield: 327 mg 76%; 1H NMR (400 MHz,CDCl3) δ 7.84 (2H, d, J = 8.8 Hz, ArH), 
7.32-7.43 (7H, m, ArH), 7.21 (1H, d, J = 1.6 Hz, , 2-CH), 6.05 (1H, d, J = 6.0 Hz, 5-CH), 5.03 
(1H, dd, J = 2.6 Hz, 4-CH), 2.46 (3H, s, ArCH3); 
13C NMR (101 MHz, CDCl3)
 δ 159.4 (2-C), 
145.7, 137.7, 133.2, 129.9, 129.5, 129.1, 129.0, 125.2 (ArC), 92.6 (4-CH), 76.4 (5-CH), 21.7 
(ArCCH3); FTIR νmax/cm
-1 (KBr): 2894, 2875, 1622, 1316, 1304, 1148, 1102, 968, 814. 
 
8.3.2. Synthesis of ethyl 2-formamidoacetate 104 
O
1
2
O
3
4
H
N
6
O
5
 
A mixture of ethyl glycine ester hydrochloride (10.00 g, 71.6 mmol), ethyl formate (31.0g, 418.4 
mmol) and triethylamine (14.60 g, 144.3 mmol) was stirred at room temperature for 3 days. 
Upon completion, the precipitate was filtered off and the filtered solution was cooled with ice, 
The resulting precipitate was filtered off and the filtrate was concentrated in vacuo to give ethyl 2-
formamidoacetate 104; Physical characteristics: colourless oil; Yield: 7.61 g; 81%; 1H NMR 
(400 MHz, CDCl3) δ 8.17 (1H, s, 2-CH), 7.38 (1H, s, NH), 4.14 (2H, q, J= 7.6 Hz, 5-CH2), 3.98 
(2H, d, J= 5.6 Hz, 3-CH2), 1.20-1.24 (3H, t, J= 7.6 Hz, 6-CH3); 
13C NMR (101 MHz, CDCl3)
 δ 
169.4 (4-C), 161.4 (2-C), 61.5 (5-C), 39.8 (3-C), 13.9 (6-C). 
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8.3.3. Synthesis of N-(2-hydrazinyl-2-oxoethyl)formamide 103 
N
H
1
2
O
3
H
N
4
O
H2N
 
Hydrazine monohydrate (9.54 g, 190.5 mol) was added to a solution of ethyl 2-formamidoacetate 
(5.00 g, 38.1 mol) in MeOH (100 ml). The resulting reaction mixture was stirred at room 
temperature for 3 hours. The precipitate was filtered off and dried under high vacuum to afford 
N-(2-hydrazinyl-2-oxoethyl)formamide 103; Physical characteristics: White solid; Yield: 3.17 
g, 71%; Melting Point: 130-133°C (lit355,356); 1H NMR (400 MHz, DMSO-d6) δ 9.12 (1H, s, 1-
NH), 8.25 (1H, s, NH2NH), 8.08 (1H, s, 2-CH), 4.26 (2H, s, NH2NH), 3.72 (2H, d, J = 5.6 Hz, 
3-CH2); 
13C NMR (101 MHz, DMSO-d6) δ 167.9 (4-C), 161.6 (2-C), 40.2 (3-C). 
 
8.3.4. Synthesis of N-aryl-2-formamidoacetamide  
8.3.4.1. General synthetic procedure  
To a solution of the N-(2-hydrazinyl-2-oxoethyl)formamide (1 molar equivalent) in 1M HC1 (40 
ml) was added dropwise a solution of NaNO2 (1 molar equivalent) in H2O (20 ml) at 0°C over a 
period of 15 minutes. After stirring for 20 minutes at the same temperature, the mixture was 
neutralized with saturated aqueous NaHCO3 and then a solution of aniline (3 molar equivalents) 
in THF (40 ml) was added to the mixture at 0°C over a period of 20 minutes. After stirring for 5 
hours at the same temperature, THF was evaporated in vacuo. The crude was separated by 
column chromatography [elution with ethyl acetate: hexane (1:7)], followed by ethyl acetate: 
hexane (1:1) afford pure N-aryl-2-formamidoacetamide derivatives. The Rf value = 0.5-1.0 in 
ethyl acetate: hexane (1:1).  
 
8.3.4.2. N-(4-Bromophenyl)-2-formamidoacetamide 102a 
1
2
O
3
N
H
4
O
H
N
Br
  
N-(4-Bromophenyl)-2-formamidoacetamide 102a was successfully synthesized according to the 
general procedure using N-(2-hydrazinyl-2-oxoethyl)formamide 103 (228 mg, 1.95 mmol), 4-
bromoaniline (1.01 g, 5.86 mmol); Physical characteristics: white solid; Yield: 678 mg, 45%; 
Melting point: 189-192oC; 1H NMR (400 MHz, DMSO-d6) δ 10.2 (1H, s, ArNH), 8.39 (1H, s, 
NHCHO), 8.16 (1H, s, 2-CHO), 7.59-7.61 (2H, dd, J = 5.2 Hz, 2.0 Hz, ArH), 7.52-7.54 (2H, m, 
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ArH), 3.97 (2H, d, J = 6.0 Hz, 3-CH2); 
13C NMR (101 MHz, DMSO-d6) δ 168.4 (4-C), 162.5 (2-
C), 139.1, 132.5,  123.6, 115.8 (ArC), 42.2 (3-C). 
 
8.3.4.2. N-(2,4-Dimethoxyphenyl)-2-formamidoacetamides 102b 
1
2
O
3
N
H
4
O
H
N
O
O
 
N-(2,4-Dimethoxyphenyl)-2-formamidoacetamide 102b was successfully synthesized according 
to the general procedure using N-(2-hydrazinyl-2-oxoethyl)formamide (325 mg, 2.78 mmol), 2,4-
dimethoxyaniline (1.26 mg, 8.34 mmol); Physical characteristics: light brown solid; Yield: 1.35 
g, 68%; Melting point: 141-144oC; 1H NMR (400 MHz, DMSO-d6) δ 9.09 (1H, s, ArNH), 8.36 
(1H, s, NHCHO), 8.16 (1H, s, 2-CHO), 7.75 (1H, d, J = 8.4 Hz, ArH), 6.65 (1H, s, ArH), 6.52 
(1H, d, J = 7.6 Hz, ArH), 3.98 (2H, d, J = 5.6 Hz, NCH2), 3.78 and 3.89 (6H, 2 x s, 2 xArOCH3); 
13C NMR (101 MHz, DMSO-d6) δ 167.9 (4-C), 162.5 (2-C), 157.7 and 152.0 (2 x ArCOCH3), 
124.0, 120.8, 105.0, 99.8 (ArC), 56.7 and 56.2 (2 x ArCOCH3), 42.2 (3-C). 
 
8.3.5. Synthesis of 2-isocyano-N-arylacetamide 101 
8.3.5.1. General procedure 
To a suspension of N-aryl-2-formamidoacetamide (1 molar equivalent) and triethylamine (4 
molar equivalents) in DCM (10 ml) was added dropwise phosphoryl chloride (2 molar 
equivalents) at 10-15°C over a period of 20 min. After stirring for 30 min at room temperature, 
25 % aqueous Na2CO3 (15 ml) was added to the reaction mixture under ice cooling and the 
DCM layer was separated. The aqueous layer was extracted with DCM (3 x 15 ml). The 
combined organic layer was washed with H2O, dried over MgSO4, and then evaporated in vacuo 
to give crude product, which was then subjected to chromatography on silica gel eluting with 
ethyl acetate to give N-aryl-2-isocyanoacetamide 
  
8.3.5.2. Synthesis of 2-isocyano-N-(4-bromophenyl)acetamide 101a 
O
3
N
H
N
1
Br
C
2
 
2-Isocyano-N-(4-bromophenyl)acetamide 101a was successfully synthesized from reaction of N-
(4-bromophenyl)-2-formamidoacetamide 102a (1.10 g, 4.28 mmol) Et3N (1.73 g, 17.12 mmol) 
and POCl3 (1.12 g, 9.64 mmol) in DCM as described in the general procedure;  Physical 
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characteristics: white solid; Yield: 348 mg, 34%; Melting point: 204-207oC; 1H NMR (400 
MHz, CDCl3) δ 10.3 (1H, s, ArNH), 7.96 (2H, dd, J = 2.9 Hz, ArH), 7.68-7.57(1H, m, ArH), 
4.32 (2H, s, 3-CH2); 
13C NMR (101 MHz, CDCl3) δ 162.1 (C=O), 159.3 (2-C), 137.8, 132.4, 
131.5, 114.3 (ArC), 42.6 (4-C); FTIR νmax/cm
-1 (KBr): 3340, 3250 (NH), 2883, 2736, 2675, 2160 
(NC), 1702, 1652, 1592, 1536, 1412, 1378, 1275, 1223, 989, 829. 
 
8.3.5.4. Synthesis of 2-isocyano-N-(2,4-dimethoxyphenyl)acetamide 101b 
O
3
N
H
N
1
O
O
C
2
 
2-Isocyano-N-(2,4-dimethoxyphenyl)acetamide 101b was successfully synthesized from reaction 
of N-(2,4-dimethoxyphenyl)-2-formamidoacetamide 102b (774 mg, 3.25 mmol), Et3N (1.32 g, 
13.00 mmol) and POCl3 (757 mg, 6.50 mmol) in DCM as described in the general procedure; 
Physical characteristics: white solid; Yield: 659 mg, 92%; Melting point: 144-147oC; 1H 
NMR (400 MHz, CDCl3) δ 8.50 (1H, s, ArNH), 8.12 (1H, d, J = 8.8 Hz, ArH), 6.45-6.50 (2H, m, 
ArH), 4.30 (2H, s, 3-CH2), 3.83 (6H, 2 x s, 2 x ArOCH3); 
13C NMR (101 MHz, CDCl3) δ 162.8 
(C=O), 159.4 (2-C), 157.3 and 149.7 (2 x ArCOCH3), 120.7, 119.5, 103.7, 98.6 (ArC), 55.9 & 55.5 
(2 x ArCOCH3), 45.8 (3-C) ; FTIR νmax/cm
-1 (KBr): 3291 (NH), 2959, 2929, 2880, 2157 (NC), 
1728, 1549, 1464, 1282, 1209, 1126, 1072. 
 
8.3.6. Attempted reaction of N-aryl-2-isocyanoacetamide with benzoyl chloride and 
benzaldehydes 
8.3.6.1. General procedure A 
N-(2,4-dimethoxyphenyl)-2-isocyanoacetamide (0.91 mmol) and triethylamine (1.18 mmol) in dry 
DCM (3 ml) were cooled to 0oC in an ice bath, followed by slow addition of a solution of 
benzoyl chloride (0.91 mmol) in dry DCM (2 ml). The resulting reaction mixture was stirred for 
1 hour at 0oC and then allowed to warm to room temperature and further stirred for 24-48 
hours. TLC analysis showed no product formation. 
 
8.3.6.2. General procedure B 
N-(2,4-dimethoxyphenyl)-2-isocyanoacetamide (1.23 mmol) and DBU (1.23 mmol) in dry DCM 
(3ml) were cooled to 0oC in an ice bath, followed by slow addition of a solution of benzoyl 
chloride (1.23 mmol) in dry DCM (2 ml). The reaction was stirred for 1 hour at 0oC and then 
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allowed to warm to room temperature and stirred for 48 hours. Once the reaction appeared 
complete by TLC analysis, the reaction mixture was poured into 10% aqueous NaHCO3 solution 
and extracted with DCM (3 x 2 ml). The combined organic layers were washed again with the 
NaHCO3 solution and brine then dried over MgSO4, filtered and concentrated in vacuo. Crude 
material obtained was purified by silica gel column chromatography with a 1:10 to 1:1 ethyl 
acetate: hexane gradient solvent system to afforded the starting material N-(2,4-
dimethoxyphenyl)-2-isocyanoacetamide 249 mg, 85% recovered yield. 
 
8.3.7. Reaction of N-aryl-2-isocyanoacetamide with benzaldehydes 
8.3.7.1. General procedure 
N-(2,4-dimethoxyphenyl)-2-isocyanoacetamide (1 molar equivalent)) was added in one portion to 
a solution of benzaldehydes (1 molar equivalent), DBU (1 molar equivalent) in CH2Cl2 (5.0 ml) at 
0°C. The mixture was allowed to warm to room temperature and stirred for 48 hours (monitored 
by TLC). The solvent was removed and then a saturated aqueous solution of NaHCO3 (10 ml) 
was added and the resulting mixture was extracted with ethyl acetate (3 x 10 ml). The combined 
organic layers were dried (MgSO4) and concentrated under reduced pressure. Products were 
purified by silica gel chromatography, elution with EtOAc/hexane (1:4) followed by 1. 
8.3.7.2. (4R,5R/4S,5S)-N-(2,4-Dimethoxyphenyl)-5-(4-fluorophenyl)-4,5-dihydrooxazole-
4-carboxamide 107a 
1
2
O
34 N
51'
O
NH
O
O
(rac)
F
 
(4R,5R/4S,5S)-N-(2,4-Dimethoxyphenyl)-5-(4-fluorophenyl)-4,5-dihydrooxazole-4-carboxamide 
107a was successfully synthesized according to the general procedure using N-(2,4-
dimethoxyphenyl)-2-isocyanoacetamide 101b (145 mg, 0.66 mmol), 4-fluorobenzaldehyde (82 
mg, 0.66 mmol) and DBU (100 mg, 0.66 mmol) in DCM; Physical characteristics: light yellow 
solid; Yield: 159 mg, 70%; Melting point: 187-189oC; 1H NMR (400 MHz, CDCl3) δ 8.72 (1H, 
s, NH), 8.27 (1H, d, J = 8.8 Hz, ArH), 7.42-7.46 (2H, m, ArH), 7.07-7.10 (2H, m, ArH), 7.18 
(1H, s, 2-CH) 6.46-6.49 (2H, m, ArH), 5.72 (1H, d, J = 7.6 Hz, 5-CH), 4.62 (1H, d, J = 7.6 Hz, 4-
CH), 3.80 and 3.87 (6H, 2 x s, ArOCH3); 
13C NMR  (101 MHz, CDCl3) δ 167.9 (C=O), 162.6 
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(d,1JC,F= 247 Hz, para-CF), 156.8 and 149.7 ( 2x ArCOCH3), 135.6 (ArC), 127.3 (d, 
4JC,F= 3 Hz, 
1‟-C), 121.1 (ArC), 120.3 (d, 3JC,F= 8.1 Hz, ortho-C), 115.8 (d, 
4JC,F= 22.1 Hz, meta-C), 114.3, 103.7, 
98.7 (ArC), 82.1 (4-C), 71.3 (5-C), 55.7 and 55.5 (2 x ArCOCH3);  
 
8.3.7.3. (4R,5R/4S,5S)-N-(2,4-Dimethoxyphenyl)-5-(2-chlorophenyl)-4,5-dihydrooxazole-
4-carboxamide 107b 
1
2
O
34 N
51'
O
NH
O
O
(rac)
Cl
 
((4R,5R/4S,5S)-N-(2,4-Dimethoxyphenyl)-5-(2-chlorophenyl)-4,5-dihydrooxazole-4-
carboxamide 107b was successfully synthesized according to the general procedure using N-(2,4-
dimethoxyphenyl)-2-isocyanoacetamide 101b (308 mg, 1.40 mmol), 2-chlorobenzaldehyde (197 
mg, 1.40 mmol) and DBU (213 mg, 1.40 mmol) in DCM; Physical characteristics: light yellow 
solid; Yield: 303 mg, 60%; Melting point: 189-191oC; 1H NMR (400 MHz, CDCl3) δ 8.62 (1H, 
s, NH), 8.25 (1H, d, J = 8.8 Hz, ArH), 7.42-7.44 (4H, m, ArH), 7.16 (1H, s, 2-CH), 6.44-6.49 
(2H, m, ArH), 6.07 (1H, d, J = 8.4 Hz, 5-CH), 4.80-4.82 (1H, d, J = 8.4 Hz, 4-CH), 3.87 and 3.79 
(6H, 2 x s, 2 x ArOCH3); 
13C NMR (101 MHz, CDCl3) δ 168.2 (C=O), 161.6 (2-C), 157.0 and 
149.8 (ArCOCH3), 136.1, 131.5, 130.1, 129.5, 128.7, 126.9, 120.6, 115.4, 103.7, 98.6 (ArC), 80.7 
(4-C), 75.2 (5-C), 55.8 and 55.5 (2 x ArCOCH3). 
 
8.3.7.4. (4R,5R,4S,5S)-N-(2,4-Dimethoxyphenyl)-5-(3,4-dimethoxyphenyl)-4,5-
dihydrooxazole-4-carboxamide 107c 
1
2
O
34 N
51'
O
NH
O
O
(rac)
O
O
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(4R,5R/4S,5S)-N-(2,4-Dimethoxyphenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydrooxazole-4-
carboxamide 107c was successfully synthesized according to the general procedure using N-(2,4-
dimethoxyphenyl)-2-isocyanoacetamide 101b (275 mg, 1.36 mmol), 3-methoxybenzaldehyde (226 
mg, 1.36 mmol) and DBU (207 mg, 1.36 mmol) in DCM;  Physical characteristics: light yellow 
solid; Yield: 289 mg, 55%; Melting point: 182 -185oC; 1H NMR (400 MHz, CDCl3) δ 8.61 (1H, 
s, NH), 8.18 (1H, d, J = 8.4 Hz, ArH), 7.15-7.20 (2H, m, ArH), 6.36-6.54 (3H, m, ArH), 6.99 
(1H, d, J = 1.6 Hz, 2-CH), 5.69 (1H, d, J = 8.4 Hz, 5-CH), 4.71-4.73 (1H, dd, J = 3 Hz, 4-CH), 
3.71, 3.75, 3.79 and 3.80 (12H, 4 x s, 4 x ArOCH3); 
13C NMR (101 MHz, CDCl3) δ 168.7 (C=O), 
161.7 (2-C), 156.5, 156.2, 152.5 and 149.6 (4 x  ArCOCH3), 135.5, 130.0, 128.1, 124.6, 120.8, 
105.9 , 104.3, 98.6 (ArC); (4-C), 75.2 (5-C), 55.6, 55.8, 59.5 and 59.6 (4 x ArCOCH3). 
 
8.3.7.5. (4R,5R/4S,5S)-N-(2,4-Dimethoxyphenyl)-5-phenyl-4,5-dihydrooxazole-4-
carboxamide 107d 
1
2
O
34 N
51'
O
NH
O
O
(rac)  
(4R,5R/4S,5S)-N-(2,4-Dimethoxyphenyl)-5-phenyl-4,5-dihydrooxazole-4-carboxamide 107d was 
successfully synthesized according to the general procedure using N-(2,4-dimethoxyphenyl)-2-
isocyanoacetamide 101b (115 mg, 0.57 mmol), benzaldehyde (61 mg, 0.57 mmol) and DBU (87 
mg, 0.57 mmol) in DCM; Physical characteristics: light yellow solid; Yield: 134 mg, 72%; 
Melting point: 156-159oC; 1H NMR (400 MHz, CDCl3) δ 8.72 (1H, s, NH), 8.27 (1H, d, J = 8.8 
Hz, ArH), 7.34-7.47 (4H, m, ArH), 7.18 (1H, s, 2-CH), 6.46-6.49 (3H, m, ArH), 5.76 (1H, d, J = 
8.0 Hz, 5-CH), 4.80-4.82 (1H, d, J = 7.4 Hz, 4-CH), 3.87 and  3.80 (6H, 2 x s, 2 x ArOCH3); 
13C 
NMR (101 MHz, CDCl3) δ 168.1 (C=O), 156.8 (2-C), 156.6 and 149.7 (2 x ArCOCH3), 139.9, 
132.4, 128.8, 128.4, 125.4, 120.5, 103.6, 98.7 (ArC), 82.6 (4-C), 60.4 (5-C), 55.7 and 55.5 (2 x 
ArCOCH3). 
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8.3.8. Attempted oxidation of 4,5-aryl-4,5-dihydro-N-(3,5-dimethoxyphenyl)oxazole-
4-carboxamides 
(4R,5R/4S,5S)-5-Aryl-4,5-dihydro-N-(3,5-dimethoxyphenyl)oxazole-4-carboxamides (0.5 mmol) 
was dissolved in 5 ml of dry DCM and cool in an ice bath. DBU (1.4 mmol) was then added 
followed by slow addition of bromotrichloromethane (1.4 mmol). The reaction was stirred for 1 
hour and then allowed to warm to room temperature and was stirred for a further 24-48 hours. 
Unfortunately no desired products were obtained. 
 
8.3.9. Synthesis of ethy-5-aryl-1,3-oxazole-4-carboxylates  
8.3.9.1. General procedure 
To a solution of ethyl 2-isocyanoacetate (1 molar equivalent) and triethylamine (3 molar 
equivalents) in THF (20 ml) was added a solution of benzoyl chloride (1 molar equivalent) in 
THF (4 ml) slowly at 0 °C. After stirring for 40 minutes at 0 °C, the reaction mixture was 
warmed to room temperature. After stirring for 48 hours, water was added to the reaction 
mixture (30 ml). The aqueous layer was extracted with EtOAc (2 x 20 ml) and the combined 
organic layer was washed with 1N HCl (2 x 10 ml), water (15 ml), then dried over MgSO4 and 
then filtered. The solvent was then evaporated under reduced pressure to obtain brown oily 
crude material which was purified by flash column chromatography [eluting with hexane: EtOAc 
(6:1) followed by (4:1) and then (1:1)] to afford the desired ethy-5-aryl-1,3-oxazole-4-
carboxylates 
 
8.3.9.2. Ethyl 5-(4-fluorophenyl)oxazole-4-carboxylate 109a 
1'
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O
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Ethyl 5-(4-fluorophenyl)oxazole-4-carboxylate 109a was successfully synthesized using ethyl 2-
isocyanoacetate (1.08 g, 9.57 mmol), Et3N (2.90 g, 28.7 mmol) and 4-fluorobenzoyl chloride 
(1.52 g, 9.57 mmol in THF (20 ml) as described in the general procedure; Physical 
characteristics: pale yellow solids; Yield: 1.62 g, 72%; 1H NMR (400 MHz, CDCl3) δ 8.08 (2H, 
dd, J = 5.2 Hz, 2.6 Hz, ArH), 7.90 (1H, s, 2-CH), 7.13 (2H, t, J = 8.8 Hz, ArH), 3.38 (2H, q, J = 
7.2 Hz, OCH2CH3), 1.38-1.42 (3H, t, J = 7.2 Hz, OCH2CH3); 
13C NMR (101 MHz, CDCl3) δ 
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163.8 (d, 1JC,F = 252 Hz, para-CF), 161.9 (C=O), 154.7 (5-C), 148.8 (2-C), 130.7 (d, 
3JC,F = 8 Hz, 
ortho-C), 126.3 (4-C), 122.9 (d, 4JC,F = 4 Hz, 1‟-C), 115.6 (d, 
2JC,F = 21 Hz, meta-C), 61.5 ( 7-C), 
14.2 (8-C) . 
8.3.9.3. Ethyl 5-(3-methoxyphenyl)oxazole-4-carboxylate 109c 
1'
1
2
O
3
4
N
5
O
6O
7
8
O
 
Ethyl 5-(3-methoxyphenyl)oxazole-4-carboxylate 109c was synthesized from ethyl 2-
isocyanoacetate (967 mg, 8.55 mmol), Et3N (2.60 g, 25.7 mmol) and 3-methoxybenzoyl chloride 
(1.46 g, 8.55 mmol) in THF (20 ml) as described in general procedure; Physical characteristics: 
yellow solids; Yield: 1.42 g, 67%; 1H NMR (400 MHz, CDCl3) δ 7.89 (1H, s, 2-CH), 7.62 (1H, 
d, J = 8.4 Hz, ArH), 7.34 (1H, t, J = 8.4 Hz, ArH), 7.01 (1H, d, J = 8.4 Hz, ArH), 6.97-6.99 (1H, 
m, ArH), 4.37 (2H, q, J = 7.2 Hz, OCH2CH3), 3.85 (3H, s, ArOCH3), 1.37-1.41 (3H, t, J = 7.2 
Hz, OCH2CH3); 
13C NMR (101 MHz, CDCl3) δ  161.8 (C=O), 159.4 (ArCOCH3), 155.2 (5-C), 
148.8 (2-C), 129.4, 127.7 (ArC), 126.7 (4-C), 120.7, 116.5, 113.6 (ArC), 61.4 (7-C), 55.3 
(ArCOCH3), 14.2 (8-C). 
 
8.3.10. Hydrolysis of ethyl 1,5-diaryl-oxazole-4-carboxylates  
8.3.10.1 . General synthetic procedure 
NaOH (1.5 molar equivalent) was added to a solution of ethyl 5-aryl-1,3-oxazole-4-carboxylate 
(1 molar equivalent) in MeOH (5 ml) and H2O (5 ml). The resulting reaction solution was 
refluxed until disappearance of the starting material (observed by TLC). Volatile methanol was 
removed in vacuo and the remaining aqueous crude material was slowly neutralized with 1M HCl. 
The product was then extracted with EtOAc, washed with brine and dried over MgSO4 to give 
the 1,5-diaryl-oxazole-carboxylic acids. 
 
8.3.10.2. 5-(4-Fluorophenyl)oxazole-4-carboxylic acid 108a 
1'
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O
3
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N
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F  
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5-(4-Fluorophenyl)oxazole-4-carboxylic acid 3.13a was successful synthesized from ethyl 5-(4-
flurorphenyl)oxazole-4-carboxylate 109a (442 mg, 1.88 mmol) and NaOH (113 mg, 2.82 mmol) 
as described in the general procedure; Physical characteristics: pale yellow solids; Yield: 347 
mg, 89%; Melting Point: 168-171 °C; 1H NMR (400 MHz, DMSO-d6) δ 13.2 (1H, s, COOH), 
8.52 (1H, s, 2-CH), 8.03 (2H, dd, J = 5.6 Hz, 3.2 Hz, ArH), 7.33 (2H, t, J = 8.8 Hz, ArH); 13C 
NMR (101 MHz, DMSO-d6) δ 163.0 (d, 
1J C,F  = 250 Hz, para-CF), 162.9 (C=O), 153.1 (5-C), 
150.7 (2-C), 130.9 (d, 3J C,F  = 9 Hz, ortho-C), 126.7 (4-C), 123.4 (d, 
4J C,F  = 3 Hz, 1‟-C), 115.6 (d, 
2J 
C,F  = 22 Hz, meta-C); FTIR νmax/cm
-1 (KBr): 3047, 2917, 2856, 2461 (OH), 1727, 1608, 1506, 
1243, 1165, 833, 799, 622, 504. 
 
8.3.10.3. 5-(3-Methoxyphenyl)oxazole-4-carboxylic acid 108c 
1'
1
2
O
3
4
N
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5-(3-Methoxyphenyl)oxazole-4-carboxylic acid 108c was successful synthesized from ethyl 5-(3-
methoxyphenyl)oxazole-4-carboxylate 109c (2.00 g, 8.09 mmol) and NaOH (484 mg, 12.1 mmol) 
as described in the general synthetic procedure; Physical characteristics: yellow solid; Yield: 
1.45 g, 82%; Melting point: 115-118oC; 1H NMR (400 MHz, DMSO-d6) δ 13.2 (1H, s, COOH), 
8.53 (1H, s, 2-CH), 7.65 (1H, s, ArH), 7.55 (1H, d, J = 8.0 Hz, ArH), 7.44 (1H, t, J = 8.2 Hz, 
ArH), 7.07 (1H, dd, J = 6.0 Hz, 2.0 Hz, ArH), 3.82 (3H, s, ArOCH3); 
13C NMR (101 MHz, 
DMSO-d6) δ 163.0 (C=O), 159.3 (ArCOCH3), 153.5 (5-C), 150.6 (2-C), 129.7, 127.9, 127.1 (4-C), 
120.4, 115.9, 113.9 (ArC), 55.3 (ArCOCH3); FTIR νmax/cm
-1 (KBr): 2913, 2878, 2569 (OH), 
1709, 1596, 1570, 1495, 1296, 1214, 1189, 848, 747. 
 
8.3.11. Preparation of 5-aryloxazole-4-carbonyl chloride  
8.3.11.1 General synthetic procedure  
A mixture 5-aryloxazole-4-carboxylic acid (1 molar equivalent) and thionyl chloride (6 molar 
equivalents) was refluxed for 8 hours. Upon reaction completion, the excess thionyl chloride was 
removed by co-evaporation with toluene to afford 5-aryloxazole-4-carbonyl chloride after drying 
under high vacuum.  
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8.3.11.2. 5-(4-Fluorophenyl)oxazole-4-carbonyl chloride 112a 
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5-(4-Fluorophenyl)oxazole-4-carbonyl chloride 112a was successfully synthesized by refluxing of 
5-(4-fluorophenyl)oxazole-4-carboxylic acid 108a (218 g, 1.05 mmol) and SOCl2 (6.30 mmol) as 
described by the general procedure; Physical characteristics: yellow solid; Yield: 211 mg, 89%; 
1H NMR (400 MHz, CDCl3) δ 8.03 (2H, dd, J = 5.6 Hz, 2.0 Hz, ArH), 7.94 (1H, s, 2-CH), 7.17 
(2H, t, J = 8.4 Hz, ArH); 13C NMR (101 MHz, CDCl3) δ 164.1 (d, 
1JC,F  = 255 Hz, para-CF), 
163.1 (C=O), 156.0 (5-C), 148.6 (2-C), 130.8 (d, 3JC,F = 9 Hz, ortho-C), 128.8 (C-4), 121.7 (d, 
4JC,F 
= 3.0 Hz,1‟-C), 116.1 (d, 2JC,F = 22 Hz, meta-C). 
 
8.3.11.3. 5-(3-Methoxyphenyl)oxazole-4-carbonyl chloride 112c 
1'
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O
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5-(3-Methoxyphenyl)oxazole-4-carbonyl chloride 112c was successfully synthesized by refluxing 
of 5-(3-methoxyphenyl)oxazole-4-carboxylic acid 108c (340 mg, 1.55 mmol) and SOCl2 (9.30 
mmol) as described by the general procedure; Physical characteristics: yellow solid; Yield: 302 
mg, 82%; 1H NMR (400 MHz, CDCl3) 7.92 (1H, s, 2-CH), 7.62 (2H, overlapping doublet and 
singlet, J = 8.4 Hz, ArH), 7.35 (1H, t, J = 8.4 Hz, ArH), 7.34 (1H, d, J = 8.4 Hz, ArH), 3.81 (3H, 
s, ArOCH3); 
13C NMR (101 MHz, DMSO-d6): δ 162.9 (C=O), 159.5 (ArCOCH3), 156.6 (5-C), 
148.5 (2-C), 129.7, 128.9, 126.4, 120.6, 118.1, 113.1 (ArC), 55.3 (ArCOCH3); 
 
8.3.12.  Synthesis of N,5-diaryl-4-carboxamide-1,3-oxazole  
8.3.12.1 General synthetic procedure 
To a mixture of aniline (1 molar equivalent) and 5-aryloxazole-4-carbonyl chloride (1 molar 
equivalent) in ethyl acetate (7 ml) was added triethylamine (1.3 molar equivalents) at 0°C with 
stirring. The resulting mixture was stirred for 48 hours at room temperature. Upon completion, 
1M HCl was added and the mixture was extracted with EtOAc (2 x 5 ml).  The combined 
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organic layer was washed with water (5 ml), dried over MgSO4, filtered and solvent was 
concentrated in vacuo.  The resulting crude material was purified by column chromatography on 
silica gel, [elution with hexane: EtOAc ratio of (7:1), followed by (1:1)] to furnish the N,5-diaryl-
4-carboxamide-1,3-oxazole 100a-e and 100g-i, whereas in the cases where product containing a 
carboxylic acid, the crude material was crystallized from DCM to afford the  desired products 
100f, 100j and 100k.  
 
8.3.12.2. 5-(4-Fluorophenyl)-N-(2-hydroxyphenyl)oxazole-4-carboxamide 100a 
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5-(4-Fluorophenyl)-N-(2-hydroxyphenyl)oxazole-4-carboxamide 100a was successfully 
synthesized from 2-hydroxylaniline (48 mg, 0.45 mmol), 5-(4-fluorophenyl)oxazole-4-carbonyl 
chloride 112a (12 mg, 0.45 mmol) and Et3N (60 mg, 0.59 mmol) in EtOAc as described by the 
general procedure; Physical characteristics: brownish yellow solid; Yield: 113 mg, 84%; 
Melting point: 89-92°C; 1H NMR (400 MHz, CDCl3) δ 9.26 (1H, s, NH), 8.19 (2H, dd, J = 6.0 
Hz, 2.8 ArH), 7.80 (1H, s, 2-CH), 6.80-7.22 (7H, overlapping signals, OH and ArH); 13C NMR 
(101 MHz, CDCl3) δ 163.9 (d, 
1JC,F = 252 Hz, para-CF), 160.1 (C=O), 153.4 (5-C), 148.5 (2-C), 
148.0 (ArCOH), 130.8 (d, 3JC,F = 8 Hz, ortho-C), 127.4 (4-C), 127.0, 125.3 (ArC), 122.7 (d, 
4JC,F = 3 
Hz, 1‟-C), 122.3, 120.5, 119.4, 115.7 (d, 2JC,F = 22 Hz, meta-C); FTIR νmax/cm
-1 (KBr): 3352, 3126, 
1669,1604, 1533, 1456, 1361, 1282, 1234, 965, 761; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for 
C16H12FN2O3 299.0826, found 299.0841 . 
 
8.3.12.3. 5-(4-Fluorophenyl)-N-(2,4-dimethoxyphenyl)oxazole-4-carboxamide 100b 
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5-(4-Fluorophenyl)-N-(2,4-dimethoxyphenyl)oxazole-4-carboxamide 100b was successfully 
synthesized from 2.4-dimethoxyaniline (110 mg, 0.72 mmol), 5-(4-fluorophenyl)oxazole-4-
carbonyl chloride 112a (162 mg, 0.72 mmol) and Et3N (95 mg, 0.94 mmol) in EtOAc as 
described by the general procedure; Physical characteristics: brown crystals; Yield: 168 mg, 
68%; Melting point: 154-157°C; 1H NMR (400 MHz, CDCl3) δ 9.50 (1H, s, NH), 8.33-8.39 
(3H, m, ArH), 7.86 (1H, s, 2-CH), 7.14 (2H, t, J = 8.8 Hz, ArH), 6.52 (1H, s, ArH), 6.49 (1H, d, J 
= 8.8 Hz, ArH), 3.91 and 3.80 (6H, 2 x s, 2 x ArOCH3); 
13C NMR (101 MHz, CDCl3) δ 163.6 (d, 
1J C,F  = 252 Hz, para-CF), 158.4 (C=O), 156.6 (ArCOCH3), 152.2 (5-C), 149.8 (ArCOCH3), 147.7 
(2-C), 130.6 (d, 3J C,F  = 9 Hz, ortho-C), 129.0 (4-C), 123.3 (d, 
4JC,F = 3 Hz, 1‟-C), 121.0, 120.6 
(ArC), 115.5 (d, 2JC,F = 22 Hz, meta-C), 103.7, 98.6 (ArC), 55.5 and 55.8 (2 x ArCOCH3); FTIR 
νmax/cm
-1 (KBr): 3367, 3128, 3034, 3013, 2956, 2921, 2834, 1666, 1606, 1548, 1454, 1417, 1280, 
1208, 1158, 1128, 1067, 1036, 920, 882, 834, 818, 787, 691, 636, 513; HRMS (ESI-TOF) m/z: 
[M+H]+ Calcd for C16H16FN2O4, 343.1089 found 343.1116.  
 
8.3.12.3. 5-(4-Fluorophenyl)-N-(4-bromophenyl)oxazole-4-carboxamide 100c 
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5-(4-Fluorophenyl)-N-(4-bromophenyl)oxazole-4-carboxamide 100c was successfully synthesized 
from 4-bromoaniline (138 mg, 0.80 mmol), 5-(4-fluorophenyl)oxazole-4-carbonyl chloride 112a 
(181 mg, 0.80 mmol) and Et3N (105 mg, 1.04 mmol) in EtOAc as described by the general 
procedure; Physical characteristics: pale yellow solid; Yield: 211 mg, 73%; Melting point: 
176-179 °C; 1H NMR (400 MHz, DMSO-d6): δ 9.09 (1H, s, NH), 8.32 (2H, dd, J = 6.0 Hz, 2.8 
Hz ArH), 7.87 (1H, s, 2-CH), 7.58-7.60 (2H, d, J = 8.8 Hz, ArH), 7.46 (2H, d, J = 8.4 Hz, ArH), 
7.15 (2H, dd, J = 8.8 Hz, ArH); 13C NMR (101 MHz, DMSO-d6): δ 163.8 (d, 
1JC,F = 250.4 Hz, 
para-CF), 158.9 (C=O), 153.0 (5-C), 147.7 (2-C), 136.8, 132.0, 130.6 (d, C-6‟, 3JC,F = 9.0 Hz, ortho-
C), 127.4 (ArC),, 122.7 (d, 4JC,F = 3.1 Hz, 1‟-C ), 121.4 (4-C), 117.03 (ArC), 115.7 (d, 
3JC,F = 22.1 
Hz, meta-C); FTIR νmax/cm
-1 (KBr): 3370, 3136, 2924, 2857, 1673, 1609, 1336, 1371, 1245, 1120, 
1064, 873, 835, 629, 499; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C16H11
79BrFN2O2 
360.9982, found 361.0004 . 
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8.3.12.4. 5-(4-Fluorophenyl)-N-(2,4-dimethylphenyl)oxazole-4-carboxamide 100d 
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5-(4-Fluorophenyl)-N-(2,4-dimethylphenyl)oxazole-4-carboxamide 100d was successfully 
synthesized from 2,4-dimethylaniline (93 mg, 0.77 mmol), 5-(4-fluorophenyl)oxazole-4-carbonyl 
chloride 112a (174 mg, 0.77 mmol) and Et3N (101 mg, 1.00 mmol) in EtOAc as described by the 
general procedure; Physical characteristics: pale yellow crystals; Yield 167 mg, 70%; Melting 
point: 141-143 °C; 1H NMR (400 MHz, CDCl3) δ 9.02 (1H, s, NH), 8.37 (2H, dd, J = 5.6 Hz, 
3.2 Hz, ArH), 7.94 (1H, d, J = 8.4 Hz, ArH), 7.87 (1H, s, 2-CH), 7.14 (2H, t, J = 8.8 Hz, ArH), 
7.05 (1H, overlapping singlet and doublet, J = 10.8 Hz, ArH), 7.05 ( 1H, s, ArH), 2.32 and 2.34 
(6H, 2 x s, 2x  ArCH3); 
13C NMR (101 MHz, CDCl3) δ 163.7 (d, 
1JC,F = 255 Hz, para-CF), 158.9 
(C=O), 152.5 (5-C), 147.7 (2-C), 136.8 (ArC), 134.6 and 132.9 ( 2 x ArCCH3), 131.1, 130.6 (d, 
3JC,F = 9 Hz, ortho-C), 128.8, 128.6 (4-C), 127.3 (ArC), 123.1 (d, 
4JC,F = 3 Hz, 1-C), 122.1 (4-C), 
115.4 (d, 2JC,F = 22 Hz, meta-C), 20.9 and 17.6 (2 x ArCCH3); FTIR νmax/cm
-1 (KBr): 3397, 3130, 
3017, 2919, 1680, 1614, 1536, 1443, 1299, 1231, 1160, 1111, 1068, 938, 873, 832, 763, 624, 553, 
515; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C18H10FN2O2 311.1186, found 311.1190. 
 
8.3.12.5. (2,4-Dichlorophenyl)-5-(4-fluorophenyl)oxazole-4-carboxamide 100e 
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(2,5-Dichlorophenyl)-5-(4-fluorophenyl)oxazole-4-carboxamide 100e was successfully 
synthesized from 2,4-dichloroaniline (105 mg, 0.65 mmol), 5-(4-fluorophenyl)oxazole-4-carbonyl 
chloride 112a (147 mg, 0.65 mmol) and Et3N (86 mg, 0.85 mmol) in EtOAc as described by the 
general procedure; Physical characteristics: white solid; Yield: 64 mg, 72%; Melting point: 
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218-221 °C; 1H NMR (400 MHz, DMSO-d6): δ 9.71 (1H, s, NH), 8.61 (1H, s, 2-CH), 8.93 (1H, 
t, J = 5.6 Hz, ArH), 7.85 (1H, s, ArH), 7.26 (1H, d, J = 8.4 Hz, ArH), 7.19 (1H, s, ArH), 7.11 
(2H, t, J = 8.4 Hz, ArH), 6.97 (1H, d, J = 8.4 Hz, ArH); 13C NMR (101 MHz, DMSO-d6): δ 
163.6 (d, 1JC,F = 252 Hz, para-CF), 158.9 (C=O), 153.4 (2-C), 147.9 (ArC), 152.2 (5-C), 147.9, 
133.6, 130.7 (d, 3JC,F = 9 Hz, ortho-C), 129.8 (ArC), 124.6 (d, 
4JC,F = 3 Hz, 1‟-C), 124.6, 122.5,  
120.1 (ArC), 115.8 (d, 2JC,F = 22 Hz, meta-C); FTIR νmax/cm
-1 (KBr): 3331, 3124, 2926, 2847, 
1682, 1587, 1525, 1412, 1241, 1168, 843, 804, 682, 636, 513; HRMS (ESI-TOF) m/z: [M+H]+ 
Calcd for C16H10Cl2FN2O2 351.0098, found 351.0095. 
 
282-(5-(4-Fluorophenyl)oxazole-4-carboxamido)benzoic acid 100f 
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2-(5-(4-Fluorophenyl)oxazole-4-carboxamido)benzoic acid 100f was successfully synthesized 
from 2-aminobenzoic acid (82 mg, 0.60 mmol), 5-(4-fluorophenyl)oxazole-4-carbonyl chloride 
112a (135 mg, 0.60 mmol) and Et3N (78 mg, 0.78 mmol) in EtOAc as described by the general 
procedure; Physical characteristics: pale yellow solid; Yield: 125 mg, 64%; Melting point: 
180-183 °C; 1H NMR (400 MHz, DMSO-d6) δ 13.6 (1H, s, COOH), 12.5 (1H, s, NH), 8.78 (2H, 
d, J = 8.4 Hz, ArH), 8.66 (1H, s, 2-CH), 8.28 (2H, t, J = 7.2 Hz, ArH), 8.06 (2H, d, J = 8.4 Hz, 
ArH), 7.62 (2H, d, J = 8.4 Hz, ArH); 13C NMR (101 MHz, DMSO-d6) δ 169.0 (COOH), 163.0 
(d, 1JC,F = 250.2 Hz, para-CF), 159.4 (CONH), 151.3 (2-C), 150.3 (5-C), 140.4, 134.0, 131.3 (ArC),  
130.7 (d, 3JC,F = 8.1 Hz, ortho-C), 128.6 (ArC), 123.7 (d, 
4JC,F = 3.0 Hz, 1‟-C), 123.0, 120.0, 116.8 
(ArC), 115.6 (d, 2JC,F = 22.1 Hz, meta-C); FTIR νmax/cm
-1 (KBr): 3092, 3008, 2456, 2255, 1672, 
1608, 1584, 1504, 1451, 1408, 1303, 1243, 1164, 984, 842, 762, 659, 643, 540; HRMS (ESI-TOF) 
m/z: [M+H]+ Calcd for C17H12FN2O4 327.0781, found 327.0795. 
 
 
 
 
 
 
277 
 
 
 
8.3.12.6.  5-(3-Methoxyphenyl)-N-(2-hydroxyphenyl)oxazole-4-carboxamide 100g 
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5-(3-Methoxyphenyl)-N-(2-hydroxyphenyl)oxazole-4-carboxamide 100g was successfully 
synthesized from 2-hydroxylaniline (101 mg, 0.93 mmol), 5-(3-methoxyphenyl)oxazole-4-
carbonyl chloride 112c (221 mg, 0.93 mmol) and Et3N (122 mg, 1.21 mmol) in EtOAc as 
described by the general procedure; Physical characteristics: yellow solid; Yield: 150 mg, 52%; 
Melting point: 99-1102°C; 1H NMR (400 MHz, CDCl3) δ 9.36 (1H, s, NH), 9.06 (1H, s, 
ArOH), 8.02 (1H, s, ArH), 7.92 (1H, s, 2-CH), 7.79 (1H, d, J = 8.4 Hz, ArH), 7.37 (1H, t, J = 8.4 
Hz, ArH), 7.14-7.20 (2H, m, ArH), 7.01-7.07 (2H, m, ArH), 6.90 (1H, t, J = 8.4 Hz, ArH), 3.88 
(1H, s, ArOCH3); 
13C NMR (101 MHz, CDCl3) δ 160.3 (C=O), 159.5 (ArCOH), 154.2 (5-C), 
148.9 (ArCOCH3), 148.9 (2-C), 148.0, 129.5, 127.7, 127.5, 125.3, 122.5, 120.6, 120.5, 119.9, 
117.2, 113.4 (ArC), 55.4 (ArOCH3); FTIR νmax/cm
-1 (KBr): 3609, 3443, 3357, 3134, 1730, 1660, 
1570, 1535, 1493, 1456, 1331, 1235, 1057, 1013, 880, 828, 742, 641, 610; HRMS (ESI-TOF) 
m/z: [M+H]+ Calcd for C19H15N2O5 311.1026, found 311.1036. 
 
8.3.12.7. 5-(3-Methoxyphenyl)-N-(2,4-dimethoxyphenyl)oxazole-4-carboxamide 100h  
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5-(3-Methoxyphenyl)-N-(2-hydroxyphenyl)oxazole-4-carboxamide 100h was successfully 
synthesized from 2,4-dimethoxyaniline (124 mg, 0.81 mmol), 5-(3-methoxyphenyl)oxazole-4-
carbonyl chloride 112c (193 mg, 0.81 mmol) and Et3N (111 mg, 1.10 mmol) in EtOAc as 
described by the general procedure; Physical characteristics: brownish white solid; Yield: 207 
mg, 72%; Melting point: 169-172°C; 1H NMR (400 MHz, CDCl3) δ 9.45 (1H, s, NH), 8.33-8.39 
 
278 
 
(3H, m, ArH), 7.86 (1H, s, 2-CH), 7.14 (2H, t, J = 8.8 Hz, ArH), 6.52 ( 1H, s, ArH), 6.49 (1H, d, 
J = 8.8 Hz, ArH), 3.91, 3.88 & 3.80 (9H, 3 x s, 3 x ArOCH3); 
13C NMR (101 MHz, CDCl3) δ 
159.5 (C=O), 158.4, 156.5 and 152.9 (3 x ArCOCH3), 149.8, 147.8, 129.6, 129.4, 128.1, 1212.2, 
120.6, 120.4, 116.4, 113.3, 103.7, 98.6 (ArC), 55.8, 55.5 and 55.4 (3 x ArCOCH3); FTIR νmax/cm
-1 
(KBr): 3371, 3117, 3078, 2925, 2830, 1662, 1536, 1498, 1368, 1296, 1249, 1212, 1161, 1127, 
1030, 788, 698, 637; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C19H19N2O5 355.1288, found 
355.1309. 
 
8.3.12.8. 5-(3-Methoxyphenyl)-N-(4-bromophenyl)oxazole-4-carboxamide 100i 
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5-(3-Methoxyphenyl)-N-(4-bromophenyl)oxazole-4-carboxamide 100i was successfully 
synthesized from 4-bromoaniline (146 mg, 0.85 mmol), 5-(3-methoxyphenyl)oxazole-4-carbonyl 
chloride 112c (202 mg, 0.85 mmol) and Et3N (112 mg, 1.11 mmol) in EtOAc as described by the 
general procedure; Physical characteristics: pale yellow crystals; Yield: 266 mg, 84%; Melting 
point: 167-169 °C; 1H NMR (400 MHz, CDCl3) δ 9.12 (1H, s, NH), 8.00 (1H, s, ArH), 7.86 
(2H, overlapping singlet and doublet, J = 8.8 Hz, ArH and 2-CH), 7.61 (2H, d, J = 8.8 Hz, ArH), 
7.46 (2H, d, J = 8.4 Hz, ArH),7.38 (1H, t, J = 8.4 Hz, ArH), 7.00 (1H, dd, J = 6.4 Hz, 2 Hz , 
ArH), 3.90 (3H, s, ArOCH3); 
13C NMR (101 MHz, CDCl3) δ 159.5 (C=O), 158.8 (ArCOCH3), 
153.6 (5-C), 147.7 (2-C), 136.8, 132.0, 129.5, 128.7 (ArC), 127.8 (C-4), 121.4, 120.6, 117.0, 116.7, 
113.4 (ArC), 55.4 (ArCOCH3); FTIR νmax/cm
-1 (KBr): 3360, 3133, 3004, 2952, 2834, 1678, 1586, 
1530, 1456, 1396, 1246, 1120, 1059, 826, 635, 508; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for 
C17H14
79BrN2O3 373.0182, found 373.0200 
 
8.3.12.9. 2-(5-(3-Methoxyphenyl)oxazole-4-carboxamido)benzoic acid 100j 
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2-(5-(3-Methoxyphenyl)oxazole-4-carboxamido)benzoic acid 100j was successfully synthesized 
from 2-aminobenzoic acid (130 mg, 0.95 mmol), 5-(3-methoxyphenyl)oxazole-4-carbonyl 
chloride (226 mg, 0.95 mmol) and Et3N ( 126 mg, 1.24 mmol) in EtOAc as described by the 
general procedure;  Physical characteristics: pale yellow solid; Yield: 167 mg, 52%; Melting 
point: 187-190°C; 1H NMR(400 MHz, DMSO-d6): δ 13.54 (1H, br, COOH), 12,50 (1H, s, NH), 
8.77 (1H, d, J = 8.4 Hz, ArH), 8.66 (1H, s, 2-CH), 8.04 (1H, d, J = 8.4 Hz, ArH), 7.93 (1H, s, 
ArH), 7.74 (1H, d, J = 8.4 Hz, ArH), 7.62 (1H, t, J = 7.6 Hz, ArH), 7.43(1H, t, J = 7.6 Hz, ArH), 
7.18 (1H, t, J = 7.2 Hz, ArH), 7.07-7.10 (1H, m, ArH), 3.83 (3H, s, ArOCH3); 
13C NMR (101 
MHz, DMSO-d6): δ 169.0 (COOH), 159.5 (CONH), 159.1 (ArCOCH3), 152.5 (5-C), 150.3 (2-C), 
140.4, 134.1, 131.3, 129.7 (ArC), 129.0 (4-C), 127.8, 123.0, 120.3, 120.0, 116.8, 116.0, 113.7 
(ArC), 55.3 (ArCOCH3); FTIR νmax/cm
-1 (KBr): 3252, 3130, 2830, 2634, 1678, 1586, 1560, 1448, 
1404, 1262, 1012, 877, 827, 757, 663, 639; HRMS (ESI-TOF) m/z: [M+H]+ Calcd For 
C18H15N2O5 399.0975, found 399.0977. 
 
8.3.12.10. 2-(5-(4-Methoxyphenyl)oxazole-4-carboxamido)-4-fluorobenzoic acid 100k 
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2-(5-(4-Methoxyphenyl)oxazole-4-carboxamido)-4-fluorobenzoic acid 100k was successfully 
synthesized from 2-amino-5-fluorobenzoic acid (154 mg, 0.99 mmol), 5-(3-
methoxyphenyl)oxazole-4-carbonyl chloride 112c (235 mg, 0.99 mmol) and Et3N(131 mg, 1.29 
mmol) in EtOAc as described by the general procedure; Physical characteristics: yellow solid; 
Yield: 212 mg, 60%; Melting point: 191-194 °C; 1H NMR (400 MHz, DMSO-d6) δ 13.8 (1H, 
br, COOH), 12.7 (1H, s, NH), 8.60-8.73 (2H, m, ArH), 8.57 (1H, s, 2-CH), 7.60-7. 8.18 (2H, m, 
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ArH), 7.07-7.16 (1H, s, ArH), 7.07-7.53 (2H, m, ArH), 3.86 (3H, s, ArOCH3); 
13C NMR (101 
MHz, DMSO-d6) δ 168.7 (COOH), 163.6 (d, 
1JC,F = 252 Hz, CF), 159.8 (CONH), 159.1 
(ArCOCH3), 152.9 (5-C), 150.4 (2-C), 140.4, 133.9, 129.7, 128.6, 127.6, 120.3, 116.1, 113.7, 113.2, 
110.1, 106.4 (ArC), 55.3 (ArCOCH3); FTIR νmax/cm
-1 (KBr): 3200, 3133, 2843, 2656, 1673, 1591, 
1523, 1409, 1257, 1178, 1012, 876, 778, 641; HRMS (ESI-TOF) m/z: [M+H]+ Calcd. for 
C18H14N2O5 357.0881; found 357.0906. 
 
8.4. Chapter 4 experimental procedures 
8.4.1. Synthesis of ethyl 2-amino hydrochloride salts 
8.4.1.1. General synthetic procedure  
Thionyl chloride (1.2 molar equivalents) was added slowly to a mixture containing amino acid (1 
molar equivalent) in ethanol (100 ml) at 0°C. After removal of the ice bath, the mixture was 
stirred for 5 hours under reflux. After cooling to room temperature, the excess ethanol and 
thionyl chloride were removed under reduce pressure. The resultant white solid was combined 
twice with ethanol and this was again removed under reduce pressure to remove adhering thionyl 
chloride completely. The product was then recrystallized from ethanol and dried under high 
vacuum.  
 
8.4.1.2. Ethyl glycinate hydrochloride 105a 
5
4
O 3
2
O
NH2.HCl
1
 
 
Ethyl glycinate hydrochloride 105a was successfully synthesized using glycine (9.98 g, 133 mmol) 
and thionyl chloride (19.04 g, 160 mmol) in ethanol (100 ml) according to the general procedure; 
Physical characteristics:  white solid; Yield: 16.71 g, 90%; Melting point: 144-147°C (lit.263,266); 
1H NMR (400 MHz, CD3OD) 4.36 (2H, q, J = 7.2 Hz, OCH2CH3), 3.87 (2H, s, NH2), 1.37 (3H, 
t, J = 7.1, OCH2CH3); 
13C NMR (101 MHz, CD3OD) 168.5 (C=O), 63.4 (4-C), 41.1 (2-C), 14.39 
(5-C). 
 
8.4.1.3. L-Ethyl 2-aminopropanoate hydrochloride 105b 
5
4
O 3
2
O
NH2.HCl
1
6  
 
281 
 
 
L-Ethyl 2-aminopropanoate hydrochloride 105b was successfully synthesized using L-alanine 
(12.03 g, 135 mmol) and thionyl chloride (24.89 g, 162 mmol) in ethanol (100 ml) according to 
the general procedure; Physical characteristics: white solid; Yield: 20.53 g, 99%; Melting 
point: 76-78 OC (lit.270,271); : 1H NMR (400 MHz, D2O) 4.10 (2H, q, J = 7.2 Hz, OCH2CH3), 3.45 
(2H, q, J = 7.2 Hz, 2-CH2CH3), 1.62 (2H, s, NH2), 1.19 (3H, d, J = 7.6 Hz, CHCH3), 1.16  (3H, t, 
J = 7.6 Hz, OCH2CH3); 
13C NMR (101 MHz, D2O) δ 170.2 (C=O), 60.5 (4-C), 49.4 (2-C), 19.9 
(6-C), 14.0 (5-C). 
8.4.1.4. D-Ethyl 2-amino-4-methylpentanoate hydrochloride 105c 
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D-Ethyl 2-amino-4-methylpentanoate hydrochloride 105c was successfully synthesized using D-
leucine (13.77 g, 105 mmol) and thionyl chloride (14.99 g, 126 mmol) in ethanol (100 ml) 
according to the general procedure; Physical characteristics: white solid; Yield: 19.52 g, 95%; 
Melting point: 133-135oC (lit.357 )1H NMR (400 MHz, CD3OD) δ 4.12 (2H, q, J = 7.2 Hz, 
OCH2CH3), 3.45 [1H, d, J = 7.4 Hz, NHCH], 1.82 (2H, s, NH2), 1.64-1.77 [1H, m, 
CHCH2CH(CH3)2], 1.46-1.56 [1H, m, CHCH2CH(CH3)2], 1.18 (3H, t, J = 7.4 Hz, OCH2CH3), 
1.03 [1H, d, J = 7.2 Hz, CHCH2CH(CH3)2]; 
13C NMR (101 MHz, CD3OD) δ 176.5 (C=O), 60.5 
(4-C), 52.6 (2-C), 43.3 (7-C), 24.8 (6-C) 22.9 and 21.7(2 x 8-C), 13.4 (5-C). 
 
8.4.2. Synthesis of ethyl 2-aminoacylates 
8.4.2.1. General synthetic procedure  
To a suspension of amino acid ethyl ester hydrochloride (1 molar equivalent) in chloroform (15 
ml) was added a dropwise solution of triethylamine (1 molar equivalent) in chloroform (10 ml) at 
room temperature. The resulting reaction mixture was stirred at the same temperature for 6 
hours, followed by refluxing for 1 hour. The mixture was allowed to cool to room temperature 
and solvent was concentrated in vacuo under reduced pressure to afford a white solid. The 
product was extracted with diethyl ether (3 x 25 ml) and then filtered. The filtrates were washed 
with ether (2 x 10 ml). The filtered solution was concentrated in vacuo under reduced pressure to 
afford pure ethyl -2-aminoacylates. 
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8.4.2.2. Ethyl 2-aminoacetate 115a 
1
2
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O
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Glycine ethyl ester 115a  was successfully synthesized from glycine ethyl ester hydrochloride salts 
(10.00 g, 71.6 mmol) and Et3N (7.25 g, 71.6 mmol) in CHCl3 as described by the general 
synthetic procedure; Physical characteristics: yellow oil; Yield: 7.09 g, 96%; Melting point: 
145-148oC (lit358); 1H NMR (400 MHz, CDCl3) δ 4.14 (2H, q, J = 7.2 Hz, OCH2CH3), 3.40 (2H, 
s, CH2CO), 1.67 (2H, s, NH2), 1.23 (3H, t, J = 7.2 Hz, OCH2CH3); 
13C NMR (101 MHz, CDCl3) 
δ 174.2 (C=O), 60.8 (4-C) 43.9 (2-C), 14.2 (5-C). 
 
8.4.2.3. L-Alanine ethyl ester 115b   
H2N1
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L-Alanine ethyl ester 115b was successful synthesized from L-ethyl 2-aminopropanoate 
hydrochloride (10.85 g, 70.6 mmol) and Et3N (8.40 g, 70.6 mmol) in CHCl3 as described by the 
general synthetic procedure; Physical characteristics: yellow oil; Yield: 8.11 g, 98%: 1H NMR 
(400 MHz, CDCl3) δ 4.01 (2H, q, J = 7.2 Hz, OCH2CH3), 3.43 (2H, q, J = 7.2 Hz, 2-CHCH3), 
1.59 (2H, s, NH2), 1.19 (3H, d, J = 7.4 Hz, CHCH3), 1.13 (3H, t, J = 7.2 Hz, OCH2CH3); 
13C 
NMR (101 MHz, CDCl3) δ 176.3 (C=O), 60.5 (4-C), 49.8 (2-C), 20.4 (6-C), 13.9 (5-C). 
 
8.4.2.4. D-leucine ethyl ester 115c 
1
2
O3
O
4
H2N
5
6 7
8
8
 
D-leucine ethyl ester 115c as was successful synthesized from D-ethyl 2-amino-4-
methylpentanoate hydrochloride (16.05 g, 82.0 mmol) and Et3N (8.30 g, 82.0 mmol) in CHCl3 as 
described by the general synthetic procedure; Physical characteristics: yellow oil; Yield: 13.06 
g, 98%; 1H NMR (400 MHz, CDCl3) δ 4.05 (2H, d, J = 7.4 Hz, OCH2CH3), 3.36 (1H, d, J = 7.2 
Hz, NH2CH2), 1.80 (2H, s, NH2), 1.65-1.72 [2H, m, CHCH2CH(CH3)2], 1.44-1.51 [1H, m, 
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CHCH2CH(CH3)2], 1.17 (3H, t, J = 7.4 Hz, OCH2CH3), 1.14 [6H, J = 7.4 Hz, 
CHCH2CH(CH3)2]; 
13C NMR (101 MHz, CDCl3) δ 176.3 (C=O), 60.5 (4-C), 52.6 (2-C), 43.8 (7-
C), 24.5 (6-C), 22.7 and 21.6 (2 x 8-C), 13.9 (5-C). 
 
 
8.4.3. Preparation of ethyl 2-arylideneamino acyl intermediates 
8.4.3.1. General procedure  
A solution of free amino acid ethyl ester (2 molar equivalents), aryl aldehyde (1 molar equivalent) 
and dried magnesium sulphate (0.5 g) was stirred in dry dichloromethane (15 ml) at room 
temperature for 16 hours. Upon completion, the magnesium sulphate was filtered off and 
washed with DCM. The combined organic layer was concentrated in vacuo and resulting products 
were kept at 80oC for 1 hour under reduced pressure in a rotavapor and dried under high 
vacuum to give pure ethyl 2-arylideneamino acyl intermediates.. 
 
8.4.3.2. (E)-Ethyl 2-(4-fluorobenzylideneamino)acetate 116a 
1'
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(E)-Ethyl 2-(4-fluorobenzylideneamino)acetate 116a was successfully synthesized from 4-
fluorobenzaldehyde (1.69 g, 13.60 mmol), ethyl 2-aminoacetate 115a (2.80 g, 27.20 mmol) and 
MgSO4  in DCM as described by the general procedure; Physical characteristics: light yellow 
oil; Yield: 2.59 g, 91%: 1H NMR (400 MHz, CDCl3) δ 8.20 (1H, s, N=CH), 7.71-7.74 (2H, m, 
ArH), 7.03-7.07 (2H, m, ArH), 4.33 (2H, s, 2-CH2), 4.15 (2H, q, J = 7.4 Hz, OCH2CH3), 1.23 
(3H, t, J = 7.2 Hz, OCH2CH3); 
13C NMR (101 MHz, CDCl3) δ 170.0 (C=O), 164.5 (d, J C,F  = 
247 Hz, para-CF), 163.8 (N=CH), 131.3 (d, 4JCF = 3 Hz, 1‟-C,), 115.7 (d, 
3JCF = 9.0 Hz, ortho-C), 
115.5 (d, 2JCF = 22 Hz, meta-C), 61.7 (4-C), 60.9 (2-C), 14.0 (5-C). 
 
8.4.3.3. (E)-Ethyl 2-(2-chlorobenzylideneamino)acetate 116b 
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(E)-Ethyl 2-(3-methoxybenzylideneamino)acetate 116b was successfully synthesized from 2-
chlorobenzaldehyde (938 mg, 6.67 mmol), ethyl 2-aminoacetate 115a (1.37 g, 13.34 mmol) and 
MgSO4 in DCM as described by the general procedure; Physical characteristics: pale yellow 
oil; Yield; 1.31 g, 87%; 1H NMR (400MHz, CDCl3) δ 8.18 (1H, s, N=CH), 7.55 (1H, J = 8.4 
Hz, ArH), 7.27-7.30 (3H, m, ArH), 4.52 (2H, s, 2-CH2), 4.12 (2H, J = 7.4 Hz, OCH2CH3), 1.17 
(3H, t, J = 7.0 Hz, OCH2CH3);
13C NMR (101 MHz, CDCl3) δ 170.2 (C=O), 163.5 (N=CH), 
139.6, 134.9, 131.8, 129.8, 127.1 (ArC), 61.6 (2-C), 61.0 (4-C), 14.1 (5-C). 
 
8.4.3.4. (E)-Ethyl 2 –(3-methoxybenzylideneamino)acetate 116c 
1'
N1
2
3 O
4
O
5
6O
 
(E)-Ethyl 2-(3-methoxybenzylideneamino)acetate 116c was successfully synthesized from 3-
methoxybenzaldehyde (688 mg, 5.03 mmol), ethyl 2-aminoacetate 115a (10.06 mmol) and MgSO4 
in DCM as described by the general procedure; Physical characteristics: pale yellow oil; Yield: 
1.00 g, 90%; 1H NMR (400 MHz, CDCl3) δ 8.24 (1H, s, N=CH), 7.38 (1H, s, ArH), 6.98-7.33 
(3H, m, ArH), 4.39 (2H, s, 2-CH2), 4.20 (2H, q, J = 7.2 Hz, OCH2CH3), 3.83 (3H, s, ArOCH3), 
1.27 (3H, t, J = 7.2 Hz, OCH2CH3); 
13C NMR (101 MHz, CDCl3) δ 170.0 (C=O), 165.3 
(N=CH), 159.7 (ArCOCH3), 136.9, 129.4, 121.8, 118.0, 111.5 (ArC), 61.8 (4-C), 61.0 (2-C), 55.2 
(ArCOCH3), 14.1 (5-C). 
 
8.4.3.5. (E)-Ethyl 2-(3,4-dimethoxybenzylideneamino)acetate 116d 
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(E)-Ethyl 2-(3,4-dimethoxybenzylideneamino)acetate 116d was successfully synthesized from 3,4-
dimethoxybenzaldehyde (1.40 g, 8.41 mmol), ethyl 2-aminoacetate 115a (1.73 g, 16.82 mmol) and 
MgSO4 in DCM as described by the general procedure; Physical characteristics: pale yellow 
oil; Yield: 1.97 g, 93%; 1H NMR (400 MHz, CDCl3) δ 8.15 (1H, s, N=CH), 7.42 (1H, s, ArH), 
7.13 (1H, dd, J = 6.4 Hz, 1.6 Hz, ArH), 7.13 (1H, d, J = 8.4 Hz, ArH), 4.33 (2H, s, 2-CH2), 4.15 
(2H, q, J = 7.4 Hz, OCH2CH3), 3.87 and 3.89 (6H, 2 x s, 2 x ArOCH3), 1.24 (3H, t, J = 7.4 Hz, 
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OCH2CH3); 
13C NMR (101 MHz, CDCl3) δ 170.2 (C=O), 164.8 (N=CH), 151.7 and 149.2 (2 x 
ArCOCH3), 128.8, 123.7, 110.2, 108.7 (ArC), 61.9 (4-C), 60.9 (2-C), 55.8 and 55.9 (2 x 
ArCOCH3), 14.1 (5-C). 
 
8.4.3.6. (E)-Ethyl 2-((benzo[d][1,3]dioxol-6-yl)methyleneamino)acetate 116e 
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(E)-Ethyl 2-((benzo[d][1,3]dioxol-6-yl)methyleneamino)acetate 116e was successfully synthesized 
from piperonal (1.22 g, 8.10 mmol), ethyl 2-aminoacetate 115a (1.67 g, 16.2 mmol) and MgSO4 in 
DCM as described by the general procedure; Physical characteristics: pale yellow oil; Yield: 
1.73 g, 91%: 1H NMR (400MHz; CDCl3) δ 8.24 (1H, s, N=CH), 7.38 (1H, s, ArH), 6.98-7.33 
(2H, m, ArH), 4.62 (2H, s, ArOCH2O-); 4.39 (2H, s, 2-CH2), 4.20 (2H, J = 7.2 Hz, OCH2CH3); 
1.27 (3H, q, t, J = 7.2 Hz, OCH2CH3); 
13C NMR (101 MHz, CDCl3) δ 170.0 (C=O), 165.3 
(N=CH), 159.7 and 149.8 (ArCOCH2O), 136.9, 129.4, 121.8, 118.0 (ArC), 101.5 (ArCOCH2O), 
61.8 (4-C), 61.0 (2-C), 14.1 (5-C). 
 
8.4.3.7. (E)-Ethyl 2 –(4-tert-butylbenzylideneamino)acetate 116f 
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(E)-Ethyl 2 –(4-tert-butylbenzylideneamino)acetate 116f was successfully synthesized from 4-tert-
butylbenzaldehyde (1.21 g, 7.45 mmol), ethyl 2-aminoacetate 115a (1.54 g, 14.90 mmol) and 
MgSO4 in DCM as described by the general procedure; Physical characteristics: yellow oil; 
Yield: 1.62 g, 88%; 1H NMR (400MHz, CDCl3) δ 8.25 (1H, s, N=CH), 7.69 (2H, d, J = 8.4 Hz, 
ArH), 7.42 (2H, q, J = 8.4 Hz, ArH), 4.38 (2H, s, 2-CH2), 4.19 (2H, J = 7.4 Hz, OCH2CH3), 1.32 
[9H, s, C(CH3)3], 1.27 (3H, t, J = 7.0 Hz, OCH2CH3); 
13C NMR (101 MHz; CDCl3) δ 170.2 
(C=O), 165.2 (N=CH), 154.6, 132.9, 128.2, 125.5 (ArC), 62.1 (4-C), 60.9 (2-C), 34.9 [ArC(CH3)3], 
31.3 [ArC(CH3)3], 14.1 (5-C). 
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8.4.3.8. (E)-Ethyl 2-(3-hydroxy-4-methoxybenzylideneamino)acetate 116g 
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(E)-Ethyl 2-(3-hydroxy-4-methoxybenzylideneamino)acetate 116g was successfully synthesized 
from 3-hydroxy-4-methoxybenzyladehyde (1.21 g, 7.92 mmol), ethyl 2-aminoacetate 115a (1.63 g, 
15.84 mmol) and MgSO4 in DCM as described by the general procedure; Physical 
characteristics: orange oil; Yield: 1.62 g, 86%; 1H NMR (400 MHz, CDCl3) δ 8.16 (1H, s, 
N=CH), 7.47 (1H, s,  ArH), 7.09 (2H, d, J = 8.4 Hz,  ArH), 5.29 (OH), 4.35 (2H, s, 2-CH2), 4.20 
(2H, q, J = 7.2 Hz, OCH2CH3), 3.89 (3H, s, ArOCH3), 1.27 (3H, t, J = 7.2 Hz, OCH2CH3);
13C 
NMR (101 MHz, CDCl3) δ 170.0 (C=O), 165.3 (N=CH), 159.7 (ArCOCH3), 149.8 (ArCOH), 
136.9, 118.0 , 111.5, 98.0 (ArC), 61.8 (2-C), 61.0 (4-C), 55.2 (ArCOCH3), 14.1 (5-C). 
 
8.4.3.9. (E)-Ethyl 2–(benzylideneamino)acetate 116h 
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(E)-Ethyl 2-(benzylideneamino)acetate 116h was successfully synthesized from benzaldehyde 
(647 mg, 6.10 mmol), ethyl 2-aminoacetate (1.26 g, 12.2 mmol) and MgSO4 in DCM as described 
by the general procedure; Physical characteristics: colourless oil; Yield: 1.12 g, 96%:1H NMR 
(400 MHz, CDCl3) δ 8.26 (1H, s, N=CH), 7.38-7.76 (5H, m, ArH), 4.37 (2H, s, 2-CH2), 4.18 
(2H, q, J = 7.2 Hz, OCH2CH3), 1.25- (3H, t, J = 7.2 Hz, OCH2CH3);
13C NMR (101 MHz, 
CDCl3) δ 170.0 (C=O), 165.8 (N=CH), 135.4, 131.7, 128.5, 128.3 (ArC), 61.9 (2-C), 60.9 (4-C), 
14.1 (5-C). 
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8.4.3.10. (S, E)-Ethyl 2 –(4-fluorobenzylideneamino)propanoate 117a 
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(S, E)-Ethyl 2 –(4-fluorobenzylideneamino)propanoate 117a was successfully synthesized from 4-
fluorobenzaldehyde (826 mg, 6.66 mmol), L-alanine ethyl ester 115b (1.56 g, 13.3 mmol) and 
MgSO4 in DCM as described by the general procedure; Physical characteristics: pale yellow 
oil; Yield: 1.35 g, 91%; 1H NMR (400 MHz, CDCl3) δ 8.29 (1H, s, N=CH), 7.74-7.76 (2H, m, 
ArH), 7.38 (2H, t, J = 8.4 Hz, ArH), 4.11-4.21 (3H, m, 2-CHCH3 and OCH2CH3 ), 1.50 (3H, q, J 
= 7.2 Hz, CHCH3), 1.23 (3H, t, J = 7.2 Hz, OCH2CH3); 
13C NMR (101 MHz, CDCl3) δ 170.0 
(C=O), 164.4 (d, 1JC,F = 247 Hz, para-CF), 163.8 (N=CH), 131.4 (d, 
4JCF = 3 Hz, 1‟-C), 126.4 (d, 
3JCF =9 Hz, ortho-C), 115.5 (d, 
2JCF = 22 Hz, meta-C), 66.8 (2-C), 61.7 (4-C), 18.3 (7-C), 14.0 (5-C). 
 
8.4.3.11. (S, E)-Ethyl 2-(3-methoxybenzylideneamino)propanoate 117b 
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(S,E)-Ethyl 2-(3-methoxybenzylideneamino)propanoate 117b was successfully synthesized from 
3-methoxybenzaldehyde (905 mg, 6.65 mmol), L-alanine ethyl ester 115b (1.56 g, 13.30 mmol) 
and MgSO4 in DCM as described by the general procedure; Physical characteristics: light 
yellow oil; Yield: 1.13 g, 72%; 1H NMR (400 MHz, CDCl3) δ 8.20 (1H, s, N=CH), 7.30 (1H, s, 
ArH), 7.19-7.24 (2H, m, ArH), 6.89-6.92 (1H, m, ArH), 4.05-4.16 (3H, m, 2-CHCH3 and 
OCH2CH3 ), 3.78 (3H, s, ArOCH3), 1.44 (3H, q, J = 7.4 Hz, CHCH3), 1.18 (3H, t, J = 7.0 Hz, 
OCH2CH3); 
13C NMR (101 MHz, CDCl3) δ 172.5 (C=O), 162.7 (N=CH), 159.8 (ArCOCH3), 
137.1, 129.5, 121.8, 117.8, 111.7 (ArC), 67.9 (2-C), 61.0 (4-C), 55.3 (ArCOCH3), 19.3 (7-C), 14.1 
(5-C). 
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8.4.3.12. (S,E)-Ethyl 2-(3,4-dimethoxybenzylideneamino)propanoate 117c 
1'
N1 2
3 O
4
O
5
6
7
O
O  
(S,E)-Ethyl 2-(3,4-dimethoxybenzylideneamino)propanoate 117c was successfully synthesized 
from 3,4-dimethoxybenzaldehyde (1.16 g, 6.98 mmol), L-alanine ethyl ester (1.64 g, 13.96 mmol) 
and MgSO4 in DCM as described by the general procedure; Physical characteristics: pale 
yellow oil; Yield: 1.54 g, 83%; 1H NMR (400 MHz, CDCl3) δ 8.17 (1H, s, N=CH), 7.41 (1H, s, 
ArH), 7.14 (1H, d, J = 8.4 Hz, ArH), 6.82 (1H, d, J = 8.4 Hz, ArH), 4.05-4.18 (3H, m, 2-CHCH3 
and OCH2CH3 ), 3.86 and 3.89 (6H, 2 x s, 2 x ArOCH3), 1.46 (3H, J = 7.4 Hz, CHCH3), 1.21 
(3H, t, J = 7.2 Hz, OCH2CH3); 
13C NMR (101 MHz, CDCl3) δ 172.6 (C=O), 162.2 (N=CH), 
151.5 and 149.1 (2 x ArCOCH3), 128.9, 123.5, 110.1, 108.8 (ArC), 67.7 (2-C), 60.8 (4-C), 55.9 and 
55.8 (2 x ArCOCH3), 19.3 (7-C), 14.0 (5-C). 
 
8.4.3.13. (R,E)-Ethyl-5-(4-Fluorobenzylideneamino)-7-methyloctan-4-one 118a 
1'
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(R,E)-Ethyl 2-(4-fluorobenzylideneamino)-4-methylpentanoate 117a was successfully synthesized 
from 4-fluorobenzaldehyde (943 mg, 7.60 mmol), D-leucine ethyl ester 115c (2.42 g, 15.20 mmol) 
and MgSO4 in DCM as described by the general procedure; Physical characteristics: pale 
yellow oil; Yield: 1.77 g, 88%; 1H NMR (400 MHz, CDCl3) δ 8.25 (1H, s, N=CH), 7.76-7.79 
(2H, m, ArH), 7.06-7.11 (2H, m, ArH), 4.03-4.23 (3H, m, 2-CH and OCH2CH3 ), 1.80-1.85 (2H, 
m, 6-CH2), 1.54-1.59 (1H, m, 7-CH), 1.27 (3H, t, J =7.2 Hz, OCH2CH3), 0.84 (6H, 2 x d, J = 6.4 
Hz each, 2 x 8-CH3);  
13C NMR (101 MHz, CDCl3) δ 172.4 (C=O), 164.0 (d, JC,F = 250.9 Hz, 
para-CF), 161.4 (N=CH), 132.0 (d, 4JCF = 3.0 Hz, 1‟-C,), 130.4 (d, 
3JCF =10.1 Hz, ortho-C), 115.6 
(d, 2JCF = 22.1 Hz, meta-C), 71.5 (2-C), 61.0 (4-C), 42.0 (6-C), 24.4 (7-C), 23.0 and 21.5 (2x 8-C), 
14.1 (5-C). 
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8.4.3.14 (R,E)-Ethyl 2-(3,4-dimethoxybenzylideneamino)-4-methylpentanoate117c 
1'
O
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O
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(R,E)-Ethyl 2-(3,4-dimethoxybenzylideneamino)-4-methylpentanoate 118c was successfully 
synthesized from 3,4-dimethoxybenzaldehyde (961 mg, 5.78 mmol), D-leucine ethyl ester (1.84 g, 
11.56 mmol) and MgSO4 in DCM as described by the general procedure; Physical 
characteristics: pale yellow oil; Yield: 1.53 g, 86%; 1H NMR (400 MHz, CDCl3) δ 8.17 (1H, s, 
N=CH), 7.41 (1H, s, ArH), 7.14 (1H, d, J = 8.4 Hz, ArH), 6.82 (1H, d, J = 8.4 Hz, ArH), 4.05-
4.18 (3H, m, 2-CHCH3 and OCH2CH3 ), 3.86 and 3.89 (6H, 2 x s, 2 x ArOCH3), 1.46 (3H, 1.80-
1.85 (2H, m, 6-CH2), 1.54-1.59 (1H, m, 7-CH), 1.27 (3H, t, J =7.2 Hz, OCH2CH3), 0.84 (6H, 2 x 
d, J = 6.4 Hz each, 2 x 8-CH3);  
13C NMR (101 MHz, CDCl3) δ 172.6 (C=O), 162.2 (N=CH), 
151.5 and 149.1 (2 x ArCOCH3), 128.9, 123.5, 110.1, 108.8 (ArC), 67.7 (2-C), 60.8 (4-C),.3 (7-C), 
14.0 (5-C), 71.5 (2-C), 61.0 (4-C), 55.9 and 55.8 (2 x ArCOCH3), 42.0 (6-C), 24.4 (7-C), 23.0 and 
21.5 (2 x 8-C), 14.1 (5-C). 
 
8.4.3.15. (R,E)-Ethyl 2-(benzylideneamino)-4-methylpentanoate 118c 
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(R,E)-Ethyl 2-(benzylideneamino)-4-methylpentanoate 118c was successful synthesized from 
benzaldehyde (653 mg, 6.15 mmol), D-leucine ethyl ester 115c (1.96 g, 12.30 mmol) and MgSO4 
in DCM as described by the general procedure; Physical characteristics: colourless oil; Yield: 
1.23 g, 81%; 1H NMR (400 MHz, CDCl3) δ 8.26 (1H, s, N=CH), 7.38-7.76 (5H, m, ArH), 4.37 
(2H, s, 2-CH2), 1.46 (3H, 1.80-1.85 (2H, m, 6-CH2), 1.54-1.59 (1H, m, 7-CH), 1.27 (3H, t, J =7.2 
Hz, OCH2CH3), 0.84 (6H, dd, J = 6.4, 2 x 8-CH3);
13C NMR (101 MHz, CDCl3) δ 170.0 (C=O), 
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165.8 (N=CH), 135.4, 131.7, 128.5, 128.3 (ArC), 42.0 71.5 (2-C), 61.0 (4-C), 4.20 (6-C), 24.4 (7-
C), 23.0 and 21.5 (2 x 8-C), 14.1 (5-C). 
 
8.4.4. Synthesis of ethyl 2-(5-aryl-1H-imidazol-1-yl)acyl derivatives 
8.4.4.1. Synthesis of ethyl 2-[5-(3,4-dimethoxyphenyl)-4-tosyl-4,5-dihydro-1H-imidazol-1-
yl)acetate 
To a stirred solution of ethyl-2-(3,4-dimethoxybenzylideneamino)acetate 116d (451 mg, 2.04 
mmol), TosMIC (398 mg, 2.04 mmol) in DCM (8 ml) was added dropwise a solution of DBU 
(311 mg, 2.04 mmol) in DCM (2 ml) at room temperature. Upon completion of addition, the 
resulted mixture was stirred at same temperature for 24 hours (monitored by TLC). After 
consumption of TosMIC, the solvent was concentrated in vacuo afforded crude brown oil. The 
crude product was separated by column chromatography elution with ethyl acetate: hexane ratio 
(1:1) afforded a diastereomeric mixture of (cis- and trans-ethyl 2-[5-(3,4-dimethoxyphenyl)-4-
tosyl-4,5-dihydro-1H-imidazol-1-yl)acetate 119.  
1'
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Physical characteristics: brown oil; Yield: 501 mg, 55%; cis- and trans-ethyl 2-[5-(3,4-
dimethoxyphenyl)-4-tosyl-4,5-dihydro-1H-imidazol-1-yl)acetate 119: 1H NMR (400MHz, CDCl3) 
δ 8.15trans (0.3H, s, 2-CH ), 7.83 (2H, d, J = 7.2 Hz, ArH), 7.33 (2H, d, J = 7.2 Hz, ArH), 7.14cis 
(0.7H, s, 2-CH), 6.78-6.93 (3H, m, ArH), 5.25cis (0.7H, d, J = 6.4 Hz, 5-CH), 5.05cis (0.7H, d, J = 
6.4 Hz, 4-CH), 4.77trans (0.6H s, 4-  and 5-CH), 4.17- 4.23 (2H, m, OCH2CH3), 3.84-3.91 (6H, m, 
2 x OCH3 and CH2CO), 2.42cis (2H, s, ArCH3), 2.04trans (1H, s, ArCH3), 1.22-1.27 (3H, m, 
OCH2CH3). 
 
8.4.4.2. Synthesis of ethyl 2-[5-(3,4-dimethoxyphenyl)-1H-imidazol-1-yl]acetate 
A diastereomeric mixture of ethyl 2-[(5-(3,4-dimethoxyphenyl)-4-tosyl-4,5-dihydro-1H-imidazol-
1-yl]acetate 119 (500 mg, 1.12 mmol) was dissolved in toluene (10 ml) and transferred into a 35 
ml microwave vessel equipped with magnetic stirrer bar and then capped. The resulting solution 
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was microwave irradiated at a set temperature of 115oC and a set time of 10 minutes. After the 
resulting solution cooled down, the solvent was concentrated in vacuo to afford a dark brown oil 
which was separated by flash column chromatography (first elution with 100% ethyl acetate 
followed by 2% MeOH in ethyl acetate) to give pure ethyl 2-[5-(3,4-dimethoxyphenyl)-1H-
imidazol-1-yl]acetate 120d after drying under high vacuum, Physical characteristics: yellow 
solid; Yield: 167 mg, 60%. 
 
8.4.4.3. Synthetic procedure  
To a stirred solution of ethyl 2-(arylideneamino)acylate (1 molar equivalent), TosMIC (1 molar 
equivalent) in DCM (8 ml) was added dropwise a solution of DBU (1 molar equivalent) in DCM 
(2 ml) at room temperature. Upon completion of addition, the resulting mixture was stirred at 
the same temperature for 24 hours (monitored by TLC). After consumption of TosMIC, the 
solvent was concentrated in vacuo afforded brown oily crude material. The crude material was re-
dissolved in toluene (10 ml) and transferred into a 35ml microwave vessel equipped with 
magnetic stirred bar and then capped. The resulting solution was microwave irradiated at a set 
temperature of 115oC and a set time of 10 minutes. After the solution cooled down, the solvent 
was concentrated in vacuo afforded dark brown oily crude material which was separated by flash 
column chromatography [first elution with (2:1) hexane: ethyl acetate followed by 1% MeOH in 
ethyl acetate] to give pure product after drying under high vacuum.   
 
8.4.4.4. Ethyl 2-[5-(4-fluorophenyl)-1H-imidazol-1-yl]acetate 120a 
1'
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Ethyl 2-[5-(4-fluorophenyl)-1H-imidazol-1-yl]acetate 120a was successfully synthesized from 
ethyl 2-(4-fluorobenzylideneamino)acetate 116a(2.59 g, 12.4 mmol), TosMIC (2.42 mg, 12.4 
mmol) and DBU (1.89 g, 12.4 mmol) as described by the general procedure; Physical 
characteristics: brown oil; Yield: 1.60 g, 52%; 1H NMR (400 MHz, CDCl3) δ 7.51 (1H, s, 2-
CH), 7.20-7.24 (2H, m, ArH), 7.02 (2H, t, J = 8.6 Hz, ArH), 6.98 (1H, s, 4-CH), 4.56 (2H, s, 
NCH2), 4.08 (2H, q, J = 7.2 Hz, OCH2CH3), 1.13 (3H, t, J = 7.2 Hz, OCH2CH3); 
13C NMR (101 
MHz, CDCl3) δ 167.6 (C=O), 163.7 (d, 
1JC,F = 249 Hz, para-CF), 138.9 (2-C), 132.4 (5-C), 130.8 
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(d, 3JC,F = 8 Hz, ortho-C), 127.9 (4-C), 125.1 (d, 
4JC,F= 3 Hz, 1‟-C), 115.7 (d, 
2J C,F= 22.1 Hz, meta-
C), 62.0 (8-C), 46.2 (6-C), 13.9 (9-C); FTIR νmax/cm
-1 (KBr): 3104, 3026, 1747, 1568, 1496, 1380, 
1478, 1278, 1163, 854, 824, 698, 694, 543; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for 
C13H14FN2O2 249.1034, found 249.1027. 
 
8.4.4.5. Ethyl 2-(5-(2-chlorophenyl)-1H-imidazol-1-yl)acetate 120b 
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Ethyl 2-(5-(2-chlorophenyl)-1H-imidazol-1-yl)acetate 120b was successfully synthesized from 
ethyl 2-(2-chlorobenzylideneamino)acetate 116b (824 mg, 3.65 mmol) TosMIC (713 mg, 3.65 
mmol) and DBU (556 mg, 3.65 mmol) as described by the general procedure; Physical 
characteristics: brown oil; Yield: 237 g, 26%; 1H NMR (400 MHz, CDCl3) δ 7.88 (1H, s, 2-
CH), 7.38-7.50 (2H, m, ArH), 7.32-7.33 (2H, m, ArH), 7.10 (1H, s 4-CH), 4.62 (2H, s, NCH2), 
4.16 (2H, q, J = 7.2 Hz, OCH2CH3), 1.21 (3H, t, J = 7.2 Hz, OCH2CH3); 
13C NMR (101 MHz, 
CDCl3) δ 167.7 (C=O), 138.5 (2-C), 134.8, 133.2, 130.9, 130.4, 129.7 (ArC),, 127.5 (4-C), 127.1 
(ArC), 62.2 (8-C), 46.4 (6-C), 14.1 (9-C); FTIR νmax/cm
-1 (KBr): 2955, 2930, 1748, 1617, 1566, 
1503, 1435, 1356, 1217, 1143, 1039, 759, 665, 513; HRMS (ESI-TOF) m/z: [M+H]+ Calcd. 
for C13H14N2O2Cl
+ 265.0738; Found 265.0738. 
 
8.4.4.6. Ethyl 2-[5-(3-methoxyphenyl)-1H-imidazol-1-yl]acetate 120c 
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Ethyl 2-[5-(3-methoxyphenyl)-1H-imidazol-1-yl]acetate 120c was successfully synthesized from 
ethyl 2-(3-methoxybenzylideneamino)acetate 116c (1.05 g, 4.76 mmol) TosMIC (929 mg, 4.76 
mmol) and DBU (725 mg, 4.76 mmol) as described by the general procedure; Physical 
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characteristics: brownish yellow oil; Yield: 471 mg, 38%; 1H NMR (400 MHz, CDCl3) δ 7.57 
(1H, s, 2-CH), 7.29-7.33 (1H, m, ArH), 7.08 (1H, s, 4-CH), 6.84-6.92 (3H, m, ArH), 4.66 (2H, s, 
NCH2), 4.15 (2H, q,
 J = 7.2 Hz, OCH2CH3), 3.79 (3H, s, ArOCH3), 1.19 (3H, t,
 J =7.2 Hz, 
OCH2CH3); 
13C NMR (101 MHz, CDCl3) δ 167.7 (C=O), 159.8 (ArCOCH3), 139.0 (2-C), 133.2 
(5-C), 130.3, 129.8, 127.8 (ArC), 121.01 (4-C), 114.3, 113.9 (ArC), 62.0 (8-C), 46.4 (6-C), 13.9 (9-
C); FTIR νmax/cm
-1 (KBr): 3126, 2887, 1745, 1604, 1591, 1536, 1453, 1425, 1379, 1326, 1292, 
1225, 1027, 928, 800, 699, 516; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C14H17N2O3 
261.1234, found 261.1232. 
 
8.4.4.7. Ethyl 2-[5-(3,4-dimethoxyphenyl)-1H-imidazol-1-yl]acetate 120d 
1'
1O
O
N
2
3
N
4
5
6
7
O
O 8
9  
Ethyl 2-[5-(3,4-dimethoxyphenyl)-1H-imidazol-1-yl]acetate 120d was successfully synthesized 
from ethyl 2-(2,4-dimethoxybenzylideneamino)acetate 116d (837 mg, 3.33 mmol) TosMIC (650 
mg, 3.33 mmol) and DBU (507 mg, 3.33 mmol) as described by the general procedure; Physical 
characteristics: yellow solid; Yield: 715 mg, 74%; Melting point: 67-70°C; 1H NMR 
(400MHz, CDCl3) δ 7.56 (1H, s, 2-CH), 7.01 (1H, s, 4-CH), 6.81-6.88 (3H, m, ArH), 4.61 (2H, s, 
NCH2), 4.13 (2H, q, J = 7.2 Hz, OCH2CH3) 3.83 and 3.87 (6H, 2 x s, 2 x ArOCH3), 1.18 (3H, t, J 
= 7.2 Hz, OCH2CH3); 
13C NMR (101 MHz, CDCl3) δ 167.8 (C=O), 149.2 and 148.9 (2 x 
ArCOCH3), 138.5 (2-C), 133.3 (5-C), 127.3, 121.6, (ArC), 121.5 (4-C), 112.3, 111.2 (ArC), 61.9 
(8-C), 55.81 and 55.78 (2 x ArCOCH3), 46.3 (6-C), 13.9 (9-C); FTIR νmax/cm
-1 (KBr): 2955, 2930, 
1748, 1617, 1566, 1503, 1435, 1356, 1217, 1143, 1039, 759, 665, 513; HRMS (ESI-TOF) m/z: 
[M+H]+ Calcd for C15H21N2O4 291.1339, found 291.1332 
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8.4.4.8. Ethyl 2-(5-(benzo[d][1,3]dioxol-6-yl)-1H-imidazol-1-yl)acetate 120e 
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Ethyl 2-(5-(benzo[d][1,3]dioxol-6-yl)-1H-imidazol-1-yl)acetate 120e was successfully synthesized 
from ethyl 2-{(benzo[d][1,3]dioxol-6-yl)methyleneamino}acetate 116e (838 mg, 3.56 mmol), 
TosMIC (695 mg, 3.56 mmol) and DBU (542 mg, 3.56 mmol) as described by the general 
synthetic procedure C; Physical characteristics: pale yellow solid; Yield: 439 mg, 45%; 
Melting point: 83-86oC; 1H NMR (400MHz, CDCl3) δ 7.52 (1H, s, 2-CH), 6.97 (1H, s, 4-CH), 
6.79 (1H, d, J = 7.4 Hz, ArH), 6.71-6.72 (2H, overlapping singlet and doublet, ArH), 5.95 (2H, s, 
ArOCH2O), 4.60 (2H, s, NCH2), 4.13 (3H, q, J = 7.2 Hz, OCH2CH3), 1.18 (3H, t, J = 7.2 Hz, 
OCH2CH3); 
13C NMR (101 MHz, CDCl3) δ 167.7 (C=O), 147.8 and 148.7 (2 x ArCOCH2O), 
138.6 (2-C), 133.0 (5-C), 127.4, (ArC), 122.8 (4-C), 122.5, 109.4, 108.5 (ArC), 101.2 
(ArCOCH2O), 61.9 (8-C), 46.2 (6-C), 13.9 (9-C); FTIR νmax/cm
-1 (KBr): 3097, 2986, 2908, 2782, 
1741, 1504, 1479, 1336, 1243, 1213, 1104, 1041, 921, 887, 813; HRMS (ESI-TOF) m/z: [M+H]+ 
Calcd for C13H13N2O4 261.1183, found 261.1186. 
 
8.4.4.9. Ethyl 2-(5-(4-tert-butylphenyl)-1H-imidazol-1-yl)acetate 120f 
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Ethyl 2-(5-(4-tert-butylphenyl)-1H-imidazol-1-yl)acetate 120f was successfully synthesized from 
ethyl 2-(4-tert-butylbenzylideneamino)acetate  116f (1.06 g, 4.30 mmol) TosMIC (839 mg,, 4.30 
mmol) and DBU (656 mg, 4.30 mmol) as described by the general procedure C; Physical 
characteristics: brown oil; Yield: 431 mg, 35%; 1H NMR (400 MHz, CDCl3) δ 7.64 (1H, s, 2-
CH), 7.45 (2H, d, J = 8.4 Hz, ArH), 7.28 (2H, d, J = 8.4 Hz, ArH), 7.10 (1H,s, 4-CH), 4.70 (2H, 
s, NCH2), 4.19 (2H, q, J = 7.2 Hz, OCH2CH3), 1.37 [9H, s, C(CH3)3], 1.21 (3H, t, J = 7.2 Hz, 
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OCH2CH3); 
13C NMR (101 MHz, CDCl3) δ 167.8 (C=O), 151.5 [ArCC(CH3)3], 138.8 (2-C), 
133.4, 128.6, 127.5, 126.1, 125.7 (ArC), 62.0 (8-C), 46.4 (6-C), 34.6 [ArCC(CH3)3], 31.2 
[ArCC(CH3)3], 14.0 (9-C); FTIR νmax/cm
-1 (KBr): 2966, 2904, 2870, 1755, 1480, 1363, 1265, 
1219, 1113, 1011, 913, 840, 656, 565; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C17H23N2O2 
287.1754, found 287.1764. 
 
8.4.4.10. Ethyl 2-(5-(3-hydroxy-4-methoxyphenyl)-1H-imidazol-1-yl)acetate 120g 
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Ethyl 2-(5-(3-hydroxy-4-methoxyphenyl)-1H-imidazol-1-yl)acetate 120g was successfully 
synthesized from ethyl 2-(3-hydrozyl-4-methoxybenzylideneamino)acetate 116g (1.26 g, 5.32 
mmol), TosMIC (1.04 g, 5.32 mmol) and DBU ( 810 mg, 5.32 mmol) as described by the general  
procedure; Physical characteristics: yellow solid; Yield: 750 mg, 51%; Melting point: 137-
140oC; 1H NMR (400 MHz, CDCl3) δ 7.76 (1H, s, 2-CH), 7.06 (1H, s , 4-CH), 6.95-6.97 (1H, d, 
J = 8.4 Hz, ArH), 6.76-6.81 (2H, m, ArH), 5.24 (1H, brs, ArOH), 4.67 (2H, s, NCH2), 4.16 (2H, 
q, J = 7.2 Hz, OCH2CH3), 3.87 (3H, s, ArOCH3), 1.21 (3H, t, J = 7.2 Hz, OCH2CH3); 
13C NMR 
(101 MHz, CDCl3) δ 167.8 (C=O), 147.0 and 146.7 (ArCOCH3 and ArCOH), 138.2 (2-C), 133.8 
(5-C), 126.0, 122.5 (ArC), 120.1 (4-C), 115.0, 112.2 (ArC), 62.2 (8-C), 56.0 (ArCOCH3), 46.5 (6-
C), 14.1 (9-C); FTIR νmax/cm
-1 (KBr): 2974, 2929, 2608, 1748, 1596, 1552, 1501, 1494, 1474, 
1334, 1213, 1112, 1026, 956, 813, 616; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C14H17N2O4 
277.1183, found 277.1184. 
 
8.4.4.11. Ethyl 2-[(5-phenyl)-1H-imidazol-1-yl]acetate 120h 
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Ethyl 2-[(5-phenyl)-1H-imidazol-1-yl]acetate 120h was successfully synthesized from ethyl 2-
(benzylideneamino)acetate 116h ( 996 mg, 5.21  mmol) TosMIC (1.02 g, 5.21 mmol) and DBU 
(793 mg, 5.21 mmol) as described by the general procedure C; Physical characteristics: pale 
yellow solid; Yield: 396 mg, 33%; Melting point: 144-147°C; 1H NMR (400MHz; CDCl3) δ 
7.58 (1H, s, 2-CH), 7.29-7.41 (5H, m, ArH), 7.08 (1H, s, 4-CH), 4.66 (2H, s, NCH2), 4.14 (2H, q,
 
J = 7.2 Hz, OCH2CH3), 1.18 (3H, t,
 J = 7.2 Hz, OCH2CH3); 
13C NMR (101 MHz, CDCl3) δ 
167.7 (C=O), 139.0 (2-C), 133.4 (5-C), 129.1, 128.9, 128.8, 128.3 (ArC), 127.8 (4-C), 62.0 (8-C), 
46.4 (6-C), 13.9 (9-C); FTIR νmax/cm
-1 (KBr): 3122, 2936, 2954, 1736, 1602, 1484, 1444, 1376, 
1321, 1216, 1160, 1118, 1080, 978, 852, 824, 768, 700, 660; HRMS (ESI-TOF) m/z: [M+H]+ 
Calcd for C13H15N2O2 231.1128, found 231.1126. 
 
8.4.4.12. (R)-Ethyl 2-(5-(4-fluorophenyl)-1H-imidazol-1-yl)propanoate 121a 
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(R)-Ethyl 2-(5-(4-fluorophenyl)-1H-imidazol-1-yl)propanoate 121a was successfully synthesized 
from (R, E)-ethyl 2-(4-fluorobenzylideneamino)propanoate 117a (299 mg, 1.34 mmol), TosMIC ( 
262 mg, 1.34 mmol) and DBU ( 204 mg, 1.34 mmol) as described by the general synthetic 
procedure C; Physical characteristics: pale yellow oil; Yield: 39 mg, 11%; 1H NMR (400 
MHz, CDCl3) δ 7.52 (1H, s, 2-CH), 7.20-7.24 (2H, m, ArH), 7.02 (2H, t, J = 8.8 Hz, ArH), 6.97 
(1H, s, 4-CH), 4.56 (2H, s, NCH2), 4.81 (1H, q, J = 7.2 Hz, CHCH3), 4.17-4.25 (2H, q, J = 7 Hz, 
OCH2CH3), 1.65-1.72 )3H, d, J = 8 Hz, CHCH3), 1.14 (3H, t, J = 7.2 Hz, OCH2CH3); 
13C NMR 
(101 MHz, CDCl3) δ 167.3 (C=O), 163.2 (d,
1J C,F = 249 Hz, para-CF), 138.97 (2-C), 132.4 (5-C), 
130.8 (d, 3JC,F= 8 Hz, ortho-C), 127.9 (4-C), 125.1 (d, 
4JC,F = 3.0 Hz, 1‟-C), 115.7 (d, 
2J C,F= 22 Hz, 
meta-C), 62.0 (8-C), 50.6 (6-C), 18.6 (10-C), 13.9 (9-C).; FTIR νmax/cm
-1 (KBr): 2955, 2930, 1748, 
1617, 1566, 1503, 1435, 1356, 1217, 1143, 1039, 759, 665, 513; HRMS (ESI-TOF) m/z: [M+H]+ 
Calcd for C14H16FN2O2 263.1173, found 263.1190. 
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8.4.4.13. (R)-Ethyl 2-(5-(3,4-dimethoxyphenyl)-1H-imidazol-1-yl)propanoate 121b 
1'
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(R)-Ethyl 2-(5-(3,4-dimethoxyphenyl)-1H-imidazol-1-yl)propanoate 121b was successfully 
synthesized from (R, E)-ethyl 2-(2,4-dimethoxybenzylideneamino)propanoate 117c (483 mg, 1.82 
mmol), TosMIC (355 mg, 1.82 mmol) and DBU ( 277 mg, 1.82 mmol) as described by the 
general synthetic procedure C; Physical characteristics: yellow solid; Yield: 127 mg, 23%; 1H 
NMR (400 MHz, CDCl3) δ 7.69 (1H, s, 2-CH), 6.96 (1H, s, 4-CH), 6.78-6.88 (3H, m, ArH), 4.78 
(1H, q, J = 8.4 Hz, CHCH3), 4.10 (2H, q, J = 7.2 Hz, 2 x OCH2CH3), 3.82 and 3.86 (6H, 2 x s, 
ArOCH3), 1.66 (3H, d, J = 7.2 Hz, CHCH3),  1.16-1.20 (3H, t, J = 7.2 Hz, OCH2CH3); 
13C NMR 
(101 MHz, CDCl3) δ 167.4 (C=O), 149.15 and 148.9 (2 x ArCOCH3), 135.7 (2-C), 130.7 (5-C), 
127.5, 127.7, 127.6, 112.6, 111.2 (ArC), 61.8 (8-C), 55.7 (6-C), 55.7 and 55.8 (2 x ArCOCH3), 18.8 
(10-C), 13.9 (9-C); FTIR νmax/cm
-1 (KBr): 3635, 2954, 2896, 2783, 1750, 1668, 1479, 1440, 1378, 
1306, 1225, 1108, 1038, 933, 880, 815, 726, 668, 579; HRMS (ESI-TOF) m/z: [M+H]+ Calcd 
for C16H21N2O4 305.1476, found 305.1503. 
 
8.4.4.14. (R)-Ethyl 2-(5-phenyl-1H-imidazol-1-yl)propanoate 121d 
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(R)-Ethyl 2-(5-(phenyl)-1H-imidazol-1-yl)propanoate 121d was successful synthesized from (R, 
E)-ethyl 2-(benzylideneamino)propanoate 117h (372 mg, 1.81 mmol) TosMIC (353 mg, 1.81 
mmol) and DBU (276 mg, 1.81 mmol) as described by the general synthetic procedure C; 
Physical characteristics: yellow solid; Yield: 88 mg, 20%; 1H NMR (400 MHz, CDCl3) δ 7.76 
(1H, s, 2-CH), 7.37-7.41 (3H, m, ArH), 7.27-7.29 (2H, m, ArH), 7.03 (1H, s, 4-CH), 4.80 (1H, q, 
J = 8.4 Hz, CHCH3), 4.12 (2H, q, J = 7.2 Hz, OCH2CH3), 1.70 (3H, d, J = 7.2 Hz, CHCH3), 1.17 
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(3H, t, J = 7.2 Hz, OCH2CH3); 
13C NMR (101 MHz, CDCl3) δ 170.3 (C=O), 136.0 (2-C), 133.1 
(5-C), 129.3, 129.2, 128.7, 128.3, 127.2 (ArC), 61.9 (8-C), 52.9 (6-C), 18.8 (10-C), 13.9 (9-C); 
HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C14H17N2O2 245.1258; found 245.1279. 
 
8.4.5. Synthesis of 2-(5-aryl)-1H-imidazol-1-yl)acetic acid derivatives 
8.4.5.1 Synthetic procedure A 
NaOH (3 molar equivalents) was added to a solution of ethyl 2-(5-aryl-1H-imidazol-1-yl)acetate 
(1 molar equivalent) in 15 ml of 1:1 MeOH: H2O, and the solution was refluxed until 
disappearance of the starting material (observed by TLC). Volatile methanol was removed in 
vacuo and the remaining aqueous crude material was slowly neutralized with 1M HCl. 
Unfortunately, attempts to extract with ethyl acetate the product with ethyl  acetate were 
unsuccessful. 
 
8.4.5.2. Synthetic procedure B 
In a 10 ml microwave vessels equipped with a magnetic stirrer bar, was added ethyl 2-(5-aryl-1H-
imidazol-1-yl)acetate 120 (1 molar equivalent) and water (5 ml). The cap was placed and the 
resulting mixture was microwave irradiated at a set power of 200 Watts and a temperature of 
105oC for 3 hours. After completion of the reaction, mixture was transferred into separating 
funnel, water (5 ml) was added, followed by the wash with ethyl acetate (3 x 10 ml). The water 
layer was evaporated in vacuo and dried under high vacuum to afford the desired pure 2-(5-aryl)-
1H-imidazol-1-yl)acetic acids. 
 
8.4.5.3. 2-[5-(4-Flurorophenyl)-1H-imidazol-1-yl]acetic acid 123a 
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2-[5-(4-Flurorophenyl)-1H-imidazol-1-yl]acetic acid 123a was successfully synthesized by 
microwave irradiation of ethyl 2-[5-(4-fluorophenyl)-1H-imidazol-1-yl]acetate 120a (186 mg, 0.75 
mmol) in water according to the general procedure B; Physical characteristics: pale yellow 
solid; Yield:119 mg, 72%; Melting point: 189-192oC; 1H NMR (400 MHz, DMSO-d6) δ 7.89 
(1H, s, 2-CH), 7.45 -7.49 (2H, m, ArH), 7.31-7.35 (2H, m, ArH), 7.11 (1H, s, 4-CH), 6.61 (1H, 
broad s, OH), 4.88 (2H, s, NCH2);
13C NMR (101 MHz, DMSO-d6) δ 170.7 (C=O), 162.3 (d, JC,F 
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= 246 Hz, para-CF), 140.8 (2-C), 132.8 (5-C), 131.3 (d, 3JC,F = 8 Hz, ortho-C), 127.6 (4-C), 126.8 
(d, 4JC,F = 3 Hz, 1‟-C), 116.8 (d, 
2JC,F = 22 Hz, meta-C), 47.4 (6-C); FTIR νmax/cm
-1 (KBr): 3105, 
3032, 2434, 1645, 1540,1496, 1380, 1290, 1226, 1165, 1110, 544, 823, 767, 697, 693, 544; HRMS 
(ESI-TOF) m/z: [M+H]+ Calcd for C11H10FN2O2 221.0721, found 221.0720. 
 
8.4.5.4. 2-[5-(3-Methoxyphenyl)-1H-imidazol-1-yl]acetic acid 123c 
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2-[5-(3-Methoxyphenyl)-1H-imidazol-1-yl]acetic acid 123c was successfully synthesized by 
microwave irradiation of ethyl 2-[5-(3-methoxyphenyl)-1H-imidazol-1-yl]acetate 120c (250 mg, 
0.96 mmol) in water according to the general procedure B; Physical characteristics: yellow 
solid; Yield: 125 mg, 56%; 1H NMR (400 MHz, DMSO-d6) δ 7.87 (1H, s, 2-CH), 7.37-7.41 (1H, 
m, ArH), 7.13 (1H, s, 4-CH), 6.97-7.00 (3H, m, ArH), 6.51 (1H, brs, OH), 4.85 (2H, s, NCH2), 
3.80 (3H, s, ArOCH3);
13C NMR (101 MHz, DMSO-d6) δ 171.0 (C=O), 160.4 (ArCOCH3), 140.9 
(2-C), 133.6 (5-C), 130.9, 131.6, 127.6 (ArC), 121.2 (4-C), 114.6, 114.3 (ArC), 56.1 (ArCOCH3), 
47.9 (6-C); FTIR νmax/cm
-1 (KBr): 3126, 2946, 2450, 1696, 1609, 1578, 1487, 1394, 1300, 1207, 
1168, 1028, 854, 777, 693; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C12H13N2O3 233.0921, 
found 233.0922. 
 
8.4.5.5. 2-[5-(3,4-Dimethoxyphenyl)-1H-imidazol-1-yl]acetic acid 123d 
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2-[5-(3,4-Dimethoxyphenyl)-1H-imidazol-1-yl]acetic acid 123d was successfully synthesized by 
microwave irradiation of ethyl 2-[5-(3,4-dimethoxyphenyl)-1H-imidazol-1-yl]acetate 120d (139 
mg, 0.48 mmol) in water according to the general procedure B; Physical characteristics: yellow 
solid; Yield: 89 mg, 71%; Melting point: 124-127oC; 1H NMR (400 MHz, DMSO-d6) δ 7.82 
(1H, s, 2-CH), 7.06 (1H, s, ArH), 6.92-7.04 (3H, m, ArH), 6.01 (1H, brs, OH), 4.78 (2H, s, 
NCH2), 3.79 and 3.81 (6H, 2 x s, 2 x ArOCH3); 
13C NMR (101 MHz, DMSO-d6) δ 171.2 (C=O), 
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149.6 and 149.6 (2 x ArCOCH3), 140.3 (2-C), 133.8 (5-C), 126.8, 122.8 (ArC), 121.6 (4-C), 112.9, 
111.8 (ArC), 56.4 and 56.5 (2 x ArCOCH3), 47.8 (6-C); FTIR νmax/cm
-1 (KBr): 3126, 3050, 2970, 
2841, 2604, 1612, 1512, 1471, 1447, 1380, 1324, 1256, 1224, 1181, 1146, 1021, 826, 806, 695, 
676; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C13H15N2O4 263.1040, Found 263.1017. 
 
8.4.5.6. 2-(5-(Benzo[d][1,3]dioxol-6-yl)-1H-imidazol-1-yl)acetic acid 123e 
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2-(5-(Benzo[d][1,3]dioxol-6-yl)-1H-imidazol-1-yl)acetic 123e was successfully synthesized by 
microwave irradiation of ethyl 2-(5-(benzo[d][1,3]dioxol-6-yl)-1H-imidazol-1-yl)acetate 120e (304 
mg, 1.11 mmol) in water according to the general procedure B; Physical characteristics: yellow 
solid; Yield: 186 mg, 68% ; Melting point: 233-236oC; 1H NMR (400 MHz, DMSO-d6) δ 
7.82(1H, s, 2-CH), 7.00 (1H, d, J = 8.0 Hz, ArH), 6.97 (1H, s, 4-CH), 6.85 (2H, d, J = 8.0 Hz, 
ArH), 6.09 (2H, s, ArOCH2O), 4.81 (2H, s, NCH2); 
13C NMR (101 MHz, DMSO-d6) δ 170 
(C=O), 148.5 and 148.1 (ArCOCH2O), 140.4 (2-C), 133.5 (5-C), 127.1, 124.0, 123.0, 109.6 (ArC), 
102 (ArCOCH2O), 47.6 (6-C); FTIR νmax/cm
-1 (KBr): 3435, 3152, 3096, 2500, 1652, 1604, 1504, 
1474, 1388, 1313, 1257, 1226, 1035, 882, 691; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for 
C12H11N2O4 247.0713, found 247.0702. 
 
8.4.5.7. 2-(5-(4-tert-Butylphenyl)-1H-imidazol-1-yl)acetic acid 123f 
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2-(5-(4-tert-Butylphenyl)-1H-imidazol-1-yl)acetic acid 123f was successfully synthesized by 
microwave irradiation of ethyl 2-(5-(4-tert-butylphenyl)-1H-imidazol-1-yl)acetate (189 mg, 0.66 
mmol) in water according to the general procedure B; Physical characteristics: yellow solid; 
Yield: 96 mg, 56% ; Melting point: 170-173oC; 1H NMR (400 MHz, DMSO-d6) δ 7.84 (1H, s, 
2-CH), 7.47 (2H, d, J = 7.6 Hz, ArH), 7.32 (2H, d, J = 7.6 Hz, ArH), 7.06 (1H, s, 4-CH), 4.70 
(2H, s, NCH2), 1.37 [9H, s, C(CH3)3]; 
13C NMR (101 MHz, DMSO-d6) δ 167.8 (C=O), 151.5 
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[ArCC(CH3)3], 138.8 (2-C), 133.4, 128.6, 127.5, 126.1, 125.7 (ArC), 46.4 (6-C), 34.6 
[ArCC(CH3)3], 31.2 [ArCC(CH3)3]; FTIR νmax/cm
-1 (KBr): 3132, 3035, 2961, 2905, 2868, 2509, 
1722, 1678, 1625, 1463, 1378, 1335, 1269, 1233, 1112, 1035, 1010, 841, 677; HRMS (ESI-TOF) 
m/z: [M+H]+ Calcd  for C15H19N2O2
+ 259.1441, Found 259.1440. 
 
8.4.5.8. 2-(5-(3-Hydroxy-4-methoxyphenyl)-1H-imidazol-1-yl)acetic acid 123g 
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2-(5-(3-Hydroxy-4-methoxyphenyl)-1H-imidazol-1-yl)acetic acid 123g was successfully 
synthesized from microwave irradiation of ethyl 2-(5-(3-hydroxy-4-methoxyphenyl)-1H-
imidazol-1-yl)acetate 120g (251 mg, 0.91 mmol) in water according to the general procedure B; 
Physical characteristics: yellow solid; Yield: 131 mg, 58%; Melting point: 211-214oC; 1H 
NMR (400 MHz, DMSO-d6) δ 7.80 (1H, s, 2-CH), 6.97 (1H, s , 4-CH), 6.83 (1H, d, J = 8.0 Hz, 
ArH), 6.75 (2H, d, J = 8.0, ArH), 5.24 (1H, br, ArOH), 4.69 (2H, s, NCH2), 3.75 (3H, s, 
ArOCH3); 
13C NMR (101 MHz, DMSO-d6) δ 170.3 (C=O), 147.6 and 146.7 (ArCOCH3 and 
ArCOH), 139.0 (2-C), 133.2 (5-C), 125.1(ArC), 121.2 (4-C), 120.2, 115.8, 112.4 (ArC), 55.6 
(ArCOCH3), 47.1 (6-C); FTIR νmax/cm
-1 (KBr): 2973, 2930, 2600, 1748, 1604, 1552, 1514, 1358, 
1312, 1280, 1214, 1139, 1109, 1026, 865, 822; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for 
C12H13N2O4 249.2421, found 249.2438. 
 
8.4.5.9. 2-(5-Phenyl-1H-imidazol-1-yl)acetic acid 123h 
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2-(5-Phenyl)-1H-imidazol-1-yl)acetic acid 123h was successfully synthesized by microwave 
irradiation of ethyl 2-[5-phenyl-1H-imidazol-1-yl]acetate 120h (200 mg, 0.87 mmol) in water 
according to the general procedure B; Physical characteristics: pale yellow solid; Yield: 120 
mg, 68%; Melting point: 175-178oC; 1H NMR (400 MHz, CDCl3) δ 10.0 (1H, s, OH), 8.54 
(1H, s, 2-CH), 7.2 (5H, m, ArH), 7.01 (1H, s, 4-CH), 4.55 (2H, s, NCH2); 
13C NMR (101 MHz, 
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CDCl3) δ 170.9 (C=O), 137.5 (2-C), 134.3 (5-C), 129.4, 129.2, 129.2 (ArC), 128.9 (C-4), 118.9 
(ArC), 49.2 (6-C); FTIR νmax/cm
-1 (KBr): 3139, 2957, 2900, 2861, 2517, 1730, 1691, 1626, 1378, 
1270, 1113, 766, 687; HRMS (ESI-TOF) m/z: [M+H] + Calcd for C11H11N2O2 203.0815; found 
203.0807. 
 
8.4.6. Synthesis of 2-(5-aryl-1H-imidazol-1-yl)acetohydrazide 
8.4.6.1. General synthetic procedure A 
A mixture of ethyl 5-aryl-1H-imidazol-1-yl acylate (1 molar equivalent) and hydrazine 
monohydrate (3 molar equivalents), 64% in water) in MeOH (5 ml) was stirred for 24 hours at 
room temperature. Upon completion of reaction, the solvent was removed and DCM was added 
to generate a precipitate which was then filtered and dried to afford 2-(5-aryl-1H-imidazol-1-
yl)acetohydrazides. 
 
8.4.6.2. General synthetic procedure B 
Ethyl 5-aryl-1H-imidazol-1-yl acylate (1 equivalent) and hydrazine monohydrate (3 equivalents) 
and MeOH (4 ml) were placed in a 10 ml microwave vessel equipped with a magnetic stirrer bar. 
The capped was then fitted and the resulting mixture was microwave irradiated at a set 
temperature of 75oC for 30 minutes. After completion of the reaction, the solvent was removed 
and DCM was added to generate precipitate which was then filtered and dried to afford 2-(5-
aryl-1H-imidazol-1-yl)acetohydrazides. 
 
(NB: 1H and 13C NMR spectra reported below are for major rotamer only)  
 
8.4.6.3. 2-[5-(4-Fluorophenyl)-1H-imidazol-1-yl]acetohydrazide 125a 
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2-[5-(4-Fluorophenyl)-1H-imidazol-1-yl]acetohydrazide 125a was successfully synthesized 
according to the general procedure A {ethyl 2-[5-(4-fluorophenyl)-1H-imidazol-1-yl]acetate 120a 
(223 mg, 0.90 mmol) and hydrazine monohydrate (135 mg, 2.70 mmol)} and procedure B{ethyl 
2-[5-(4-fluorophenyl)-1H-imidazol-1-yl]acetate 120a (186 mg ,0.75 mmol) and hydrazine 
monohydrate (113 mg, 2.25 mmol}; Physical characteristics: white solid; Yields: 181 mg, 86% 
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for procedure A and 162 mg, 92%; Melting point: 178-180oC;  1H NMR (400 MHz, DMSO-d6) 
δ 9.35 (1H, s, NHNH2), 7.23 (1H, s, 2-CH), 7.29-7.49 (4H, m, ArH), 7.03 (1H, s, 4-CH), 4.63 
(2H, s, NCH2), 3.40 (2H, s, NHNH2); 
13C NMR (101 MHz, DMSO-d6) δ 167.4 (C=O), 162.7 (d, 
1JC,F= 243 Hz, para-CF), 140.9 (2-C), 132.7 (5-C), 131.4 (d, 
3JC,F = 8 Hz, ortho-C), 128.2 (4-C), 
127.0 (d, 4JC,F = 3 Hz, 1‟-C), 116.6 (d, 
2JC,F = 22 Hz, meta-C), 46.78 (6-C); FTIR νmax/cm
-1 (KBr): 
3104, 3026, 2417, 1747, 1495, 1380, 1223, 1163, 1110, 928, 824, 698, 674, 544, HRMS (ESI-
TOF) m/z: [M+H]+Calcd for C11H12FN4O 235.0990, found 235.0995. 
 
8.4.6.4. 2-[5-(3-Methoxyphenyl)-1H-imidazol-1-yl]acetohydrazide 125c 
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2-[5-(3-Methoxyphenyl)-1H-imidazol-1-yl]acetohydrazide 125c was successfully synthesized 
according to the general procedure A {ethyl 2-[5-(3-methoxyphenyl)-1H-imidazol-1-yl]acetate 
120c (172 mg, 0.66 mmol) and hydrazine monohydrate (99 mg, 1.98 mmol)} and procedure B{ 
ethyl 2-[5-(3-methoxyphenyl)-1H-imidazol-1-yl]acetate 120c (122 mg, 0.47 mmol) and hydrazine 
hydrate (71 mg, 1.41 mmol}; Physical characteristics: white solid; Yields: 117 mg, 72% for 
procedure A and 100 mg, 86%; Melting point: 152-154oC; 1H NMR (400 MHz, DMSO-d6) δ 
9.39 (1H, s, NHNH2), 7.23 (1H, s, 2-CH), 7.36-7.40 (1H, m, ArH), 7.06 (1H, s, 4-CH), 6.95-7.00 
(3H, m, ArH), 4.67 (2H, s, NCH2), 4.35 (2H, s, NHNH2) 3.81 (3H, s, ArOCH3); 
13C NMR (101 
MHz, DMSO-d6) δ 167.5 (C=O), 160.3 (ArCOCH3), 141.1 (2-C), 133.6 (5-C), 131.7, 130.9 (ArC), 
128.2 (4-C), 121.3, 114.6, 114.2 (ArC), 56.1 (ArCOCH3), 46.8 (6-C); FTIR νmax/cm
-1 (KBr): 3320, 
3198, 3012, 2954, 1677, 1606, 1589, 1563, 1493, 1482, 1473, 1425, 1319, 1293, 1250, 1218, 1118, 
1113, 1030, 1008, 866, 849, 818, 797, 722, 700, 650, 574; HRMS (ESI-TOF) m/z: [M+H]+ Calcd 
for C12H15N4O2 247.1195, found 247.1208 . 
 
 
 
 
 
 
8.5.4.5. 2-[5-(3,5-Dimethoxyphenyl)-1H-imidazol-1-yl]acetohydrazide 125d 
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2-[5-(3,5-Dimethoxyphenyl)-1H-imidazol-1-yl]acetohydrazide 125d was successfully synthesized 
according to the general procedure A {ethyl 2-[5-(3,4-dimethoxyphenyl)-1H-imidazol-1-
yl]acetate 120d (247 mg, 0.85 mmol) and hydrazine monohydrate (128 mg, 2.55 mmol)} and 
procedure B{ethyl 2-[5-(3,4-dimethoxyphenyl)-1H-imidazol-1-yl]acetate 120d (238 mg, 0.82 
mmol) and hydrazine monohydrate (123 mg, 2.46 mmol}; Physical characteristics: yellow 
solid; Yields: 204 mg, 87% for procedure A and 213 mg, 94%; Melting point: 89-91oC; 1H 
NMR (400 MHz, DMSO-d6) δ 9.38 (1H, s, NHNH2), 7.69 (1H, s, 2-CH), 6.92-7.05 (4H, 
overlapping multiplets, ArH and 4-CH), 4.62 (2H, s, NCH2), 3.80 and 3.82 (6H, 2 x s, 2 x 
ArOCH3), 3.41(2H, s, NHNH2); 
13C NMR (101 MHz, DMSO-d6) δ 167.6 (C=O), 149.5 & 149.6 
(2 x ArCOCH3), 140.5 (2-C), 133.7 (5-C), 127.5 (4-C), 122.9, 121.8, 112.8, 112.8 (ArC), 563 and 
56.5 (2 x ArCOCH3), 46.7 (6-C); FTIR νmax/cm
-1 (KBr): 3565, 3209, 2938, 2838, 1693, 1586, 
1557, 1511, 1463, 1418, 1321, 1254, 1168, 1142, 1112, 1024, 868, 815, 766, 656, 628, 601, 534; 
HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C13H17N4O3 277.1295, found 277.1260. 
8.4.6.5. 2-(5-(Benzo[d][1,3]dioxol-6-yl)-1H-imidazol-1-yl)acetohydrazide 125e 
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2-(5-(Benzo[d][1,3]dioxol-6-yl)-1H-imidazol-1-yl)acetohydrazide125e was successfully 
synthesized according to the general procedure A { ethyl 2-(5-(benzo[d][1,3]dioxol-6-yl)-1H-
imidazol-1-yl)acetate 120e (263 mg, 0.96 mmol) and hydrazine monohydrate (144 mg, 2.88 
mmol)} and procedure B { ethyl 2-(5-(benzo[d][1,3]dioxol-6-yl)-1H-imidazol-1-yl)acetate 120e 
(200 mg, 0.73 mmol) and hydrazine monohydrate (110 mg, 2.19 mmol}; Physical 
characteristics: pale yellow solid; Yields: 215 mg, 86% for procedure A and 171 mg, 90% for 
synthetic procedure B); Melting point: 169-171oC;  1H NMR (400 MHz, DMSO-d6) δ 9.33 (1H, 
s, NHNH2), 7.65 (1H, s, 2-CH), 6.98 (1H, s, 4-CH), 6.92 (1H, d, J = 7.2 Hz, ArH), 6.84 (2H, d, J 
= 1.2 Hz, ArH), 6.06 (2H, s, ArOCH2O), 4.58 (2H, s, NCH2), 3.42 (2H, s, NHNH2); 
13C NMR 
(101 MHz, DMSO-d6) δ 170.9 (C=O), 147.5 and 147.1 (2 x ArCOCH2O), 139.6 (2-C), 132.7 (5-
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C), 127.2 (4-C), 126.7, 123.2, 122.0, 108.8 (ArC), 101.3 (ArCOCH2O), 45.7 (6-C); FTIR νmax/cm
-
1 (KBr): 3318, 3210, 3104, 2994, 2929, 1655, 1619, 1561, 1500, 1428, 1344, 1321, 1292, 1231, 
1121, 1142, 1040, 968, 934, 918, 880, 874, 841, 833, 809, 759, 665, 642, 579;  HRMS (ESI-TOF) 
m/z: [M+H]+ Calcd. for C12H13N4O3 261.0982, found 261.0992. 
 
8.4.6.7. 2-[5-(4-tert-Butylphenyl)-1H-imidazol-1-yl]acetohydrazide 125f 
1'
1
N
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N
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O
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NH2  
2-[5-(4-tert-Butylphenyl)-1H-imidazol-1-yl]acetohydrazide 125f was successfully synthesized 
according to the general procedure A {ethyl 2-(5-(4-tert-butylphenyl)-1H-imidazol-1-yl)acetate 
(229 mg, 0.80 mmol) and hydrazine monohydrate (120 mg, 2.40 mmol)} and synthetic procedure 
B{ ethyl 2-(5-(4-tert-butylphenyl)-1H-imidazol-1-yl)acetate (238 mg, 0.83 mmol) and hydrazine 
monohydrate (125 mg, 2.49 mmol}; Physical characteristics: pale yellow solid; Yields: 174 mg, 
80% for procedure A and 210 mg, 93% for synthetic procedure B; Melting point: 178-180oC; 
1H NMR (400 MHz, DMSO-d6) δ 9.28 (1H, s, NHNH2), 7.69 (1H, s, 2-CH), 7.47 (2H, d, J = 8.0 
Hz, ArH), 7.35 (2H, d, J = 8.0 Hz, ArH), 6.99 (1H, s, 4-CH), 4.63 (2H, s, NCH2), 4.46 (2H, brs, 
NHNH2), 1.34 [9H, s, C(CH3)3]; 
13C NMR (101 MHz, DMSO-d6) δ 166.6 (C=O), 150.2 
[ArCC(CH3)3], 140.2 (2-C), 132.8, 127.9, 127.0, 126.7, 125.6 (ArC), 45.8 (6-C), 34.4 
[ArCC(CH3)3], 31.1 [ArCC(CH3)3]; FTIR νmax/cm
-1 (KBr): 3335, 3220, 3062, 2957, 2865, 1663, 
1603, 1589, 1501, 1478, 1382, 1362, 1296, 1274, 1228, 1116, 992, 964, 913, 842, 828, 783, 740, 
648, 585, 564; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C15H21N4O 273.1710, found 
273.1727.
 
 
8.4.6.8. 2-(5-(3-Hydroxy-4-methoxyphenyl)-1H-imidazol-1-yl)acetohydrazide 125g 
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2-(5-(3-Hydroxy-4-methoxyphenyl)-1H-imidazol-1-yl)acetohydrazide 125g was successfully 
according to the general procedure B using ethyl 2-(5-(3-hydroxy-4-methoxyphenyl)-1H-
imidazol-1-yl)acetate 120g (301 mg, 1.09 mmol) and hydrazine monohydrate (166 mg, 3.25 
mmol) in MeOH; Physical characteristics: pale yellow solid; Yield: 269 mg, 94%; Melting 
point: 217-219oC;  1H NMR (400 MHz, DMSO-d6) δ 9.28 (1H, s, NHNH2), 7.76 (1H, s, 2-CH), 
7.06 (1H, s , 4-CH), 6.95 (1H, d, J = 8.4 Hz, ArH), 6.76-6.81 (2H, m, ArH), 5.24 (1H, br, 
ArOH), 4.67 (2H, s, NCH2), 3.87 (3H, s, ArOCH3), 4.42 (2H, brs, NHNH2); 
13C NMR (101 
MHz, DMSO-d6) δ 167.8 (C=O), 147.0 and 146.7 (ArCOCH3 and ArCOH), 138.2 (2-C), 133.8 
(5-C), 126.0, 122.5 (ArC), 120.1 (4-C), 115.0, 112.2 (ArC), 56.0 (ArCOCH3), 46.5 (6-C); FTIR 
νmax/cm
-1 (KBr): 3146, 3120, 3051, 2994, 2603, 1614, 1574, 1523, 1460, 1387, 1331, 1318, 1289, 
1247, 1219, 1182, 1155, 1132, 1032, 857, 782, 673; HRMS (ESI-TOF) m/z: [M+H]+ Calcd for 
C12H15N4O3 263.1139, found 263.1145. 
 
8.4.6.9. 2-(5-Phenyl-1H-imidazol-1-yl)acetohydrazide 125h 
1'
1
N
2
3
N
4
5
6
7
O
HN
NH2  
2-(5-Phenyl-1H-imidazol-1-yl)acetohydrazide 125h was successfully synthesized was successfully 
synthesized according to the general procedure A {ethyl 2-(5-phenyl-1H-imidazol-1-yl)acetate 
(219 mg, 0.95 mmol) and hydrazine monohydrate 120h (143 mg, 2.85 mmol)} and procedure B 
{ethyl 2-(5-phenyl-1H-imidazol-1-yl)acetate 120h (115 mg, 0.50 mmol) and hydrazine 
monohydrate (75 mg, 1.50 mmol}; Physical characteristics: pale yellow solid; Yields: 152 mg, 
74% for procedure A and 97 mg, 90% for synthetic procedure B; Melting point: 172-174oC; 
 
 
1H NMR (400 MHz, DMSO-d6) δ 9.36 (1H, s, NHNH2), 7.73 (1H, s, 2-CH), 7.41-7.48 (5H, m, 
ArH), 7.05 (1H, s, 4-CH), 4.66 (2H, s, NCH2), 3.41 (2H, s, NHNH2); 
13C NMR (101 MHz, 
DMSO-d6) δ 167.5 (C=O), 141.1 (2-C), 133.2 (5-C), 130.5, 129.7, 129.1, 128.7, 128.1 (ArC), 128.1 
(4-C), 46.8 (6-C); FTIR νmax/cm
-1 (KBr): 3321, 3197, 3119, 3026, 2950, 1676, 1638, 1608, 1553, 
1489, 1425, 1298, 1285, 1229, 1112, 1006, 927, 909, 820, 767, 718, 703, 678, 647, 581, 534;  
HRMS (ESI (ESI-TOF) m/z: [M+H]+ Calcd for C11H13N4O 217.1084, found 217.1082. 
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8.4.7. Synthesis of (E)-N'-arylidene-2-(5-aryl-1H-imidazol-1-yl)acetohydrazide 
8.4.7.1. General synthetic procedure  
2-(5-Aryl-1H-imidazol-1-yl)acetohydrazide (1 molar equivalent) was dissolved in anhydrous 
methanol (20 mL). To this solution was added aryl aldehyde (1.3 molar equivalents) slowly at 
room temperature. After addition, the mixture was refluxed for 16 hours until reaction 
completion, as monitored by TLC. The solvent was evaporated and the product purified by 
recrystallization from 75% EtOH and followed by drying under high vacuum.  
 
N.B: Only proton NMR signals of the major rotamer are presented and assigned, while 13 C data 
is not assigned due to multiplicity of signals arising from rotamers at 30oC. Furthermore, the 13C 
NMR spectra of fluorinated compounds were further complicated by additional signals as a 
result of fluorine splitting. 
 
 
8.4.7.2. (E)-N'-(4-Fluorobenzylidene)-2-(5-(3-hydroxy-4-methoxyphenyl)-1H-imidazol-1-
yl)acetohydrazide 127a 
1'
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(E)-N'-(4-Fluorobenzylidene)-2-(5-(3-hydroxy-4-methoxyphenyl)-1H-imidazol-1-
yl)acetohydrazide 127a was successfully synthesized from reaction of 2-(5-(3-hydroxy-4-
methoxyphenyl)-1H-imidazol-1-yl)acetohydrazide 125g (214 mg, 0.82 mmol) and 4-
fluorobenzaldehyde (135 mg, 1.09 mmol) in MeOH according to the general procedure; 
Physical characteristics: white solid; Yield: 202 mg, 73%; 1H NMR (400 MHz, DMSO-d6) δ 
11.7 (1H, s, NH), 9.24 (1H, brs, OH), 7.99 (1H, s, N=CH), 7.23-7.75 (3H, m, ArH and 2-CH), 
7.25-7.27 (2H, m, ArH), 6.95 (1H, s, 4-CH), 6.90 (1H, s, ArH), 6.77 (2H, d, J = 6.0 Hz, ArH), 
5.24 (2H, s, NCH2), 3.71 (3H, s ArOCH3); 
13C NMR (101 MHz, DMSO-d6) δ 169.1, 164.31, 
164.0, 161.9, 147.6, 146.6, 146.5, 146.3, 143.1, 139.6, 133.19, 132.4, 132.3, 130.5, 129.4, 129.3, 
129.2, 129.1, 126.2, 126.1, 121.3, 121.1, 120.6, 120.3, 116.5, 116.3, 115.9, 115.8, 115.7, 112.4, 
112.2, 55.4, 45.9, 40.2; FTIR νmax/cm
-1 (KBr): 3072, 2974, 2836, 1672, 1613, 1600, 1518, 1503, 
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1491, 1433, 1413, 1306, 1290, 1256, 1155, 1106, 1033, 837, 812, 786, 661, 519; HRMS (ESI-
TOF) m/z: Calcd for C19H18FN4O3 369.1357, found 369.1366. 
 
8.4.7.3. (E)-N'-(2-Chlorobenzylidene)-2-(5-(3-hydroxy-4-methoxyphenyl)-1H-imidazol-1-
yl)acetohydrazide 127b 
1'
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(E)-N'-(2-Chlorobenzylidene)-2-(5-(3-hydroxy-4-methoxyphenyl)-1H-imidazol-1-
yl)acetohydrazide 127b was successfully synthesized from reaction of 2-(5-(3-hydroxy-4-
methoxyphenyl)-1H-imidazol-1-yl)acetohydrazide 125g (315 mg, 1.20 mmol) and 2-
chlorobenzaldehyde (219 mg, 1.56 mmol) in MeOH according to the general procedure; 
Physical characteristics: yellow solid; Yield: 296 mg, 64%; 1H NMR (400 MHz, DMSO-d6) δ 
11.9 (1H, s, NH), 9.23 (1H, brs, OH), 8.37 (1H, s, N=CH), 7.72 (1H, s, 2-CH), 7.37-7.44 (3H, m, 
ArH), 7.50 (1H, d, J = 8.4 Hz, ArH), 6.89 (1H, s, 4-CH), 6.90 (1H, s, ArH), 6.76-6.781 (2H, m, 
ArH), 5.27 (2H, s, NCH2), 3.72 (3H, s ArOCH3); 
13C NMR (101 MHz, DMSO-d6) δ 169.2, 
164.2, 147.6, 146.5, 143.4, 140.2, 139.6, 133.2, 133.0, 131.5, 131.1, 131.0, 130.7, 130.6, 129.9, 
127.6, 127.2, 1276.9, 126.2, 121.3, 121.0, 120.6, 120.3, 115.7, 112.4, 112.2, 55.4, 45.6, 40.2; FTIR 
νmax/cm
-1 (KBr): 3116, 3002, 2964, 2843, 1691, 1604, 1556, 1509, 1416, 1399, 1273, 1212, 1050, 
1030, 965, 876, 773, 656, 561; HRMS (ESI-TOF) m/z: Calcd for C19H18ClN4O3 385.1062, found 
385.1062. 
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8.4.7.4. (E)-N'-(3,4-Dimethoxybenzylidene)-2-(5-(3-hydroxy-4-methoxyphenyl)-1H-
imidazol-1-yl)acetohydrazide 127c 
1'
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(E)-N'-(3,4-Dimethoxybenzylidene)-2-(5-(3-hydroxy-4-methoxyphenyl)-1H-imidazol-1-
yl)acetohydrazide 127c was successfully synthesized from reaction of 2-(5-(3-hydroxy-4-
methoxyphenyl)-1H-imidazol-1-yl)acetohydrazide 125g (354 mg, 1.35 mmol) and 3,4-
dimethoxybenzaldehyde (293 mg, 1.76 mmol) in MeOH according to the general procedure; 
Physical characteristics: yellow solid; Yield: 416 mg, 75%; 1H NMR (400 MHz, DMSO-d6) δ 
11.9 (1H, s, NH), 9.23 (1H, brs, OH), 8.37 (1H, s, N=CH), 7.72 (1H, s, 2-CH), 7.37-7.44 (4H, m, 
ArH), 7.50 (1H, d, J = 8.4 Hz, ArH), 6.89 (1H, s, 4-CH), 6.90 (1H, s, ArH), 6.76-6.78 (2H, m, 
ArH), 5.27 (2H, s, NCH2), 3.72 (3H, s ArOCH3); 
13C NMR (101 MHz, DMSO-d6) δ 168.8, 
161.7, 158.4, 158.3, 158.1, 158.0, 149.6, 149.5, 149.2, 149.0, 146.0, 130.4, 129.7, 129.2, 128.3, 
127.1, 126.0, 125.7, 122.9, 109.5, 108.6, 101.2, 55.7, 55.6, 55.0, 55.4, 55.39, 55.2; 45.7, 40.1; FTIR 
νmax/cm
-1 (KBr): 3539, 3100, 3065, 2940, 2839, 1682, 1600, 1578, 1568, 1498, 1435, 1421, 1375, 
1286, 1262, 1236, 1202, 1140, 1128, 1025, 864, 784, 753, 613, 578 ; HRMS (ESI-TOF) m/z: 
Calcd for C21H23N4O5 411.1663, Found 411.1674. 
 
8.4.7.5. (E)-N'-(4-tert-Butylbenzylidene)-2-(5-(3-hydroxy-4-methoxyphenyl)-1H-
imidazol- 1-yl)acetohydrazide 127d 
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(E)-N'-(4-tert-Butylbenzylidene)-2-(5-(3-hydroxy-4-methoxyphenyl)-1H-imidazol-1-
yl)acetohydrazide 127d was successfully synthesized from reaction of 2-(5-(3-hydroxy-4-
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methoxyphenyl)-1H-imidazol-1-yl)acetohydrazide 125g (218 mg, 0.83 mmol) and 4-tert-
butylbenzaldehyde (217 mg, 1.08 mmol) in MeOH according to the general procedure; Physical 
characteristics: pale yellow solid; Yield: 236 mg, 70%: 1H NMR (400 MHz, DMSO-d6) δ 11.7 
(1H, s, NH), 9.17 (1H, brs, OH), 7.97 (1H, s, N=CH), 7.76 (1H, s, 2-CH), 7.57-7.59 (2H, d, J = 
8 Hz, ArH), 7.41 (1H, d, J = 8.4 Hz, ArH), 6.97 (1H, s, 4-CH), 6.90 (1H, s, ArH), 6.78-6.82 (2H, 
m, ArH), 5.23 (2H, s, NCH2), 3.72 (3H, s ArOCH3), 1.26 [9H, s, C(CH3)3]; 
13C NMR (101 MHz, 
DMSO-d6) δ 168.9, 167.4, 163.9, 153.1, 152.9, 147.6, 147.5, 146.7, 146.6, 144.3, 139.7, 133.3, 
131.3, 131.1, 126.5, 129.2, 128.2, 127.0, 126.8, 126.0, 125.9, 125.6, 125.4, 121.3, 121.1, 120.6, 
115.8, 112.5, 112.2, 55.4, 45.9, 40.2; FTIR νmax/cm
-1 (KBr):  3096, 2965, 2900, 2865, 2730, 2596, 
1694, 1587, 1517, 1482, 1393, 1277, 1239, 1213, 1113, 1023, 1004, 826, 809, 583, 570, 530; 
HRMS (ESI-TOF) m/z: Calcd for C23H27N4O3 407.2078, found 407.2083. 
 
8.4.7.6. (E)-N'-(3-Hydroxy-4-methoxybenzylidene)-2-(5-(3-hydroxy-4-methoxyphenyl)-
1H-imidazol-1-yl)acetohydrazide 127e 
1'
1
N
2
3
N4
5
6 7
O
HN
N
O
HO
O
OH
 
 (E)-N'-(3-Hydroxy-4-methoxybenzylidene)-2-(5-(3-hydroxy-4-methoxyphenyl)-1H-imidazol-1-
yl)acetohydrazide 127e was successfully synthesized from reaction of 2-(5-(3-hydroxy-4-
methoxyphenyl)-1H-imidazol-1-yl)acetohydrazide 125g (326 mg, 1.24 mmol) and 3-hydroxy-4-
methoxybenzaldehyde (227 mg, 1.49 mmol) in MeOH according to the general procedure; 
Physical characteristics: orange solid; Yield: 374 mg, 76%: 1H NMR (400 MHz, DMSO-d6) δ 
11.60 (1H, s, NH), 9.19 and 9.52 (2H, 2 x brs, OH), 7.86 (1H, s, N=CH), 7.73 (1H, s, 2-CH), 
7.76 (1H, s, 4-CH), 7.38 (1H, d, J = 8.4 Hz, ArH), 7.25 (1H, s, ArH), 7.23 (1H, s, ArH), 6.75-6.82 
(3H, m, ArH), 5.22 (2H, s, NCH2), 3.71 and 3.77 (6H, 2 x s, 2 x ArOCH3); 
13C NMR (101 MHz, 
DMSO-d6) δ 168.4, 161.3, 158.4, 158.29, 158.2, 158.1, 149.4, 149.36, 149.33, 149.1, 146.8, 130.1, 
130.0, 129.5, 128.7, 127.0, 125.5, 125.4, 1131.2, 110.0, 108.5, 101.3, 55.8, 55.5, 55.0; 45.5, 40.3; 
FTIR νmax/cm
-1 (KBr): (KBr): 3216, 3073, 2947, 2838, 1682, 1598, 1514, 1464, 1428, 1390, 1282, 
1213, 1165, 1124, 1031, 957, 861, 817, 782, 565; HRMS (ESI-TOF) m/z: Calcd. for C20H21N4O5 
397.1506, found 397.1510. 
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8.4.7.7. (E)-N'-Benzylidene-2-(5-(3-hydroxy-4-methoxyphenyl)-1H-imidazol-1-
yl)acetohydrazide 127f 
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 (E)-N'-Benzylidene-2-(5-(3-hydroxy-4-methoxyphenyl)-1H-imidazol-1-yl)acetohydrazide 127f 
was successfully synthesized from reaction of 2-(5-(3-hydroxy-4-methoxyphenyl)-1H-imidazol-1-
yl)acetohydrazide 125g (213 mg, 0.81 mmol) and benzaldehyde (112 mg, .06 mmol) in MeOH 
according to the general procedure; Physical characteristics: white solid; Yield: 374 mg, 63%; 
1H NMR (400 MHz, DMSO-d6) δ 11.7 (1H, s, NH), 9.28 (1H, br, OH), 8.00 (1H, s, N=CH), 
7.73 (1H, s, 2-CH), 7.68 -7.41 (5H, m, ArH), 6.95 (1H, s, 4-CH), 7.91 (1H, s, ArH), 6.77-6.82 
(2H, m, ArH), 5.26 (2H, s, NCH2), 3.72 (3H, s, ArOCH3); 
13C NMR (101 MHz, DMSO-d6) δ 
169.1, 164.0, 147.5, 147.4, 146.6, 146.4, 144., 139.6, 39.5, 136.2, 134.6, 133.9, 133.8, 133.2, 130.2, 
130.0, 129.4, 129.1, 127.7, 127.1, 126.9, 126.1, 121.3, 121.0, 120.6, 120.3, 115.7, 112.4, 112.2, 
55.4, 46.3, 45.8; FTIR νmax/cm
-1 (KBr): 3361, 3404, 3126, 3078, 3026, 2969, 2895, 2821, 2556, 
1696, 1590, 1517, 1494, 1404, 1276, 1232, 1211, 1117, 1025, 960, 936, 821, 704; HRMS (ESI-
TOF) m/z: Calcd for C19H19N4O3 351.1452, found 351.1455. 
 
8.4.7.8. (E)-N'-(4-Fluorobenzylidene)-2-(5-(4-fluorophenyl)-1H-imidazol-1-  
yl)acetohydrazide 127g 
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(E)-N'-(4-Fluorobenzylidene)-2-(5-(4-fluorophenyl)-1H-imidazol-1-yl)acetohydrazide 127g was 
successfully synthesized from reaction of 2-(5-(4-fluorophenyl)-1H-imidazol-1-yl)acetohydrazide 
125a (353 mg, 1.51 mmol) and 4-fluorobenzaldehyde (225 mg, 1.96 mmol) in MeOH according 
to the general procedure; Physical characteristics: white solid; Yield: 278 mg, 54%; 1H NMR 
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(400 MHz, DMSO-d6) δ 11.7 (1H, s, NH), 7.99 (1H, s, N=CH), 7.81 (1H, s, 2-CH), 7.74 -7.79 
(2H, m, ArH), 7.42-7.44 (2H, m, ArH), 7.24-7.28 (4H, m, ArH), 7.04 (1H, s, 4-CH), 5.29 (2H, s, 
NCH2); 
13C NMR (101 MHz, DMSO-d6) δ 165.2, 164.4, 163.7, 163.1, 163.0, 162.7, 162.0, 160.9, 
160.7, 160.6, 160.5, 146.4, 143.3, 140.4, 140.2, 132.1, 130.6, 130.5, 130.4, 130.3, 130.2, 129.4, 
129.1, 127.3, 127.2, 126.3, 126.2, 126.0, 116.2, 116.0, 115.9, 115.8, 115.7, 115.6, 115.5, 46.4, 46.0; 
FTIR νmax/cm
-1 (KBr): 3182, 3084, 2957, 2835, 1683, 1619, 1600, 1556, 1504, 1409, 1367, 1304, 
1275, 1231, 1157, 1119, 961, 913, 841, 828, 786, 660, 529, 514; HRMS (ESI-TOF) m/z: Calcd 
for C18H15F2N4O
+ 341.1208, Found 341.1217. 
 
7.4.7.9. (E)-N'-(2-Chlorobenzylidene)-2-(5-(4-fluorophenyl)-1H-imidazol-1- 
yl)acetohydrazide 127h 
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(E)-N'-(2-Chlorobenzylidene)-2-(5-(4-fluorophenyl)-1H-imidazol-1-yl)acetohydrazide 127h was 
successfully synthesized from reaction of 2-(5-(4-fluorophenyl)-1H-imidazol-1-yl)acetohydrazide 
125a (478 mg, 2.04 mmol) and 2-chlorobenzaldehyde (287 mg, 2.65 mmol) in MeOH according 
to the general procedure; Physical characteristics: pale yellow solid; Yield: 495 mg, 68%; 1H 
NMR (400 MHz, DMSO-d6) δ 11.8 (1H, s, NH), 8.37 (1H, s, N=CH), 7.95 (1H, d, J = 8.0 Hz, 
ArH), 7.81 (1H, s, 2-CH), 7.37 -7.51 (6H, m, ArH), 7.21-7.26 (2H, m, ArH), 7.03 (1H, s, 4-CH), 
5.31 (2H, s, NCH2); 
13C NMR (101 MHz, DMSO-d6) δ 168.8, 163.8, 162.9, 160.5, 158.2, 143.4, 
140.3, 134.7, 133.1, 133.0, 132.5, 132.0, 131.6, 131.1, 130.8, 130.6, 130.5, 130.3, 130.1, 129.8, 
128.2, 127.6, 127.5, 127.2, 127.1, 127.0, 126.2, 115.8, 115.6, 46.4, 45.9; FTIR νmax/cm
-1 (KBr): 
3068, 3001, 2892, 2794, 1693, 1601, 1561, 1482, 1504, 1411, 1364, 1351, 1271, 1232, 1157, 1114, 
1049, 1032, 954, 924, 846, 816, 759, 660, 594, 531; HRMS (ESI-TOF) m/z: Calcd for 
C18H15FClN4O
 357.0913, Found 357.0918. 
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8.4.7.10. (E)-N'-(3,4-Dimethoxybenzylidene)-2-(5-(4-fluorophenyl)-1H-imidazol-1- 
yl)acetohydrazide 127i 
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E)-N'-(3,4-Dimethoxybenzylidene)-2-(5-(4-fluorophenyl)-1H-imidazol-1-yl)acetohydrazide 127i 
was successfully synthesized from reaction of 2-(5-(4-fluorophenyl)-1H-imidazol-1-
yl)acetohydrazide 125a (461 mg, 1.97 mmol) and 3,4-dimethoxybenzaldehyde (393 mg, 2.56 
mmol) in MeOH according to the general procedure; Physical characteristics: white solid; 
Yield: 495 mg, 68%; 1H NMR (400 MHz, DMSO-d6) δ 11.6 (1H, s, NH), 8.64 (1H, s, N=CH), 
7.90 (1H, s, ArH), 7.78 (1H, s, 2-CH), 7.48 (1H, s, ArH), 7.36-7.38 (2H, m, ArH), 7.15 (1H, d, J 
= 8.0 Hz,  ArH), 6.97-7.08 (3H, m, ArH and 4-CH), 5.27 (2H, s, NCH2), 3.78 and 3.82 (6H, 2 x 
s, ArOCH3); 
13C NMR (101 MHz, DMSO-d6) δ 168.5, 163.3, 162.9, 160.7, 160.5, 151.6, 150.8, 
150.6, 150.7, 149.0, 147.6, 144.3, 140.1, 131.9, 130.5, 130.3, 130.2, 130.1, 127.3, 126.7, 126.5, 
126.4, 123.5, 121.5, 115.8, 111.5, 111.4, 109.1, 108.5, 108.3, 55.6, 55.5, 55.4, 55.4, 46.5, 40.4; 
FTIR νmax/cm
-1 (KBr): 3304, 3182, 3092, 2978, 2939, 2847, 1681, 1599, 1573, 1502, 1464, 1442, 
1420, 1287, 1239, 1267, 1218, 116, 1141, 1027, 921, 851, 620, 534; HRMS (ESI-TOF) m/z: 
Calcd for C20H20FN4O3
+ 383.1514, Found 383.1521. 
 
8.4.7.11. (E)-N'-(4-tert-Butylbenzylidene)-2-(5-(4-fluorophenyl)-1H-imidazol-1- 
yl)acetohydrazide 127j 
1'
1
N
2
3
N4
5
6
7
O
HN
N
F
 
 (E)-N'-(4-tert-Butylbenzylidene)-2-(5-(4-fluorophenyl)-1H-imidazol-1-yl)acetohydrazide 127j was 
successfully synthesized from reaction of 2-(5-(4-fluorophenyl)-1H-imidazol-1-yl)acetohydrazide 
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125a (285 mg, 1.22 mmol) and 4-tert-butylbenzaldehyde (257 mg, 1.59 mmol) in MeOH 
according to the general procedure; Physical characteristics: yellow solid; Yield: 268 mg, 58%; 
1H NMR (400 MHz, DMSO-d6) δ 11.7 (1H, s, NH), 7.98 (1H, s, N=CH), 7.81 (1H, s, 2-CH), 
7.58-7.60 (2H, d, J = 8.0 Hz, ArH), 7.42-7.50 (6H, m, ArH), 7.23-7.25 (2H, d, J = 8.0 Hz, ArH), 
7.04 (1H, s, 4-CH), 5.27 (2H, s, NCH2), 1.26 [9H, 2 x s, C(CH3)3]; 
13C NMR (101 MHz, DMSO-
d6) δ 168.6, 166.4, 163.5, 163.6, 160.6, 153.1, 152.9, 152.9, 147.5, 144.3, 140.3, 140.2, 139.9, 132.0, 
131.9, 131.8, 131.2, 131.1, 130.5, 130.5, 130.2, 129.2, 128.2, 127.2, 127.0, 126.8, 126.3, 126.0, 
125.5, 125.3, 124.9, 115.8, 115.5, 56.1, 46.4, 45.9, 45.8, 38.9, 34.5, 31.0, 30.9, 18.5; FTIR νmax/cm
-
1 (KBr): 3211, 3069, 2962, 2904, 2868, 1698, 1608, 1564, 1503, 1394, 1365, 1315, 1268, 1226, 
1175, 1159, 1108, 833, 711, 607, 560; HRMS (ESI-TOF) m/z: Calcd for C22H24FN4O 379.1929, 
found 379.1933. 
 
8.4.7.12. (E)-N'-(3-Hydroxy-4-methoxybenzylidene)-2-(5-(4-fluorophenyl)-1H-imidazol-
1-yl)acetohydrazide 128k 
1'
1
N
2
3
N4
5
6
7
O
HN
N
F
OH
O
 
(E)-N'-(3-Hydroxy-4-methoxybenzylidene)-2-(5-(4-fluorophenyl)-1H-imidazol-1-
yl)acetohydrazide 128k was successfully synthesized from reaction of 2-(5-(4-fluorophenyl)-1H-
imidazol-1-yl)acetohydrazide 120a (586 mg, 2.50 mmol) and 3-hydroxy-4-methoxybenzaldehyde 
(494 mg, 3.25 mmol) in MeOH according to the general procedure; Physical characteristics: 
white solid; Yield: 699 mg, 76%;  1H NMR (400 MHz, DMSO-d6) δ 11.5 (1H, s, NH), 9.61 (1H, 
brs, OH), 7.87 (1H, s, N=CH), 7.79 (1H, s, 2-CH), 7.41-7.46 (2H, m, ArH), 7.24-7.28 (3H, m, 
ArH), 7.05 (1H, d, J = 8.0 Hz, ArH), 7.03 (1H, s, 4-CH), 6.80 (1H, d, J = 8.0 Hz, ArH), 5.26 
(2H, s, NCH2), 3.80 (3H, s, ArOCH3); 
13C NMR (101 MHz, DMSO-d6) δ 168.5, 163.3, 163.0, 
160.6, 149.2, 148.9, 148.0, 144.7, 140.4, 140.2, 132.0, 130.5, 130.4, 130.3, 130.2, 127.3, 127.2, 
126.4, 126, 124.3, 122.2, 121.6, 115.90, 115.85, 115.7, 115.5, 115.4, 109.5, 109.14, 55.6, 48.6, 46.1, 
40.1; FTIR νmax/cm
-1 (KBr): 3674, 3519, 3072, 2938, 1698, 1590, 1564, 1469, 1492, 1436, 1409, 
1367, 1289, 1219, 1200, 1169, 1113, 1125, 1036, 950, 933, 857, 849, 812, 666, 615, 530; HRMS 
(ESI-TOF) m/z: Calcd for C19H18FN4O3 369.1357, found 369.1363. 
 
315 
 
8.4.7.13. (E)-N'-Benzylidene-2-(5-(4-fluorophenyl)-1H-imidazol-1-yl)acetohydrazide 127l 
1'
1
N
2
3
N4
5
6
7
O
HN
N
F
 
(E)-N'-Benzylidene-2-(5-(4-fluorophenyl)-1H-imidazol-1-yl)acetohydrazide 127l was successfully 
synthesized from reaction of 2-(5-(4-fluorophenyl)-1H-imidazol-1-yl)acetohydrazide 125a (360 
mg, 1.54 mmol) and benzaldehyde (254 mg, 2.39 mmol) in MeOH according to the general 
procedure; Physical characteristics: pale yellow solid; Yield: 387 mg, 78%; 1H NMR (400 
MHz, DMSO-d6) δ 11.7 (1H, s, NH), 8.00 (1H, s, N=CH), 7.80 (1H, s, 2-CH), 7.67-7.72 (2H, d, 
J = 4 Hz, ArCH), 7.41-7.45 (5H, m, ArH), 7.21-7.30 (2H, m, ArH), 7.04 (1H, s, 4-CH), 5.29 (2H, 
s, NCH2); 
13C NMR (101 MHz, DMSO-d6) δ 168.7, 163.7, 162.9, 16.4, 160.6, 147.5, 144.3, 133.9, 
133.8, 132.0, 130.5, 130.4, 130.3, 130.3, 130.2, 130.0, 128.9, 128.8, 127.2, 127.1, 126.9, 126.3, 
126.2, 115.8, 115.8, 115.6, 115.5, 46.3, 45.9; FTIR νmax/cm
-1 (KBr): 3661, 3404, 3126, 3078, 3026, 
2969, 2895, 2821, 1696, 1590, 1560, 1517, 1494, 1404, 1276, 1232, 1211, 1117, 1025, 960, 938, 
821, 704; HRMS (ESI-TOF) m/z: Calcd for C18H16FN4O 323.1303, found 323.1304. 
 
8.4.7.14. (E)-N'-(4-Fluorobenzylidene)-2-(5-(3,4-dimethoxyphenyl)-1H-imidazol-1- 
yl)acetohydrazide 127m 
1'
1
N
2
3
N4
5
6 7
O
HN
N
O
O
F  
(E)-N'-(4-Fluorobenzylidene)-2-(5-(3,4-dimethoxyphenyl)-1H-imidazol-1-yl)acetohydrazide 
127m was successfully synthesized from reaction of 2-(5-(3,4-dimethoxyphenyl)-1H-imidazol-1-
yl)acetohydrazide 125d (503 mg, 1.82 mmol) and 4-fluorobenzaldehyde (297 mg, 2.39 mmol) in 
MeOH according to the general procedure; Physical characteristics: pale yellow solid; Yield: 
578 mg, 83%; 1H NMR (400 MHz, DMSO-d6) δ 11.8 (1H, s, NH), 8.73 (1H, s, N=CH), 8.23 
(1H, s, 2-CH), 8.00 (2H, d, J = 11.8 Hz, ArH), 7.41-7.47.28-7.34 (2H, m, ArH), 6.91-7.01 (4H, m, 
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ArH  and 4-CH), 5.30 (2H, s, NCH2), 3.74 and 3.75 (6H, 2 x s, 2 x ArOCH3); 
13C NMR (101 
MHz, DMSO-d6) δ 168.6, 163.4, 162.8, 160.7, 160.5, 151.8, 151.0, 150.7, 150.5, 149.1, 147.7, 
144.4, 140.0, 132.0, 132.1, 131.2, 130.8, 130.5, 127.9, 126.4, 126.0, 123.3, 121.5, 115.8, 111.5, 
111.9, 109.5, 108.7, 108.6, 55.7, 55.5, 55.4, 55.3, 46.2, 40.1; FTIR νmax/cm
-1 (KBr): 3661, 3404, 
3126, 3078, 3026, 2969, 2895, 2821, 1696, 1590, 1560, 1517, 1494, 1404, 1276, 1232, 1211, 1117, 
1025, 960, 938, 821, 704; HRMS (ESI-TOF) m/z: Calcd for C20H20FN4O3 383.1514, found 
383.1522. 
 
8.4.7.15. (E)-N'-(4-tert-Butylbenzylidene)-2-(5-(3,4-dimethoxyphenyl)-1H-imidazol-1- 
yl)acetohydrazide 127n 
1'
1
N
2
3
N4
5
6 7
O
HN
N
O
O
 
 (E)-N'-(4-tert-Butylbenzylidene)-2-(5-(3,4-dimethoxyphenyl)-1H-imidazol-1-yl)acetohydrazide 
127n was successfully synthesized from reaction of 2-(5-(3,4-dimethoxyphenyl)-1H-imidazol-1-
yl)acetohydrazide 125d (1.33 mmol) and 4-tert-butylbenzaldehyde (1.73 mmol) in MeOH 
according to the general procedure; Physical characteristics: yellow solid; Yield: 397 mg, 71%; 
1H NMR (400 MHz, DMSO-d6) δ 10.8 (1H, s, NH), 7.95 (1H, s, N=CH), 7.88 (1H, s, 2-CH), 
7.51 (2H, d, J = 8.4 Hz, ArH), 7.39 (2H, d, J = 8.4 Hz, ArH), 7.30 (1H, s, ArH), 7.13 (1H, s, 4-
CH), 6.86 (2H, d, J = 8.8 Hz, ArH), 5.18 (2H, s, NCH2), 3.84 and 3.86 (6H, 2 x s, ArOCH3), 1.34 
[9H, s, C(CH3)3]; 
13C NMR (101 MHz, DMSO-d6) δ 168.9, 167.4, 152.8, 150.8, 150.6, 149.4, 
147.4, 147.0, 146.8, 146.5, 144.0, 140, 133.3, 131.2, 131.0, 126.2, 128.6, 127.3, 126.7, 125.9, 125.9, 
125.6, 125.1, 121.4, 115.9, 113.1, 112.8, 55.6, 55.4, 55.3, 45.9, 45.8, 45.7, 45.6; 38.8, 34.6, 31.0, 
30.9, 18.5; FTIR νmax/cm
-1 (KBr): 3661, 3404, 3126, 3078, 3026, 2969, 2895, 2821, 1696, 1590, 
1560, 1517, 1494, 1404, 1276, 1232, 1211, 1117, 1025, 960, 938, 821, 704; HRMS (ESI-TOF) 
m/z: Calcd for C20H20FN4O3 421.2234, found 421.2238. 
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8.4.7.16. (E)-2-(5-(4-tert-Butylphenyl)-1H-imidazol-1-yl)-N'-benzylideneacetohydrazide 
4.12o 
1'
1
N
2
3
N4
5
6 7
O
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(E)-2-(5-(4-tert-Butylphenyl)-1H-imidazol-1-yl)-N'-benzylideneacetohydrazide 127o was 
successfully synthesized from reaction of 2-(5-(4-tert-butylphenyl)-1H-imidazol-1-
yl)acetohydrazide 125f (253 mg, 0.93 mmol) and benzaldehyde (128 mg, 1.21 mmol)in MeOH 
according to the general procedure; Physical characteristics: yellow solid; Yield: 272 mg, 
81%); 1H NMR (400 MHz, DMSO-d6) δ 11.7 (1H, s, NH), 8.00 (1H, s, N=CH), 7.80 (1H, s, 2-
CH), 7.67 (2H, d, J = 3.6 Hz, ArH), 7.41-7.45 (5H, m, ArH), 7.21-7.30 (2H, m, ArH), 7.04 (1H, 
s, 4-CH), 5.29 (2H, s, NCH2); 
13C NMR (101 MHz, DMSO-d6) δ 168.9, 161.5, 149.7, 149.6, 
146.2, 146.0, 138.9, 138.5, 133.6, 131.2, 130.5, 128.2, 126.9, 125.8, 125.6, 125.5, 122.4, 122.3, 
109.4, 108.5, 45.9, 45.7,  38.6, 34.7, 31.0, 30.9; FTIR νmax/cm
-1 (KBr): 3661, 3404, 3126, 3078, 
3026, 2969, 2895, 2821, 1696, 1590, 1560, 1517, 1494, 1404, 1276, 1232, 1211, 1117, 1025, 960, 
938, 821, 704; HRMS (ESI-TOF) m/z: Calcd for C22H25N4O 361.2023, found 361.2025. 
 
8.4.8. Synthesis of N-aryl-2-(5-aryl-1H-imidazol-1-yl)acetamide 
8.4.8.1. General synthetic procedure  
To a solution of the 2-(5-(4-fluorophenyl)-1H-imidazol-1-yl)acetohydrazide (1 molar equivalent) 
in 1M HC1 (40 ml) was added dropwise a solution of NaNO2 (1 molar equivalent) in H2O (20 
ml) at 0°C over a period of 15 minutes. After stirring for 20 minutes at the same temperature, 
the mixture was neutralized with saturated aqueous NaHCO3 and then an aniline derivative (3 
molar equivalents) in THF (40 ml) was added to the mixture at 0°C over a period of 20 minutes. 
After stirring for 3 hours at the same temperature, THF was evaporated in vacuo. The crude 
material was separated by column chromatography [elution with ethyl acetate: hexane (1:7), 
followed by 100% ethyl acetate: hexane] to afford pure products with Rf value of 0.5-1.0 in ethyl 
acetate: hexane (1:1). 
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8.4.8.2. 2-(5-(4-Fluorophenyl)-1H-imidazol-1-yl)-N-(2,4-dimethoxyphenyl)acetamide 128a 
1'
1
N
2
3
N4
5
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7
O
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2-(5-(4-Fluorophenyl)-1H-imidazol-1-yl)-N-(2,4-dimethoxyphenyl)acetamide 128a was 
successfully synthesized using 2-(5-(4-fluorophenyl)-1H-imidazol-1-yl)acetohydrazide 125a(343 
mg, 1.38 mmol) and 2,4-dimethoxyaniline (634 mg, 4.14 mmol) as described by the general 
procedure; Physical characteristics: light brown solid; Yield: 309 g, 63%; 1H NMR (400 MHz, 
CDCl3) δ 8.02 (1H, d, J = 8.8 Hz, ArH), 8.01 (1H, s, NH), 7.76 (1H, s, 2-CH), 7.31-7.35 (2H, m, 
ArH), 7.16 (1H, s, ArH), 6.98 (2H, t, J = 8.8 Hz, ArH), 6.43 (2H, d, J = 8.0 Hz, ArH), 4.74 (2H, 
s, NCH2), 3.72 and 3.78 (6H, 2 x s, 2 x ArOCH3); 
13C NMR (101 MHz, CDCl3) δ 164.2 (C=O), 
162.9 (d, 1JCF = 253 Hz, para-CF), 157.2 and 149.6 (2 x ArCOCH3), 138.9 (2-C), 132.5 (5-C), 
130.9 (d, 3JCF = 8 Hz, ortho-C), 128.1 (ArC), 124.5 (d, 
4JCF = 4 Hz, 1‟-C), 121.1, 119.5 (ArC), 115.9 
(d, 2JCF = 22 Hz, meta-C), 103.7, 98.6 (ArC), 55.7 and 55.5 (2 x ArCOCH3), 48.8 (6-C);  
 
8.4.8.3. 2-(5-(4-Fluorophenyl)-1H-imidazol-1-yl)-N-(2,4-dimethylphenyl)acetamide 128b 
1'
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2-(5-(4-Fluorophenyl)-1H-imidazol-1-yl)-N-(2,4-dimethylphenyl)acetamide 128b was successfully 
synthesized using 2-(5-(4-fluorophenyl)-1H-imidazol-1-yl)acetohydrazide 125a (335 mg, 1.35 
mmol) and 2,4-dimethylaniline (491 mg, 4.05 mmol) as described by the general procedure; 
Physical characteristics: brown solid; Yield: 253 mg, 58%; 1H NMR (400 MHz, CDCl3) δ 
8.03 (1H, s, NH), 7.69 (1H, s, 2-CH), 7.34-7.40 (3H, m, ArH), 7.09-7.15 (3H, m, ArH), 6.92 (2H, 
s, ArH), 4.88 (2H, s, NCH2), 2.24 and 1.97 (6H, 2 x s, 2 x ArCH3); 
13C NMR (101 MHz, CDCl3) 
δ 164.9 (C=O), 163.1 (d, 1JCF = 250 Hz, para-CF), 138.8 (2-C), 136.0 (ArC) 131.6 (5-C), 131.09, 
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130.9 (d, 3JCF = 8 Hz, ortho-C), 130.1, 128.8, 127.3, 127.1 (ArC), 123.5 (d, 
4JCF = 4 Hz, 1‟-C), 116.4 
(ArC), 115.9 (d, 2JCF = 22 Hz, meta-C), 48.9 (6-C), 20.8 and 17.4 (2 x ArCCH3). 
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8.5. Chapter 5 experimental procedures  
8.5.1. Synthesis of 2,2,2-trichloro-1-arylethanol 
8.5.1.1. General synthetic procedure  
To mixture of benzaldehyde (1 molar equivalent) and chloroform (3 molar equivalent) was added 
dropwise DBU (1 molar equivalent) under argon. The reaction was stirred for 4-48 hours and 
then diluted with chloroform (40 mL) and washed with 2M HCl (3 x 10 ml). The organic phase 
was then dried over MgSO4 and evaporated to produce 2,2,2-trichloro-1-arylethanone derivatives 
as enantiomer.  
 
8.5.1.2. 2,2,2-Trichloro-1-(4-fluorophenyl)ethanol 132a 
1 2
OH
1'
Cl
Cl
Cl
F  
2,2,2-Trichloro-1-(4-fluorophenyl)ethanol 132a was successfully synthesized from 4-
fluorobenzaldehyde (770 mg, 6.20 mmol) and chloroform (1.5 ml, 18.60 mmol) according to the 
general procedure; Physical characteristics: brown oil; Yield: 1.42 g, 94%; 1H NMR (400 
MHz, CDCl3): δ 7.12 (2H, m, Hz, ArH), 7.02 (2H, t, J = 8.8 Hz, ArH), 5.24 (1H, s, 1-CH), 3.44 
(1H, s, OH); 13C NMR (101 MHz, CDCl3): δ 163.9 (d, 
1JCF = 250 Hz, para-CF), 132.6 (d, 
4JCF = 3 
Hz, 1‟-C), 129.5 (d, 3JCF = 9 Hz, ortho-C) 115.7 (d, 
2JCF = 22 Hz, meta-C), 103.6 (2-C), 84.8 (1-C); 
FTIR νmax/cm
-1 (KBr): 3447 (OH), 3117, 3082, 1700, 1605, 1510, 1378, 1228, 1160, 1069, 827, 
647, 564. 
 
8.5.1.3. 2,2,2-Trichloro-1-(4-chlorophenyl)ethanol 132b 
1 2
OH
1'
Cl
Cl
Cl
Cl
 
2,2,2-Trichloro-1-(4-chorophenyl)ethanol 132b was successfully synthesized from 4-
chlorobenzaldehyde (486 mg, 3.46 mmol) and chloroform (0.85 ml, 10.38 mmol) according to 
the general procedure; Physical characteristics: colourless oil; Yield: 792 mg, 88%; 1H NMR 
(400 MHz, CDCl3) δ 7.61-7.64 (2H, m, ArH), 7.38-7.42 (2H, m, ArH), 5.21 (1H, s, 1-CH), 3.45 
(1H, s, OH); 13C NMR (101 MHz, CDCl3) δ 134.8 (ArCCl), 129.4, 129.1, 127.8, 120.5 (ArC), 
103.0 (2-C), 84.4 (1-C); FTIR νmax/cm
-1 (KBr): 3326 (OH), 3073, 2930, 1717, 1604, 1473, 1440, 
1186, 1075, 1049, 1037, 754, 642, 547. 
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8.7.5.1.4. 2,2,2-Trichloro-1-phenylethanol 132c  
1 2
OH
1'
Cl
Cl
Cl
 
2,2,2-Trichloro-1-phenylethanol 132c was successfully synthesized from benzaldehyde (533 mg, 
5.02 mmol) and chloroform ( 1.20 ml, 15.06 mmol) according to the general procedure; Physical 
characteristics: colourless oil; Yield: 1.05 g, 93%; Melting point: 34-37oC (lit.359); 1H NMR 
(400 MHz, CDCl3) δ 7.61-7.64 (2H, m, ArH), 7.38-7.42 (3H, m, ArH), 5.21 (1H, s, 1-CH), 3.45 
(1H, s, OH); 13C NMR (101 MHz, CDCl3) δ 134.8, 129.4, 129.1, 120.6 (ArC), 103.0 (2-C), 84.4 
(1-C); FTIR νmax/cm
-1 (KBr): 3426 (OH), 3065, 3034, 1701, 1595, 1586, 1494, 1454, 1388, 1091, 
1194, 778, 644, 523. 
 
8.5.1.5. 1-(Benzo[d][1,3]dioxol-6-yl)-2,2,2-trichloroethanol 132d 
1 2
OH
1'
Cl
Cl
Cl
O
O  
1-(Benzo[d][1,3]dioxol-6-yl)-2,2,2-trichloroethanol 132d was successfully synthesized from 
piperonal (800 mg, 5.33 mmol) and chloroform (1.30 ml, 15.99 mmol) according to the general 
procedure; Physical characteristics: pale yellow oil; Yield: 1.38 g, 96%; 1H NMR (400 MHz, 
CDCl3) δ 7.19 (1H, d, s, ArH), 7.05 (1H, d, J = 8.0 Hz, ArH), 6.80 (1H, d, J = 8.0 Hz, ArH), 5.98 
(2H, s, ArOCH2O-), 5.13 (1H, s, 1-CH), 3.40 (1H, s OH); 
13C NMR (101 MHz, CDCl3) δ 148.5 
and 147.2 (ArCOCH2O), 128.5, 123.5, 109.2, 107.5, (ArC), 103.3 (2-C), 101.3 (ArCOCH2O), 84.2 
(1-C); FTIR νmax/cm
-1 (KBr): 3500 (OH), 3304, 2899, 1607, 1503, 1489, 1445, 1260, 1039, 870, 
919, 755, 654, 547. 
 
8.5.2. Synthesis of 2-chloro-1-arylethanone by oxidation 
8.5.2.1. General synthetic procedure 
In a three-necked flame dried round bottomed flask equipped with a refluxing condenser was 
created an oxygen free environment by degassing through evacuating and refilling with argon 
three times. The flask was charged with 2,2,2-trichloro-1-arylethanone (1 molar equivalent), CuCl 
(2 molar equivalents) and dry 1,2-dichloroethane (DCE) (10 ml). The resulting reaction mixture  
was stirred with a magnetic stirrer bar and a solution of 2,2‟-bipyridine (2 molar equivalents) in 
DCE (10 ml) was added. The reaction mixture was heated at reflux for 8 hours (the progress of 
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the reaction was monitored by TLC). The reaction mixture was then cooled and filtered through 
a celite pad and the filtrate was evaporated under reduced pressure. The crude product was 
purified by flash column chromatography on a short silica gel column using a mixture of ethyl 
acetate and hexane as the solvent for elution to afford 2-chloro-1-aryl-ethanones. 
 
8.5.2.2. 2-Chloro-1-(4-fluorophenyl)ethanone 133a 
1'
1
F
O
2
Cl
 
2-Chloro-1-(4-fluorophenyl)ethanone 133a was successfully synthesized from (R)-2,2,2-trichloro-
1-(4-fluorophenyl)ethanol 132a (170 mg, 0.70 mmol), CuCl (188 mg, 1.40 mmol) and bipyridine 
(219 mg, 1.40 mmol) in DCE (10 ml) according to the general procedure; Physical 
characteristics: white solid; Yield: 112 mg, 66%; Melting point: 47-49oC (lit360); 1H NMR (400 
MHz, CDCl3) δ 7.12-7.68 (2H, m, ArH), 7.02-7.09 (2H, t, J =8.8 Hz, ArH), 4.56 (2H, s, 2-CH); 
13C NMR (101 MHz, CDCl3) δ 164.1 (d, 
1JCF = 250 Hz, para-CF), 159.1 (C=O) 132.6 (d, 
4JCF = 3 
Hz, 1‟-C), 129.8 (d, 3JCF = 9 Hz, ortho-C) 115.5 (d, 
2JCF = 22 Hz, meta-C); FTIR νmax/cm
-1 (KBr): 
3366, 29995, 2947, 1706 (C=O), 1697, 1593, 1507, 1413, 1212, 1159, 1101, 1003, 830, 817, 790, 
590, 557. 
 
8.5.2.3. 2-Chloro-1-(4-chlorophenyl)ethanone 133b 
1'
1
Cl
O
2
Cl
 
2-Chloro-1-(4-chlorophenyl)ethanone 133b was successfully synthesized from (R)-2,2,2-
trichloro-1-(4-chorophenyl)ethanol 132b (164 mg, 0.63 mmol), CuCl (169 mg, 1.26 mmol) and 
bipyridine (187 mg, 1.26 mmol) in DCE according to the general procedure; Physical 
characteristics: white solid; Yield: 98 mg, 60%; Melting point: 100-103oC (lit.361,362); 1H NMR 
(400 MHz, CDCl3) δ 7.84 (2H, m, ArH), 7.45-7.48 (2H, m, ArH), 4.66 (2H, s, 2-CH2); 
13C NMR 
(101 MHz, CDCl3) δ 189.0 (C=O), 140.5, 132.4, 129.9, 129.2 (ArC), 45.6 (2-C); FTIR νmax/cm
-1 
(KBr): 3360, 3066, 2954, 1736( C=O), 1693, 1590, 1483, 1396, 1313, 1213, 1034, 1000, 782, 526. 
 
 
323 
 
8.5.2.4. 2-Chloro-1-phenylethanone 133c 
1'
1
O
2
Cl
 
2,2,2-Chloro-1-(4-chlorophenyl)ethanone 133c  was successfully synthesized from (R)-2,2,2-
trichloro-1-phenylethanol (717 mg, 3.18 mmol), CuCl (855 mg, 6.36 mmol) and bipyridine 993 
mg, (6.36 mmol) in DCE (15 ml) according to the general procedure; Physical characteristics: 
pale yellow solid; Yield: 384 mg, 54%; Melting point: 55-58oC (lit.363); 1H NMR (400 MHz, 
CDCl3) δ 7.90-7.96 (2H, m, ArH), 7.59-7.64 (1H, m, ArH), 7.48-7.7.51 (2H, m, ArH), 4.72 (2H, 
s, 2-CH2); 
13C NMR (101 MHz, CDCl3) δ 191.0 (C=O), 133.9, 133.2, 128.9, 128.5 (ArC), 46.0 (2-
C); FTIR νmax/cm
-1 (KBr): 33373, 3036, 2994, 1701 (C=O), 1596, 1581, 1449, 1399, 1329, 1212, 
1099, 1000, 905, 789, 758, 686, 559. 
 
8.5.2.5. 1-(Benzo[d][1,3]dioxol-6-yl)-2-chloroethanone 133d 
1
O
2
ClO
O  
1-(Benzo[d][1,3]dioxol-6-yl)-2-chloroethanone 133d was successfully synthesized from (R)-1-
(benzo[d][1,3]dioxol-6-yl)-2,2,2-trichloroethanol (2.27 g, 7.66 mmol), CuCl (2.06 g, 15.32 mmol) 
and bipyridine (2.39 g, 15.3 mmol) in DCE (30 ml) according to the general procedure; Physical 
characteristics:  pale yellow solid; Yield: 365 mg, 24%; Melting point: 88-90oC (lit.364); 1H 
NMR (400 MHz, CDCl3: δ 7.19 (1H, s, ArH), 7.05 (1H, d, J = 8.4 Hz, ArH), 6.80 (1H, d, J = 8.4 
Hz, ArH), 5.98 (2H, s, ArOCH2O-), 4.72 (2H, s, 2-CH2); 
13C NMR (101 MHz, CDCl3) δ 148.5 
and 147.2 (ArCOCH2O), 134.8, 129.4, 129.1, 127.8 (ArC), 101.4 (ArCOCH2O-), 46.0 (2-C); 
FTIR νmax/cm
-1 (KBr): 3356, 3065, 2900, 2791, 1686 (C=O), 1503, 1488, 1448, 1401, 1355, 1283, 
1261, 1209, 1098, 1037, 927, 810, 784, 688, 643, 558. 
 
8.5.3. Synthesis of 2-chloro-1-arylethanone oxime 
8.5.3.1. General synthetic procedure  
To a solution of 2-chloro-1-arylethanone (1 molar equivalent) in methanol (20 ml) and water (5 
ml) was added NH2OH.HCl (3 molar equivalents) at room temperature. The homogenous clear 
solution was allowed to stir for 12 hours prior to concentration in vacuo. The resulting solids were 
dissolved in water (3 ml) and extracted with CHCl3 (3 x 10 ml), the organic layer was dried over 
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MgSO4 and concentrated in vacuo. The resulting solids were washed with hexanes (3 x 5 ml) and 
dried under high vacuum to yield (E) - and (Z) isomers of 2-chloro-1-aryl-ethanone oximes. 
 
8.5.3.2. (E/Z)-2-Chloro-1-(4-fluorophenyl)ethanone oxime 129a 
1'
1
N
2
Cl
F
OH
 
(E/Z)-2-Chloro-1-(4-fluorophenyl)ethanone oxime 129a was successfully synthesized from 2-
chloro-1-(4-fluorophenyl)ethanone 133a (1.86 g, 7.70 mmol) and NH2OH.HCl (1.61 g, 23.10 
mmol) in MeOH (30 ml) and water (4 ml) according to the general procedure; Physical 
characteristics: pale yellow solid; Yield: 1.86 g, 94%; 1H NMR (400 MHz, CDCl3) δ 9.25 and 
8.95 (1H, s, OH), 7.99-8.02 and 7.66-7.69 (2H, m, ArH), 7.62-7.64 and 7.09-7.60 (2H, m, ArH), 
4.60 and 4.45 (2H, s, 2-CH2); 
13C NMR (101 MHz, CDCl3) δ 162.6 & 162.0 (d, 
1JCF = 250 Hz, 
para-CF), 130.7 and 131.4r (d, 
4JCF = 3 Hz, 1‟-C), 129.3 and 128.2 (d, 
3JCF = 9 Hz. ortho-C), 115.7 
and 115.5 (d, 1JCF = 22 Hz, meta-C), 44.6 and 32.2 (2-C); FTIR νmax/cm
-1 (KBr): 3295 (OH), 3082, 
2986, 2986, 1701 (C=O), 1686, 1571, 1508, 1413, 1401, 1314, 1284, 1209, 1159, 836, 589.  
 
8.5.3.3. (E/Z)-2-Chloro-1-(4-chlorophenyl)ethanone oxime 129b 
1'
1
N
2
Cl
Cl
OH
 
(E/Z)-2-Chloro-1-(4-chlorophenyl)ethanone oxime 129b was successfully synthesized from 2-
chloro-1-(4-chlorophenyl)ethanone 133b (2.77 g, 10.70 mmol) and NH2OH.HCl (2.23 g, 32.10 
mmol) in MeOH (18 ml) and water (2.5 ml) according to the general procedure; Physical 
characteristics: yellow solid; Yield: 2.72 g, 93%; 1H NMR (400 MHz, CDCl3):δ 9.41and 9.11 
(1H, s, OH), 7.89-7.91 and 7.61 (2H, d, J = 8.4 Hz each, ArH), 7.55-7.57and 7.38-7.41 (2H, m, 
ArH), 4.59 and 4.44 (2H, s, 2-CH2); 
13C NMR (101 MHz, CDCl3) δ 153.5 and 152.9 (C=NOH), 
136.1, 136.6, 129.9, 129.0, 127.5,, 128.72, 122.6, 122.7 (ArC), 44.5 and 32.1 (2-C); FTIR νmax/cm
-1 
(KBr): 3360 (OH), 3000, 2947, 1686, 1589, 1570, 1448, 1489, 1314, 1297, 1211, 1093, 1013, 833, 
818, 766, 588. 
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8.5.3.4. (E/Z)-2-Chloro-1-phenylethanone oxime 129c 
1'
1
N
2
Cl
OH
 
(E/Z)-2-Chloro-1-phenylethanone oxime 129c was successfully synthesized from 2-chloro-1-(4-
chlorophenyl)ethanone (1.77 g, 7.93 mmol) and NH2OH.HCl (1.65 g, 23.79 mmol) in MeOH 
(20 ml) and water (3 ml) according to the general procedure; Physical characteristics: pale 
yellow solid; Yield: 1.66 g, 88%; Melting point: 78-79 °C; 1H NMR (400 MHz, CDCl3) δ 8.26 
(1H, br, OH), 7.96-7.98 and 7.69-7.71 (2H, m, ArH), 7.58-7.60 and 7.43-7.47 (3H, m, ArH), 4.63 
and 4.46 (2H, s, 2-CH2); 
13C NMR (101 MHz, CDCl3) δ 154.3 & 153.9 (C=NOH), 134.0, 133.2, 
130.3, 130.0, 128.8, 128.7, 128.3, 126.2 (ArC), 44.7 and 32.3 (2-C) ; FTIR νmax/cm
-1 (KBr): 3226 
(OH), 3060, 2986, 2917, 1700, 1604, 1569, 1449, 1326, 1314, 1264, 960, 917, 766, 692, 527. 
 
8.3.5.5. (E/Z)-1-(Benzo[d][1,3]dioxol-6-yl)-2-chloroethanone oxime 129d 
1'
1
N
2
Cl
OH
O
O  
(E/Z)-1-(Benzo[d][1,3]dioxol-6-yl)-2-chloroethanone oxime 129d was successfully synthesized 
from 2-chloro-1-(4-chlorophenyl)ethanone (238 mg, 0.89 mmol) and NH2OH.HCl (186 mg, 2.67 
mmol) in MeOH (1.5 ml) and water (0.2 ml) according to the general procedure; Physical 
characteristics:  white solid; Yield: 236 mg, 94%; 1H NMR (400 MHz, DMSO-d6): δ 11.9, 11.8 
(1H, s, OH), 7.19-7.23 (2H, m, ArH), 6.95-6.97 (1H, m, ArH), 6.06 and 6.05 (2H, s, ArOCH2O-), 
4.67 and 4.61 (2H, s, 2-CH2); 
13C NMR (101 MHz, DMSO-d6): δ 151 (C=NOH), 148.2 and 
147.7 (2 x ArCOCH2O), 127.7, 120.3, 108.2, 105.6 (ArC), 101.4 (ArCOCH2O), 32.0 (2-C); FTIR 
νmax/cm
-1 (KBr): 3269 (OH), 3008, 2908, 1717, 1604, 1501, 1455, 1308, 1270, 1252, 1231, 1037, 
953, 818, 569. 
 
8.5.4. Synthesis of N-aryl formamide  
8.5.4.1. General synthetic procedure 
A mixture of an aniline (1 molar equivalent) and formic acid (10 molar equivalents) was placed in 
a 35 ml microwave vessel and then capped. This mixture was irradiated using standard method at 
110oC for 1 hour. TLC monitored the progress of the reaction. After completion of the reaction, 
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ethyl acetate (10 ml) was added and mixture was washed with water (3 x 5 ml) and the organic 
layer dried over anhydrous MgSO4 and then filtered. The ethyl acetate was evaporated under 
vacuum to afford N-formylated aryl amines. The presence of rotamers was evident from the 1H 
and 13C NMR spectra. 
 
8.5.4.2. N-(4-Bromophenyl)formamide 139a 
NHCHO
Br  
 N-(4-Bromophenyl)formamide 139a was successfully synthesized from 4-bromoaniline (433 mg, 
2.52 mmol) and formic acid (0.85 ml, 25.20 mmol) according to the general procedure; Physical 
characteristics: pale yellow solid; Yield: 464 mg, 92%; Melting point: 118-120oC (lit.365); 1H 
NMR (400 MHz, CDCl3) δ 8.68major (0.7H, s, CHO), 8.36minor (0.3H, s, CHO), 7.96minor (0.3H, br, 
NH), 7.95minor (0.3H, d, J=2.4 Hz, ArH), 7.047major (0.7H, br, NH), 7.011-7.32 (3.7H, m, ArH); 
13C 
NMR (101 MHz, CDCl3): δ 162.6major and 159.2minor (CHO), 134.1, 133.7, 132.8, 132.1, 121.6, 120.3, 
118.9, 117.7 (ArC both major and minor). 
 
7.5.4.3. N-(2,4-Dimethylphenyl)formamide 139b 
NHCHO
 
N-(2,4-Dimethylphenyl)formamide 139b was successfully synthesized from 42,4-dimethylaniline 
(2.07 g, 48.50 mmol) and formic acid (18 ml, 485.00 mmol) according to the general procedure; 
Physical characteristics: pale yellow solid; Yield: 5.72 g, 79%; Melting point: 115-117 oC 
(lit.366); 1H NMR (400 MHz, CDCl3) δ 8.54major (0.6H, d, J= 11.6 Hz, CHO), 8.39minor (0.4 H, s, 
CHO), 7.96major (0.6H, br, NH), 7.95minor (0.4H, d, J=2.4 Hz, ArH), 7.17minor (0.4H, br, NH), 7.011-
7.32overlapping major and minor (2.6H, m, ArH), 2.30 & 2.26majorand 2.29 & 2.23minor (2 x ArCH3); 
13C NMR 
(101 MHz, CDCl3) δ 163.5major and 159.2minor (2-CHO), 135.9, 135.3, 132.4, 131.9, 131.8, 131.2, 
130.0, 129.9, 127.5, 20.8, 20.7 (ArC both major and minor), 20.8, 20.7, 17.6, 17.5 (ArCCH3 both major and minor ); 
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8.5.4.4. N-(2,4-Dimethoxyphenyl)formamide 139c 
NHCHO
O
O
 
N-(2,4-Dimethoxyphenyl)formamide 139c was successfully synthesized from 2,4-
dimethoxyaniline (5.33 g, 34.8 mmol) and formic acid (13 ml, 348.00 mmol) according to the 
general procedure; Physical characteristics: pale yellow solid; Yield: 4.67 g, 74%; 1H NMR 
(400 MHz, CDCl3) δ 8.54major (0.3H, dd, J= 11.8 Hz, CHO), 8.39minor (0.7H, d, J= 11.8 Hz, CHO), 
8.24major(0.7H, d, J= 8.4 Hz, ArH), 7.62minor (0.7H, br, NH), 7.45major (0.3H, br, NH), 7.08minor (1.3H, 
d, J= 8.8 Hz, ArH) 6.45-6.51overlapping major and minor signals (2H, m, ArH), 2.30 & 2.26major  and 2.29 & 2.23minor 
(6H, 2 x s, ArOCH3); 
13C NMR (101 MHz, CDCl3) δ 162.1major and 158.4minor (CHO), 158.1, 156.7, 
150.9 and 149.1 (ArCOCH3 both major and minor), 121.2, 120.3, 119.3, 119.2, 104.1, 103.7, 99.5, 98.7 (ArC 
both major and minor), 55.7, 55.5 and 55.1 (ArCOCH3 for both major and minor). 
 
8.5.4.5. N-(2,4-Dichlorophenyl)formamide 139d 
NHCHO
Cl
Cl
 
N-(2,4-Dichlorophenyl)formamide 139d was successfully synthesized from 2,4-dichloroaniline 
(5.70 g, 35.20 mmol) and formic acid (13 ml, 353.00 mmol) according to the general procedure; 
Physical characteristics: pale yellow solid; Melting point: 157-158oC (lit.367); Yield: 5.55 g, 
83%; 1H NMR (400 MHz, CDCl3) δ 8.73major (0.2H, dd, J= 11.6 Hz, NH), 8.51major and minor (2H, s, 
CHO and ArH), 7.74minor (0.8, br, NH), 7.07-7.03overlapping major and minor signals (2H, m, ArH); 
13C NMR (101 
MHz, CDCl3) δ 160.9majorand 158.7cis (CHO), 134.4, 133.7, 131.1, 129.7, 125.7, 125.1, 122.1, 121.7, 
120.5, 118.3 (ArC both major and minor). 
 
8.5.5. Dehydration of N-arylformamide 
8.5.5.1. General synthetic procedure  
To a suspension of N-formylated aryl formamide (1 molar equivalent) and triethylamine (3 molar 
equivalents) in DCM (10 ml) was added dropwise phosphoryl chloride (1.2 molar equivalents) at 
5-10°C over a period of 30 min. After stirring for 2 hours at room temperature, 25 % aqueous 
Na2CO3 (80 ml) was added to the reaction mixture under ice cooling and the DCM layer was 
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separated. The aqueous layer was extracted with DCM. The combined organic layer was washed 
with water, dried over MgSO4, and then evaporated in vacuo to obtained crude product, which 
was subjected to column chromatography [eluting with hexane and EtOAc (1:1)] to furnish pure 
aryl isocyanide. 
 
8.5.5.2. 1-Isocyano-4-bromobenzene 130a 
1'
Br
N
C
 
1-Isocyano-4-bromobenzene 130a was successfully synthesized from N-(4-
bromophenyl)formamide 139a (1.50 g, 7.50 mmol); triethylamine (2.28 g, 22.5 mmol)  and 
phosphoryl chloride (1.08 g, 9.00 mmol) in DCM (20 ml) according to the general procedure; 
Physical characteristics: pale yellow solid; Yield: 1.28 g, 94%; Melting point: 96-98oC (lit.368); 
1H NMR (400 MHz, CDCl3): δ 7.16 (2H, d, J= 8.8 Hz, ArH); 6.34 (2H, d, J= 8.8 Hz, ArH), 
13C 
NMR (101 MHz, CDCl3): δ 165.7 (NC), 133.1, 131.6, 16.8, 124.5 (ArC). 
 
8.5.5.3. 1-Isocyano-2,4-dimethylbenzene 130b 
1'
N
C
 
1-Isocyano-2,4-dimethylbenzene 130b was successfully synthesized from N-(2,4-
dimethylphenyl)formamide 139b (701 mg, 4.70 mmol); triethylamine (1.43 g, 14.10 mmol)  and 
phosphoryl chloride (657 mg, 5.64 mmol) in DCM (10 ml) according to the general procedure; 
Physical characteristics: Pale yellow solid; Yield: 573 mg, 93%; Melting point: 55-58oC 
(lit.369); 1H NMR (400 MHz, CDCl3) δ 7.19 (1H, d, J = 8.4 Hz, ArH), 7.06 (1H, s, ArH), 6.99 
(2H, d, J = 8.4 Hz, ArH), 2.37 and 2.33 (3H, 2 x s, 2 x ArCH3); 
13C NMR (101 MHz, CDCl3) δ 
164.8 (t, J = 6 Hz, NC), 139.4, 134.5, 131.0, 127.2, 126.1 (ArC), 123.9 (t, J = 13 Hz, 1‟-C), 21.1 
and 18.3 (2 x ArCCH3). 
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8.5.5.4. 1-Isocyano-2,4-dimethoxybenzene 130c 
1'
O
N
C
O
 
1-Isocyano-2,4-dimethoxybenzene 130c was successfully synthesized from N-(2,4-
dimethoxyphenyl)formamide 139c (1.12 g, 6.20 mmol); triethylamine (1.88 g, 18.60 mmol)  and 
phosphoryl chloride (866 mg, 7.44 mmol) in DCM (15 ml) according to the general procedure; 
Physical characteristics: pink solid; Yield: 890 mg, 88%; Melting point: 67-69oC (lit.370); 1H 
NMR (400 MHz, CDCl3): δ 7.25 (1H, d, J =8.8 Hz, ArH), 6.39-6.46 (2H, overlapping doublet 
and singlet, ArH), 3.88 and 3.81 (6H, 2 x s, 2 x ArOCH3); 
13C NMR (101 MHz, CDCl3) δ 165.72 
(NC), 161.1 and 156.1 (2 x ArCOCH3), 128.3, 109.5, 104.5 (ArC), 55.9 and 55.6 (2 x ArCOCH3).  
 
8.5.5.5. 1-Isocyano-2.4-dichlorobenzene 130d 
1'
Cl
N
C
Cl
 
1-Isocyano-2.4-dichlorobenzene 130d was successfully synthesized from N-(2,4-
dichlorophenyl)formamide 133d (437 mg, 2.30 mmol); triethylamine (698 mg, 6.90 mmol)  and 
phosphoryl chloride (320 mg, 2.75 mmol) in DCM according to the general procedure; Physical 
characteristics: pale yellow solid; Yield: 371 mg, 94%, 1H NMR (400 MHz, CDCl3): δ 7.33 
(1H, s, ArH), 7.48 (2H, m, ArH); 13C NMR (101 MHz, CDCl3) δ 164.8 (t, J = 6 Hz, NC), 139.4, 
134.5, 131.0, 127.2, 126.1, 123.9 (t, J = 13 Hz, 1‟-C). 
 
8.5.6. Synthesis of 3-aryl-N-substituted-isoxazol-5-amine derivatives 
8.5.6.1. General synthetic procedure: method A 
To a solution of 1-chloro-1-arylethanone oxime intermediates (1 molar equivalent) in dry 
CH2C12 (10 ml) was added the isocyanide (2 molar equivalents). The reaction mixture was stirred 
at room temperature for 24 hours (monitored by TLC). Upon completion, water was added and 
the crude material was extracted with CH2Cl2 (2 x 10ml).The combine organic layers were dried 
over MgSO4 and concentrated in vacuo and the product separated by column chromatography.  
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8.5.6.2. General synthetic procedure: mmethod B 
To a solution of 1-chloro-1-arylethanone oxime intermediates (1 molar equivalent) in dry 
CH2C12 (10 ml) was added the isocyanide (2 molar equivalents) and Na2CO3 (4 molar 
equivalent). The reaction mixture was stirred at room temperature for 24 hours (monitored by 
TLC). Upon completion, water was added and the crude material was extracted with CH2Cl2 (2 x 
10ml).The combine organic layers were dried over MgSO4 and concentrated in vacuo and the 
product separated by column chromatography 
 
8.5.6.3. General synthetic procedure: method C 
To a solution of 1-chloro-1-aryl-ethanone oxime intermediates (1 molar equivalent) in dry 
CH2C12 (10 ml) was added the isocyanide (2 molar equivalents) and NaOAc.H2O (4 molar 
equivalents). The reaction mixture was stirred at room temperature for 7 days (monitored by 
TLC). Upon completion, water was added and the crude material was extracted with CH2Cl2 (2 x 
10ml).The combine organic layers were dried over MgSO4 and concentrated in vacuo and the 
product separated by column chromatography 
 
8.5.6.4. General synthetic procedure: method D 
To a solution of 1-chloro-1-aryl-ethanone oxime intermediates (1 molar equivalent) in dry 
CH2C12 (10 ml) was added the isocyanide (2 molar equivalents) and K2CO3 (4 molar 
equivalents). The reaction mixture was stirred at room temperature for 5 days (monitored by 
TLC). Upon completion, water was added and the crude material was extracted with CH2Cl2 (2 x 
10ml).The combine organic layers were dried over MgSO4 and concentrated in vacuo and the 
product separated by column chromatography. 
 
8.5.6.5. General synthetic procedure: method E 
To a solution of -chloro-1-aryl-ethanone oxime intermediates (1 molar equivalent) in dry CH2C12 
(10 ml) was added the isocyanide (2 molar equivalents) and Cs2CO3 (4 molar equivalents). The 
reaction mixture was stirred at room temperature for 1 hour (monitored by TLC). Upon 
completion, water was added and the crude material was extracted with CH2Cl2 (2 x 10ml).The 
combine organic layer was dried over MgSO4 and concentrated in vacuo and the product 
separated by column chromatography 
 
 
331 
 
8.5.6.6. General synthetic procedure: method F 
A solution of 1-chloro-1-arylethanone oxime intermediates (1 molar equivalent) in dry CH2C12 
(10 ml) was cooled to -10oC, followed by addition of the isocyanide (2 molar equivalent) and 
Na2CO3 (4 molar equivalent). The reaction mixture was stirred at THE same temperate for 2 
hours, followed by additional stirring at room temperature for 24 hours (monitored by TLC 
plate). Upon completion, water was added and the crude material was extracted with CH2Cl2 (2 x 
10ml). Combine organic layer was dried over MgSO4 and concentrated in vacuo and the product 
was separated by column chromatography 
 
8.5.6.7. N-(2,4-Dimethoxyphenyl)-3-phenylisoxazol-5-amine 131a 
1
2
3
O
4
N
5
NH O
O  
N-(2,4-Dimethoxyphenyl)-3-phenylisoxazol-5-amine 131a was successfully synthesized as 
described by the general procedure B {2-chloro-1-phenylethanone oxime 129c (562 mg, 1.18 
mmol), 1-isocyano-2,4-dimethoxybenzene 130c (385 mg, 2.36 mmol) and Na2CO3 (500 g, 4.72 
mmol) in DCM (10 ml)}; synthetic procedure C{2-chloro-1-phenylethanone oxime 129c (215 
mg, 0.90 mmol), 1-isocyano-2,4-dimethoxybenzene 130c (292 mg, 1.79 mmol) and NaOAc.H2O 
(3.58 mmol) in DCM }; synthetic procedure D {2-chloro-1-phenylethanone oxime 129c (141 
mg, 0.59 mmol), 1-isocyano-2,4-dimethoxybenzene 130c (193 mg, 1.18 mmol) and K2CO3 (326 
mg, 2.36 mmol) in DCM (10 ml)}; synthetic procedure E {2-chloro-1-phenylethanone oxime 
129c (146 mg, 0.61 mmol), 1-isocyano-2,4-dimethoxybenzene 130c (197 mg, 1.21 mmol) and 
Cs2CO3 (792 mg, 2.43 mmol) in DCM (1 0ml)} and synthetic procedure F {2-chloro-1-
phenylethanone oxime 129c (162 mg, 0.68 mmol), 1-isocyano-2,4-dimethoxybenzene 130c (222 
mg, 1.36 mmol) and Na2CO3 (287 mg, 2.71 mmol) in DCM at -10
oC; Physical characteristics: 
brown oil; Yield: 42 mg, 12% for procedure B; 35 mg,13% for procedure C; 19 mg, 11% for 
procedure D; 20 mg, 11% for procedure E; 24 mg, 12% for procedure F; 1H NMR (400 MHz, 
CDCl3) δ 7.78 (1H, m, ArH), 7.32-7.45 (5H, m, ArH), 6.93 (1H, s, NH), 6.45-6-6.54 (2H, m, 
ArH), 5.8- (1H, s, 4-CH), 3.88 and 3.81 (6H, 2 x s, 2 x ArOCH3); 
13C NMR (101 MHz, CDCl3) δ 
166.4 (5-C), 163.5 (3-C), 155.7 and 149.4 (2 x ArCOCH3), 129.7, 128.6, 126.6, 122.4, 120.5, 
117.2, 103.9, 99.3 (ArC), 78.3 (4-C), 55.8 and 55.6 (2 x ArCOCH3); FTIR νmax/cm
-1 (KBr): 3314 
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(NH), 3001, 2936, 2836, 1747, 1686, 1621, 1586, 1531, 1464, 1418, 1285, 1208, 1182, 1158, 1071, 
1033, 948, 832, 730, 695. 
 
8.5.6.8. N-(2,4-Dimethyphenyl)-3-phenylisoxazol-5-amine 131b 
1
2
3
O
4
N
5
NH
 
N-(2,4-Dimethyphenyl)-3-phenylisoxazol-5-amine 131b was successfully synthesized from 2-
chloro-1-phenylethanone oxime 129c (909 mg, 3.81 mmol), 1-isocyano-2,4-dimethylbenzene 
130b (1.00 g, 7.62 mmol) and Na2CO3 (1.62 g, 15.24 mmol) in DCM (15) according to the 
general procedure B; Physical characteristics: pale yellow solid; Yield: 201 mg, 20%; 1H NMR 
(400 MHz, CDCl3) δ 7.68 (2H, d, J = 7.6 Hz, ArH), 7.35 (3H, m, ArH), 7.19 (1H, d, J = 8.4 Hz, 
ArH), 6.98 (2H, d, J = 7.2 Hz, ArH), 6.56 (1H, s, NH), 5.83 (1H, s, 4-CH), 2.55 and 2.50 (2 x 
ArCH3); 
13C NMR (101 MHz, CDCl3) δ 167.1 (5-C), 163.6 (3-C), 134.9, 133.9, 131.7, 129.7, 
129.6, 128.7, 128.6, 127.6, 126.6, 120.1, 116.1 (ArC), 78.4 (4-C), 20.7 and 17.5 (ArCCH3); FTIR 
νmax/cm
-1 (KBr): 3268 (NH), 3143, 3021, 1632, 1612, 1581, 1525, 1487, 1416, 1292, 1263, 1219, 
958, 811, 736, 692, 625. 
 
8.5.6.9. 3-(4-Fluorophenyl)-N-(2,4-dimethylphenyl)isoxazol-5-amine 131c 
1
2
3
O
4
N
5
NH
F
 
3-(4-Fluorophenyl)-N-(2,4-dimethylphenyl)isoxazol-5-amine 13c was successfully synthesized 
from 2-chloro-1-(4-fluorophenyl)ethanone oxime 129a (1.58 g, 6.16 mmol), 1-isocyano-2,4-
dimethylbenzene 130b (1.62 g, 12.32 mmol) and Na2CO3 (2.61 g, 24.64 mmol) in DCM (20 ml) 
according to the general procedure B; Physical characteristics: pale yellow solid; Yield: 156 
mg, 9%; 1H NMR (400 MHz, CDCl3) δ 7.60 (2H, m, ArH), 7.12 (1H, J = 8.4 Hz, ArH), 6.92-
7.00 (4H, m, ArH), 6.35 (1H, s, NH), 5.43 (1H, s, 4-CH), 2.21 and 2.15 (2 x ArCH3); 
13C NMR 
(101 MHz, CDCl3) δ 167.4 (5-C), 163. 6 (d, 
1JCF =249 Hz, para-CF), 162.7 (3-C), 134.7, 131.7, 
129.0, 128.4, 127.6, 125.8, 120.31, 120.5, 115.6 (ArC), 78.1 (4-C), 20.7 and 17.5 (2 x ArCCH3); 
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FTIR νmax/cm-1 (KBr): 3267 (NH), 3077, 2921, 1620, 1586, 1549, 1448, 1391, 1307, 1266, 
1219, 1157, 1012, 952, 844, 827, 742, 609. 
 
8.5.6.10. N-(4-Bromophenyl)-3-phenylisoxazol-5-amine 131d 
1
2
3
O
4
N
5
NH
Br  
N-(4-Bromophenyl)-3-phenylisoxazol-5-amine 131d was successfully synthesized from 2-
chloro-1-phenylethanone oxime 129c (157 mg, 0.66 mmol), 1-isocyano-4-bromobenzene 130a 
(240 mg, 1.32 mmol) and Na2CO3 (278 mg, 2.64 mmol) in DCM (5 ml) according to the general 
procedure B; Physical characteristics: pale yellow solid; Yield: 23 mg, 11%; 1H NMR (400 
MHz, DMSO-d6) δ 10.2 (1H, s, NH), 7.85-7.88 (2H, m, ArH), 7.48-7.51 (5H, m, ArH), 7.21-7.23 
(2H, m, ArH), 6.29 (1H, s, 4-CH); 13C NMR (101 MHz, DMSO-d6) 155.4 (5-C), 162.7 (3-C), 
139.2, 132.1, 129.9, 129.2, 128.9, 126.4, 118.5, 112.7 (ArC), 79.5 (4-C); FTIR νmax/cm
-1 (KBr): 
3391 (NH), 3208, 3158, 3103, 1652, 1598, 1576, 1492, 1475, 1426, 1395, 1306, 1284, 1232, 1183, 
1074, 1007, 819, 767, 741, 706, 696, 499.  
 
8.5.6.11. N-(4-Bromophenyl)-3-(4-fluorophenyl)isoxazol-5-amine 131e 
1 2
3
O
4
N
5
NH
Br
F
 
N-(4-Bromophenyl)-3-(4-fluorophenyl)isoxazol-5-amine 131e was successfully synthesized 
from 2-chloro-1-(4-fluorophenyl)ethanone oxime 129a (216 mg, 0.84 mmol), 1-isocyano-4-
bromobenzene 130a (606 mg, 1.68 mmol) and Na2CO3 (356 mg, 3.36 mmol) in DCM (10 ml) 
according to the general procedure B; Physical characteristics: pale yellow solid; Yield: 25 mg, 
9%; 1H NMR (400 MHz, CDCl3): δ 10.2 (1H, s, NH),7.90-7.94 (2H, m, ArH), 7.51 (2H, d, J = 
8.8 Hz, ArH), 7.30 (2H, d, J = 8.4 Hz, ArH), 7.21 (2H, d, J = 8.8 Hz, ArH), 6.30 (1H, s, 4-CH); 
13C NMR (101 MHz, CDCl3) δ 165.5 (5-C), 164.3 (d, 
1J= 249 Hz, para-CF), 161.9 (3-C), 139.2, 
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132.1, 128.8, 118.5, 116.0, 115.8, 112.8 (ArC), 79.5 (4-C); FTIR νmax/cm
-1 (KBr): 3281 (NH), 
3208, 3137, 3090, 2923, 2855, 1650, 1530, 1466, 1439, 1388, 1301, 1233, 1159, 1098, 1011, 953, 
847, 746, 719, 603, 528, 499. 
 
8.5.6.12. Methyl 2-(3-(4-fluorophenyl)isoxazol-5-ylamino)acetate 141a 
1
2
3
O
4
N
5
NH
F
O
O
 
Methyl 2-(3-(4-fluorophenyl)isoxazol-5-ylamino)acetate 141a was successfully synthesized 
from 2-chloro-1-(4-fluorophenyl)ethanone oxime 129a (1.59 g, 6.21 mmol), methyl 
isocyanoacetate (1.23 g, 12.42 mmol) and Na2CO3 (2.60 g, 24.48 mmol) in DCM (30 ml) 
according to the general procedure B; Physical characteristics: pale yellow solid; Yield: 544 
mg, 35%; 1H NMR (400 MHz, CDCl3): δ 7.68-7.71 (2H, m, ArH), 7.06-7.11 (2H, m, ArH), 5.34 
(1H, t, J = 5.0 Hz, NH), 5.28 (1H, s, 4-CH), 4.00 (2H, d, J = 5.5 Hz, NHCH2), 3.79 (3H, s, 
OCH3); 
13C NMR (101 MHz, CDCl3) δ 170.1 (C=O), 169.3 (5-C), 163.6 (d, 1J = 249 Hz, para-
CF), 162.7 (3-C), 128 (d, 3J = 8 Hz, ortho-C), 125.8 (d, 4J = 3 Hz, 1‟-C), 115.7 (d, 2J = 21 Hz, 
ArC), 77.3 (4-C), 52.5 (OCH3), 45.3 (NHCH2); FTIR νmax/cm
-1 (KBr): 3407 (NH), 3123, 2958, 
2924, 2852, 1742, 1619, 1597, 1506, 1445, 1396, 1246, 1222, 1161, 1017, 980, 950, 887, 841, 757, 
596, 514. 
 
8.5.6.13. Methyl 2-(3-(4-chlorophenyl)isoxazol-5-ylamino)acetate 141b 
1
2
3
O
4
N
5
NH
Cl
O
O
 
Methyl 2-(3-(4-fluorophenyl)isoxazol-5-ylamino)acetate 141c was successfully synthesized 
from  2-chloro-1-(4-chlorophenyl)ethanone oxime 129b (622 mg, 2.28 mmol), methyl 
isocyanoacetate (452 mg, 4.56 mmol) and Na2CO3 (697 mg, 9.12 mmol) in DCM (10 ml) 
according to the general procedure B; Physical characteristics: pale yellow solid; Yield: 274 
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mg, 45%; 1H NMR (400 MHz, CDCl3):δ 9.10 (1H, s, NH), 7.74 (2H, d, J = 8.4 Hz, ArH), 7.42 
(2H, d, J = 8.4 Hz, ArH), 6.75 (1H, s, 4-CH), 4.27 (2H, s, NHCH2), 3.85 (3H, s, OCH3); 
13C 
NMR (101 MHz, CDCl3) δ 170.4 (C=O), 162.8 (5-C), 162.2 (3-C), 154.6, 136.4, 128.1, 127.2 
(ArC), 77.6 (4-C), 55.3 (OCH3), 42.2 (NHCH2); FTIR νmax/cm
-1 (KBr): 3381 (NH), 3113, 2982, 
2917, 2860, 1743, 1630, 1572, 1514, 1441, 1225, 1330, 1016, 953, 835, 756, 504. 
 
8.5.7. Synthesis of 3-aryl-isoxazol-5-amine derivatives 
8.5.7.1 General synthetic procedure  
To a suspension of KCN (1.2 molar equivalent) in MeOH (10 ml) was added dropwise a solution 
of 2-chloro-aryl-ethanone oximes (1 molar equivalent) in MeOH (10 ml) at room temperature. 
The mixture was stirred for 30 min, followed by removal of KCl by filtration. Evaporation of the 
solvent in the filtrate gave a residue, which was chromatographed on silica gel using a mixture of 
EtOAc and hexane (2: 1) as an eluent to afford 3-aryl-isoxazol-5-amine derivatives  
 
8.5.7.2. 3-(4-Fluorophenyl)isoxazol-5-amine 144a 
1'
1
2
3
O
4
N
5
NH2
F  
3-(4-Fluorophenyl)isoxazol-5-amine 144a was successfully synthesized from 2-chloro-1-(4-
fluorophenyl)ethanone oxime 129a (1.28 g, 5.00 mmol), KCN (378 mg, 6.00 mmol) in MeOH 
(10 ml) according to the general procedure; Physical characteristics: brown oil; Yield: 606 mg, 
68%; 1H NMR (400 MHz, CDCl3) δ 7.67 (2H, m, ArH), 7.06 (2H, t, J = 8.4 Hz, ArH), 5.37 (1H, 
s, 4-CH), 4.70 (1H, s, NH2);. 
13C NMR (101 MHz, CDCl3) δ 169.1 (5-C), 163.6 (d, 
1JCF = 248.5 
Hz, para-CF), 162.9 (3-C), 128.4 (d, 3JCF = 8 Hz, ortho-C), 125.8 (d, 
4JCF = 3 Hz, 1‟-C), 115.7 (d, 
2JCF = 21 Hz, meta-C), 78.0 (4-C); FTIR νmax/cm
-1 (KBr): 3454 (NH2), 3285, 3224, 3133, 1639, 
1610, 1579, 1529, 1480, 1334, 1222, 1156, 954, 899, 843, 746, 589, 529. 
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8.5.7.3. 3-(4-Chlorophenyl)isoxazol-5-amine 144b 
1'
1
2
3
O
4
N
5
NH2
Cl  
3-(4-Chlorophenyl)isoxazol-5-amine 144b was successfully synthesized from 2-chloro-1-(4-
chlorophenyl)ethanone oxime 129b (3.36 g, 12.31 mmol), KCN (962 mg, .77 mmol) in MeOH 
(20 ml) according to the general procedure; Physical characteristics: pal orange solid; Yield: 
1.51 g, 63%; Melting point: 164-166oC (lit.371); 1H NMR (400 MHz, CDCl3): δ 7.67 (2H, d, J = 
8.4 Hz, ArH), 7.06 (2H, d, J = 8.4 Hz, ArH), 5.37 (1H, s, 4-CH), 4.70 (1H, s, NH2); 
13C NMR 
(101 MHz, CDCl3): δ 169.1 (5-C), 162.9 (3-C), 136.1, 129.9, 127.5, 128.72 (ArC), 78.0 (4-C); 
FTIR νmax/cm
-1 (KBr): 3433 (NH2), 3301, 3243, 3189, 1642, 1595, 1569, 1569, 1476, 1442, 1088, 
1012, 952, 891, 836, 750, 499.  
 
8.5.7.4. 3-Phenylisoxazol-5-amine 144c 
1'
1
2
3
O
4
N
5
NH2
 
3-Phenylisoxazol-5-amine 144c successfully synthesized from 2-chloro-1-(4-
chlorophenyl)ethanone oxime 129c (5.68 g, 23.8 mmol), KCN (1.86 g, 28.5 mmol) in MeOH (20 
ml) according to the general procedure; Physical characteristics: pale yellow solid; Yield: 2.02 
g, 53%; Melting point: 109-111oC (lit.372); 1H NMR (400 MHz, CDCl3): δ 7.71 (2H, m, ArH), 
7.40 (3H, m, ArH), 5.42 (1H, s, 4-CH), 4.50 (1H, s, NH2); 
13C NMR (101 MHz, CDCl3): δ 168.9 
(5-C), 163.8 (3-C), 129.7, 129.6, 128.7, 126.5 (ArC), 78.2 (4-C); FTIR νmax/cm
-1 (KBr): 3321 
(NH2), 3175, 1644, 1578, 1485, 1430, 1340, 1308, 1286, 1213, 1025, 849, 821, 736, 695, 654. 
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APPENDIX: A: Virtual screening of pepMMsMIMIC 3-dimensinal database using BST-
2-Vpu interaction 
The main aim of virtual screening of the MMsINC® database 
(http://mms.dsfarm.unipd.it/pepMMsMIMIC)373 is to suggest possible peptidomimetic 
molecules as a starting point, whose essential pharmacophoric group is able to inhibit the BST-2-
Vpu interaction. The workflow diagram (Figure A) below illustrates the basic procedure followed 
by PepMMsMIMIC, a web-oriented tool. A pdb file of BST-2 (ID. 2LK9) was used as a template 
for querying the MMsINC® database.  
 
 
 
Figure A: pepMMsMIMIC's workflow 
 
In all cases the pharmacophore is generated by the web-tool using BST-2 residues Ile34, Ile37 
and Lue41. The following scoring functions were used to rank the compounds in the database; 
namely: 1) hybrid scoring function { 60% of pharmacophore finger similarity based on weighted 
similarity coefficient and 40% of shape score similarity based on the ultra-shape recognition}; 2) 
fingerprint based filtering of shape similarity; 3) based only on the pharmacophoric similarity 
{“Pharmacophoric fingerprint similarity method, based on weighted Tversky coefficient 
(wTv).}” and 4) based only on shape similarity.  The pepMMsMIMIC search returned with the 
best 200 peptidomimetic compounds per scoring method. A selection of the top molecules per 
scoring method are shown in the Figure B below.  
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Figure B: A selection of high-ranked in silico identified peptidomimetic compounds 
 
Recurring heterocyclic scaffolds from the virtual screening can be highlighted, namely: 
benzimidazole, benzothiazole, benzoxazole, imidazopyridine, pyrimidinone, 
tetrahydrobenzothiophene and piperazine. These nitrogen containing heterocyclic systems have 
the potential to be developed into new series of compounds by varying the substituents R1, R2 
and R3 (Figure C).  
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Figure 8: Nitrogen heterocyclic scaffolds of interest 
 
Figure C: Highlighted recurring heterocyclic scaffolds from the virtual screening.  
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APPENDIX B: Selected spectra 
1H NMR spectrum of compound 79d 
 
 
 
13C NMR spectrum of compound 79d 
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1H NMR spectrum of compound 80c 
 
 
13C NMR spectrum of compound 80c 
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1H NMR spectrum of compound 81d 
 
 
13C NMR spectrum of compound 81d 
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1H NMR spectrum of compound 88a 
 
 
13C NMR spectrum of compound 88a 
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1H NMR of compound 88d 
 
 
13C NMR spectrum of compound 88a 
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1H NMR spectrum of compound 87b 
 
 
13C NMR spectrum of compound 87b 
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1H NMR spectrum of compound 87c 
 
 
13C NMR spectrum of compound 87c 
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1H NMR spectrum of compound 96c 
 
 
13C NMR spectrum of compound 96c 
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1H NMR spectrum of compound 97e 
 
 
13C NMR spectrum of compound 97e 
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1H NMR spectrum of compound 100i 
 
 
13C NMR spectrum of compound 100i 
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1H NMR spectrum of compound 120d 
 
 
13C NMR spectrum of compound 120d 
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1H NMR spectrum of compound 123g 
 
 
13C NMR spectrum of compound 123g 
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1H NMR spectrum of compound 131b 
 
 
13C NMR spectrum of compound 131b 
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1H NMR spectrum of compound 141a 
 
 
13C NMR spectrum of compound 141a 
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